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The application of fluid shear stress on leukocytes and tumor cells in the 
circulation plays a critical role in the progression of inflammation and cancer 
metastasis, respectively. Specifically, fluid shear forces are known to help mediate 
selectin-based interactions between endothelial cells and circulating cells such as 
tumor cells and leukocytes, which can lead to their subsequent transmigration into 
tissues. However, how fluid shear forces induce mechanotransduction in circulating 
cells remains largely unknown, and could provide insight into potentially controlling 
pathological conditions such as inflammation and metastasis for therapeutic purposes. 
 
Herein, fluid forces are shown to exert control over how leukocytes respond to 
inflammatory agents found in the circulation. Leukocyte pre-exposure to fluid shear 
stress was found to suppress early leukocyte activation in the presence of the bacterial 
peptide fMLP, as indicated by reductions in selectin adhesion molecule shedding, 
integrin activation, and cell morphological changes. Conversely, leukocyte exposure 
can also increase leukocyte activation in the presence of platelet-activating factor, a 
molecule typically upregulated during vascular injury. 
 
Utilizing the same in vitro system, tumor cells became sensitized to the 
apoptosis-inducing ligand TRAIL in the presence of fluid shear stress conditions of 
 the vasculature. This effect is not witnessed upon tumor cell treatment with the 
commonly utilized chemotherapeutic doxorubicin, which enacts its therapeutic effect 
via DNA intercalation. Results from this work suggest that TRAIL is well suited for 
systemic delivery, and that receptor-mediated apoptosis in general could be an ideal 
approach for circulating tumor cell therapies. 
 
The unique apoptotic effects of TRAIL in the presence of fluid shear stress 
were then exploited to develop a novel nanoparticle platform for therapeutic targeting 
of cancer cells in the circulation in vivo. Specifically, E-selectin functionalized 
liposomes were effective at rapidly targeting and adhering to cancer cells under shear 
stress conditions in the circulation, while also delivering therapeutic cargo. Utilizing 
both E-selectin and TRAIL, a nanoparticle platform was developed to functionalize 
circulating leukocytes of the bloodstream in attempt to neutralize circulating cancer 
cells. This approach, demonstrated in vitro with human blood and also in the 
circulation of mice in vivo, mimics the cytotoxic activity of natural killer cells and 
increases the surface area available for delivery of the receptor-mediated signal. The 
resulting “unnatural killer cells” hold promise as an effective means to neutralize 
circulating tumor cells that enter blood with the potential to form new metastases. 
 
 v 
BIOGRAPHICAL SKETCH 
 
Michael John Mitchell was born to John and Grace Mitchell on December 20th, 
1986, in Brooklyn, New York. His father, John, grew up in Brooklyn and had a 
successful financial career in New York City. His mother, Grace, was raised in 
Buenos Aires, Argentina, until leaving as a teenager with her parents for the United 
States. He was raised in Manalapan, New Jersey, for the majority of his youth, until 
beginning his undergraduate studies at the Stevens Institute of Technology in 
Hoboken, New Jersey. It was there that he found his passion for research, majoring in 
biomedical engineering and materials science, and conducting research on in vitro 
microfluidic tissue models in the laboratory of Dr. Woo Y. Lee. 
 
Michael then began his graduate studies at Cornell University in the 
Department of Biomedical Engineering, in the lab of Dr. Michael R. King. His 
research has focused on the interface of cellular engineering, nanotechnology, and 
drug delivery. Specifically, he is focused on leukocyte and tumor cell 
mechanotransduction, nanomaterial-based approaches to isolate and kill circulating 
tumor cells, and the use of functionalized leukocytes to target and kill cancer cells in 
the bloodstream in vivo to interfere with metastatic progression. He has received 
awards from the Biomedical Engineering Research Society, American Institute of 
Chemical Engineers, École Nationale Supérieure des Mines de Saint Etienne, and the 
International Society of Biorheology for his graduate research. Michael will continue 
has career as a postdoctoral research fellow at the Massachusetts Institute of 
Technology, in the laboratory of Dr. Robert S. Langer. He looks forward to a career in 
biotechnology and academics, and mentoring researchers and students from diverse 
backgrounds. 
 vi 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents, John and Grace, and my brother, Marc.  
To my dear friend Bobby, who left us much too early. 
 
 vii 
ACKNOWLEDGMENTS 
 
I have been quite fortunate to receive guidance, love, and support of many 
individuals throughout my doctoral studies, including my family, girlfriend, advisor, 
mentors, lab members, colleagues and friends.  
 
 I am incredibly grateful to my parents, John and Grace Mitchell, for the 
sacrifices they have made throughout my education. Throughout my upbringing, my 
parents constantly stressed education to my brother and I. However, they never 
pressured us into a particular field or career, but rather challenged my brother and I to 
search and find fields that we were passionate about. I can honestly say that I am now 
part of a field that I truly love; I will never be able to repay them for this gift.  
  
Throughout my studies, I have been fortunate to receive praise from my 
colleagues for my ability to present to a wide range of audiences. I owe this ability to 
my father, John. Whether it be conversing with colleagues and co-workers, hosting a 
great summer party, helping a stranger, or coaching my baseball and basketball teams, 
my father always possessed a unique ability to bring people together. I am thankful for 
my mother, Grace, for providing perhaps the most important component of my 
studies: incredible food. My mother stressed the importance of our family having 
dinner together every night, and took the time to provide a delicious spread for each of 
those meals. I took this for granted as a child; today, I cherish those meals, and how 
they have kept our family so close together. I am thankful for my brother, Marc, for 
being kind enough to knock me off my high horse when I get excited about my 
research. I cannot count the number of times I have heard him say “we all know 
Michael got lucky and ended up with the best BME professor at Cornell.” He is right.   
 viii 
My loving girlfriend, Karin Wang, has had the patience to not only support, 
but also live with me throughout the majority of doctoral studies. I have learned much 
from her patience and kindness, and would not be the undergraduate mentor that I am 
today without her. It has been a joy to work in the same building as her, and share our 
research hardships and accomplishments with each other. I cannot wait to see where 
our future in research will take us. 
 
 I have had the privilege of conducting my doctoral studies under the 
supervision of Dr. Michael King, who knew long before me that I would be a great fit 
in his lab. Dr. King was the first person I met during my original visit to Cornell, and 
he was the first Professor to email me after my visit. He introduced me to the field that 
I love, constantly challenged me with new projects, and pushed me to achieve goals 
that I never thought I would be able to accomplish, such as publishing impactful 
journals and securing a postdoctoral position in Robert Langer’s lab at MIT. He taught 
me how to take ownership of my research, write my first scientific paper, and present 
at my first conference. I will never be able to repay him for these gifts. 
 
 I would also like to acknowledge my committee members, Dr. Richard Cerione 
and Dr. Jeffrey Varner, for their kind support and guidance throughout my studies. I 
would like to thank BME Professors Dr. Cynthia Reinhart-King, Dr. David Putnam, 
Dr. Chris Schaffer, Dr. Ben Cosgrove, and Dr. Steven Adie for their helpful 
discussions and unique insights throughout my career. I would also like to thank Dr. 
Michael Shuler, Dr. Peter Doerschuk, and Ms. Belinda Floyd for their help with the 
Ph.D. admissions process, welcoming me to Cornell, and providing great support 
throughout my studies. 
 
 ix 
 My “Fellow Kings”, also known as the members of the King lab, have been 
like family throughout my studies. I would like to acknowledge old members of the 
King lab, particularly Dr. Kuldeep Rana and Carissa Ball for ushering me into lab and 
being excellent role models as I began to pursue my own independent research. 
Andrew Hughes, Sivaprakash Agastin, Varun Ponmudi, John Lindsey, Weiwei Wang, 
Christina Chen, and Adelaide de Guillebon provided friendship and support, and made 
the King lab a special place from the very beginning. Jeff Mattison, our lab manager, 
has been a father-like figure to our entire lab, and a stabilizing presence from the very 
beginning. I have enjoyed welcoming and working with the new era of King lab, 
including Kevin Anderson, Anne Rocheleau, Jocelyn Marshall, Siddarth 
Chandrasekaran, and Thong Cao. I cannot wait to see their research come to fruition in 
the upcoming years. I would also like thank one honorary King lab member, Liz 
Wayne, and her advisor, Dr. Chris Schaffer, for partnering with us on my final 
research project that culminated in a new therapeutic approach to eliminate tumor cells 
from the bloodstream. Finally, I would like to thank the diverse group students that I 
had the privilege of mentoring, including Kimberly Lin, Maxine Chan, Ana Steen, Sue 
Yan, Dennis Zhou, Ryan Ashley, Zhexiao Wang, and Carlos Castellanos. They have 
reaffirmed my commitment to mentor students from diverse backgrounds as I continue 
my academic career. 
 
 I was able to maintain a happy and balanced life throughout my studies large 
due to the love and support from my friends. To my Ithaca and Cornell friends, 
including Mingchee, Jose, Thong, John, Joe, Kevin, Roman, Jon, Brandon, Rouge, 
Warden, Peter, Robby, Kuldeep, Adelaide, Christina, J.C., Ryan, Kirk, and Liz, for 
incredible weekends, football games outside Weill, beers at the Big Red Barn, and 
unforgettable conference trips across the world. To my friends from my undergraduate 
 x 
days, including Scott, Henry, Sean, Steve, Dan, Amy, Kyle, Nicole, John, Dan, Brian, 
Dan, and Jay, I will never forget our all-nighters as we pursued engineering degrees, 
and our endless adventures in NYC and beyond as we all learned from each other, and 
grew together. To my friends from home, including Scotty Moz, Ray, Samaan, Marc, 
Anthony, Jay, Peter, Bucci, Sal, Jay, Cozz, Dan, Sean, Monica, Sam, Alfie, Jeff, and 
Alex for being there through thick and thin, all the way from our earliest school years. 
I am fortunate that we not only stay in touch, but still meet up with each other on a 
regular basis. Finally, I would acknowledge the late Robert “Bobby” Mozia, my dear 
friend who was taken from us much too early. We began our Ph.D. career together, 
and my journey would not have been possible without his larger-than-life personality, 
kindness, generosity, and huge heart. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xi 
TABLE OF CONTENTS 
 
BIOGRAPHICAL SKETCH                  v 
ACKNOWLEDGEMENTS                  vii 
LIST OF FIGURES                   xvi 
LIST OF TABLES                   xxiii 
CHAPTER 1: INTRODUCTION 1 
1.1 EXPERIMENTAL AND COMPUTATIONAL MODELS OF 
CIRCULATING CELL RESPONSE TO FLUID SHEAR STRESS  2 
1.1.1 FLUID SHEAR STRESS EXPOSURE IN THE TUMOR 
MICROENVIRONMENT      4 
1.1.2 FLUID SHEAR STRESS EXPOSURE IN THE VASCULAR 
MICROENVIRONMENT      6 
1.1.3 COMPUTATIONAL METHODS TO MODEL            
INTERSTITIAL FLOWS      8 
1.1.4 COMPUTATIONAL METHODS TO MODEL CELL        
BEHAVIOR IN THE CIRCULATION    10 
1.1.5 CANCER CELL MECHANOTRANSDUCTION           
PHENOMENA IN EXPERIEMENTS    14 
1.1.6 CURRENT ADVANCES IN MODELING LEUKOCYTE AND 
TUMOR CELL MECHANOTRANSDUCTION PHENOMENA 19 
1.1.7 SUMMARY        23 
1.2 LEUKOCYTES AS CARRIERS FOR TARGETED CANCER DRUG 
DELIVERY         25 
1.2.1 CURRENT NANOPARTICLE PLATFORMS FOR            
DELIVERY OF CANCER DRUGS     27 
 xii 
1.2.2 TUMOR CELL/LEUKOCYTE SIMILARITIES IN FUNCTION 31  
1.2.3 METHODS TO ATTACH NANOPARTICLES TO      
LEUKOCYTES       36 
1.2.4 LEUKOCYTES AS CARRIERS OF NANOPARTICLES TO 
METASTATIC CELLS AND TUMORS: INITIAL RESULTS 39 
1.2.5 SUMMARY        49 
CHAPTER 2: SHEAR-INDUCED RESISTANCE TO NEUTROPHIL 
ACTIVATION VIA THE FORMYL PEPTIDE RECEPTOR   63 
2.1 INTRODUCTION        64 
2.2. MATERIALS AND METHODS      66 
2.3 RESULTS         74 
2.4 DISCUSSION         81 
2.5 CONCLUSION        87 
CHAPTER 3: FLUID SHEAR STRESS INCREASES NEUTROPHIL 
ACTIVATION VIA PLATELET ACTIVATING FACTOR   101 
3.1 INTRODUCTION        102 
3.2 MATERIALS AND METHODS      106 
3.3 RESULTS         111 
3.4 DISCUSSION         117 
CHAPTER 4: FLUID SHEAR STRESS SENSITIZES CANCER                
CELLS TO RECEPTOR-MEDIATED APOPTOSIS VIA TRIMERIC     
DEATH RECEPTORS        137 
4.1 INTRODUCTION        138 
4.2 MATERIALS AND METHODS      140 
4.3 RESULTS         146 
4.4 DISCUSSION         153 
 xiii 
4.5 CONCLUSION        157 
CHAPTER 5: E-SELECTIN LIPOSOMAL AND NANOTUBE-TARGETED 
DELIVERY OF DOXORUBICIN TO CIRCULATING TUMOR CELLS 171 
5.1 INTRODUCTION        172 
5.2 MATERIALS AND METHODS      174 
5.3 RESULTS         182 
5.4 DISCUSSION         188 
5.5 CONCLUSION        191 
CHAPTER 6: NANOSTRUCTURED SURFACES TO TARGET AND         
KILL CIRCULATING TUMOR CELLS WHILE REPELLING  
LEUKOCYTES         207 
6.1 INTRODUCTION        208 
6.2 MATERIALS AND METHODS      210 
6.3 RESULTS AND DISCUSSION      217 
6.4 CONCLUSION        223 
CHAPTER 7:  UNNATURAL KILLER CELLS. TRAIL-COATED 
LEUKOCYTES THAT KILL CANCER CELLS IN THE CIRCULATION 233 
7.1 INTRODUCTION        234 
7.2 MATERIALS AND METHODS      236 
7.3 RESULTS         248 
7.4 DISCUSSION         257 
CHAPTER 8: AN NSF GK-12 EXPERIENCE. FABRICATION OF  
JELL-O MILLI-FLUIDIC CHIPS FOR INQUIRY-BASED EDUCATION  
OF HEMODYNAMICS AND BLOOD CELL ADHESION   281 
8.1 INTRODUCTION AND SCIENCE CONTENT FOR TEACHERS  282 
8.2 MATERIALS AND METHODS      284 
 xiv 
8.3 RESULTS         285 
8.4 ASSESSMENT        288 
8.5 RESULTS AND DISCUSSION      292 
8.6 CONCLUSION        293 
CHAPTER 9: CONCLUSIONS AND FUTURE WORK    301 
9.1 INTRODUCTION        302 
9.2 FLUID SHEAR STRESS DIFFERENTIALLY ALTERS NEUTROPHIL 
ACTIVATION IN THE PRESENCE OF CHEMOATTRACTANTS 303 
9.3 FLUID SHEAR STRESS ENHANCES TRAIL-MEDIATED        
APOPTOSIS OF CIRCULATING CANCER CELLS   305 
9.4 E-SELECTIN FUNCTIONALIZED LIPOSOMES TO TARGET       
CANCER CELLS AND DELIVER THERAPEUTIC CARGO  
UNDER FLOW        306 
9.5 TRAIL-COATED LEUKOCYTES TARGET AND KILL CANCER     
CELLS IN FLOWING HUMAN BLOOD IN VITRO AND IN THE      
PERIPHERAL CIRCULATION OF MICE IN VIVO    307 
9.6  FUTURE WORK        311 
APPENDIX I: THE ROLE OF CELL GLYCOCALYX IN VASCULAR 
TRANSPORT OF CIRCULATING TUMOR CELLS    320 
I.1 INTRODUCTION        321 
I.2 ENDOTHELIAL CELL GLYCOCALYX STRUCTURE   323 
I.3 TUMOR CELL GLYCOCALYX STRUCTURE    324 
I.4 EC GLYCOCALYX EFFECTS ON CTC ADHESION   326 
I.5 GLYCOCALYX EFFECTS ON THERAPEUTIC TREATMENT                 
OF CTCs         333 
I.6 CONCLUSION        338 
 xv 
APPENDIX II: MILLISECOND PULSES OF FLUID SHEAR  
STRESS SUPPRESS CHEMOATTRACTANT-INDUCED  
NEUTROPHIL ACTIVATION       344 
II.1 INTRODUCTION        345 
II.2 MATERIALS AND METHODS      345 
II.3 RESULTS AND DISCUSSION      346 
II.4 CONCLUSION        347 
APPENDIX III: ROLE TO LAMIN A/C IN TUMOR CELL  
RESISTANCE TO FLUID SHEAR STRESS     357 
II.1 INTRODUCTION        358 
II.2 MATERIALS AND METHODS      359 
II.3 RESULTS AND DISCUSSION      360 
II.4 CONCLUSION        362 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
LIST OF FIGURES 
 
Figure 1.1: Cancer cell exposure to shear stress in the tumor and vascular 
microenvironment ……………………………………………………………... 50 
Figure 1.2: Computational models of cells exposed to blood and                     
interstitial flows………………………………………………………………... 51 
Figure 1.3: Fluid shear stress sensitizes cancer cells to the apoptosis-inducing      
ligand TRAIL…………………………………………………………………... 52 
Figure 1.4: Experimental techniques to study cancer cell mechanotransduction….. 53 
Figure 1.5: Advances in computational modeling reveal                
mechanotransduction phenomena…………………………………………….... 54 
Figure 1.6: Tumor cell and leukocyte trafficking similarities……………………....55 
Figure 1.7: Approaches to functionalize leukocytes with drug delivery              
vehicles (DDVs)………………………….……………………….……………. 57 
Figure 1.8: Cellular “Trojan horse” mechanism to deliver nanoparticle-based 
therapeutics to solid tumors……………………………………………............. 58 
Figure 1.9: Functionalized natural killer (NK) cells to target lymph nodes 
micrometastases………………………………...…………………………........ 59 
Figure 1.10: Unnatural killer cells to target and kill cancer cells in flowing          
human blood in vitro and in the peripheral circulation of mice in vivo………... 60 
Figure 2.1: Loss of neutrophil L-selectin under various shear rates……………….. 89 
Figure 2.2: Fluid shear stress increases neutrophil resistance to L-selectin        
shedding and αMβ2 integrin activation………………………………................. 90 
Figure 2.3: Neutrophil shear-induced resistance to activation at 23°C and 37°C…. 92 
Figure 2.4: Increasing fluid shear stress reduces fMLP-induced L-selectin       
shedding and αMβ2 integrin activation of neutrophils………………......……....93 
 xvii 
Figure 2.5: Neutrophil resistance to activation increases with increasing fluid        
shear stress duration……………………………………………………………. 94 
Figure 2.6: Neutrophils develop resistance to fMLP-induced L-selectin shedding     
and αMβ2 integrin activation with increasing shear stress magnitude and          
shear stress duration…………………………………………………….……… 95 
Figure 2.7: Fluid shear stress alters fMLP-induced neutrophil morphology………. 96 
Figure 2.8: Fluid shear stress induces a loss of FPR surface expression……..……. 97 
Figure 2.9: Protease inhibition does not affect FPR surface expression upon    
exposure to fluid shear stress…………………………………………………... 98 
Figure 2.10: Fluid shear stress induces FPR internalization in neutrophils………... 99 
Figure 2.11: Changes in FPR surface expression contribute to the neutrophil  
resistance to activation…………………………………………………………. 100 
Figure 3.1: Fluid shear stress exposure and platelet activating factor increase 
neutrophil activation…………………………………………………………… 124 
Figure 3.2: PAF activation of neutrophils is fluid shear stress magnitude        
dependent………………………………………………………………………. 126 
Figure 3.3: Increased neutrophil PAF activation is fluid shear stress time-
dependent………………………………………………………………………. 128 
Figure 3.4: Fluid shear stress increases neutrophil morphological changes in the 
presence of PAF………………………………………………………………... 130 
Figure 3.5: Fluid shear stress does not alter PAF receptor expression…………...... 131 
Figure 3.6: Shear and PAF-induced L-selectin shedding is ADAM-17 and p38      
MAP kinase-dependent………………………………………………………… 133 
Figure 3.7: Comparison of fluid shear stress effects on neutrophil activation              
via PAF and fMLP…………………………………………………………....... 135 
Figure 4.1: Fluid shear stress sensitizes cancer cells to TRAIL…………………… 159 
 xviii 
Figure 4.2: Brightfield microscopy images of untreated COLO 205 cells exposed       
to static conditions and 2.0 dyn/cm2 of fluid shear stress in the absence and 
presence of TRAIL…………………………………………………………….. 160 
Figure 4.3: Percent necrotic COLO 205 cells and PC-3 cells after treatment with 
TRAIL under static and shear stress conditions………………………………...162 
Figure 4.4: Increased fluid shear stress sensitizes cancer cells to TRAIL…………. 163 
Figure 4.5: Shear-induced sensitization to TRAIL increases with increasing           
fluid shear stress exposure time………………………………………………... 164 
Figure 4.6: Cancer cells develop sensitization to TRAIL-mediated apoptosis with 
increasing shear stress magnitude and exposure time………………………...... 165 
Figure 4.7: Fluid shear stress does not sensitize cancer cells to doxorubicin…….... 166 
Figure 4.8: Fluid shear stress sensitization to TRAIL-mediated apoptosis is      
caspase-dependent……………………………………………………………… 168 
Figure 4.9: Fluid shear stress does not alter death receptor surface expression…… 170 
Figure 5.1: Schematic of E-selectin-targeted PEGylated liposome synthesis…....... 192 
Figure 5.2: E-selectin conjugated liposome adhesion to the cancer cell surface…... 194 
Figure 5.3: Doxorubicin encapsulation and leakage from liposomes……………… 195 
Figure 5.4: Liposome uptake and cytotoxic potential on cancer cells under static 
conditions………………………………………………………………………. 196 
Figure 5.5: E-selectin conjugated liposomal doxorubicin internalization               
within cancer cells……………………………………………………………… 197 
Figure 5.6: Growth curves of cancer cells after treatment with E-selectin      
conjugated liposomal doxorubicin………………………………………..……. 198 
Figure 5.7: Cancer cell morphology after treatment with E-selectin conjugated 
liposomal doxorubicin…………………………………………………………. 199 
 
 xix 
Figure 5.8: E-selectin conjugated liposomal doxorubicin immobilization                     
to microtube surface……………………………………………………..……... 200 
Figure 5.9: Viability and recovery of flowing cancer cells, erythrocytes, and 
leukocytes after exposed to immobilized E-selectin functionalized            
liposomal doxorubicin……………………………………………………......... 201 
Figure 5.10: Confocal micrographs of E-selectin functionalized liposomal  
doxorubicin adhered to the surface of KG-1a and COLO 205 cells after     
exposure to shear flow…………………………………………………………. 202 
Figure 5.11: Viability of KG-1a and COLO 205 cells at day 4 following         
treatment with targeted L-DXR under shear in a dilute suspension……….…... 203 
Figure 5.12: Schematic of halloysite nanotube (HNT)-coated microtube device       
with immobilized targeted L-DXR to enhance capture and killing of               
tumor cells under  flow………………………………………………………… 204 
Figure 5.13: Comparison of smooth and HNT-coated tube with immobilized              
E-selectin conjugated liposomal doxorubicin on cancer cell viability after 
perfusion through microtubes………………………………………………….. 205 
Figure 5.14: E-selectin functionalized liposomal doxorubicin adhesion to             
cancer cells after exposure to HNT-coated microtubes………………………... 206 
Figure 6.1: E-selectin targeted liposomes adhesively bind and deliver                
doxorubicin to MCF7 breast cancer cells……………………………………… 225 
Figure 6.2: HNT-liposome coated surfaces enhance MCF7 and COLO 205              
cell capture……………………………………………………………………... 227 
Figure 6.3: HNT-liposome coated surfaces reduce and weaken                       
neutrophil adhesion……………………………..……………………………… 228 
Figure 6.4: E-selectin targeted liposomes immobilize on both smooth and             
HNT-coated microtube surfaces……………………………………………….. 229 
 xx 
Figure 6.5: HNT-liposome surfaces simultaneously enhance MCF7 and              
COLO 205 cell adhesion and reduce neutrophil adhesion from a               
combined suspension of cancer cells and neutrophils…………………………. 230 
Figure 6.6: HNT-liposome coated surfaces successfully deliver doxorubicin               
to cancer cells from a combined solution of cancer cells and neutrophils……... 232 
Figure 7.1: ES/TRAIL liposomes adhesively interact with and kill cancer cells     
under uniform shear flow………………………………………………………. 260 
Figure 7.2: Incorporation of Ni-NTA conjugated lipids on liposomes            
maximizes protein conjugation to the liposome surface…………………...…... 262 
Figure 7.3: ES/TRAIL liposomes are somewhat effective in targeting and            
killing COLO 205 cells under static conditions………………………………... 265 
Figure 7.4: ES/TRAIL liposomes adhesively interact with cancer cells…………... 266 
Figure 7.5: ES/TRAIL liposomes adhere to multiple leukocyte subpopulations       
after exposure to shear flow in whole blood…………………………………… 267 
Figure 7.6: Leukocyte functionalization with ES/TRAIL does not induce       
significant leukocyte death…………………………………………………….. 269 
Figure 7.7: Leukocyte functionalization with ES/TRAIL does not induce       
significant endothelial cell death……………………………………………..... 270 
Figure 7.8: ES/TRAIL liposome therapeutic effects are enhanced in human          
blood under flow in vitro………………………………………………………. 272 
Figure 7.9: ES/TRAIL liposomes functionalize leukocytes under shear flow               
in vitro to target and kill cancer cells…………………………………………... 274 
Figure 7.10: Low toxicity of blood plasma after treatment with ES/TRAIL   
liposomes………………………………………………………………………. 276 
Figure 7.11: ES/TRAIL functionalized leukocytes target and kill cancer cells              
in the circulation of mice in vivo……………………………………………….. 277 
 xxi 
Figure 7.12: Decreased number and increased apoptosis in COLO 205 cells         
lodged in mouse lung after treatment with ES/TRAIL liposomes……………... 279 
Figure 8.1: Schematic to fabricate Jell-O chips using soft lithography……………. 294 
Figure 8.2: Materials needed for outreach activity……………………………….....295 
Figure 8.3: Perfusion of fluid through a Jell-O milli-fluidic chip………………….. 300 
Figure 9.1: Bioluminescent imaging (BLI) of a spontaneous metastasis model            
of prostate cancer………………………………………………………………. 316 
Figure 9.2: Circulating tumor cells (CTCs) isolated from a spontaneous         
metastasis mouse model of prostate cancer……………………………………. 317 
Figure 9.3: Formation of metastases in mouse lung in a spontaneous metastasis   
model of prostate cancer……………………………………………………….. 318 
Figure 9.4: Unnatural killer cells induce DU145 cancer cell death in human          
blood under flow in vitro………………………………………………………. 319 
Figure I.1: Schematics of the endothelial cell and tumor cell glycocalyx………..... 340 
Figure I.2: Glycocalyx effects on circulating tumor cell (CTC) adhesion in the 
microvasculature...……………………………………………………………... 341 
Figure I.3: E-selectin mediated delivery of therapeutics to circulating tumor           
cells (CTCs) in the bloodstream……………………………………………….. 342 
Figure I.4: Glycocalyx as a barrier to therapeutic delivery………………………... 343 
Figure II.1: Representative flow cytometry plots of fMLP-induced neutrophil 
activation after exposure to millisecond fluid shear stress pulses…………........349 
Figure II.2: Millisecond pulses of fluid shear stress suppress fMLP-induced  
 neutrophil activation...…......................................................................................350 
Figure II.3: Suppression of fMLP-induced neutrophil activation is fluid shear  
 stress pulse-dependent ………………………………………………………….351 
 
 xxii 
Figure II.4: Dependence of shear stress magnitude and shear stress exposure  
 time on fmlp-induced neutrophil activation …………………………….….…...352 
Figure II.5: Shear stress exposure time has a larger effect on neutrophil  
 activation suppression than shear stress magnitude ………………………..…...353 
Figure II.6: Effect of millisecond fluid shear stress pulse pre-exposure on  
 TNF-alpha induced neutrophil activation…..……………………………....…...354 
Figure II.7: Representative neutrophil thresholding for shape factor calculations.....355 
Figure II.8: Shape factor calculations of neutrophils after millisecond shear stress 
pulse exposure and fMLP treatment ……………………………………….…...356 
Figure III.1: Tumor cells resist fluid shear stress-induced cell death compared to 
 non-malignant epithelial cells………..……………………………….………....364 
Figure III.2: Exposure to FSS induces both apoptotic and necrotic cell death in  
 MDA-MB-231 and MCF10A cells.…….…………………………….………....365 
Figure III.3: Decreased apoptosis and necrosis in malignant MDA-MB-231 cells 
compared to non-malignant MCF10A cells……………………………………..367 
Figure III.4: Lamin A/C deficiency reduces tumor cell resistance to fluid  
 shear stress………………………………………………………………………369 
Figure III.5: Fluid shear stress-induced cell death in lamin A/C-deficient  
 MDA-MB-231 tumor cells is fluid shear stress dose-dependent……………..…370 
Figure III.6: Exposure to FSS induces both apoptotic and necrotic cell death in  
 lamin A/C-deficient MDA-MB-231 cells……………………………………….372 
Figure III.7: Increased apoptosis and necrosis in lamin A/C-deficient  
 MDA-MB-231 tumor cells………………………………………………..……..374 
 
 
 
 xxiii 
LIST OF TABLES 
 
Table 5.1: Hydrodynamic radius and zeta potential of liposome formulations……. 193 
Table 7.1: Weight ratios of liposome formulations………………………………... 264 
Table 8.1: Data for calculation of Reynolds number……………………………......296 
Table 8.2: Reynolds numbers that indicate various flow conditions……………......297 
Table 8.3: Number of microspheres adhered to Jell-O devices…………………......298 
Table 8.4: Rubric to assess students during outreach activity……..……………......299
1 
CHAPTER 1: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
1.1 EXPERIMENTAL AND COMPUTATIONAL MODELS OF 
CIRCULATING CELL RESPONSE TO FLUID SHEAR STRESS 
 
*This section is adapted from the following publication: M.J. Mitchell and M.R. King. 
Frontiers in Oncology. 3(44): 1-11, 2013. 
 
To initiate the metastatic spread of cancer through the bloodstream, tumor cells 
must transit through microenvironments of dramatically varying physical forces. 
Cancer cells a must be able to migrate through the stroma, intravasate through the 
endothelium into blood or lymphatic vessels, flow within the vessels and subsequently 
extravasate through the endothelium, and migrate and colonize in tissue at a secondary 
site [1-3]. In soft tissues, cancer cells are exposed to mechanical forces due to fluid 
shear stress, hydrostatic pressure, and tension and compression forces [4,5]. During 
intravasation and extravasation, cells undergo dramatic elastic deformations to 
transmigrate through endothelial cell-cell junctions [6,7]. Once in the circulation, 
tumor cells must be able to withstand immunological stress, blood cell collisions, and 
hemodynamic shear forces, while also utilizing flow to adhere to the endothelial wall 
and subsequently extravasate to form a secondary tumor [8]. Across all of these steps, 
a deeper understanding is needed of how biophysical forces contribute to biochemical 
changes in cancer cells, which can reveal novel strategies in the treatment of 
metastasis. 
Fluid shear stress is one of the prominent forces that cells are exposed to, and its 
effects on blood cells, endothelial cells, smooth muscle cells, and others have been 
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extensively studied [9-11]. However, much less is known about fluid shear stress 
effects on tumor cells. Cancer cells experience two main types of fluid shear stress: 
stresses generated by blood flow in the vascular microenvironment, and those 
generated by interstitial flows in the tumor microenvironment [12,13]. Stresses 
generated by interstitial and blood flows could contribute to the metastatic process by 
enhancing tumor cell invasion and CTC adhesion to blood vessels, respectively. 
However, it is difficult to predict tumor cell behavior to such forces; it is difficult to 
experimentally measure such flows in the tumor microenvironment [14], and there is a 
general lack of data on force-dependent CTC receptor-ligand interactions with the 
endothelium [15]. Sophisticated experimental techniques coupled with computational 
modeling are needed to predict cell behavior upon exposure to varying complex 
physical forces. 
Here, I provide examples of both experimental and computational methods to 
model and predict how cancer cells respond to fluid shear forces. I begin by describing 
the fluid shear forces that cancer cells are exposed to in both the tumor and vascular 
microenvironments, generated mainly by blood and interstitial flows. An overview is 
provided on computational modeling to estimate the forces exerted on cells in blood 
and tissues, along with simulations to predict cell behavior under such flows. I then 
describe recent cancer cell mechanotransduction phenomena upon exposure to fluid 
shear stress, such as altering cancer cell resistance to fluid shear stress, sensitivity to 
apoptosis-inducing ligands, and invasive and migratory potential. I conclude with 
current computational models that aim to integrate fluid shear forces with chemical 
signaling, such as the effect of the glycocalyx on transmitting physical forces and 
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inducing mechanotransduction in cancer cells, as well as the integration of signal 
transduction networks into adhesive dynamics simulations to predict cell adhesion to 
the microvasculature. 
 
1.1.1 FLUID SHEAR STRESS EXPOSURE IN THE TUMOR 
MICROENVIRONMENT 
 
Cancer cells in the tumor microenvironment are exposed to multiple physical 
forces including fluid shear stress, hydrostatic pressure, tension, and compression, 
which have been treated in detail previously [5,6,12]. Here, cancer cell exposure to 
physical forces generated by interstitial flows will be discussed briefly.  
Interstitial flow is the slow movement of fluid around cells and through the pores 
of the extracellular matrix (ECM) that comprise the interstitium (Figure 1.1A). One of 
the main functions of interstitial flow is lymphatic drainage, which returns plasma 
from leaky capillaries back to the bloodstream. Drainage occurs due to Starling’s 
forces, which are osmotic and hydrostatic pressure gradients between blood vessels, 
interstitium, and the lymphatics [16]. The composition of interstitial fluid can vary 
depending on the location in the body, but in soft tissues is generally similar to the 
blood plasma that leaks from capillaries, and contains approximately 40% of the 
protein concentration of plasma [17]. The velocities of interstitial flows are believed to 
range from 0.1-1.0 µm/s in normal tissues [18,19]. Cell surface shear stresses are 
believed to be on the order of 0.1 dyn/cm2 [20,21]. 
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Interstitial flows can be elevated significantly in the tumor microenvironment, and 
could play a crucial role in tumor progression. Chary et al. utilized fluorescence 
recovery after photobleaching (FRAP) to measure interstitial fluid velocities of bovine 
serum albumin in normal and neoplastic tissues [19]. Harrell et al. utilized live 
imaging of tumor-bearing mice to measure downstream lymph flow via injection of 
fluorescent nanoparticles. Measurements were performed in both normal and 
neoplastic tissues; all tumor-bearing mice in the study showed increases in lymph 
flow, compared to control mice with no tumors [22]. 
Elevated interstitial flows in the tumor microenvironment are likely due to 
increases in tumor interstitial fluid pressure (IFP). Boucher et al. implanted colon 
adenocarcinoma cells into mice, tracked the development of the tumor vasculature 
using intravital microscopy, and measured the IFP using micropipettes and a servo-
null system [23]. IFP measurements increased significantly as the vasculature 
developed, demonstrating that tumor interstitial hypertension is associated with tumor 
angiogenesis [24]. IFP is elevated in a uniform manner throughout tumors, and drops 
significantly at the tumor periphery [25]. Thus, IFP gradients facilitate fluid flow 
outward from tumors, presenting a mass transport barrier for the delivery of 
chemotherapeutics [26,27].  
Increased IFP also effects tumor biology, as it applies increased physical force to 
the ECM and alters interstitial flows that the tumor and surrounding cells are exposed 
to. Nearby lymphatic vessels respond to elevated interstitial flow by upregulating 
chemokine CCL21 expression, along with cell adhesion molecules E-selectin and 
ICAM-1 [28]. Secretion of CCL21 directs tumor cells toward lymphatic vessels [29], 
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while ICAM-1 and E-selectin upregulation enhances cell transmigration into 
lymphatic vessels [28,30]. Lymph nodes can also be affected, as increased interstitial 
flows aid in lymph node architecture remodeling to colonize tumor cells, as well as 
protect the tumor from an immune response [14].  
Fibroblasts, which deposit, turn over, and remodel ECM to maintain connective 
tissue homeostasis, may aid in tumor progression due to elevated interstitial flows. 
Elevated interstitial flows can upregulate transforming growth factor beta-1 (TGF-β1) 
expression [31-34], which can induce a tumor-associated fibroblast phenotype 
characterized by enhanced contractility and increased secretion of cytokines, 
angiogenic growth factors, and matrix metalloproteinase (MMPs) [35-38]. Recently, 
Shieh et al. demonstrated that interstitial flows can enhance tumor cell invasion when 
cocultured with dermal fibroblasts in a 3D collagen matrix [39]. Fibroblast invasion 
was enhanced due to increased expression of TGF-β1 and MMPs, while it appeared 
that tumor cell invasion was enhanced due to fibroblast-dependent remodeling of the 
ECM [39]. 
 
1.1.2 FLUID SHEAR STRESS EXPOSURE IN THE VASCULAR 
MICROENVIRONMENT 
 
To enter the vascular microenvironment, cancer cells penetrate surrounding tissue 
and enter nearby blood and lymphatic vessels in a process called intravasation. The 
underlying mechanisms that govern intravasation are not well understood; it is still in 
question whether intravasation is an active or passive process [40], and whether tumor 
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cells enter the circulation via endothelial cell-cell junctions or directly through 
endothelial cells themselves [41]. Regardless of their mechanism of entry, cancer cells 
are exposed to a new set of conditions once in the vascular microenvironment, 
including immunological stress, collisions with normal blood cells, and hemodynamic 
shear forces, all of which can affect their survival and proliferation. 
Cancer cells are primarily exposed to erythrocytes, leukocytes, and platelets upon 
entering the bloodstream, as studies have shown that the concentration of cancer cells 
in the blood of patients is on the order of one in a million leukocytes [42], or one in a 
billion normal blood cells [43]. Exposure to such cells can lead to immunological 
stresses and blood cell collisions that can affect cancer cell viability [6], although there 
is evidence that the association of platelets with cancer cells in the bloodstream can 
promote tumor metastasis [44,45].  
Cancer cells are also exposed to hemodynamic shear forces in the bloodstream 
(Figure 1.1B), which range from 1.0-4.0 dyn/cm2 in the venous circulation and 4.0-
30.0 dyn/cm2 in arterial circulation [46]. Shear rates can range from approximately 
160 s-1 in veins to 900 s-1 in arteries. Such shear stresses and rates can affect cancer 
cell viability and thus the chances of metastasis. For example, B16 melanoma cell 
exposure to fluid shear stress in a cone-and-plate viscometer at shear rates greater than 
300 s-1 induced a significant loss of cell viability [47].  
In contrast, fluid shear stress is an essential component of cancer metastasis, as it 
is critical for cancer cell adhesion to the endothelial cell wall and subsequent 
extravasation into tissues. A variety of cancer cell lines are known to express 
sialylated carbohydrate ligands, which adhesively interact with selectin proteins on the 
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inflamed microvasculature [48-50]. Thus cancer cells are believed to undergo an 
adhesion cascade similar to leukocytes, which consists of a sequence of steps 
involving tethering, rolling, and firm adhesion to the endothelium [51,52]. Multiple 
studies have documented that a variety of tumor cell lines bind to E-selectin proteins 
under physiological shear stresses of the post-capillary venules [53,54]. 
Much less is known about fluid shear stresses that cancer cells could be exposed to 
in lymphatic vessels. Lymphatic vessels have been stained with fluorescein 
isothiocyanate (FITC)-labeled macromolecules to measure lymphatic flow in single 
lymphatic capillaries of humans in vivo using intravital capillary microscopy [55]. The 
recorded median linear velocity in lymphatic capillaries was 9.7 µm/s, and shear 
stresses in lymph node sinuses have been estimated to be 10-fold lower than 
hematogenous shear stresses [56]. Despite the dramatic decrease in shear stress levels, 
parallel plate flow chamber studies have shown that human head and neck squamous 
cell cancer cells can bind to lymphocyte L-selectin at lymphatic shear stress levels of 
0.07-0.08 dyn/cm2 [56].  
 
1.1.3 COMPUTATIONAL METHODS TO MODEL INTERSTITIAL FLOWS 
 
Interstitial flow mechanics were initially described by French hydraulics engineer 
Henry Darcy, who studied the flow of water through sandbeds as a means of providing 
filtered drinking water to his city.  
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During his studies, he developed the formula known as Darcy’s law:  
 
! = !−!∇!! , 
 
where !  is the permeability of the medium, !∇P  is the pressure gradient vector, !!  is 
the viscosity of the fluid, and u is the averaged velocity through the bulk. Darcy’s law 
works well when the average velocity or mass flow rate needs to be determined, but is 
first order with respect to velocity. To account for interstitial flows between 
boundaries, Brinkman developed a second order term, taking into account no-slip 
boundary conditions adjacent to bounding walls (Figure 1.2A) [57]. The Brinkman 
equation is described as: 
 ∇! = − !!! ! + !∇!!.!!! 
 
Permeability measurements have been performed for a variety of tissues in vitro, in 
vivo, and ex vivo, including muscle [58], dermis [59], cartilage [60], tumors [61,62], 
and fibrin and collagen gels [63,64], making the Darcy and Brinkman equations useful 
for both experimental measurements of interstitial flows and computational models of 
cells exposed to such flows. 
 Initial models of interstitial flows exerted on cells were developed for tissues 
including smooth muscle, cartilage, and bone [65-67]. For example, Wang and Tarbell 
modeled the tunica media of an artery as a periodic array of cylindrical, impermeable 
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smooth muscle cells (SMCs) embedded in a matrix consisting of collagen and 
proteoglycans, and used Brinkman’s theory to model interstitial flow across the tissue 
[68]. The model was able to estimate the effective hydraulic permeability of the tissue 
and shear stresses exerted on SMCs, which were estimated to be on the order of 1.0 
dyn/cm2 despite exposure to low interstitial flows [68]. In an early model describing 
the mechanics of interstitial-lymphatic transport, Swartz et al. developed a theoretical 
and experimental model demonstrating how interstitial flow is dependent on hydraulic 
conductivity, elasticity, and lymphatic conductance. They then utilized this model to 
examine fluid balance in normal and chronically swollen (edematous conditions) 
mouse tails, in which they found that remodeling of the matrix dampened and 
eventually stagnated fluid movement in the case of edema [69]. 
 
1.1.4 COMPUTATIONAL METHODS TO MODEL CELL BEHAVIOR IN 
THE CIRCULATION 
 
A variety of computational methods have been developed to model cell behavior 
in the vascular microenvironment, including adhesive dynamics (AD), which has been 
utilized to simulate cell adhesion to the endothelial cell surface under flow [70,71]. 
The motivation of such simulations is to predict how adhesiveness quantitatively 
depends on factors such as shear rate and viscosity, which can reveal adhesion 
phenomena that might not necessarily follow intuition. Adhesive dynamics is a 
mechanically rigorous cell adhesion simulation that models individual molecular 
bonds as compliant springs. In the simulation, the cell can be modeled as a rigid 
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spherical particle covered with a random distribution of adhesion molecules (Figure 
1.2B). The endothelial cell wall can be modeled as a surface covered with counter-
receptor molecules of random distribution. Bonds randomly form between adhesion 
molecules of the cell and counter-receptors on the wall; these bonds can then break 
contingent on the appropriate kinetics, which depend on the instantaneous force 
loading on the spring endpoints. The rates of bond formation and rupture can be 
calculated using the Bell model for kinetics of single biomolecular bond failure 
[72,73]: 
 
!! = !!!exp(!!!!!!) 
 
where k! is the rate of dissociation, !k!! is the unstressed off-rate, !F  is the force on the 
bond, r!is the reactive compliance, !T  is the temperature, and k! is the Boltzmann 
constant. The rate of bond formation follows from the Boltzmann distribution of 
affinity, while also incorporating the effects of relative motion between the cell and 
surface [74]. To solve the algorithm, unbound receptors in the defined contact area are 
first tested for formation against the probability: 
 !! = 1− exp(−!!∆!) 
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where P! is the probability of bond formation, and ! is time. Next, bound receptors are 
tested for breakage against the probability: 
 !! = 1− exp(−!!∆!) 
 
where P! is the probability of bond rupture. External forces and torques on the cell are 
then summed, and a mobility calculation determines the motion of the cell. Cell and 
bond positions are updated based on the kinematics of cell motion. Torques exerted by 
fluid flow and hydrodynamic forces cause the adherent cell to slowly roll forward on a 
reactive surface. The motion of fluid is governed by the Stokes equation: 
 !∇!! = ∇!,!!!∇ ⋅ ! = 0, 
 
where !u  is the velocity, !!  is the viscosity of the fluid, and !P  is the pressure. No slip 
boundary conditions are applied at the cell surface and the planar wall. 
While adhesive dynamics have not yet been used to model cancer cell adhesion, 
many simulations have been performed using leukocytes, which can be a close parallel 
to a circulating tumor cell that has undergone the epithelial-mesenchymal transition 
(EMT). Chang et al. utilized adhesive dynamics to develop a state diagram for 
leukocyte adhesion under flow [75]. In the diagram, observed adhesive behaviors 
(rolling, firm adhesion, or no adhesion) were plotted at given dissociation rates and 
bond interaction lengths, which ranged several orders of magnitude. Caputo et al. 
incorporated deformable microvilli with clustered adhesion molecules onto the surface 
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of the simulated leukocyte, and found that the deformability of the microvilli can 
affect the cell’s ability to roll on a surface [76]. King et al. modeled the effect of cell-
cell hydrodynamic interactions on the dynamics of leukocyte adhesion using 
Multiparticle Adhesive Dynamics (MAD), which revealed a mechanism for secondary 
hydrodynamic recruitment of leukocytes to the blood vessel wall, independent of 
leukocyte-leukocyte interactions [77,78].  
Critical parameters of AD simulations are the kinetics of selectin-carbohydrate 
bonds, as force-dependent dissociation rates dictate the rolling adhesion of leukocytes. 
Numerous studies have investigated the kinetics for leukocyte selectin ligands using 
experimental techniques flow chamber tethering experiments, atomic force 
microscopy, and dynamic force spectroscopy [79], However, such kinetics for newly 
identified selectin ligands expressed by metastatic tumor cells, which appear distinct 
from those found on the surface of leukocytes [80,81], have not yet been well 
characterized. Future experimental studies measuring bond dissociation kinetics for 
selectins and CTC selectin ligands will enable the development of more predictive 
computational models of cancer cell adhesion to microvasculature. 
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1.1.5 CANCER CELL MECHANOTRANSDUCTION PHENOMENA IN 
EXPERIMENTS 
 
Fluid shear stress alters cancer cell response to apoptosis-inducing ligands 
 
The targeting and treatment of CTCs within the circulation is currently being 
investigated as an approach to prevent metastatic spread. For example, microfluidic 
devices coated with E-selectin conjugated liposomal doxorubicin have been shown to 
capture cancer cells from flow, deliver doxorubicin into the cell, and induce cell death 
[82,83]. Similarly, microfluidic devices immobilized with E-selectin and tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) have been shown to 
capture and kill cancer cells [84] while causing minimal effects in human leukocytes 
[85]. However, little is known about how fluid shear stress exposure can affect the 
cancer cell response to drug treatments. 
Our recent study examined how colorectal adenocarcinoma COLO 205 and 
prostate adenocarcinoma PC-3 cancer cell exposure to physiologically relevant fluid 
shear stresses in a cone-and-plate viscometer altered their response to TRAIL (Figure 
1.3) [86]. Experiments were devised in such a way that fluid shear stress alone had 
negligible effects on cancer cell death. Cancer cells were treated with both TRAIL, 
which can bind to death receptors DR4 and DR5 on the cancer cell surface to initiate 
apoptosis [87], and doxorubicin, which induces cell death via inhibition of topo-
isomerase II and DNA intercalation [88,89]. Interestingly, treatment of both COLO 
205 and PC-3 cancer cell lines with TRAIL followed by exposure to 2.0 dyn/cm2 of 
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fluid shear stress significantly increased the number of apoptotic cells, compared to 
TRAIL-treated cancer cells exposed to static conditions. The sensitization effect was 
both fluid shear stress dose- and time-dependent, as the number of apoptotic cells 
increased with over a range of shear stress magnitudes (0.05-2.0 dyn/cm2) and shear 
stress exposure times (1-120 min). However, such sensitization was not evident in 
doxorubicin treatment, as the percentage of apoptotic cells remained nearly identical 
in doxorubicin-treated samples exposed to either fluid shear stress or static conditions. 
The results indicated that such sensitization could be receptor-mediated apoptosis 
specific. 
It is possible that death receptors on the cancer cell surface can sense and respond 
to fluid shear forces. The idea of circulating cells expressing mechanosensitive 
receptors has recently been investigated in leukocytes [90,91], where it is believed that 
G-protein coupled receptors can sense fluid shear stress and alter neutrophil adhesion 
to the microvasculature. However, little is known about the effects of fluid shear stress 
on CTC surface receptors. Insight into the mechanistic basis of such processes could 
reveal new strategies for treating cancer cells in the circulation, and reducing the 
likelihood of metastasis. 
 
Cancer cell resistance to fluid shear stress 
 
Recently, a microfluidic protocol was developed to assess cancer cell resistance to 
fluid shear stress [92]. In the protocol, dilute cancer cell suspensions were drawn up 
into a syringe, which is then loaded into an automatic syringe pump (Figure 1.4A). 
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Cancer cell suspensions were exposed to brief, millisecond pulses of high fluid shear 
stress as they were expelled from the syringe pump, and subsequently analyzed for 
cell viability using bioluminescent imaging. The maximum fluid shear stress that 
cancer cells were briefly exposed to in this experiment reached 6400 dyn/cm2. Note 
that CTCs are momentarily exposed to shear stresses as high as 3000 dyn/cm2 at 
vessel bifurcations, in the heart, and near the walls of large blood vessels [93,94]. 
While cancer cell viability decreased after repeated millisecond pulse exposures to 
high fluid shear stress, the study revealed that cancer cells of epithelial origin were 
surprisingly resistant to fluid shear stress, in comparison to non-transformed epithelial 
cells. Resistance to fluid shear stress was shown to be dependent on several 
oncogenes, as myc- and ras-transformed cell lines showed an increase in fluid shear 
stress resistance. The resistance response required extracellular calcium and actin 
polymerization, as the absence of calcium or treatment with EGTA, cytochalasin D, or 
ROCK inhibitor Y27632 all reduced cancer cell viability upon fluid shear stress 
exposure. In particular, extracellular calcium is important for cellular repair 
mechanisms based on an extracellular calcium-dependent membrane resealing process 
[95]. 
 
Fluid shear stress regulates cancer cell invasive potential 
 
Prior work has shown that the chemokine gradients generated by interstitial flows 
can enhance tumor cell migration [96], however it is not well understood whether fluid 
shear stress can regulate intrinsic properties of cancer cells, thus altering their invasive 
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potential. Recent work by Qazi et al. detailed a Darcy flow apparatus for the 
application of fluid shear stress to a 3D collagen gel embedded with glioma cells, 
coupled with a modified Boyden chamber invasion assay [97]. In the apparatus, a 
double reservoir system applied hydrostatic pressure, which drove media throughout 
the 3D collagen gel and exerted shear stress on the glioma cell membranes (Figure 
1.4B). Cancer cells were exposed to fluid shear stresses ranging from 0.1-0.6 dyn/cm2. 
The media filtrate from the gel was collected in a separate reservoir, and the media 
collected was used to calculate flow rates, velocities, and shear stresses. Collagen gels 
were removed at the end of the flow period, and placed within modified Boyden 
chambers containing TGF-α to initiate invasion assays.  
Fluid shear stress significantly reduced U87 and CNS-1 glioma cell migration by 
as much as 92% and 58% respectively, when compared to controls. Migration 
suppression was not due to flow-induced chemokine gradients, however, as cells were 
exposed to fluid shear stress followed by exposure to TGF-α in static Boyden 
chambers. Invasion was dependent on matrix metalloproteinases (MMP) MMP-1 and 
MMP-2, as MMP1 and MMP-2 gene expression was significantly downregulated in 
cancer cells upon exposure to 0.55 dyn cm-2 fluid shear stress. Previous studies have 
shown that fluid shear stress can affect MMP expression and activity in non-tumor cell 
types such as fibroblasts, chondrocytes, and smooth muscles cells [98-100], however 
this was one of first studies revealing that fluid shear stress-induced 
mechanotransduction is involved in interstitial flow-induced cancer cell motility. 
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Interstitial flow induces tumor cell focal adhesion kinase (FAK) activation 
 
A recent study investigated two competing mechanisms which can alter tumor cell 
migration upon exposure to interstitial flow: an autologous chemotaxis-based 
mechanism which distributes autocrine chemokine via convection to create a 
chemokine gradient, and a mechanism whereby interstitial flow activates focal 
adhesion kinase (FAK) and modulates forces critical for tumor cell migration 
[101,102]. Polacheck et al. developed a microfluidic cell culture system to investigate 
the effects of interstitial flow on the directional bias and dynamics of tumor cell 
migration in a 3D matrix [103]. Utilizing two channels separated by a region in which 
tumor cells were suspended in a 3D collagen gel, a pressure gradient was applied 
across the gel to generate consistent interstitial flow velocities ranging from 0.3 to 3.0 
µm/s, representative of a range of values measured in vivo [18,104]. Confocal 
reflective microscopy was used to track cell migration under flow, and it was found 
that interstitial flow and cell seeding density can both influence the direction of tumor 
cell migration.  
Upon exposure to interstitial flow at low seeding densities, MDA-MB-321 
metastatic breast cancer cells migrated in the downstream direction, or “with the 
flow”. However, cancer cells exposed to interstitial flow at high seeding densities 
migrated upstream, or “against the flow”. Treatment with CCR7 blocking antibodies, 
to block the binding of secreted ligand CCL21 needed to initiate autologous 
chemotaxis, caused cells to shift their migration directionality and migrated upstream 
upon exposure to flow. Cells that migrated in the opposite direction of flow displayed 
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increased phosphorylation at Tyr-397 in FAK, which plays a role in Src kinase 
activation and focal adhesion formation [105,106]. Upon blockage of Src kinase 
activity, upstream tumor cell migration decreased and displayed random cell 
migration. 
 
1.1.6 CURRENT ADVANCES IN MODELING LEUKOCYTE AND TUMOR 
CELL MECHANOTRANSDUCTION PHENOMENA 
 
Modeling glycocalyx effects on interstitial fluid shear stress transmission to cancer 
cells 
 
The glycocalyx is a layer of proteoglycans and glycoproteins that covers 
eukaryotic cells, which can serve as a mechanosensor of fluid shear stress in 
endothelial and smooth muscle cells [107,108]. Tumor cells also possess a glycocalyx 
[109], however its effects as a mechansensor have not been previously investigated. It 
has been hypothesized that fluid shear stress generated by interstitial flows are too low 
to induce mechanotransduction.  
Tarbell et al. recently developed a computational model to estimate the interstitial 
flow-generated fluid and solid stresses on the surface of a glycocalyx-covered cell 
embedded in ECM (Figure 1.5A). Previously estimated parameters such as the Darcy 
permeability of the ECM, tumor cell glycocalyx thickness, and interstitial fluid flow 
velocity were incorporated into the model to calculate the fluid and solid stresses on 
the cell surface. Brinkman equations were used to describe interstitial fluid flow 
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through pores of both the ECM and glycocalyx. A previously described model [110] 
was used to calculate mechanical equilibrium of forces in the direction of flow to 
calculate the solid stresses transmitted via the glycocalyx. While fluid stresses exerted 
on the tumor cell surface were estimated to be quite low (less than 0.1 dyn/cm2), the 
solid stresses transmitted to the cell via the glycocalyx were predicted to be over 5.0 
dyn/cm2, a magnitude which is known to activate endothelial cells [93]. Future models 
could incorporate mechanical effects along with chemical signaling pathways to better 
predict cancer cell mechanotransduction in tissues. 
 
Integrating signal transduction networks into adhesive dynamics simulations 
 
Recently, signal transduction models were incorporated into AD simulations to 
couple signaling pathways with cell adhesion (Figure 1.5B,C). In the model, 
leukocytes were assigned a random spatial distribution of integrin lymphocyte 
function-associated antigen-1 (LFA-1), in addition to selectin ligands such as PSGL-1. 
The reactive surfaces were covered with selectin molecules and intracellular adhesion 
molecule-1 (ICAM-1), which binds to active LFA-1 and mediates firm arrest. Krasik 
et al. integrated the mitogen-activated protein kinase (MAPK) signal transduction 
pathway as a modular Hill function within the AD framework to model neutrophil 
arrest with deterministic activation [111]. Selectin ligation triggered the MAPK 
cascade in this model, which can cause inactive LFA-1 to become activated, enabling 
binding to ICAM-1 and subsequent neutrophil arrest. This model has since 
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incorporated a stochastic signal transduction model, utilizing a Monte Carlo 
simulation within the microvilli of model neutrophils [112].  
Caputo et al. generated an adhesive dynamics simulation with an integrated signal 
transduction network that incorporates selectin, integrin, and chemokine interactions 
between the neutrophil and the substrate. A random distribution of the G-protein 
coupled receptor CXCR1 and chemokine interleukin-8 (IL-8) were displayed on the 
leukocyte and the reactive surfaces, respectively. CXCR1 can interact with IL-8, 
which initiates a signaling cascade leading to LFA-1 activation on the cell [113]. Beste 
et al. developed a model of T-lymphocyte arrest by combining AD with a kinetic 
model for chemokine-triggered inside-out integrin activation [114]. The model 
incorporated signaling data measured in experiments to simulate the time scale for T-
lymphocyte arrest, and provided a predictive simulation for understanding chemokine 
control of T-lymphocyte recruitment. The integration of signal transduction networks 
into AD simulations could prove particularly useful for the study of cancer metastasis, 
as molecular defects could be implemented within the signaling cascade to predict its 
effects on CTC adhesion to the endothelium. 
 
Computational models of integrin-ligand interactions at the ECM interface  
 
A model based on the Adhesive Dynamics simulation was developed to both 
chemically and mechanically model integrin dynamics at the cell-ECM interface 
[115]. Paszek et al. developed the model to determine whether the cell glycocalyx and 
the chemical and physical parameters of the ECM can control the formation of integrin 
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clusters, which act as mechanical anchors and can regulate cell survival, motility, 
differentiation, and morphogenesis [116-118]. Integrin-ligand bonds were modeled as 
individual Hookean springs, and the Bell model was utilized to calculate kinetic rates 
of bond formation and rupture, which are distance-dependent [72,73]. In addition, the 
model included a lattice spring model (LSM) of the cell-ECM interface, consisting of 
a lattice of interconnecting nodes and springs to calculate the stress-strain behavior of 
the interface [119]. Model parameters including the glycocalyx, membrane, and bond 
spring constants, on- and off-rates, and receptor and ligand density were estimated 
based on experimental measurements. 
Integrin clustering began as a fast process, as simulations showed that new integrin 
bond formation events were more likely to occur near existing integrin bonds where 
the separation distance between integrins and ligands was reduced. However, bond 
rearrangements due to bond breakage and reformation were found to slow down the 
integrin clustering process over time. Glycocalyx thickness also affected integrin 
clusters, with larger, denser clusters forming with increased glycocalyx thickness. The 
interplay between integrin-ligand affinity and cell-ECM repulsion due to the 
glycocalyx also affected clustering; high affinity interactions coupled with thinner 
glycocalyx resulted in bound integrin receptors with minimal clustering. A thicker 
glycocalyx relative to integrin bond length, along with an adequate receptor-ligand 
affinity, resulted in both integrin binding and clustering. Integrin clustering increased 
due to increases in the ratio of glycocalyx stiffness to membrane stiffness, as it 
increased the minimal matrix ligand density. Integrin clustering was shown to be 
sensitive to ECM stiffness; compliant substrates could not promote cooperative 
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binding, while integrin clustering increased with increasing substrate stiffness above 
2000 Pa.  While the computational model only incorporates basic biology, a 
combination of the mechanical model with molecular interactions revealed cell 
adhesion behavior observed in experiments [115,120]. Future models should focus on 
the incorporation of applied fluid shear forces, along with integrin-cytoskeleton 
interactions, to predict how adhesions on the cancer cell surface can sense and respond 
to the tumor microenvironment. 
 
1.1.7 SUMMARY 
 
Fluid shear stresses generated by blood and interstitial flows alter cancer cell 
behavior in the vascular and tumor microenvironments, respectively, and contribute to 
the progression of cancer metastasis. Interstitial flow-generated forces elevate tumor 
IFP, and create challenges to chemotherapeutic delivery to the tumor interior. Such 
forces also induce phenotypic changes of cells in the surrounding microenvironment, 
which enhance tumor cell migration and invasion. Shear flows in the circulation affect 
tumor cell viability while also playing a role in CTC adhesion to the endothelium, a 
crucial step for subsequent tumor cell extravasation and metastasis. Recent 
experimental studies have revealed that fluid shear stress can modulate intrinsic 
characteristics of cells, in addition to the extrinsic roles of fluid flow that have been 
previously documented. Cancer cell mechanotransduction observed in recent 
experiments, including tumor cell resistance to shear stress, regulation of migration 
and invasion, and sensitivity to chemotherapeutics, have potentially wide ranging 
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implications for metastasis. Recent computational models have incorporated 
mechanical fluid forces with chemical signaling networks, along with 
mechanotransducing components on the cancer cell surface, such as the glycocalyx. 
Future approaches utilizing computational models of fluid shear stress effects on 
intrinsic tumor cell signaling networks, coupled with in vitro and in vivo experimental 
validation, may better predict cell behavior in such dynamic microenvironments, and 
potentially provide novel approaches for the prevention of metastasis. 
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1.2 LEUKOCYTES AS CARRIERS FOR TARGETED CANCER DRUG 
DELIVERY 
 
*This section is adapted from the following publication: M.J. Mitchell and M.R. King. 
Expert Opinion on Drug Delivery. In Press, 2014. 
 
Cancer is one of the leading causes of death, with metastasis the cause of over 
90% of cancer-related mortality [1]. Metastasis is initiated when cancer cells from a 
primary tumor invade the surrounding tissue, where they can then enter the 
bloodstream or lymphatic system to translocate to anatomically distant organs. Tumor 
cells may then exit the circulation, migrate into tissues, and proliferate to form 
secondary tumors. Surgical intervention, chemotherapy, and radiation are typically 
effective at treating primary tumors. However, metastases are difficult to detect, target, 
and treat therapeutically, and typically signal a poor patient prognosis, as only one in 
five patients diagnosed with metastatic cancer will survive more than five years [121]. 
Nanoparticles have shown promise in the treatment of cancer. Perhaps one of 
the most well-known nanoparticle formulations currently in the clinic is liposomal 
doxorubicin (Doxil ®), used to treat over 300,000 patients annually for Kaposi’s 
sarcoma and ovarian cancer [122]. The advent of nanoparticles has reduced systemic 
toxicity of traditionally administered chemotherapeutics, enabled the controlled 
release of multiple small molecule drugs and proteins for continuous therapeutic 
delivery, and led to the development of targeting specific tumor cells within the body. 
Despite these advancements, it remains a challenge to deliver nanoparticle platforms 
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in patients with advanced forms of cancer. When cancer cells enter the bloodstream as 
circulating tumor cells (CTCs), they are difficult to target before they form metastases 
due to the fact that they are surrounded by billions of blood cells in vessels. Since 
nanoparticle platforms are typically administered systemically, disseminated tumor 
cells in tissues without a well-defined vascular structure can also be difficult to reach 
[121]. Additionally, hypoxic regions of tumors do not have a well defined vasculature, 
making systemic of delivery of nanoparticles inefficient [123,124]. For advanced 
nanoparticle platforms to fulfill their potential, new strategies must be developed to 
locally guide nanoparticles to poorly vascularized tumor tissue and CTCs. 
Leukocytes have recently received much attention in the treatment of a cancer, 
particularly in the field of cancer immunotherapy, which utilizes the innate ability of 
leukocyte subpopulations to elicit anti-tumor immunity [125]. In a distinct avenue of 
therapy, leukocytes, which share similar migration patterns to tumor cells in blood and 
tissue, can also be utilized to carry current nanoparticle formulations to tumor sites 
that are difficult to reach via systemic administration of nanoparticles alone. Herein, I 
discuss recent advances in utilizing leukocytes as carriers of nanoparticles for targeted 
cancer drug delivery. I first discuss current nanoparticle platforms that are utilized in 
the treatment of cancer. Similarities in leukocyte and tumor cell migration in complex 
microenvironments such as blood and tumor tissue are then reviewed, with particular 
emphasis on cell margination in blood, adhesive interactions with the vessel wall, and 
migration along chemoattractant gradients to tumors and inflammatory sites. Methods 
to functionalize nanoparticles to leukocytes are also discussed, such as surface 
functionalization and internalization within cells. Finally, I review recent in vitro and 
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in vivo strategies that have been developed to use leukocytes to deliver cancer drugs to 
tumors and CTCs. 
 
1.2.1 CURRENT NANOPARTICLE PLATFORMS FOR DELIVERY OF 
CANCER DRUGS 
 
Various nanoparticle formulations have been developed for the delivery of 
cancer drugs, and have already been discussed in detail elsewhere [121,126,127]. 
Here, currently utilized nanoparticle platforms are overviewed within the following 
broad categories: polymeric nanoparticles, liposomes, metals, carbon and halloysite 
nanotubes, and molecular targeted nanoparticles. 
 
Polymers 
 
Polymeric materials comprise perhaps the largest category of nanoparticles for 
the delivery of cancer drugs, with many formulations currently in preclinical or 
clinical trials [127,128]. Composed mainly of biocompatible and biodegradable 
polymers, most polymeric nanoparticles are synthesized using a self-assembly process 
using block-copolymers consisting of multiple polymers of varying hydrophobicity. In 
an aqueous environment the copolymers will form core-shell particles, with 
hydrophobic polymers forming the core to minimize aqueous exposure, and 
hydrophilic polymers forming the shell to stabilize the core [129-131]. The core 
allows for a high loading capacity of hydrophobic and hydrophilic small molecules, in 
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addition to macromolecules such as nucleic acids and proteins [132], while the shell of 
the nanoparticle provides steric protection. Poly(lactic-co-glycolic acid) (PLGA)-
based biodegradable nanoparticles are perhaps the most notable, as these materials are 
approved by the U.S. Food and Drug Administration and can be utilized to deliver a 
variety of cancer drugs [133,134]. Polymers such as poly(lactic acid) (PLA) and 
chitosan have also been utilized to develop polymeric nanoparticles [135,136]. The 
release of drugs from the nanoparticle can be controlled through surface or bulk 
erosion, diffusion through the polymer matrix, swelling or shrinking followed by 
diffusion, and by local changes in the environment, such as pH and temperature 
changes. 
 
Liposomes 
 
 Lipids are amphiphilic small molecules that can self-assemble into 
nanoparticles referred to as liposomes, spherical nanoscale vesicles that possess an 
aqueous core. Perhaps one of the first nanoparticle platforms to be utilized in medicine 
[137], liposomes contain either single or multiple bilayers consisting of a variety of 
lipid types, both natural and synthetic [138]. Liposomes can be easily tailored in terms 
of size and carrying capacity, and can range from tens to hundreds of nanometers in 
diameter. Their versatility as a therapeutic carrier is a key advantage, as the aqueous 
core of liposomes allows for the encapsulation of hydrophilic agents, while the 
lamellae can be utilized for the encapsulation of hydrophobic agents. Liposomes can 
also be coated with polyethylene glycol (PEG) to enhance circulation time and 
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improve stability [138]. There are over a dozen liposomal formulations approved for 
clinical use, including MyocetTM and Doxil®, with many others currently undergoing 
preclinical and clinical trials [139,140]. 
  
Metals 
 
 Metal nanoparticles, typically composed of biocompatible, inert metals such as 
gold and titanium have been extensively studied as a therapeutic platform for 
thermoablation of tumor cells [141]. Under exposure to near-infrared (NIR) light, gold 
nanoparticles such as nanoshells and nanorods can release energy, which heat tumor 
tissue and result in tumor cell death [142]. This can also cause coagulation within the 
tumor vasculature, which can enhance the effects of other targeted therapeutics [143]. 
Conversely, metal nanoparticles have also been utilized for the controlled release of 
chemotherapeutics [144], and can be functionalized with therapeutic ligands [145]. 
The long-term effects of metal nanoparticle delivery of cancer therapeutics are still 
being investigated, as a fraction of the particles are retained within the body after 
administration, and can induce unwanted toxicity after repeated doses [146]. 
 
Carbon Nanotubes 
 
 Carbon nanotubes (CNTs) are well-ordered allotropes of carbon with a 
cylindrical nanostructure. CNTs have a uniquely high aspect ratio, with lengths 
ranging from hundreds of nanometers to several micrometers, and diameters ranging 
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from 0.4-2.0 nm for single-walled CNTs (SWNTs) to 2-100 nm for multi-walled 
CNTs (MWNTs) [147]. Similar to metal nanoparticles, SWNTs can emit heat when 
they absorb energy from near-infrared (NIR) light. The extensive surface area of 
SWNTs have been utilized for functionalization of antibodies specific to tumor cells 
for highly specific thermal ablation [148]. The surface area of SWCNTs has also been 
utilized for efficient loading of chemotherapeutics [149,150]. However, further 
investigation into the potential cytotoxic effects of CNTs is necessary. In terms of the 
immune system, CNTs have been shown to be phagocytosed by B- and T-
lymphocytes, without affecting cell viability or functionality [151]. However, high 
concentrations of SWNTs can arrest cell division and induce apoptosis [152]. Chronic 
inhalation of SWNTs can also be a hazard, and have been shown to induce 
inflammation and the appearance of epithelial granulomas [153]. 
 
Molecularly Targeted Nanoparticles 
 
 The development of targeted cancer therapies has led to major breakthroughs 
in the treatment of cancer over the past two decades. Notable examples of targeted 
therapeutics include bevacizumab (Avastin®) which targets vascular endothelial 
growth factor (VEGF) to inhibit tumor angiogenesis [154,155], imatinib (Gleevec®) 
for inhibiting tyrosine kinases to treat chronic myelogenous leukemia [156], and 
trastuzumab (Herceptin®) to target human epidermal growth factor receptor type 2 
(HER-2) for the treatment of breast cancer [157,158]. The success of these therapies 
has led to extensive studies combining targeting molecules with therapeutic-containing 
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nanoparticles. Ligands or antibodies conjugated to nanoparticles typically target 
proteins on the tumor cell surface, which can then be internalized by tumor cells to 
deliver therapeutics. This approach can enhance the concentration of drug achieved 
within tumors, and limit off-target cytotoxic effects. However, expression of the 
targeted protein on undesired cell populations can lead to off-target effects, and must 
be taken into account when choosing an appropriate molecule to create targeted 
nanoparticles. 
 Despite the recent technological advances in nanoparticle platforms for 
efficient loading and controlled release of therapeutics, local delivery to cancer sites 
remains a challenge. Due to challenges such as the lack of vasculature in hypoxic 
regions of tumors and the “needle in a haystack” problem of targeting and treating 
CTCs in the complex milieu of blood, new strategies need to be devised to guide 
nanoparticle therapeutics to target tumor cells. 
 
1.2.2 TUMOR CELL/LEUKOCYTE SIMILARITIES IN FUNCTION 
 
 Leukocytes and tumor cells share common physical properties and adhesive 
interactions with vascular components. Similarities including their transport within 
blood, adhesion to the vessel wall, and migration into inflammatory sites in soft tissue, 
can potentially be exploited for efficient delivery of therapeutics. 
 
 
 
32 
Margination of CTCs and Leukocytes 
 
Despite the fact that CTCs within the bloodstream are exposed to a variety of 
factors in blood that affect their viability, including immunological stresses, blood cell 
collisions, and fluid shear stress [6,159], a small fraction of these cells are able to 
survive these conditions, and proliferate to form metastases in anatomically distant 
organs. CTCs within the bloodstream are very difficult to target and treat within the 
bloodstream, as the concentration of CTCs in patient blood is on the order of one in a 
million leukocytes [42] or one in a billion erythrocytes [43], creating what is known as 
a “needle in a haystack” problem. However, what is known about rare CTCs is that 
they share similar migration characteristics with leukocytes within the bloodstream. 
Leukocytes tend to collect near the endothelial cell wall in venules, rather than in the 
center of the vessel, in a passive rheological mechanism termed margination (Figure 
1.6A) [160,161]. During this phenomenon, highly deformable, biconcave-shaped 
erythrocytes experience a drift velocity away from the vessel wall and collect in the 
center of vessels, displacing less deformable leukocytes towards the periphery [162-
164]. CTCs, which are closer to the larger volume and spherical shape of leukocytes 
than the deformable, biconcave disk-shaped erythrocytes, are also pushed towards the 
endothelial cell wall. Such margination phenomena can effectively surround CTCs 
within the circulating leukocyte population, thus making leukocytes a potentially 
attractive carrier of treatments to CTCs by exploiting their numerous adhesion 
receptors. 
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Tumor Cell/Leukocyte Adhesion to the Blood Vessel Wall 
 
For free-flowing tumor cells and leukocytes to leave the bloodstream and 
migrate into soft tissues, they must first adhesively interact with endothelial cells that 
comprise the inner blood vessel wall  (Figure 1.6B) [15]. The mechanisms behind 
leukocyte recruitment to the endothelial cell wall have been extensively studied over 
the past two decades [165,166]. Initially, free-flowing leukocytes in the post-capillary 
venules are captured along the endothelial cell wall, in the presence of wall shear 
stresses as low as 0.4-0.5 dyn/cm2 [167-169]. After initial tethering, leukocytes exhibit 
rolling adhesion on the receptor-bearing endothelial cell wall. Rolling adhesion is 
mediated by selectins expressed on the surface of inflamed endothelial cells, which 
possess rapid, force-dependent binding kinetics, and selectin ligands on the surface of 
leukocytes included L-selectin and P-selectin glycoprotein ligand-1 (PSGL-1), 
[91,170-172]. Leukocytes can subsequently transition from rolling to firm adhesion to 
the vessel wall, mediated via intercellular adhesion molecule-1 (ICAM-1) on the 
endothelial cell surface binding to β2 integrins on the leukocyte surface, such as 
macrophage-1 antigen (Mac-1) and lymphocyte function-associated antigen-1 (LFA-1) 
[173-176]. 
CTCs can be captured on the endothelial cell wall in a manner similar to 
leukocytes (Fig. 6B). Recent studies have shown that CTCs from various types of 
tumors possess sialylated carbohydrate ligands on their surface, which cause the 
tethering and rolling of CTCs on the selectin-bearing endothelial cell wall [177,178]. 
Under physiological flow conditions, E-selectin can induce tethering and rolling of 
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cancer cells originating from prostate [53,179], breast [180,181], and colon [180,182]. 
Initial selectin-mediated rolling adhesion of CTCs has been shown to be an important 
prerequisite to metastasis formation in vivo [183,184]. For example, the number of 
spontaneous colon carcinoma metastases formed in vivo decreased by 84% in P- and 
E-selectin deficient mice [49]. The remaining 16% of metastases formed within the 
pulmonary artery as CTCs were not able to transmigrate through the endothelium in 
the absence of E-selectin. It is not yet fully elucidated which receptors facilitate firm 
adhesion of CTCs to the endothelial cell wall, however there is some evidence that the 
mucin MUC1 can ligate ICAM-1 to enable firm adhesion and subsequent 
transmigration [185]. Taken together, CTCs and leukocytes share striking similarities 
in terms of their initial adhesion to the vessel wall. This makes selectin receptors a 
potentially important mediator between leukocytes and CTCs for drug delivery 
purposes. 
 
Tumor Cell/Leukocyte Migration Toward Chemoattractant Gradients 
 
 Following firm adhesion to the blood vessel wall, leukocytes and tumor cells 
can transmigrate through the endothelium and migrate along gradients of extracellular 
matrix-bound or soluble chemoattractants to inflammatory sites and solid tumors 
(Figure 1.6C). Chemoattractants bind to G-protein coupled receptors (GPCRs) on the 
surface of leukocytes to activate downstream effectors, which initiate receptor 
internalization and signal transduction [186,187]. Such signaling induces the 
activation of β2 integrins on the leukocyte surface, which induces cell adhesion, and 
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polarization of the actin cytoskeleton, which facilitates directional sensing and cell 
polarization [188,189]. Polarization allows small GTPases, Rac, Cdc42 and PI3K to 
accumulate at the leading edge of the leukocyte, PTEN tyrosine/PIP3 phosphatases at 
the posterior edges, and Rho GTPases and its effectors at the trailing edge [186]. 
These collectively initiate actomyosin contraction and tail retraction, which induces 
leukocyte migration [190]. The ability of leukocytes to respond and migrate in the 
presence of chemoattractants is essential in the response to inflammation, infection, 
and lymphocyte homing to tissues, to name a few [176,191,192].  
Chemoattractant gradients also play a major role in tumor cell and leukocyte 
migration in the context of cancer progression [193,194]. In the tumor 
microenvironment, cancer epithelial cells produce higher levels of chemokines than 
their normal counterparts, in addition to increased expression of chemokine receptors 
[195]. This creates a highly inflammatory microenvironment that promotes the 
recruitment of leukocytes such as neutrophils, lymphocytes, and macrophages, which 
can influence the progression of cancer and its ability to metastasize [196-199]. 
Additionally, tumor cells can acquire chemoattractant receptors during transformation, 
and migrate along gradients typically utilized by leukocytes to form metastases in 
anatomically distant organs [187]. Leukocyte and tumor cell localization within 
difficult-to-reach tumor sites, along with their similarities in terms of migration to 
tissues, can be utilized to locally deliver agents such as therapeutics to induce cancer 
cell death, or anti-inflammatory agents to suppress the leukocyte’s ability to support 
the tumor microenvironment. 
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1.2.3 METHODS TO ATTACH NANOPARTICLES TO LEUKOCYTES 
 
 The drug delivery vehicles described above can be attached to leukocytes using 
a variety of methods, ranging from cell surface functionalization to internalization by 
the leukocyte. Depending on the type of therapeutic delivered, the type of leukocyte 
targeted, and the site of delivery, one or a combination of functionalization methods 
may be needed for nanoparticle attachment.  
 
Receptor-Mediated Adhesion 
 
 Receptor-ligand interactions are a potentially advantageous method to bind 
nanoparticles to the surface of leukocytes (Figure 1.7A), due to their reliability, 
reproducibility, and ability to trigger potentially desired cell receptor activation and 
signal transduction in vivo. For example, B-cells expressing CD44 have been utilized 
to bind cellular “backpacks” via interactions with its natural ligand, hyaluronic acid 
(HA) [200]. This approach has also been utilized to bind delivery vehicles to T-cells 
and macrophages [201-203]. Natural variations in receptor-ligand affinities must be 
taken into account, and could affect the binding strength of a nanoparticle to the 
leukocyte surface. Additionally, potential nonspecific receptor-ligand interactions with 
off-target cells, along with subsequent receptor activation and signaling, must be 
considered for in vivo applications. If utilized properly however, multiple receptor 
types may be conjugated to a single particle, to mediate the delivery of therapeutic 
between two cell types, such as leukocytes and cancer cells. 
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Covalent Binding 
 
 Covalent coupling of nanoparticles to the surface of leukocytes provides 
potentially stronger and more stable binding than receptor-mediated adhesion (Figure 
1.7B). Traditionally utilized to bind maleimide-functionalized nanoparticles to amino 
(lysine-NH2) or thiol (cysteine-SH) groups on proteins [204,205], similar covalent 
binding strategies have been used to stably bind nanoparticles to the surface of cells. 
Leukocytes in particular have many functional groups on their surface, such as thiols 
and amines, due to their large number of cell surface proteins [206,207]. This 
approach has been utilized to stably attach hundred of nanoparticles per cell, 
composed of materials ranging from liposomes to polymers, to the surface of T-
lymphocytes without cytotoxic effects or loss of cell function [208]. In contrast to 
nanoparticles adsorbed to the surface, which can be removed during simple washing, 
covalent bonding promoted stable attachment that can withstand through several 
washing steps. In addition to prolonged surface retention, covalent bonding of 
nanoparticles to the cell surface can resist nanoparticle internalization, along with 
potentially undesired receptor activation that could be triggered by receptor-mediated 
attachment.  
 
Selectin-Mediated Adhesion 
 
 Selectins provide a unique and effective way to rapidly attach nanoparticles to 
the surface of cells bearing selectin ligands (Figure 1.7C). The rapid, force-dependent 
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binding kinetics of selectins allow for nanoparticles to rapidly bind to the surface of 
selectin ligand-bearing cells under flow conditions. In particular, in vitro surfaces with 
immobilized P-selectin coated liposomes attached themselves to the surface of free 
flowing HL60 leukocytes. Utilizing E-selectin coated liposomes containing the 
chemotherapeutic doxorubicin, this strategy has also been utilized to attach drug-
loaded particles to the surface of free flowing cancer cells as a form of CTC 
neutralization [82,83]. Most recently, selectin-coated nanoparticles have been shown 
to attach to the surface of leukocytes directly within human blood and within the 
circulation of mice [209]. This method is currently being employed to deliver 
apoptosis-inducing ligands to cancer cells in the circulation. Given that selectin 
ligands are expressed on the surface of most circulating leukocytes [171,191], selectin-
mediated adhesion is advantageous for functionalizing a broad range of cells for 
therapeutic delivery within the circulation. In contrast to other forms of receptor-
mediated attachment, selectins can be used for direct binding to leukocytes within the 
blood, eliminating the need to isolate leukocytes from blood, with subsequent 
incubation and culture steps needed for nanoparticle attachment.  
 
Internalization 
 
 Nanoparticles can also be internalized by leukocytes for efficient delivery of 
therapeutics. One method to internalize particles is through the use of the natural 
phagocytic properties of certain leukocyte subpopulations to ingest particles (Figure 
1.7D) [210,211]. Subpopulations of neutrophils, monocytes, and macrophages all 
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possess phagocytic properties, however monocytes and macrophages are particularly 
appropriate due to their longer lifespan and ability to be cultured ex vivo. Known as 
the “Trojan Horse” method, this approach has been used to internalize particles such 
as liposomal doxorubicin, gold nanoshells, fluorescent microspheres, and nanozymes 
within leukocytes [142,212-215]. It is important to note that this approach has been 
limited to certain subpopulations of leukocytes, and thus requires careful ex vivo 
isolation from blood. Additionally, biodegradable nanoparticles such as polymers and 
lipids can potentially release therapeutic within the cell, thus reducing the amount of 
drug delivered to the target site, and potentially causing unwanted side effects to the 
leukocyte carrier. The “Trojan Horse” approach has unique advantages, however, in 
that it eliminates the need to occupy the cell membrane and potentially interfere with 
receptor-ligand interactions. Additionally, this approach avoids undesired cell surface 
receptor signaling that can be encountered with receptor-mediated attachment of 
nanoparticles. 
 
1.2.4 LEUKOCYTES AS CARRIERS OF NANOPARTICLES TO 
METASTATIC CELLS AND TUMORS: INITIAL RESULTS 
 
Over the past several years, initial results have shown that leukocytes are 
effective at carrying drugs and nanoparticles to difficult-to-target sites for cancer 
therapy. Nanoparticles can either be stably attached to the leukocyte surface, or 
internalized within the cell, to efficiently deliver drugs deep within tumors, and most 
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recently, to deliver cell death-inducing ligands to eradicate rare tumor cells within the 
bloodstream. 
 
Leukocyte “Trojan Horses” for Nanoparticle Delivery to Solid Tumors 
 
 Some of the initial studies focused on utilizing leukocytes as “Trojan Horses” 
for delivery of therapeutics to solid tumors. As tumors grow rapidly, the tumor core 
becomes distanced from the nearest capillaries, causing these cells to become necrotic 
and/or hypoxic [123,124]. Additionally, the lack of a vasculature hinders the delivery 
of nanoparticle-based therapeutics to core region of the tumor. While nanoparticles 
may lack the ability to reach these sites, monocytes can be recruited from the 
peripheral blood to sites of tumors due to chemoattractant gradients. Additionally, 
monocytes have an innate phagocytic ability, which can be utilized to internalize 
nanoparticles as a means to carry therapeutics to tumors (Figure 1.8A). 
Gold nanoshells have been suggested as an ideal therapeutic to be utilized 
within cellular “Trojan Horses” [142], given that they can be uptaken by tumor cells 
and induce cell death by photoablation via near-infrared (NIR) light, which can 
increase tumor tissue temperature by over 30°C in the presence of nanoshells [216]. 
Initial work has shown that monocytes successfully phagocytose gold nanoshells over 
a period of 24 h. Macrophages, which are differentiated from monocytes upon 
migration into tumors, also successfully phagocytose gold nanoshells over similar 
incubation periods. Cell death was induced in nanoshell-containing macrophages via 
photoablation (Figure 1.8B), which induces the release of nanoshells within the tumor 
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to allow for tumor cell uptake, and subsequent heating and killing of tumor tissue via 
NIR (Figure 1.8C). In an in vitro model of the macrophage infiltration tumor 
microenvironment, macrophages and gold nanoshells were co-cultured with breast 
tumor spheroids. Macrophages were found to infiltrate tumor spheroids in vitro, and 
cell death of macrophages was induced by photoablation.  
 The “Trojan Horse” approach has also been exploited to deliver nanoparticles 
to experimental brain metastases. Nanoparticle uptake in the brain is hindered by 
physical barriers such as the blood-brain barrier (BBB) and blood-cerebrospinal fluid 
barrier [217,218]. However, macrophages of peripheral blood monocyte origin are 
able to infiltrate brain metastases despite the presence of an intact blood brain 
barrier[219], and are also present in clinical brain tumor specimens at contents ranging 
from 4 to 70% [220]. Thus, macrophages have been utilized as “Trojan Horses” to 
cross the BBB and deliver therapeutics to metastatic deposits in the brain. Both 
nanoshells and fluorescent microspheres, utilized for therapeutic and diagnostic 
purposes, respectively, were successfully phagocytosed and localized within vacuoles 
in the cytoplasm of monocytes and macrophages [213]. Utilizing brain tumor 
xenografts in mice, both macrophages and internalized microspheres were found 
within brain metastases, 24 h post-injection into mice.  
 The “Trojan Horse” approach can also be used to deliver chemotherapeutics to 
tumors in vivo [212]. Utilizing mouse peritoneal macrophages, which were shown to 
migrate into A549 subcutaneous tumors in vivo, liposomal doxorubicin (LP-Dox) was 
internalized within macrophages, which remained viable for over 12 h, even at high 
concentrations of LP-Dox. LP-Dox was released from macrophages and induced cell 
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death in A549 cancer cells in vitro. Upon injection in vivo, macrophages containing 
LP-Dox infiltrated the interior of A549 subcutaneous tumors, and their migration was 
characterized via the intrinsic fluorescence of doxorubicin. Additionally, tumor 
treatment with systemic injections of macrophages containing LP-Dox induced A549 
subcutaneous tumor reduction over a 35-day span, compared to controls. Taken 
together, the ability of monocytes and macrophages to migrate along chemoattractant 
gradients and penetrate the BBB can be utilized in the “Trojan Horse” approach to 
deliver a variety of nanoparticle-based therapeutics and imaging agents to tumor 
tissues that are typically difficult to target via systemic injection. 
 Most recently, single walled carbon nanotubes (SWNTs) were found to be 
uptaken almost exclusively by a single subpopulation of leukocytes [221]. SWNTs 
were injected into the tail vein of mice, and intravital microscopy was used to observe 
that nanotubes were uptaken into circulating blood cells. Upon blood draw and 
subsequent FACS analysis of SWNT+ blood cells, only a specific monocyte subset, 
known as Ly-6Chi lymphocytes, displayed substantial SWNT uptake. Interestingly, 
only <3% of neutrophils, <1% of lymphocytes, and <1% of Ly-6Clow lymphocytes 
took up SWNTs, while nearly 100% of Ly-6Chi lymphocytes displayed SWNT uptake. 
The subpopulation of monocytes containing SWNTs were able to enter tumor 
interstitium, and SWNTs functionalized with an RGD peptide significantly enhanced 
the number of monocytes reaching the tumor site. While the mechanisms behind 
SWNT selectivity to specific leukocyte subpopulations and increased monocyte 
targeting to tumors in the presence of RGD are not yet understood, identification of 
specific circulating immune cell populations for the delivery of nanoparticles may 
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have important implications for both cancer therapeutics and diagnostics. Furthermore, 
the enhanced infiltration of monocytes due to presence of RGD extends the “Trojan 
Horse” approach, demonstrating that the delivery of nanotube-containing monocytes is 
not merely reliant on the innate homing abilities of monocytes. 
 
Lymphocyte Surface Engineering for Nanoparticle Delivery to Solid Tumors 
 
 In addition to uptake and internalization, nanoparticles can also be conjugated 
to the extensive surface area of leukocytes for delivery into solid tumors. Exploiting 
the thiol-rich surface of T-lymphocytes, liposomes and lipid-coated polymer 
nanoparticles with thiol-reactive maleimide headgroups were stably attached to the 
cell surface, without affecting key cellular functions [208]. Additionally, nanoparticle 
conjugation to the surface of T-cells was observed to affect their ability to traffic to 
tumors, thus allowing nanoparticles to be effectively carried to the tumor site. Particles 
were loaded with cytokines interleukin-15 (IL-15) and IL-21, to amplify the 
therapeutic functions of T-cells to treat lung and bone metastases. While systemic 
injections of free cytokines and T-cells did not have a significant effect on T-cell 
proliferation within tumors, systemic injection of T-cells carrying cytokine-loaded 
nanoparticles were able to localize within tumors and robustly proliferate in vivo. All 
mice receiving nanoparticle-conjugated T-cells were able to completely eradicate lung 
and bone tumors. 
Further investigation of maleimide-functionalized nanoparticle conjugation to 
thiols on the T-cell surface has shown the ability to deliver compounds into the T-cell 
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synapse, as a means to boost anti-tumor immunity [222].  While migrating T-cells 
carried surface-linked nanoparticles at the uropod, they were rapidly redistributed to 
the immunological synapse (IS) during target tumor cell recognition. To exploit this 
redistribution, nanoparticles were used to deliver an inhibitor of key phosphatases to 
downregulate T-cell receptor activation at the synapse, blocking suppressive signals 
from tumor cells that typically restrain anti-tumor activity. In vitro, conjugation of 
inhibitor-encapsulated nanoparticles to the T-cell surface significantly enhanced their 
proliferation, compared to controls. Conjugation of the loaded nanoparticles also 
promoted T-cell expansion in orthotopic prostate tumors in vivo, reduced tumor 
burden, and enhanced survival compared to controls. These results show that 
leukocyte-mediated delivery of therapeutics can even serve to enhance cancer 
immunotherapy, by locally delivering the cytokines and inhibitors necessary to 
enhance the T-cell response with tumors for anti-tumor immunity in vivo. 
 
NK Cell Surface Engineering to Target Models of Lymph Node Micrometastasis 
 
Approaches using functionalized leukocytes have been assessed in vitro for the 
therapeutic targeting of metastasis, which can occur via the vascular or lymphatic 
circulation [223]. Cancer cells traveling through the lymphatic circulation can lodge 
within sentinel lymph nodes (SLN), where they lie dormant for a period of time before 
forming micrometastases [224]. Also present within the lymphatic circulation and 
SLN are many immune cells that typically respond to tumor antigens, such as 
lymphocytes, macrophages, and antigen-presenting cells. In particular, natural killer 
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(NK) cells have been shown to activate apoptotic pathways in cancer cells [225], kill 
most tumor cells within the circulation [226], and reside within lymph nodes [227]. 
Despite this, cancer cells continue to evade the host immune response [228]. Evidence 
of morphological and functional variation in cancer patient SLNs suggests potential 
immune suppression, which can result in the failure to eliminate micrometastases in 
SLNs. Thus, the presence of micrometastases within SLNs typical signals a poor 
prognosis in cancer patients after surgical resection of the primary tumor [229-231].  
 In an attempt to functionalize NK cells to overcome immune suppression, the 
surface of NK cells was functionalized with TRAIL liposomes to kill cancer cells in in 
vitro models of lymph node micrometastases. TRAIL binds to death receptors DR4 
and DR5 on the surface of a variety of cancer cell types, which induces apoptosis 
through intrinsic and extrinsic pathways [86,232,233]. Thiolated TRAIL protein and 
anti-CD57 were covalently bound to maleimide groups on the surface of liposomes 
(Figure 1.9A,B). Conjugation of liposomes to the surface of NK cells was facilitated 
by antibody binding to CD57 (Figure 1.9C,D), a marker found on a subpopulation of 
NK cells [234]. As an in vitro model of SLNs, functionalized NK cells were seeded 
into microbubbles compromised of PDMS (Figure 1.9E), which mimic both the size 
and elastic modulus of lymph nodes [235]. MDA-MB-231, COLO 205, and LNCaP 
cancer cells, which typically metastasize to lymph nodes, were then cultured within 
microbubbles containing functionalized NK cells. After 24 h in culture, functionalized 
NK cells successfully induced cancer cell apoptosis in the in vitro model of SLNs 
(Figure 1.9F). This approach provides not only an in vitro model to assess the 
sensitivity of lymph node micrometastases to therapeutics, but also a potential means 
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to enhance the NK cell therapeutic response to micrometastases within lymph nodes, 
which can become immune suppressive in cancer patients. Further studies will be 
required to assess successful in vivo functionalization and subsequent localization of 
NK cells to SLNs, as a means to target metastases within lymph. 
 
Targeting Metastatic Cells in the Bloodstream 
 
 Recently, a unique approach termed “unnatural killer cells”, leukocytes 
functionalized to target and kill cancer cells within blood, was developed as a means 
to neutralize circulating tumor cells (CTCs) with the potential to form new metastases 
[209]. To target and kill cancer cells, nanoscale liposomes were functionalized with 
the adhesion receptor E-selectin (ES) and the apoptosis-inducing ligand tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) (Figure 1.10A). Selectins 
facilitate rapid, force-dependent adhesion to selectin ligands on tumor cells and 
leukocytes in blood (Figure 1.10A), which then allows TRAIL ligands to come within 
a reactive distance of death receptors on the cancer cell surface, signaling for cell 
apoptosis. TRAIL is an ideal therapeutic for this delivery method due to the fact that it 
preferentially induces apoptosis in cancer cells, while exerting minimal cytotoxic 
effects on most normal cells [236]. Interestingly, ES/TRAIL liposomes bound 
remarkably well to the surface of many types of leukocytes in blood under flow 
conditions (Figure 1.10B), with minimal cytotoxic effects. Upon treatment of cancer 
cells with ES/TRAIL liposomes in human blood under flow conditions, negligible 
viable cancer cells remained after only 2 h of treatment (Figure 1.10C,D). While blood 
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typically reduces therapeutic efficacy through cellular internalization and nonspecific 
binding of the therapeutic to plasma proteins, the ability of ES/TRAIL liposomes to 
target and kill cancer cells was enhanced in human blood, compared to conditions in 
buffer alone (Figure 1.10E). Alteration in hematocrit levels (Figure 1.10F), in addition 
to removal of all ES/TRAIL liposomes unbound to leukocytes in blood, demonstrates 
that blood cells are essential in the enhanced apoptotic response of cancer cells in 
blood. Upon addition of ES/ TRAIL liposomes to cancer cell-spiked blood, liposomes 
attach to the surface of leukocytes and are available for inducing apoptosis in cancer 
cells that they come into contact with (Figure 1.10G). Liposome tethering to the 
leukocyte surface can also enhance cancer cell apoptosis due to the compressive forces 
between cancer cells and leukocyte under flow. Compressive forces act to flatten the 
cancer cell glycocalyx [237], composed of biologically inert macromolecules, thus 
allowing TRAIL to come within a reactive distance to the cancer cell death receptors 
and form bonds. This approach is intended to neutralize CTCs as rare as 1-100 cells 
per mL in blood [42,238], and margination of leukocytes and CTCs along the vessel 
wall allows CTCs to essentially become surrounded by the circulating leukocyte 
population. Thus, upon functionalization of leukocytes in blood, CTCs can essentially 
be surrounded by both adhesion receptors and therapeutic ligands upon entering the 
bloodstream, thus increasing the probability of neutralizing rare CTCs before they are 
able to form new metastases.  
Significant progress has been made in utilizing “unnatural killer cells” to target 
and kill cancer cells in the peripheral circulation of mice in vivo. ES/TRAIL liposomes 
were injected into the peripheral circulation of mice (Figure 1.10H), where they 
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successfully tethered to the surface of leukocytes (Figure 1.10I). Following ES/TRAIL 
liposome injection, tail vein injection of cancer cells was utilized to model 
leukocyte/CTC interactions within the mouse circulation, representing a common 
model of lung metastasis [239-242] since the early work of Fidler et al. [243-245]. 
Upon removal of the peripheral blood from the circulation after 2 h via cardiac 
puncture, negligible viable cancer cells were found remaining compared to controls 
(Figure 1.10J). Upon examination of the remaining cancer cells within the mouse 
vasculature using multiphoton microscopy (Figure 1.10K), it was found that there 
were far fewer cancer cells in the lungs of treated mice, with the majority of remaining 
cancer cells apoptotic in treated mice but not in the control group (Figure 1.10L). In 
addition to the advantages of this approach discussed above, tethering liposomes to the 
surface of leukocytes in blood is beneficial for increasing liposome circulation time, 
by avoiding renal clearance mechanisms. By focusing the therapeutic effects to within 
the vascular microenvironment, reduced dosages are needed to target metastatic cells, 
as the dosages of TRAIL used in this current study were approximately two orders of 
magnitude lower than the dosages used in human clinical trials [246-248]. 
Representing an important first step in targeting CTCs in the bloodstream, the 
“unnatural killer cells” approach can potentially be utilized as a preventative measure 
upon diagnosis of highly metastatic hematogenous cancers that originate from 
epithelial tissues including breast, prostate, and lung. 
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1.2.5  SUMMARY 
 
Due to their shared ability to marginate in blood, adhesively interact with the 
blood vessel wall, and migrate along chemoattractant gradients to tumors and sites of 
inflammation, leukocytes have the potential to guide advanced nanoparticle platforms 
directed at CTCs and malignant tissues that have not previously been targeted 
successfully. Nanoparticles can be conjugated to the surface of leukocytes via methods 
such as receptor-mediated adhesion, covalent coupling, and selectin-mediated 
adhesion. Nanoparticles can also be internalized within phagocytic leukocytes, for 
efficient drug delivery while leaving the cell membrane unoccupied. Leukocyte 
carriers have proven effective in delivering drugs to solid tumors, models of lymph 
node metastasis, and cancer cells in the circulation in vivo. The promise of leukocytes 
as carriers of nanoparticle therapeutics warrants further investigation for applications 
including drug delivery to CTCs, metastatic tumor sites, and hypoxic regions of 
tumors, to name a few. 
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FIGURE 1.1: CANCER CELL EXPOSURE TO FLUID SHEAR STRESS IN 
THE TUMOR AND VASCULAR MICROENVIRONMENTS. (A) Tumor cell 
exposed to interstitial flow in a collagen matrix. (B) Circulating tumor cell (CTC) 
exposed to fluid shear forces in a blood vessel. 
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FIGURE 1.2: COMPUTATIONAL MODELS OF CELLS EXPOSED TO 
BLOOD AND INTERSTITIAL FLOWS. (A) Computational models utilizing the 
Brinkman equation to estimate interstitial flow-generated shear stresses on the cell 
surface [21]. u∞: velocity far from cell surface. (B) Adhesive dynamics (AD) 
simulations to predict selectin-mediated adhesion to the endothelium [249]. u: 
velocity. R: cell radius. sLex: sialyl-Lewis-x. ICAM-1: intercellular adhesion 
molecule-1. 
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FIGURE 1.3: FLUID SHEAR STRESS SENSITIZES CANCER CELLS TO 
THE APOPTOSIS-INDUCING LIGAND TRAIL. Colorectal adenocarcinoma 
COLO 205 cells exposed to non-shear conditions (A) and fluid shear stress (B), 
respectively. COLO 205 cells treated with TRAIL and then exposed to non-shear 
conditions (C) and fluid shear stress (D). Lower left-hand and right-hand quadrants of 
each flow cytometry figure represent viable cells and cells in early stages of apoptosis, 
respectively. Upper left-hand and right-hand quadrants represent cells undergoing 
necrosis and late stage apoptosis, respectively.  Percentage of viable (E) and apoptotic 
(F) COLO 205 cells after treatment with TRAIL followed by exposure to non-shear or 
shear conditions (n = 3). Percentage of viable (G) and apoptotic (H) PC-3 cells treated 
under the same conditions (n = 3). PI: propidium iodide. FITC: Fluorescein 
isothiocyanate. Error bars represent 95% confidence intervals. ∗P < 0.05. ∗∗P < 0.01. 
NS: non-significant. Figure reprinted with permission from Mitchell et al. [86]. 
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FIGURE 1.4: EXPERIMENTAL TECHNIQUES TO STUDY CANCER CELL 
MECHANOTRANSDUCTION. (A) Microfluidic protocol to deliver millisecond 
pulses of fluid shear stress to tumor cells [92]. Tumor cell resistance to fluid shear 
stress determined using bioluminescent imaging (BLI). (B) Darcy flow apparatus for 
the application of fluid shear stress in 3D to tumor cells embedded in collagen [97]. 
Shear stress-exposed cells are then placed in a modified Boyden chamber to measure 
their migratory and invasive potential in the presence of TGF-α. 
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FIGURE 1.5: ADVANCES IN COMPUTATIONAL MODELING REVEAL 
MECHANOTRANSDUCTION PHENOMENA. (A) Interstitial flow models 
incorporating the force-transducing cell glycocalyx to determine interstitial flow 
contributions to fluid shear stress-dependent mechanotransduction [21]. u∞: velocity 
far from cell surface. Km: matrix Darcy permeability. Kg: glycocalyx Darcy 
permeability. H: glycocalyx layer. ug∞: velocity profile in glyocalyx. τw: surface fluid 
stress. τwg: surface solid stress. (B,C) Incorporation of cell signaling networks to 
predict flow-mediated cell adhesion in the presence of chemoattractants [113]. IL-8: 
interleukin-8. PSGL-1: P-selectin glycoprotein ligand-1. LFA-1: lymphocyte function-
associated antigen 1. 
 
 
 
 
 
 
 
 
 
 
 
 
G-protein 
CXCR1 
Inactive LFA-1 
PSGL-1 
Active LFA-1 
Cell 
ICAM-1 P-selectin IL-8 
Substrate 
 
ICAM-1 IL-8 
Substrate 
 
LFA-1 
Gβϒ 
Gα 
G-protein 
Cell 
Effector 
Microvillus 
Tip 
A B 
C 
Cell 
Extracellular Matrix 
Interstitial Flow 
u 
x 
y 
Nucleus 
Mechanotransduction 
Glycocalyx ug 
Km 
Kg 
τwg 
H τw 
55 
FIGURE 1.6: TUMOR CELL AND LEUKOCYTE TRAFFICKING 
SIMILARITIES. (A) Margination in the vascular system. Deformable red blood cells 
drive leukocytes and CTCs to a marginated position near the vessel wall, due to their 
higher drift velocity away from walls. (B) Adhesion to inflamed blood vessels. Upon 
the onset of inflammation, endothelial cells upregulate E-selectin expression, which 
can cause free flowing, selectin ligand-bearing leukocytes to adhesively interact with 
the endothelial cell wall. CTCs are also known to express sialylated carbohydrate 
ligands on their surface, which can adhere to selectins on the surface of the 
endothelium. (C) Transmigration into tissues. Upon firm adhesion to the endothelial 
cell wall, leukocytes are known to transmigrate into the extravascular space and 
migrate along chemoattractant gradients to the site of inflammation. CTCs also 
respond to chemoattractants and transmigrate to inflammatory sites, where they may 
then survive and form micrometastases. 
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FIGURE 1.6: TUMOR CELL AND LEUKOCYTE TRAFFICKING 
SIMILARITIES. 
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FIGURE 1.7: APPROACHES TO FUNCTIONALIZE LEUKOCYTES WITH 
DRUG DELIVERY VEHICLES (DDV). (A) Covalent bonding of maleimide-
bearing DDVs to thiol groups on the protein-covered leukocyte surface. (B) Receptor-
ligand interactions to attach DDVs to the leukocyte surface. (C) Selectin-coated DDVs 
bind to leukocytes within the circulation under flow conditions. (D) Internalization of 
DDVs by phagocytic leukocytes. 
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FIGURE 1.8: CELLULAR “TROJAN HORSE” MECHANISM TO DELIVER 
NANOPARTICLE-BASED THERAPEUTICS TO SOLID TUMORS. (A) 
Monocytes and/or macrophages that typically infiltrate solid tumors internalize 
therapeutic and/or diagnostic nanoparticles for delivery into tumor sites. (B) 
Monocytes/macrophages containing gold nanoshells can be photoablated by near-
infrared (NIR), inducing cell death and releasing therapeutics and/or nanoshells for 
uptake into tumor cells. (C) Tumor cell death then occurs via (1) therapeutic delivery 
in tumor cells or (2) heating of nanoshell-containing tumor tissue by NIR. 
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FIGURE 1.9: FUNCTIONALIZED NATURAL KILLER (NK) CELLS TO 
TARGET LYMPH NODE MICROMETASTASES. (A,B) Liposomes with 
maleimide groups (A) react with thiolated apoptosis-inducing ligand TRAIL and anti-
CD57 antibodies. (C) Liposomes functionalized to surface of NK cells via antibody 
binding to CD57. (D) Micrographs of fluorescent liposomes functionalized to the NK 
cell surface. Scale bar = 100 µm. (E) Schematic of functionalized NK cell intervention 
in an in vitro model of lymph node micrometastasis. (F) Brightfield and fluorescent 
micrographs of functionalized NK cells inducing cancer cell apoptosis in an in vitro 
model of lymph node micrometastases comprised of MDA-MB-231, COLO 205, and 
LNCaP cancer cells. Cells are labeled with Annexin-V (green) and propidium iodide 
(red) after 12 h and 24 h to assess cell viability. Scale bar = 100 µm. Figure parts 
adapted from [250]. 
 
apoptotic cancer cells in MB arrays. The mean pixel intensity
between different treatment groups was compared for statis-
tical significance using unpaired student t-test.
2.8 Confocal microscopy
NK cells were labelled with CellTracker green (Molecular
Probes1, C7025) and LNCaP cells were labelled with
CellTracker red (Molecular Probes1, C34552) and seeded on
MB arrays following the protocol mentioned in Section 2.6.
The chips were then transferred into a glass bottomed 24-well
plate and imaged using a Zeiss 710 laser scanning confocal
microscope.
3. Results and discussion
3.1 Microbubble geometry closely recapitulates the anatomy of
deep cortical unit of a lymph node
In this work we were interested in developing a unique
application of MB arrays as a model for mimicking lymph
node micrometastases. Their semi-rounded geometry with a
single circular opening on the top closely resembles the semi-
rounded anatomy of a deep cortical unit of a lymph node
centered on the top of an afferent lymphatic. PDMS is a
commonly used polymer for cell culture applications. PDMS
provides a realistic mechanical loading to cells. The elastic
modulus of PDMS is 50–200 kPa,51 which is very close to the
modulus of several soft tissues52 including lymph nodes.53 The
top view and side view of MB formed from 100 mm circular
openings are shown in Supplementary Fig. 1.3
3.2 Characterization of TRAIL and anti-CD57 functionalized
liposome
Successful functionalization of TRAIL and anti-CD57 on the
liposome surface is mediated by maleimide-thiol conjugation
as indicated in Fig. 2A and 2B. NK cells isolated from whole
blood were maintain d in culture (Suppleme tary Fig. 2A3)
and flow cytometry histograms indicated that NK cells were
positive for CD57 expression (Supplementary Fig. 2B3). CD57 is
a marker for terminal differentiation in T-cells and it was
recently shown that it is expressed by a distinctly mature
subpopulation of human NK cells.54 The size distribution of
naked liposomes and protein-functionalized liposomes was
analysed using a zetasizer. The average size of naked
liposomes was 112.17 ¡ 1.62 nm and TRAIL and anti-CD57
functionalized liposomes were roughly 45–55 nm larger than
naked liposome (Fig. 2D). The increase in size of liposomes
after protein incubation indicated that TRAIL and anti-CD57
have been functionalized on the surface of liposomes.
3.3 Anti-CD57 on the liposome surface mediates conjugation
of liposome to NK cells
Conjugation of TRAIL-functionalized liposomes to NK cells is
mediated by CD57 expressed on the surface of NK cells and
anti-CD57 functionalized on the liposome surface (Fig. 2C).
Conjugating TRAIL-functionalized liposomes to NK cells did
not cause any detrimental effects on NK cells (Supplementary
Fig. 2C and 2D3). It has been shown that long-circulating
liposomes can effectively target solid tumors in cancer
patients.55 Conjugating liposomes to NK cells can further
increase the circulating time, which is an important criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-liposome conjugate (Super NK cell) (D.) Size distribution of
naked liposomes and protein-functionalized liposomes from Malvern zetasizer instrument. Table indicates the average size of particles in each group.
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apoptotic cancer cells in MB arrays. The mean pixel intensity
between different treatment groups was compared for statis-
tical significance using unpaired student t-test.
2.8 Confocal microscopy
NK cells were labelled with CellTracker green (Molecular
Probes1, C7025) and LNCaP cells were labelled with
CellTracker red (Molecular Probes1, C34552) and seeded on
MB arrays following the protocol mentioned in Section 2.6.
The chips were then transferred into a glass bottomed 24-well
plate and imaged using a Zeiss 710 laser scanning confocal
microscope.
3. Results and discussion
3.1 Microbubble geometry closely recapitulates the anatomy of
deep cortical unit of a lymph node
In this work we were interested in developing a unique
application of MB arrays as a model for mimicking lymph
node micrometastases. Their semi-rounded geometry with a
single circular opening on the top closely resembles the semi-
rounded anatomy of a deep cortical unit of a lymph node
centered on the top of an afferent lymphatic. PDMS is a
commonly used polymer for cell culture applications. PDMS
provides a realistic mechanical loading to cells. The elastic
modulus of PDMS is 50–200 kPa,51 which is very close to the
modulus of several soft tissues52 including lymph nodes.53 The
top view and side view of MB formed from 100 mm circular
openings are shown in Supplementary Fig. 1.3
3.2 Characterization of TRAIL and anti-CD57 functionalized
liposome
Successful functionalization of TRAIL and anti-CD57 on the
liposome surface is mediated by maleimide-thiol conjugation
as indicated in Fig. 2A and 2B. NK cells isolated from whole
blood were maintained in culture (Supplementary Fig. 2A3)
and flow cytometry histograms indicated that NK cells were
positive for CD57 expression (Supplementary Fig. 2B3). CD57 is
a marker for terminal differentiation in T-cells and it was
recently shown that it is expressed by a distinctly mature
subpopulation of human NK cells.54 The size distribution of
naked liposomes and protein-functionalized liposomes was
analysed using a zetasizer. The average size of naked
liposomes was 112.17 ¡ 1.62 nm and TRAIL and anti-CD57
functionalized liposomes were roughly 45–55 nm larger than
naked liposome (Fig. 2D). The increase in size of liposomes
after protein incubation indicated that TRAIL and anti-CD57
have been functionalized on the surface of liposomes.
3.3 Anti-CD57 on the liposome surface mediates conjugation
of liposome to NK cells
Conjugation of TRAIL-functionalized liposomes to NK cells is
mediated by CD57 expressed on the surface of NK cells and
anti-CD57 functionalized on the liposome surface (Fig. 2C).
Conjugating TRAIL-functionalized liposomes to NK cells did
not cause any detrimental effects on NK cells (Supplementary
Fig. 2C and 2D3). It has been shown that long-circulating
liposomes can effectively target solid tumors in cancer
patients.55 Conjugating liposomes to NK cells can further
increase the circulating time, which is an important criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-liposome conjugate (Super NK cell) (D.) Size distribution of
naked liposomes and protein-functionalized liposomes from Malvern zetasizer instrument. Table indicates the average size of particles in each group.
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2.2 Cell lines and culture conditions
Three lymph node seeking metastatic cell lines from different
types of cancers were used in this study. LNCaP (prostate
cancer), COLO 205 (colorectal cancer) and MDA-MB-231
(breast cancer) were purchased from American Type Culture
Collection (ATCC) and maintained in culture at 37 uC with 5%
CO2 in humidified incubator. LNCaP and COLO 205 cells were
cultured in RPMI-1640 (Cellgro, 10-040-CV) supplemented with
10% fetal bovine serum (FBS) (Atlanta Biologicals, S11050H),
and 1% penicillin/streptomycin (PS) (Gibco1, 15140-122).
MDA-MB-231 cells were cultured in high glucose DMEM
(Gibco1, 11965-092) supplemented with 10% FBS and 1%
PS. HNK-1, a hybridoma cell line (ATCC1 TIB-200TM) was
cultured in RPMI-1640 (ATCC1 30-2001TM) supplemented with
0.02 mM 2-mercaptoethanol (Gibco1, 21985-023) and 20%
ultra low IgG FBS (Gibco1, 16250-078). The hybridoma line
secretes anti-CD57 (IgM isotype), a monoclonal antibody
against human natural killer cells.50
2.3 Preparation of TRAIL and anti-CD57 functionalized
liposomes
Hydro Soy PC L-a-phosphatidylcholine (HSPC), cholesterol,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] (DSPE-mPEG2000) and 1,2-distear-
oyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (poly-
ethylene glycol)-2000] (DSPE-Mal-mPEG2000) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA). Liposomes were
composed of HSPC : cholesterol : DSPE-mPEG200 : DSPE-
Mal-mPEG2000 at a molar ratio of 2 : 1 : 0.08 : 0.02. Lipids
were mixed to produce a total of 10 mM lipid in 1 mL and kept
in a glass vial covered with parafilm inside a vacuum glass
chamber overnight to remove residual organic solvent. The
lipid cake was then hydrated in 1 mL of buffer composed of 20
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) and 150 mM sodium chloride in phosphate buffered
saline (PBS) at pH 7.5. The hydrated lipids formed multi-
lamellar vesicles which were then disrupted by 10–15 freeze (2
min)/thaw (3 min) cycles before extrusion. The lipid suspen-
sion was then forced through a polycarbonate filter with
successively smaller pore size (400 nm, 200 nm and 100 nm)
mounted on a holder in a heating block (Avanti1mini-
extruder). The temperature was maintained at 60 uC, which
is above the phase transition temperature of the lipids.
Anti-CD57 was isolated from hybridoma supernatant using a
protein-L agarose column (Thermo Scientific, 20510) following
a protocol supplied by the manufacturer for gravity-flow based
isolation of proteins. Recombinant human TRAIL (Peprotech
310-04) and anti-CD57 were thiolated using 1 mM Traut’s
reagent (Thermo Scientific, 26101) added in 6-fold molar
excess to the proteins in solution. Excess Traut’s reagent was
removed using a desalting column (Thermo Scientific, 89889)
by spinning the reaction mixture three times for 2 min at 1000
6 g. Thiolated proteins were then functionalized on the
surface of liposomes overnight at 4 uC via maleimide-thiol
chemistry by adding an appropriate amount of protein to set
the concentration of maleimide in liposomes at 6-fold molar
excess to the concentration of thiol groups in proteins. The
protein- functionalized liposomes were stored at 4 uC for up to
a week and prepared fresh whenever required. Successful
functionalization of proteins to liposomes was determined by
measuring the average particle size by dynamic light scattering
Fig. 1 Schematic diagram of (A.) Deep cortical unit of a lymph node (B.) Array of MB on a single chip (C.) Cancer cells co-cultured with NK cell-TRAIL liposome
conjugates in MB (D.) Single MB showing our proposed approach.
This journal is ! The Royal Society of Chemistry 2013 Lab Chip
Lab on a Chip Paper
Pu
bli
sh
ed
 on
 25
 Ju
ly 
20
13
. D
ow
nlo
ad
ed
 by
 C
orn
ell
 U
niv
ers
ity
 on
 10
/09
/20
13
 23
:58
:55
. 
View Article Online
2.2 Cell lines and cultur co ditions
Three lymph node seeking metastatic cell lines from different
types of cancers were used in this study. LNCaP (prostate
cancer), COLO 205 (colorectal cancer) and MDA-MB-231
(breast cancer) were purchased from American Type Culture
Collection (ATCC) and maintained in culture at 37 uC with 5%
CO2 in humidified incubator. LNCaP and COLO 205 cells were
cultured in RPMI-1640 (Cellgro, 10-040-CV) supplemented with
10% fetal bovine serum (FBS) (Atlanta Biologicals, S11050H),
and 1% penicillin/streptomycin (PS) (Gibco1, 15140-122).
MDA-MB-231 cells were cultured in high glucose DMEM
(Gibco1, 11965-092) supplemented with 10% FBS and 1%
PS. HNK-1, a hybridoma cell line (ATCC1 TIB-200TM) was
cultured in RPMI-1640 (ATCC1 30-2001TM) supplemented with
0.02 mM 2-mercaptoethanol (Gibco1, 21985-023) and 20%
ultra low IgG FBS (Gibco1, 16250-078). The hybridoma line
secretes anti-CD57 (IgM isotype), a monoclonal antibody
against human natural killer cells.50
2.3 Preparation of TRAIL and anti-CD57 functionalized
liposomes
Hydro Soy PC L-a-phosphatidylcholine (HSPC), cholesterol,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[ ethoxy
(polyethylene glycol)-2000] (DSPE-mPEG2000) and 1,2-distear-
oyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (poly-
ethylene glycol)-2000] (DSPE-Mal-mPEG2000) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA). Liposomes were
composed of HSPC : cholesterol : DSPE-mPEG200 : DSPE-
Mal-mPEG2000 at a molar ratio of 2 : 1 : 0.08 : 0.02. Lipids
were mixed to produce a total of 10 mM lipid in 1 mL and kept
in a glass vial covered with parafilm inside a vacuum glass
chamber overnight to remove residual organic solvent. The
lipid cake was then hydrated in 1 mL of buffer composed of 20
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) and 150 mM sodium chloride in phosphate buffered
saline (PBS) at pH 7.5. The hydrated lipids formed multi-
lamellar vesicles which were then disrupted by 10–15 freeze (2
min)/thaw (3 min) cycles before extrusion. The lipid suspen-
sion was then forced through a polycarbonate filter with
successively smaller pore size (400 nm, 200 nm and 100 nm)
mounted on a holder in a heating block (Avanti1mini-
extruder). The temperature was maintained at 60 uC, which
is above the phase transition temperature of the lipids.
Anti-CD57 was isolated from hybridoma supernatant using a
protein-L agarose column (Thermo Scientific, 20510) following
a protocol supplied by the manufacturer for gravity-flow based
isolation of proteins. Recombinant human TRAIL (Peprotech
310-04) and anti-CD57 were thiolated using 1 mM Traut’s
reagent (Thermo Scientific, 26101) added in 6-fold molar
excess to the proteins in solution. Excess Traut’s reagent was
removed using a desalting column (Thermo Scientific, 89889)
by spinning the reaction mixture three times for 2 min at 1000
6 g. Thiolated proteins were then functionalized on the
surface of liposomes overnight at 4 uC via maleimide-thiol
chemistry by adding an appropriate amount of protein to set
the concentration of maleimide in liposomes at 6-fold molar
excess to the concentration of thiol groups in proteins. The
protein- functionalized liposomes were stored at 4 uC for up to
a week and prepared fresh whenever required. Successful
functionalization of proteins to liposomes was determined by
measuring the average particle size by dynamic light scattering
Fig. 1 Schematic diagram of (A.) Deep cortical unit of a lymph node (B.) Array of MB on a single chip (C.) Cancer cells co-cultured with NK cell-TRAIL liposome
conjugates in MB (D.) Single MB showing our proposed approach.
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2.2 Cell lines and culture conditions
Three lymph node seeking metastatic cell lines from different
types of cancers were used in this study. LNCaP (prostate
cancer), COLO 205 (colorectal cancer) and MDA-MB-231
(breast cancer) were purchased from American Type Culture
Collection (ATCC) and maintained in culture at 37 uC with 5%
CO2 in humidified incubator. LNCaP and COLO 205 cells ere
cultured in RPMI-1640 (Cellgro, 10-040-CV) supplemented with
10% fetal bovine serum (FBS) (Atlanta Biologicals, S11050H),
and 1% penicillin/streptomycin (PS) (Gibco1, 15140-122).
MDA-MB-231 cells were cultured in high glucose DMEM
(Gibco1, 11965-092) supplemented with 10% FBS and 1%
PS. HNK-1, a hybridoma cell line (A CC1 TIB-200TM) was
cultured in RPMI-1640 (ATCC1 30-2001TM) supplemented with
0.02 mM 2-mercaptoethanol (Gibco1, 21985-023) and 20%
ultra low IgG FBS (Gibco1, 16250-078). The hybridoma line
secretes anti-CD57 (IgM isotype), a monoclonal antibody
against human natural killer cells.50
2.3 Preparation of TRAIL and anti-CD57 functionalized
liposomes
Hydro Soy PC L-a-phosphatidylcholine (HSPC), cholesterol,
1,2-distearoyl sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethyle e glyc l)-2000] (DSPE-mPEG2000) and 1,2-distear-
oyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (poly-
ethylene glycol)-2000] (DSPE-Mal-mPEG2000) were purchased
from Avanti Polar Lipids (Alabaster, AL, USA). Liposomes were
composed of HSPC : cholesterol : DSPE-mPEG200 : DSPE-
Mal-mPEG2000 at a molar ratio of 2 : 1 : 0.08 : 0.02. Lipids
were mixed to produce a total of 10 mM lipid in 1 mL and kept
in a glass vial covered with parafilm inside a vacuum glass
chamber overnight to remove residual organic solvent. The
lipid cake was then hydrated in 1 mL of buffer composed of 20
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) and 150 mM sodium chloride in phosphate buffered
saline (PBS) at pH 7.5. The hydrated lipids formed multi-
lamellar vesicles which were then disrupted by 10–15 freeze (2
min)/thaw (3 min) cycles before extrusion. The lipid suspen-
sion was then forced through a polycarbonate filter with
successively smaller pore size (400 nm, 200 nm and 100 nm)
mounted on a holder in a heating block (Avanti1mini-
extruder). The temperature was maintained at 60 uC, which
is above the phase transition temperature of the lipids.
Anti-CD57 was isolated from hybridoma supernatant using a
protein-L agarose column (Thermo Scientific, 20510) following
a protocol supplied by t e anufacturer for gravity-flow based
is lation of proteins. Recombinant human TRAIL (Peprotech
310-04) and anti-CD57 were t iolated using 1 mM Traut’s
reage t (Thermo Sci ntific, 26101) added in 6-fold molar
xcess to the proteins in solution. Excess Traut’s reagent was
removed using a desalting column (Thermo Scientific, 89889)
by spinning th reaction mixture th ee times for 2 min at 1000
6 g. Thiolated proteins were then functionalized on the
surface of li osome overnight at 4 uC via maleimide-thiol
chemistry by adding a appropriate amount of protein to set
the concentration of maleimide in lipos mes at 6-f ld molar
excess to the concentration of thiol groups in proteins. The
protein- functio alized liposomes were stored at 4 uC for up to
a week and pr pared fresh whenever required. Successful
functionalization of proteins to liposomes was determined by
measuring the average particle size by dynamic light scattering
Fig. 1 Schematic diagram of (A.) Deep cortical unit of a lymph node (B.) Array of MB on a single chip (C.) Cancer cells co-cultured with NK cell-TRAIL liposome
conjugates in MB (D.) Single MB showing our proposed approach.
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apoptotic cancer cells in MB arrays. The mean pixel intensity
betwe n different treatment groups was compared for statis-
tical significa ce using unpaired student t-test.
2.8 Confocal microscopy
NK cells were labelled with CellTrack r green (Molecular
Probes1, C7025) and LNCaP c lls were labelled with
CellTracker red (Molecular Probes1, C34552) and seeded on
MB arrays following the protocol m nt oned in Section 2.6.
The chips were then t ansferred into a glass bottomed 24-well
plate and imaged using a Zeiss 710 l s r scanning confocal
microscope.
3. Results and discussion
3.1 Microbubbl geometry closely recapitulates the anatomy of
deep cort cal unit of a lymph node
In this ork we were interested in developing a unique
application of MB rrays as a model for mimicking lymph
node microm tastases. The r semi-rounded geometry with a
s ngle circular ope ing on the top closely r embles the semi-
rounded anatomy of a deep cortical unit of a lymph node
centered on the top o an afferent lymphatic. PDMS is a
commonly used polymer for cell culture applications. PDMS
provides a realistic mechanical loading to cells. The elastic
modulus of PDMS is 50–200 kPa,51 which is very clos to the
modulus of several oft tissues52 i cluding lymph nodes.53 The
top view and side view of MB fo med fro 100 mm circular
openings are shown in Supplementary Fig. 1.3
3.2 Char cterization of TRAIL and anti-CD57 functionalized
liposome
S ccessful functionalization of TRAIL and anti-CD57 on the
liposome surface s mediated by maleimide-thiol conjugation
as ind cated in Fig. 2A and 2B. NK cells isolated fr m whole
blood were maintained in culture (Supplementary Fig. 2A3)
and fl w cytome ry histograms indicated that NK cells were
positive for CD57 expression (Supplementary Fig. 2B3). CD57 is
a marker for terminal differe t ation in T-cells and it was
recently shown that it is expressed by a distinc ly mature
s bp pulation of human NK cells.54 The ize distribution of
naked liposomes and protein-functionalized liposomes was
analy ed using a zetasiz r. The average siz of naked
liposomes was 112. 7 ¡ 1.62 nm and TRAIL and anti-CD57
functionalized liposom s were roughly 45–55 nm larger than
naked liposome (Fig. 2D). The increase in size of liposomes
af r protein incubation indicated that TRAIL and anti-CD57
have been functionalized on the surface of liposomes.
3.3 Anti-CD57 on the liposome surface mediates conjugation
of liposome to NK cells
Conjugation of TRAIL-functionalized lipos mes to NK cells is
mediated by CD57 expressed on the surface of NK cells and
anti-CD57 functionalized on the liposome surface (Fig. 2C).
Co jugating TRAIL-functionalized lipos mes to NK cells did
not cause any de rimental effects on NK cells (Supplementary
Fig. 2C and 2D3). It has been shown that long-circulating
liposomes can ffec ively target solid tumors in cancer
patients.55 Co jugating liposomes to NK cells can further
increase the circulating time, which is an impo tant criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-lip some conj gate (Super NK cell) (D.) Size distribution of
naked liposomes and pro ei -functionalized liposomes from Malvern zetasizer i strum nt. Tabl indic tes th av rage size of particles in each group.
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apoptotic cancer cells in MB arrays. The mean pixel intensity
b twe n different treatment groups was compared for statis-
ti al significance sing unpair d student t-test.
2.8 Confocal microscopy
NK c lls were lab lled with C llTrack r green (Molecular
Probes1, C7025) and LNCaP cells were labelled with
CellTracker red (Molecular Probes1, C34552) and seeded on
MB arrays foll wing th pr tocol m nti ed in Section 2.6.
The chips were then transferred int a glass bottomed 24-well
plate and imag d using Zei s 710 laser scanning confocal
microscope.
3. Results and discussion
3.1 Microbubble geometry closely recapitulates the anatomy f
deep cortical unit f a lymph node
In this ork w were int r ste in developing a unique
application of MB arrays as a odel for imicking lymph
node microm tastas s. Their semi-rounded geometry with a
single circular ope ing on the top clo ly resembles the semi-
r unded anatomy of deep cortical unit of a lymph node
centered on the top of an afferent lymphatic. PDMS is a
commonly used polymer for cell culture applications. PDMS
provides a realistic mechanical loading to cells. The el stic
modulus of PDMS is 50–200 kPa,51 which is very clos to the
modulus of sev ral oft tissues52 i cluding lymph nodes.53 Th
top view and side view of MB formed from 100 mm circular
openi gs are shown in Supplementary Fig. 1.3
3.2 Char cterization of TRAIL and anti-CD57 functionalized
liposome
Successful fu ctionalizatio of TRAIL and anti-CD57 on the
liposome surfac is ediate by maleimide-thiol conjugation
as indicated in Fig. 2A and 2B. NK cells isolat d fr m whole
blood w re maintai ed in cult re (Supplementary Fig. 2A3)
and fl w cytometry histograms indicat d that NK cells were
positive for CD57 ex r ssion (Supplementary Fig. 2B3). CD57 is
a marker for terminal differe tiation in T-cells and it was
recently shown that it is expre sed by a distinctly mature
s bp pul tion of hu an NK cells.54 The ize distribution of
naked lipos mes a d protein-functionalized liposomes was
analy ed using a zet sizer. The average size of naked
liposomes was 112. 7 ¡ 1.62 nm and TRAIL and anti-CD57
functionalized liposom s were roughly 45–55 nm larger than
naked liposome (Fig. 2D). The increase in size of liposomes
aft r protein in ubation indicated that TRAIL and anti-CD57
have been functionalized on the surface of liposomes.
3.3 Anti-CD57 on the liposome surface mediates conjugation
f liposome to NK cells
Conjugatio of TRAIL-functionalized lipos mes to NK cells is
mediated by CD57 expressed on the surface of NK cells and
anti-CD57 functionalized on the lipo ome surface (Fig. 2C).
Co jugating TRAIL-functionalized lipos mes to NK cells did
not cause any d trime tal effects on NK c lls (Supplementary
Fig. 2C and 2D3). It has been shown th t long-circulating
liposomes can effectively target solid tumors in cancer
patients.55 Co jugating liposome to NK cells can further
in re se the circulating time, which is an impo tant criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-lip som conj gate (Super NK cell) (D.) Size distribution of
naked liposomes and protein-functionalized liposomes from Malvern zetasizer i strum nt. Tabl indic tes th verage size of particles in each group.
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apoptotic cancer cells in MB arrays. The mean pixel intensity
between different treatment groups was compared for statis-
tical significance using unpaired student t-test.
2.8 Confocal microscopy
NK cells were labelled with CellTracker green (Molecular
Probes1, C7025) and LNCaP cells were labelled with
CellTracker red (Molecular Probes1, C34552) and seeded on
MB arrays following the protocol mentioned in Section 2.6.
The chips were then transferred into a glass bottomed 24-well
plate and imaged using a Zeiss 710 laser scanning confocal
microscope.
3. Results and discussion
3.1 Microbubble geometry closely recapitulates the anatomy of
deep cortical unit of a lymph node
In this work we were interested in developing a unique
application of MB arrays as a model for mimicking lymph
node micrometastases. Their semi-rounded geometry with a
single circular opening on the top closely resembles the semi-
rounded anatomy of a deep cortical unit of a lymph node
centered on the top of an afferent lymphatic. PDMS is a
commonly used polymer for cell culture applications. PDMS
provides a realistic mechanical loading to cells. The elastic
modulus of PDMS is 50–200 kPa,51 which is very close to the
modulus of several soft tissues52 including lymph nodes.53 The
top view and side view of MB formed from 100 mm circular
openings are shown in Supplementary Fig. 1.3
3.2 Characterization of TRAIL and anti-CD57 functionalized
liposome
Successful functionalization of TRAIL and anti-CD57 on the
liposome surface is mediated by maleimide-thiol conjugation
as indicated in Fig. 2A and 2B. NK cells isolated from whole
blood were maintained in culture (Supplementary Fig. 2A3)
and flow cytometry histograms indicated that NK cells were
positive for CD57 expression (Supplementary Fig. 2B3). CD57 is
a marker for terminal differentiation in T-cells and it was
recently shown that it is expressed by a distinctly mature
subpopulation of human NK cells.54 The size distribution of
naked liposomes and protein-functionalized liposomes was
analysed using a zetasizer. The average size of naked
liposomes was 112.17 ¡ 1.62 nm and TRAIL and anti-CD57
functionalized liposomes were roughly 45–55 nm larger than
naked liposome (Fig. 2D). The increase in size of liposomes
after protein incubation indicated that TRAIL and anti-CD57
have been functionalized on the surface of liposomes.
3.3 Anti-CD57 on the liposome surface mediates conjugation
of liposome to NK cells
Conjugation of TRAIL-functionalized liposomes to NK cells is
mediated by CD57 expressed on the surface of NK cells and
anti-CD57 functionalized on the liposome surface (Fig. 2C).
Conjugating TRAIL-functionalized liposomes to NK cells did
not cause any detrimental effects on NK cells (Supplementary
Fig. 2C and 2D3). It has been shown that long-circulating
liposomes can effectively target solid tumors in cancer
patients.55 Conjugating liposomes to NK cells can further
increase the circulating time, which is an important criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-liposome conjugate (Super NK cell) (D.) Size distribution of
naked liposomes and protein-functionalized liposomes from Malvern zetasizer instrument. Table indicates the average size of particles in each group.
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apoptotic cancer cells in B arrays. The ean pixel intensity
between different treat ent groups was co pared for statis-
tical significance using unpaired student t-test.
2.8 Confocal icroscopy
NK cells were labelled with CellTracker green ( olecular
Probes1, C7025) and LNCaP cells were labelled with
CellTracker red ( olecular Probes1, C34552) and seed d on
B arrays following the protocol entioned in Section 2.6.
The chips were then transferred into a glass botto ed 24-well
plate and i aged using a Zeiss 710 laser scanning confocal
icroscope.
. es lts a isc ssi
3.1 icrobubble geo etry closely recapitulates the anato y of
deep cortical unit of a ly ph node
In this work we were interested in developing a unique
pplication of B arrays as a odel for i icking ly ph
nod ic o etastases. Their se i-rounded geo etry with a
single circular opening on the top closely rese bles the se i-
rounded nato y of a deep cortical unit of a ly ph node
centered on the top of an afferent ly phatic. PD S is a
co only used poly er for cell culture applications. PD S
provides a realistic echanical loading to cells. The elastic
odulus of PD S is 50–200 kPa,51 which is very close to the
odulus of several soft tissues52 including ly ph nodes.53 The
top view and side view of B for ed fro 100 m circular
openings are shown in Supple entary Fig. 1.3
3.2 Characterization of TRAIL and anti-CD57 functionalized
liposo e
Successful functionalization of TRAIL and anti-CD57 on the
liposo e surface is ediated by alei ide-thiol conjugation
as indicated in Fig. 2A and 2B. NK cells isolated fro whole
blood were aintained in culture (Supple entary Fig. 2A3)
and flow cyto etry histogra s indicated that NK cells were
positive for CD57 expression (Supple entary Fig. 2B3). CD57 is
a arker for ter inal differentiation in T-cells and it was
recently shown that it is expressed by a distinctly ature
subpopulation of hu an NK cells.54 The size distribution of
naked liposo es and protein-functionalized liposo es was
analysed using a zetasizer. The average size of naked
liposo es was 112.17 1.62 n and TRAIL and anti-CD57
functionalized liposo es were roughly 45–55 n larger than
naked liposo e (Fig. 2D). The increase in size of liposo es
after protein incubation indicated that TRAIL and anti-CD57
have been functionalized on the surface of liposo es.
3.3 Anti-CD57 on the liposo e surface ediates conjugation
of liposo e to NK cells
Conjugation of TRAIL-functionalized liposo es to NK cells is
ediated by CD57 expressed on the surface of NK cells and
anti-CD57 functionalized on the liposo e surface (Fig. 2C).
Conjugating TRAIL-functionalized liposo es to NK cells did
not cause any detri ental effects on NK cells (Supple entary
Fig. 2C and 2D3). It has been shown that long-circulating
liposo es can effectively target solid tu ors in cancer
patients.55 Conjugating liposo es to NK cells can further
increase the circulating ti e, which is an i portant criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-liposome conjugate (Super NK cell) (D.) Size distribution of
naked liposomes and protein-functionalized liposomes from Malvern zetasizer instrument. Table indicates the average size of particles in each group.
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apoptotic cancer cel s in MB ar ays. The mean pixel intensity
betwe n dif erent treatment groups was compared for statis-
tical significance using unpaired student t-test.
2.8 Confocal microscopy
NK cel s were label ed with Cel Tracker gre n (Molecular
Probes1, C7025) and LNCaP cel s were label ed with
Cel Tracker red (Molecular Probes1, C34552) and s ded on
MB ar ays fol owing the protocol mentioned in Section 2.6.
The chips were then transfer ed into a glas bot omed 24-wel
plate and imaged using a Zeis 710 laser scanning confocal
microscope.
3. Results and discussion
3.1 Microbubble geometry closely recapitulates the a atomy of
de p cortical unit of a lymph node
In this work we were interested in developing a unique
application of MB ar ays as a model for mimicking lymph
node micrometastases. Their semi-rounded geometry with a
single circular opening on the top closely resembles the semi-
rounded anatomy of a de p cortical unit of a lymph node
centered on the top of an af erent lymphatic. PDMS is a
commonly used polymer for cel culture applications. PDMS
provides a realistic mechanical loading to cel s. The elastic
modulus of PDMS is 50–200 kPa,51 which is very close to the
modulus of several soft tis ues52 including lymph nodes.53 The
top view and side view of MB formed from 100 m circular
openings are shown in Supplementary Fig. 1.3
3.2 Characterization of TRAIL and anti-CD57 functionalized
liposome
Suc es ful functionalization of TRAIL and anti-CD57 on the
liposome surface is mediated by maleimide-thiol conjugation
as indicated in Fig. 2A and 2B. NK cel s isolated from whole
blood were maintained in culture (Supplementary Fig. 2A3)
and flow cytometry histograms indicated that NK cel s were
positive for CD57 expres ion (Supplementary Fig. 2B3). CD57 is
a marker for terminal dif erentiation in T-cel s and it was
recently shown that it is expres ed by a distinctly mature
subpopulation of human NK cel s.54 The size distribution of
naked liposomes and protein-functionalized liposomes was
analysed using a zetasizer. The average size of naked
liposomes was 112.17 ¡ 1.62 nm and TRAIL and anti-CD57
functionalized liposomes were roughly 45–55 nm larger than
naked liposome (Fig. 2D). The increase in size of liposomes
after protein incubation indicated that TRAIL and anti-CD57
have be n functionalized on the surface of liposomes.
3.3 Anti-CD57 on the liposome surface mediates conjugation
of liposome to NK cel s
Conjugation of TRAIL-functionalized liposomes to NK cel s is
mediated by CD57 expres ed on the surface of NK cel s and
anti-CD57 functionalized on the liposome surface (Fig. 2C).
Conjugating TRAIL-functionalized liposomes to NK cel s did
not cause any detrimental ef ects on NK cel s (Supplementary
Fig. 2C and 2D3). It has be n shown that long-circulating
liposomes can ef ectively target solid tumors in cancer
patients.5 Conjugating liposomes to NK cel s can further
increase the circulating time, which is an important criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-liposome conjugate (Super NK cell) (D.) Size distribution of
naked liposomes and protein-functionalized liposomes from Malvern zetasizer instrument. Table indicates the average size of particles in each group.
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apoptotic cancer cells in B arrays. The ean pixel intensity
between different treat ent groups was co pared for statis-
tical significance using unpaired student t-test.
2.8 Confocal icroscopy
NK cells were labelled with CellTracker green ( olecular
Probes1, C7025) and LNCaP cells were labelled with
CellTracker red ( olecular Probes1, C34552) and seeded on
B arrays following the protocol entioned in Section 2.6.
The chips were then transferred into a glass botto ed 24-well
plate and i aged using a Zeiss 710 laser scanning confocal
icroscope.
3. es lts a isc ssi
.1 i robubble geo etry closely recapitulates the a ato y of
deep cortical unit of a ly ph node
In this work we were interested in developing a unique
application of B arrays as a odel for i icking ly ph
node icro etastases. Their se i-rounded geo etry with a
single circular opening on the top closely rese bles the se i-
rounded anato y of a deep cortical unit of a ly ph node
centered on the top of an afferent ly phatic. PD S is a
co only used poly er for cell culture applications. PD S
provides a realistic echanical loading to cells. The elastic
odulus of PD S is 50–200 kPa,51 which is very close to the
odulus of several soft tissues52 including ly ph nodes.53 The
top view and side view of B for ed fro 100 m circular
openings are shown in Supple entary Fig. 1.3
3.2 Characterization of TRAIL and anti-CD57 functionalized
liposo e
Successful functionalization of TRAIL and anti-CD57 on the
liposo e surface is ediated by alei ide-thiol conjugation
as indicated in Fig. 2A and 2B. NK cells isolated fro whole
blood were aintained in culture (Supple entary Fig. 2A3)
and flow cyto etry histogra s indicated that NK cells were
positive for CD57 expression (Supple entary Fig. 2B3). CD57 is
a arker for ter inal differentiation in T-cells and it was
recently shown that it is expressed by a distinctly ature
subpopulation of hu an NK cells.54 The size distribution of
naked liposo es and protein-functionalized liposo es was
analysed using a zetasizer. The average size of naked
liposo es was 112.17 1.62 n and TRAIL and anti-CD57
functionalized liposo es were roughly 45–55 n larger than
naked liposo e (Fig. 2D). The increase in size of liposo es
afte protein incubation indicated that TRAIL and anti-CD57
have been functionalized on the surface of liposo es.
3.3 Anti-CD57 on the liposo e surface ediates conjugation
of liposo e to NK cells
Conjugation of TRAIL-functionalized liposo es to NK cells is
ediated by CD57 expressed on the surface of NK cells and
anti-CD57 functionalized on the liposo e surface (Fig. 2C).
Conjugating TRAIL-functionalized liposo es to NK cells did
not cause any detri ental effects on NK cells (Supple entary
Fig. 2C and 2D3). It has been shown that long-circulating
liposo es can effectively target solid tu ors in cancer
patients.55 Conjugating liposo es to NK cells can further
increase the circulating ti e, which is an i portant criterion
Fig. 2 Schematics of a (A.) Naked liposome (B.) TRAIL and anti-CD57 functionalized liposome (C.) NK cell-liposome conjugate (Super NK cell) (D.) Size distribution of
naked liposomes and protein-functionalized liposomes from Malvern zetasizer instrument. Table indicates the average size of particles in each group.
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FIGURE 1.10: UNNATURAL KILLER CELLS TO TARGET AND KILL 
CANCER CELLS IN FLOWING HUMAN BLOOD IN VITRO AND IN THE 
PERIPHERAL CIRCULATION OF MICE IN VIVO. (A) Schematic of E-
selectin(ES)/TRAIL functionalized liposome synthesis. (B) Confocal micrographs of 
fluorescent ES/TRAIL liposomes functionalized to the surface of leukocytes after 
exposure to blood flow. Scale bar = 5 µm. Green: ES/TRAIL liposome. Blue: 
leukocyte nucleus. (C) Micrographs of COLO 205 cells (white) after treatment with 
ES/TRAIL liposomes (left) or ES-conjugated liposomes in blood under shear flow for 
2 h. Scale bar = 50 µm. (D) Flow cytometry of COLO 205 cancer cells after treatment 
with ES/TRAIL or ES liposomes in blood under shear flow in a cone-and-plate 
viscometer (shear rate: 188 s−1) for 2 h. Unsheared: viable untreated cancer cell 
control. (E) Comparison of fraction of viable COLO 205 and PC-3 cancer cells after 
treatment with ES/TRAIL liposomes in buffer versus blood. n = 3 for all samples. 
Bars represent the mean ± SD in each treatment group. ***P < 0.0001 (unpaired t 
test). (F) Fraction of viable COLO 205 and PC-3 cancer cells after treatment with 
ES/TRAIL liposomes in blood with varying percentages of hematocrit. Hematocrit 
was varied whereas other blood components remained constant, based on a normal 
hematocrit of 45%. Plasma indicates removal of all blood cells. n = 3 for all samples. 
Bars represent the mean ± SD in each treatment group. *P < 0.05 (one-way ANOVA 
with Tukey post-test). (G) Schematic of two-step mechanism involving 
functionalization of leukocytes with liposomes (left), which then contact circulating 
cancer cells and activate the death receptor (right). (H) Schematic of in vivo mouse 
experiment to functionalize leukocytes via systemic delivery of ES/TRAIL liposomes, 
61 
followed by targeting of circulating cancer cells in the bloodstream. (I) Representative 
micrographs of COLO 205 cancer cells removed from mouse circulation after 
treatment with ES/TRAIL liposomes (Upper Left), sTRAIL (Upper Right), ES 
liposomes (Lower Left), and buffer (Lower Right) injections. Scale bar = 20 µm. (J) 
Leukocytes functionalized with fluorescent ES/TRAIL liposomes (green) upon 
removal from mouse circulation 2.5 h after systemic injection. Scale bar = 50 µm. (K) 
Schematic of mouse lung and example two-photon excited fluorescence (2PEF) image 
stack from mouse lung where Hoechst-labeled COLO 205 cells (green) are arrested in 
vasculature of lung (visible by autofluorescence, yellow). Scale bar =  80 µm. (L) 
2PEF images of Hoescht-labeled COLO 205 cells (green) with Alexa Fluor 568- 
labeled Annexin-V apoptosis probe (red) for each experimental group. Red arrows 
point to apoptotic COLO 205 cells (red and green colocalized), and blue arrows 
indicate non-apoptotic COLO 205 cells (green only). White circles indicate regions of 
autofluorescence from lung tissue. Scale bar = 30 µm.  Figure parts adapted from 
[209]. 
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FIGURE 1.10: UNNATURAL KILLER CELLS TO TARGET AND KILL 
CANCER CELLS IN FLOWING HUMAN BLOOD IN VITRO AND IN THE 
PERIPHERAL CIRCULATION OF MICE IN VIVO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the postcapillary venules where selectin-mediated adhesion
and cell extravasation into tissues typically occur, moderate shear
rates can initiate flowing cell interactions with the endothelial
cell wall (20, 21). To recreate these physical forces in vitro,
a cone-and-plate shear assay was developed to probe the inter-
actions of cancer cells and ES/TRAIL liposomes under venular
shear rates. After exposure to shear flow (shear rate: 188 s−1) for
2 h, COLO 205 cells exposed to ES liposomes displayed their
normal morphology whereas substantial membrane blebbing was
observed in samples exposed to ES/TRAIL liposomes, character-
istic of cells undergoing apoptosis (Fig. 1B). Annexin-V assay
revealed that exposure to shear flow for 2 h induced minimal
COLO 205 cell apoptosis in untreated controls (Fig. 1C), in ad-
dition to treatment with liposomes in the absence of conjugated
protein (Fig. 1D) or conjugated solely with ES (Fig. 1E) or TRAIL
(Fig. 1F). However, a combination of ES/TRAIL conjugated to the
liposome surface induced a significant decrease in COLO 205 vi-
ability following exposure to shear flow (Fig. 1 G and H).
To investigate the adhesive characteristics of ES/TRAIL
liposomes to cancer cells under flow, COLO 205 cells were ex-
posed to ES/TRAIL liposomes consisting of fluorescent choles-
terol and exposed to shear flow as in previous in vitro shear assays.
Flow cytometry revealed that >99.9% of the COLO 205 cell
population was adhered to ES/TRAIL liposomes after exposure to
shear flow (Fig. S3 A and B). Fluorescent micrographs and
brightfield overlay images clearly displayed ES/TRAIL lip-
osomes adhered to the surface of COLO 205 cells (Fig. S3 C and
D). These data suggest that the presence of the ES adhesion
receptor enhances the effect of TRAIL by promoting tighter
contacts with the cancer-cell membrane.
ES/TRAIL Liposomes Functionalize Leukocytes in Whole Blood Under
Shear Flow in Vitro. In addition to CTCs, circulating leukocytes
also possess ligands for ES, which are necessary in the in-
flammatory response and lymphocyte homing to lymphatic tis-
sues (1, 22). To assess the potential to functionalize leukocytes
with ES/TRAIL to target and kill CTCs, we treated human blood
with fluorescent ES/TRAIL liposomes under shear flow in a cone-
and-plate viscometer. Upon exposure to shear (shear rate: 188 s−1),
ES/TRAIL liposomes readily bind to leukocytes via selectin
ligands on the leukocyte surface (Fig. 2A).
To quantify leukocyte subpopulations that adhere to ES/TRAIL
liposomes under flow, leukocytes were separated from whole
blood and analyzed for both leukocyte marker expression and
adherent ES/TRAIL liposomes using flow cytometry. Function-
alized leukocytes were labeled with CD3, CD14, CD16, CD19,
and CD56 antibodies, as such markers are commonly expressed
on most T lymphocytes, monocytes, neutrophils, B-lymphocytes,
and natural killer (NK) cells, respectively (23). Minimal adhesion
of ES/TRAIL liposomes to leukocytes in blood was observed in
the presence of a functional blocking ES antibody (Fig. 2 B–G).
Minimal ES/TRAIL liposome adhesion was also observed im-
mediately after treatment with whole blood. However, after
exposure to shear flow, flow cytometry analysis revealed that
leukocyte subpopulations positive for CD3 (Fig. 2B), CD14 (Fig.
2C), CD16 (Fig. 2D), CD19 (Fig. 2E), and CD56 (Fig. 2F) ad-
hered to ES/TRAIL liposomes to varying degrees (Fig. 2G). Ad-
hesion was also observed on populations of lymphocytes, which
suggests that some cytotoxic patrolling of the lymphatic system may
also occur in vivo. Leukocyte subpopulations can vary in their E-
selectin ligand expression (24) and thus could explain the varia-
tions in the number of bound ES/TRAIL liposomes.
ES/TRAIL Functionalization Does Not Induce Significant Leukocyte or
Endothelial Cell Death. To assess the effects of ES/TRAIL func-
tionalization on leukocyte viability, mononuclear leukocytes iso-
lated from human blood were treated with ES/TRAIL liposomes
under both static and shear-flow conditions. Annexin-V assays
revealed no significant differences in leukocyte viability when
leukocytes were incubated with ES (Fig. S4B) or ES/TRAIL
(Fig. S4C) liposomes under static conditions for 24 h, compared
with untreated leukocyte controls (Fig. S4 A and D). Upon
functionalization with liposomes under shear flow for 2 h (shear
rate, 188 s−1), no significant decreases were found in ES (Fig.
S4F) or ES/TRAIL (Fig. S4G) functionalized leukocytes, com-
pared with untreated leukocyte controls (Fig. S4 E andH). These
data suggest that ES/TRAIL liposomes can functionalize leu-
kocytes under flow to target and kill cancer cells, while exerting
negligible cytotoxic effects on leukocytes. It is important to note
that individual subpopulations of leukocytes have shown apo-
ptotic effects in the presence of TRAIL (25); however, this study
focused on the overall effects of ES/TRAIL liposomes on blood-
borne leukocytes.
To assess the effects of ES/TRAIL functionalization on en-
dothelial cell viability, human umbilical vein endothelial cells
(HUVECs) were treated with ES/TRAIL liposomes in human
blood under shear-flow conditions in vitro. Treatment with ES/
TRAIL liposomes or an equivalent concentration of soluble
TRAIL in human blood under shear flow for 4 h induced no
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Fig. 1. ES/TRAIL liposomes adhesively interact with and kill cancer cells
under uniform shear flow. (A) Synthesis of ES, TRAIL, and ES/TRAIL uni-
lamellar liposomes using a thin film hydration method. Briefly, lipids in
chloroform were dried overnight to form a thin lipid film. Lipids were then
hydrated and subjected to freeze–thaw cycles to formmultilamellar liposomes,
which were extruded through membranes to form unilamellar liposomes. ES,
TRAIL, or a combination of ES and TRAIL was then conjugated to Ni-NTA on the
liposome surface. To assess the ability of ES/TRAIL liposomes to target and kill
cancer cells under flow, ES/TRAIL liposomes were added to a suspension of
COLO 205 cancer cells and exposed to shear flow in a cone-and-plate viscometer
at a shear rate of 188 s−1 for 2 h. Cells were then removed, washed, placed into
culture for 24 h, and assessed for cell viability. (B) COLO 205 morphology after
treatment with ES (Upper) and ES/TRAIL (Lower) liposomes under shear flow.
(Scale bar, 20 μm.) (C–G) Representative propidium iodide/Annexin-V flow
cytometry plots of unsheared cancer cells (C) and cells sheared with naked (D),
TRAIL-bound (E), ES-bound (F), and ES/TRAIL-bound liposomes (G) under shear
flow. Cells were classified into four categories based on dye uptake: viable cells
[negative for Annexin-V and propidium iodide (PI)], early apoptotic cells (posi-
tive for Annexin-V only), late apoptotic cells (positive for Annexin-V and PI), and
necrotic cells (positive for PI only). (H) Percent of viable cells after treatment
for each group. n = 3 for all samples. Bars represent the mean ± SD in each
treatment group. ***P < 0.0001 (one-way ANOVA with Tukey posttest).
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significant differences in HUVEC viability, compared with un-
treated HUVECs exposed to shear in human blood (Fig. S5).
These data suggest that ES/TRAIL-functionalized leukocytes
exert negligible toxic effects on um n endothelial cells under
blood-flow conditions.
Apoptotic Effects of ES/TRAIL Therapy Are Enhanced in Human Blood
Under Flow. Clinically, CTCs ar sparsely distributed in the
complex milieu of whole blood, at concentrations as low as 1–100
cells per mL (3, 12). To examine whether ES/TRAIL liposomes
would effectively target cancer cells in the presence of blood cells
and serum under flow conditions, we fluorescently labeled co-
lorectal COLO 205 and prostate PC-3 cancer-cell lines and
spiked them into human peripheral blood. Surprisingly, under
identical shear-flow conditions, ES/TRAIL therapy was even
more effective at killing cancer cells in the presence of human
blood (Fig. 3 A–D), compared with shearing COLO 205 or PC-3
cells alone in buffer (Fig. 3E), with <5% of the fluorescent, viable
cancer-cell populations remaining after ES/TRAIL treatment (Fig.
3E). These results suggest that ES/TRAIL therapy is effective at
targeting circulating cancer cells derived from multiple organs in
human blood.
To evaluate the impact of blood cells on the efficacy of ES/
TRAIL treatment, fluorescent COLO 205 and PC-3 cells were
spiked in human blood of varying hematocrit percentages. All
additional blood-cell components were maintained whereas the
volume of removed erythrocytes was replaced with plasma from
the same blood donor. Interestingly, the apoptotic effects were
hematocrit-dependent, as higher hematocrit significantly de-
creased the number of viable COLO 205 and PC-3 cells after ES/
TRAIL treatment (Fig. 3F). The enhanced apoptotic effect
suggests that blood-cell collisions under flow can promote the
apoptotic effects of ES/TRAIL liposomes and agrees with our
intuitive understanding of blood rheology, as the presence of
erythrocytes is known to create erratic cell paths with frequent
cross-streamline displacements (26) and increase the lifetime of
colliding doublets to promote aggregate formation (27).
To assess the mechanism by which leukocytes act as a pervading
carrier surface for functional TRAIL, blood was pretreated with
ES/TRAIL liposomes under shear flow, with blood cells sub-
sequently separated from unbound ES/TRAIL via centrifugation
and replaced with fresh blood plasma. ES/TRAIL therapeutic
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Fig. 2. ES/TRAIL liposomes adhere to multiple leukocyte subpopulations
after exposure to shear flow in whole blood. (A) Confocal images of ES/TRAIL
liposomes (green) bound to human leukocytes (blue, cell nuclei) after ex-
posure to shear flow in whole blood in a cone-and-plate viscometer at
188 s−1 for 30 min. Leukocytes have nuclear morphology characteristic of
monocytes (Left), lymphocytes (Center), and neutrophils (Right). (Scale bar,
5 μm.) (B–G) To assess the adhesion of ES/TRAIL liposomes to leukocyte
subpopulations, fluorescent ES/TRAIL liposomes were added to human blood
and exposed to shear flow in a cone-and-plate viscometer at a shear rate of
188 s−1 for 30 min. Leukocytes were isolated from blood using a Polymorphs
density gradient and labeled with CD3, CD14, CD16, CD19, and CD56, which
is typically expressed on T lymphocytes, monocytes, neutrophils, B-lympho-
cytes, and natural killer cells, respect vely. Expression of fluorescent ES/TRAIL
(FL ES/TRAIL) liposomes on the surface of leukocytes that are CD3+ (B),
CD14+ (C), CD16+ (D), CD19+ (E ), and CD56+ (F ), determined using flow
cytometry. Expression of CD3, CD14, CD16, CD19, and CD56 on the leu-
kocyte surface was determined using isotype controls. No label, unsheared
cells that were not treated with fluorescent ES/TRAIL liposomes; ES Block,
cells treated with fluorescent ES/TRAIL liposomes that were pretreated
with an ES functional blocking antibody; Post-Mix, cells labeled with
fluorescent ES/TRAIL liposomes immediately after mixing liposomes in
whole blood. (G) Percent of CD3+, CD14+, CD16+, CD19+, and CD56+
leukocytes adhered to ES/TRAIL liposomes. n = 3 for all samples. Bars
represent the mean ± SD in each treatment group. ***P < 0.0001 (one-way
ANOVA with Tukey posttest).
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Fig. 3. ES/TRAIL liposome therapeutic effects are enhanced in human blood
under flow in vitro. (A) Flow cytometry of COLO 205 cancer cells after
treatment wi h ES/TRAIL or ES liposomes in blood under shear flow in a
cone-and-plate viscometer at 188 s−1 for 2 h. Unsheared, viable untreated
cancer c ll control. (B) Representative flow cytometry histogram showing
th number of viable ancer cells collected. (C) Representative micrographs
of L 205 cells (white) in blood when treated with ES/TRAIL (Left) and ES
only (Right) liposomes in blood under shear flow. (Scale bar, 50 μm.) (D)
Number of viable COLO 205 and PC-3 cells per volume of blood after
treatment with ES/TRAIL or ES liposomes in blood under shear flow. n = 3 for
all samples. Bars represent the mean ± SD in each treatment group. **P <
0.001, ***P < 0.0001 (unpaired t test). (E) Comparison of fraction of COLO 205
and PC-3 cells tha remained viable after treatment with ES/TRAIL lipo omes
in bu fer versus blood. n = 3 for all samp es. Bars repres nt the mean ± SD in
each tr atment group. ***P < 0.0001 (unpaired t test). (F) Fraction of COLO
205 and PC-3 cells that r mained viable after treatment with ES/TRAIL lip-
osomes in blood with varying percentages of normal hematocrit. Hematocrit
was varied whereas other blood components remained constant, based on
a normal hematocrit of 45%. Plasma indicates removal of all blood cells. n = 3
for all samples. Bars represent the mean ± SD in each treatment group. *P <
0.05 (one-way ANOVA with Tukey posttest).
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significant differences in HUVEC viability, compared with un-
treated HUVECs exposed to shear in human blood (Fig. S5).
These data suggest that ES/TRAIL-functionalized leukocytes
exert negligible toxic effects on human endothelial cells under
blood-flow conditions.
Apoptotic Effects of ES/TRAIL Therapy Are Enhanced in Human Blood
Under Flow. Clinically, CTCs are spar ely distributed i the
complex milieu of whole blood, at concentrations as low as 1–100
cells per mL (3, 12). To examine whether ES/TRAIL liposomes
would effectively target cancer cells in th presence of blood cells
and serum under flow conditions, we flu rescently labeled co-
lorectal COLO 205 and prostate PC-3 cancer-cell lines and
spiked them into human peripheral blood. Surprisingly, under
identical shear-flow conditions, ES/TRAIL therapy was even
more effective at killing cancer cells in the r sence of human
blood (Fig. 3 A–D), compared with shearing COLO 205 or PC-3
cells alone in buffer (Fig. 3E), with <5% of the fluoresc nt, viable
cancer-cell populations remaining after ES/TRAIL treatment (Fig.
3E). These results suggest that ES/TRAIL therapy is effective at
targeting circulating cancer cells derived from multiple organs in
human blood.
To evaluate the impact of blood cells on the efficacy of ES/
TRAIL treatment, fluorescent COLO 205 and PC-3 cells were
spiked in human blood of varying hematocrit percentages. All
additional blood-cell components were maintained whereas the
volume of removed erythrocytes was replaced with plasma from
the same blood donor. Interestingly, the apoptotic effects were
hematocrit-dependent, as higher hematocrit significantly de-
creased the number of viable COLO 205 and PC-3 cells after ES/
TRAIL treatment (Fig. 3F). The enhanced apoptotic effect
suggests that blood-cell collisions under flow can promote the
apoptotic effects of ES/TRAIL liposomes and agrees with our
intuitive understanding of blood rheology, as the presence of
erythrocytes is known to create erratic cell paths with frequent
cross-streamline displacements (26) and increase the lifetime of
colliding doublets to promote aggregate formation (27).
To assess the mechanism by which leukocytes act as a pervading
carrier surface for functional TRAIL, blood was pretreated with
ES/TRAIL liposomes under shear flow, with blood cells sub-
sequently separated from unbound ES/TRAIL via centrifugation
and replaced with fresh blood plasma. ES/TRAIL therapeutic
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Fig. 2. ES/TRAIL liposomes adhere to multiple leukocyte subpopulations
after exposure to shear flow in whole blood. (A) Confocal images of ES/TRAIL
liposomes (green) bound to human leukocytes (blue, cell nuclei) after ex-
posure to shear flow in whole blood in a cone-and-plate viscometer at
188 s−1 for 30 min. Leukocytes have nuclear morphology characteristic of
monocytes (Left), lymphocytes (Center), and neutrophils (Right). (Scale bar,
5 μm.) (B–G) To assess the adhesion of ES/TRAIL liposomes to leukocyte
subpopulations, fluorescent ES/TRAIL liposomes were added to human blood
and exposed to shear flow in a cone-and-plate viscometer at a shear rate of
188 s−1 for 30 min. Leukocytes were isolated from blood using a Polymorphs
density gradient and labeled with CD3, CD14, CD16, CD19, and CD56, which
is typically expressed on T lymphocytes, monocytes, neutrophils, B-lympho-
cytes, and natural killer cells, respectively. Expression of fluorescent ES/TRAIL
(FL ES/TRAIL) liposomes on the surface of leukocytes that are CD3+ (B),
CD14+ (C), CD16+ (D), CD19+ (E ), and CD56+ (F ), determined using flow
cytometry. Expression of CD3, CD14, CD16, CD19, and CD56 on the leu-
kocyte surface was determined using isotype controls. No label, unsheared
cells that were not treated with fluorescent ES/TRAIL liposomes; ES Block,
cells treated with fluorescent ES/TRAIL liposomes that were pretreated
with an ES functional blocking antibody; Post-Mix, cells labeled with
fluorescent ES/TRAIL liposomes immediately after mixing liposomes in
whole blood. (G) Percent of CD3+, CD14+, CD16+, CD19+, and CD56+
leukocytes adhered to ES/TRAIL liposomes. n = 3 for all samples. Bars
represent the mean ± SD in each treatment group. ***P < 0.0001 (one-way
ANOVA with Tukey posttest).
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Fig. 3. ES/TRAIL liposome therapeutic effects are enhanced in human blood
under fl w i vitro. (A) Flow cytometry of COLO 205 cancer cells after
treat nt with ES/TRAIL or ES lip somes in blood under shear flow in a
cone-and-plate viscometer at 188 s−1 for 2 h. Unsheared, viable untreated
cancer cell control. (B) Representative flow cytometry histogram showing
the nu ber of viable cancer cells c ll cted. (C) Representative micrographs
of COLO 205 cells (white) in blood when treated with ES/TRAIL (Left) and ES
only (Right) liposomes in blood under shear flow. (Scale bar, 50 μm.) (D)
Number of viable COLO 205 and PC-3 cells per volume of blood after
treatment with ES/TRAIL or ES liposomes in blood under shear flow. n = 3 for
all samples. Bars represent the mean ± SD in each treatment group. **P <
0.001, ***P < 0.0001 (unpaired t test). (E) Comparison of fraction of COLO 205
and PC-3 cells that remained viable after treatment with ES/TRAIL liposomes
in buffer versus blood. n = 3 for all samples. Bars represent the mean ± SD in
each treatment group. ***P < 0.0001 (unpaired t test). (F) Fraction of COLO
205 and PC-3 cells that remained viable after treatment with ES/TRAIL lip-
osomes in blood with varying percentages of normal hematocrit. Hematocrit
was varied whereas other blood components remained constant, based on
a normal hematocrit of 45%. Plasma indicates removal of all blood cells. n = 3
for all samples. Bars represent the mean ± SD in each treatment group. *P <
0.05 (one-way ANOVA with Tukey postt st).
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significant differences in HUVEC viability, compared with un-
treated HUVECs exposed to shear in human blood (Fig. S5).
These data suggest that ES/TRAIL-functionalized leukocytes
exert negligible toxic effects on human endothelial cells under
blood-flow conditions.
Apoptotic Effects of ES/TRAIL Therapy Are Enhanced in Human Blood
Under Flow. Clinically, CTCs are sparsely distributed in the
complex milieu of whole blood, at concentrations as low as 1–100
cells per mL (3, 12). To examine whether ES/TRAIL liposomes
would effectively target cancer cells in the presence of blood cells
and serum under flow conditions, we fluorescently labeled co-
lorectal COLO 205 and prostate PC-3 cancer-cell lines and
spiked them into human peripheral blood. Surprisingly, under
identical shear-flow conditions, ES/TRAIL therapy was even
more effective at killing cancer cells in the presence of human
blood (Fig. 3 A–D), compared with shearing COLO 205 or PC-3
cells alone in buffer (Fig. 3E), with <5% of the fluorescent, viable
cancer-cell populations remaining after ES/TRAIL treatment (Fig.
3E). These results suggest tha ES/TRAIL therapy is effective at
targeting circulating cancer cells derived fr m multiple organs in
human blood.
To evaluate the impact of blood cells on the efficacy of ES/
TRAIL treatment, fluorescent COLO 205 and PC-3 cells w re
spiked in human blood of varying hematocrit percentag s. All
additional blood-cell components were maintained whereas the
volume of removed erythrocytes was replaced with plasma from
the same blood donor. Interestingly, the apoptotic effects were
hematocrit-dependent, as higher hematocrit significantly de-
creased the number of viable COLO 205 a d PC-3 cells after ES/
TRAIL treatment (Fig. 3F). The e ha ced apoptotic effect
suggests that blood-cell collisions un er flow ca promote t
apoptotic effects of ES/TRAIL liposomes and agrees with our
intuitive understanding f blood rheology, as the presence of
erythrocytes is known to create erratic cell paths with frequent
cross-streamline displacements (26) and increas the lifetime of
colliding doublets to promote aggregate for ation (27).
To assess the mech ism by which leukocytes act as a perv ding
carrier surface for functional TRAIL, blood was pretreated with
ES/TRAIL liposomes under shear flow, with blood cells sub-
sequently separated from unbound ES/TRAIL via centrifugation
and replaced with fresh blood plasma. ES/TRAIL therapeutic
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Fig. 2. ES/TRAIL liposomes adhere to multiple leukocyte subpopulations
after exposure to shear flow in whole blood. (A) Confocal images of ES/TRAIL
liposomes (green) bound to human leukocytes (blue, cell nuclei) after ex-
posure to shear flow in whole blood in a cone-and-plate viscometer at
188 s−1 for 30 min. Leukocytes have nuclear morphology characteristic of
monocytes (Left), lymphocytes (Center), and neutrophils (Right). (Scale bar,
5 μm.) (B–G) To assess the adhesion of ES/TRAIL liposomes to leukocyte
subpopulations, fluorescent ES/TRAIL liposomes were added to human blood
and exposed to shear flow in a cone-and-plate viscometer at a shear rate of
188 s−1 for 30 min. Leukocytes were isolated from blood using a Polymorphs
density gradient and labeled with CD3, CD14, CD16, CD19, and CD56, which
is typically expressed on T lymphocytes, monocytes, neutrophils, B-lympho-
cytes, and natural killer cells, respectively. Expression of fluorescent ES/TRAIL
(FL ES/TRAIL) liposomes on the surface of leukocytes that are CD3+ (B),
CD14+ (C), CD16+ (D), CD19+ (E ), and CD56+ (F ), determined using flow
cytometry. Expression of CD3, CD14, CD16, CD19, and CD56 on the leu-
kocyte surface was determined using isotype controls. No label, unsheared
cells that were not treated with fluorescent ES/TRAIL liposomes; ES Block,
cells treated with fluorescent ES/TRAIL liposomes that were pretreated
with an ES functional blocking antibody; Post-Mix, cells labeled with
fluorescent ES/TRAIL liposomes immediately after mixing liposomes in
whole blood. (G) Percent of CD3+, CD14+, CD16+, CD19+, and CD56+
leukocytes adhered to ES/TRAIL liposomes. n = 3 for all samples. Bars
represent the mean ± SD in each treatment group. ***P < 0.0001 (one-way
ANOVA with Tukey posttest).
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Fig. 3. ES/TRAIL liposome therapeutic effects are enh nced in human blo d
under flow in vitro. (A) Flow cyto etry of COLO 205 cancer cells after
treatment with ES/TRAIL or ES liposomes in blood under s ear flow in a
cone-and-plate viscometer at 188 s−1 for 2 h. Unsheared, via le untreated
cancer cell control. (B) Representative flow cytometry histogram showi g
the number of viable cancer cells collected. (C) Representative micrographs
of COLO 205 cells (white) in blood when tr ated with ES/TRAIL (Left) and ES
only (Right) liposomes in blood under shear flow. (Scal bar, 50 μm.) (D)
Number of viable COLO 205 and PC-3 cells per volume of blood after
treatment with ES/TRAIL or ES lipos mes in blood under shear flow. n = 3 for
all samples. Bars represent the an ± SD in each treatment group. **P <
0.001, ***P < 0.0001 (unpaired t test). (E) Co parison of fraction of COLO 205
and PC-3 cells that remained viable after treatment with ES/TRAIL liposomes
in buffer versus blood. n = 3 for all samples. Bars represent the mean ± SD i
each treatment group. ***P < 0.0001 (unpaired t test). (F) Frac ion of COLO
205 and PC-3 cells that remained viable aft r treatment w th ES/TRAIL lip-
osomes in blood with varying perce tages of normal hematocrit. Hematocrit
was varied whereas other blood omponen s remained constant, based on
a normal hematocrit of 45%. Plasma indicates rem val of all b ood cells. n = 3
for all samples. Bars represent the mean ± SD in each treatment group. *P <
0.05 (one-way ANOVA with Tukey posttest).
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significant differences in HUVEC viability, compared with un-
treated HUVECs exposed to shear in human blood (Fig. S5).
These data suggest that ES/TRAIL-functionalized leukocytes
exert negligible toxic effects on human endothelial cells under
blood-flow conditions.
Apop otic Effects of ES/TRAIL Therapy Are Enhanced in Human Blood
Under Flow. Clinically, CTCs are sparsely distributed in he
complex milieu of whole blood, at concentrations as low as 1–100
cells per mL (3, 12). To examine whether ES/TRAIL liposomes
wo ld effect vely target ca cer cells in the presence of blood cells
and serum under flow conditions, we fluorescently labeled co-
lorectal COLO 205 and prostate PC-3 cancer-cell lines and
spiked them into human peripheral bl . Su prisingly, und r
identical shear-flow c nditions, ES/TRAIL therapy was ev n
or effective at killi g anc r c lls in the presence of human
blood (Fig. 3 A–D), compared with shearing COLO 205 or PC-3
cells alone in buffer (Fig. 3E), with <5% of the fluorescent, viable
cancer-cell populations remaining after ES/TRAIL treatment (Fig.
3E). These results suggest that ES/TRAIL therapy is effective at
targeting circulating cancer cells derived from multiple organs in
human blood.
To evaluate the impact of blood cells on the efficacy of ES/
TRAIL treatment, fluorescent COLO 205 and PC-3 cells were
spiked in human blood of varying hematocrit percentages. All
additional blood-cell components were maintained whereas the
volume of removed erythrocytes was replaced with plasma from
the same blood donor. Interestingly, the apoptotic effects were
hematocrit-dependent, as higher hematocrit significantly de-
creased the number of viable COLO 205 and PC-3 cells after ES/
TRAIL treatment (Fig. 3F). The enhanced apoptotic effect
suggests that blood-cell collisions under flow can promote the
apoptotic effects of ES/TRAIL liposomes and agrees with our
intuitive understanding of blood rheology, as the presence of
erythrocytes is known to create erratic cell paths with frequent
cross-streamline displacements (26) and increase the lifetime of
colliding doublets to promote aggregate formation (27).
To assess the mechanism by which leukocytes act as a pervading
carrier surface for functional TRAIL, blood was pretreated with
ES/TRAIL liposomes under shear flow, with blood cells sub-
sequently separated from unbound ES/TRAIL via centrifugation
and replaced with fresh blood plasma. ES/TRAIL therapeutic
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Fig. 2. ES/TRAIL liposomes adhere to multiple leukocyte subpopulations
after exposure to shear flow in whole blood. (A) Confocal images of ES/TRAIL
liposomes (green) bound to human leukocytes (blue, cell nuclei) after ex-
posure to shear flow in whole blood in a cone-and-plate viscometer at
188 s−1 for 30 min. Leukocytes have nuclear morphology characteristic of
monocytes (Left), ly phocytes (Center), and neutrophils (Right). (Scale bar,
5 μm.) (B–G) To assess the adhesion of ES/TRAIL liposo es to leukocyte
subpopulations, fluorescent ES/TRAIL liposomes were added to human blood
and exposed to shear flow in a cone-and-plate viscometer at shear rate of
188 s−1 fo 30 min. Leukocytes were isolated fr m blood sing a Polymorphs
density gradient and labeled with CD3, CD14, CD16, CD19, and CD56, which
is typically expressed on T lymphocytes, monocytes, n utrophils, B-lympho-
cytes, and natural killer cells, respectively. Expression of fluorescent ES/TRAIL
(FL ES/TRAIL) liposomes on the surface of leukocytes that are CD3+ (B),
CD14+ (C), CD1 + (D), CD19+ (E ), and CD56+ (F ), determined using flow
cytometry. Expression of CD3, CD14, CD16, CD19, and CD56 on the leu-
kocyte surface was determined using isotype controls. No label, unsheared
cells that were not treated with fluorescent ES/TRAIL liposomes; ES Block,
cells treated with fluorescent ES/TRAIL liposomes that were pretreated
with an ES functional blocking antibody; Post-Mix, cells labeled with
fluorescent ES/TRAIL liposomes immediately after mixing liposomes in
whole blood. (G) Percent of CD3+, CD14+, CD16+, CD19+, and CD56+
leukocytes adhered to ES/TRAIL liposomes. n = 3 for all samples. Bars
represent the mean ± SD in each treatment group. ***P < 0.0001 (one-way
ANOVA with Tukey posttest).
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Fig. 3. ES/TRAIL liposome therapeutic effects are enhanced in human blood
under flow in vitro. (A) Flow cytometry of COLO 205 cancer cells after
treatment with ES/TRAIL or ES liposomes in blood under shear flow in a
cone-and-plate viscometer at 188 s−1 for 2 h. Unsheared, viable untreated
cancer cell contr l. (B) Representative flow cytometry histogram showing
the number of viabl cancer cells coll cted. (C) Representative micrographs
of COLO 205 cells (white) in bl od when treated with ES/TRAIL (Left) and ES
only (Right) liposomes in blood under shear flow. (Scale bar, 50 μm.) (D)
Number of viable COLO 205 and PC-3 cells per volume of blood after
treatment with ES/TRAIL or ES liposomes in blood under shear flow. n = 3 for
all samples. Bars represent the mean ± SD in each treatment group. **P <
0.001, ***P < 0.0001 (unpaired t test). (E) Comparison of fraction of COLO 205
and PC-3 cells that remained viable after treatment with ES/TRAIL liposomes
in buffer versus blood. n = 3 for all samples. Bars represent the mean ± SD in
each treatment group. ***P < 0.0001 (unpaired t test). (F) Fraction of COLO
205 and PC-3 cells that remained viable after treatment with ES/TRAIL lip-
osomes in blood with varying percentages of normal hematocrit. Hematocrit
was varied whereas other blood components remained constant, based on
a normal hematocrit of 45%. Plasma indicates removal of all blood cells. n = 3
for all samples. Bars represent the mean ± SD in each treatment group. *P <
0.05 (one-way ANOVA with Tukey posttest).
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effects under shear flow remained nearly identical, as COLO 205
and PC-3 cells, spiked into a suspension of blood with washed,
pretreated blood cells, were killed at roughly the same rate as
unwashed blood (Fig. 4 A–C). Thus, upon addition of the ES/
TRAIL liposomes to cancer cell-spiked blood, liposomes attach o
the surface of leukocytes and are available for inducing apoptosis in
cancer cells that they come into contact with (Fig. 4D and E). As an
indicator of unbound ES/TRAIL liposomes and/or liposome frag-
ments r maining in human blood after shearing pretreatment, the
toxicity of supernatant collected from pretreated blood was
t sted in COLO 205 culture. An Annexin-V assay showed min-
imal COLO 205 cell death after treatment with a supernatant of
human pl sma and unbound ES/TRAIL, c mpared with cells
treated with plasma supernatant alone (Fig. S6). These data sug-
gest that ES/TRAIL liposomes readily bind to the surface of
leukocytes, with minimal unbound liposomes remaining to target
and kill cancer cells under flow.
ES/TRAIL Functionalized Leukocytes Reduce Number of Viable Cancer
Cells in Mouse Circulation in Vivo. To assess and compare the cy-
totoxic effects in vivo with our previous results in vitro, ES/
TRAIL liposomes were also tested for their ability to kill cancer
cells flowing in the peripheral circulation of mice. Two million
fluorescently labeled COLO 205 cells were injected into the tail
vein of immunocompetent C57BL/6J mice, 30 min after injection
of 120 μL of either ES/TRAIL liposomes, ES liposomes, or
soluble TRAIL (Fig. 5A). Tail-vein injection was used to model
leukocyte/CTC interactions in mouse circulation, as this tech-
nique has been an accepted and widely used model of lung
metastasis (28–31) since the pioneering work of Fidler et al. (32–
34). For these studies, the use of recombinant human E-selectin
was continued because of its ability to bind both human COLO
205 cancer cells and mouse neutrophils, which were previously
shown to have cross-reactivity and roll on E-selectin (35). Mice
were killed 2.5 h after the initial injection, and cancer cells were
recovered from the circulation via cardiac puncture. Cancer cells
were placed back into culture for 2–3 h before the number of
viable cells was quantified.
Using flow cytometry, we measured ∼130,000 cancer cells per
mL of blood for mice injected with control ES liposomes, com-
pared with <2,000 cancer cells per mL of blood surviving from
ES/TRAIL-treated mice (Fig. 5 B and C). Mice injected with
buffer or soluble TRAIL had intermediate numbers of cells
(Fig. 5C) compared with ES and ES/TRAIL-treated samples,
likely indicating that ES functionalized liposomes help to retain
cancer cells i the circulation by blocking selectin-mediated in-
teraction of the COLO 205 cells with the endothelium. Brightfield
micrographs of COLO 205 cells exposed to buffer and soluble
TRAIL showed characteristic cancer-cell morphology (Fig. 5D).
Micrographs of COLO 205 cells exposed to ES revealed adherent
leukocytes on the COLO 205 cell surface without significant mor-
phological change whereas the cancer cells from ES/TRAIL-
treated mice showed notable membrane blebbing of COLO 205
cells in the proximity of leukocytes (Fig. 5D). To assess the ad-
hesion of ES/TRAIL liposomes to leukocytes in mouse circula-
tion, mice were injected with ES/TRAIL liposomes containing
fluorescent cholesterol and were allowed to circulate for 2.5 h.
Brightfield overlay micrographs showed that leukocytes recov-
ered from the mouse circulation were functionalized with ES/
TRAIL liposomes (Fig. 5E), suggesting that ES/TRAIL remains
functionalized to leukocytes, which can exert cytotoxic effects
onto cancer cells in mouse circulation.
ES/TRAIL Treatment Reduces Number and Increases Apoptosis of
Remaining Circulating COLO 205 Cells Lodged in Vivo in Mouse
Lung. Previous studies have shown that tumor cells that enter
the vasculature via tail-vein injection can lodge into lung vascu-
lature within the first two hours (36). To assess the viability of
the r aining circulating cancer cells lodged within mice, fluo-
resc nt COLO 205 cells lodged within the lungs of mice were
identified using two-photon excited fluorescence microscopy
(Fig. 6 A an B). Immediately following euthanasia, the lungs
were resected, and two-photon images were acquired in three
regi ns of the lung that were identical for each animal, to obtain
accurate estimate of cell counts (Fig. 6A). Roughly twice as
m ny cells w re found in the ES-, soluble TRAIL (sTRAIL)-,
and buffer-treated animals as the ES/TRAIL-treated animals
(Fig. 6C), suggesting that many COLO 205 cells had already
died and degenerated. The cancer-cell density found in lung
suggests that about 1.4 million cancer cells were lodged in the
lung for buffer-treated animals (assuming a lung volume of
∼0.4 L), representing the bulk of the two million COLO 205
cells injected.
We then evaluated the apoptotic effects of ES/TRAIL liposomes
on cancer cells that have already lodged into the lungs of mice.
After the injections of liposomes and COLO 205 at previously
used time points (Fig. 5A), we injected a solution of Annexin-V
tagged with a fluorescent Alexa 594 dye to assess for phosphati-
dylserine flipping on the COLO 205 cell membrane, characteristic
A
B C
D E
Fig. 4. ES/TRAIL liposomes functionalize leukocytes under shear flow in
vitro to arget and kill cancer cells. (A) Flow cytometry plots of COLO 205
cells in untreated samples (Left) and whe treated i human blo d with ES
(C nter) or ES/TRAIL (Right) functionalized leukocytes (but no unbound
liposomes) u der shear flow. (B and C) Number of viable COLO 205 (B) and
PC-3 (C) cells per volum f blo d after treatment with leukocytes func-
tionalized with ES/TRAIL or ES liposomes, but with no unbound liposomes, in
hu a blood (Washed), or after treatment with ES or ES/TRAIL liposomes
in blood (Unwashed). n = 3 for all samples. Bars represent the mean ± SD in
e ch treatme group. **P < 0.001, ***P < 0.0001 (unpaired t test). (D and
E ) Schematic of the two-step mechanism involving decoration of leuko-
cytes wi h liposomes (D), which then contact circulating cancer cells and
activate the death receptor (E ).
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significant differences in HUVEC viability, compared with un-
treated HUVECs exposed to shear in human blood (Fig. S5).
These ata suggest that ES/TRAIL-functionalized leukocytes
exert negligible toxic effects on human endothelial cells under
blood-flow conditions.
Ap ptotic Effects of ES/TRAIL Therapy Are Enhanced in Human Blood
Under Flow. Clinically, CTCs are sparsely distributed in the
complex milieu of whole blood, at concentrations as low as 1–100
cells per mL (3, 12). To examine whether ES/TRAIL liposomes
would effectively target cancer cells in the presence of blood cells
and serum under flow conditions, we fluorescently labeled co-
lorectal COLO 205 and prostate PC-3 can er-cell lines and
spiked them into human peripheral blood. Surprisingly, under
identical shear-flow conditions, ES/TRAIL therapy was even
more effective at killing cancer cells in the presence of human
blood (Fig. 3 A–D), compared with shearing COLO 205 or PC-3
cells alone in buffer (Fig. 3E), with <5% of the fluorescent, viable
cancer-cell populations remaining after ES/TRAIL treatment (Fig.
3E). These results suggest that ES/TRAIL therapy is effective at
targeting circulating cancer cells derived from multiple organs in
human blood.
To evaluate the impact of blood cells on the efficacy of ES/
TRAIL treatment, fluorescent COLO 205 and PC-3 cells were
spiked in human blood of varying hematocrit percentages. All
additional blood-cell components were maintained whereas the
volume of removed erythrocytes was replaced with plasma from
the same blood donor. Interestingly, the apoptotic effects were
hematocrit-dependent, as higher hematocrit significantly de-
creased the number of viable COLO 205 and PC-3 cells after ES/
TRAIL treatment (Fig. 3F). The enhanced apoptotic effect
suggests that blood-cell collisions under flow can promote the
apoptotic effects of ES/TRAIL liposomes and agrees with our
intuitive understanding of blood rheology, as the presence of
erythrocytes is known to create erratic cell paths with frequent
cross-streamline displacements (26) and increase the lifetime of
colliding doublets to promote aggregate formation (27).
To assess the mechanism by which leukocytes act as a pervading
car ier s rface for functional TRAIL, blood was pretreated with
ES/TRAIL liposomes under shear flow, with blood cells sub-
sequently separated from nbound ES/TRAIL via centrifugation
a d replaced with fresh blood plasma. ES/TRAIL therapeutic
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Fig. 2. ES/TRAIL lipo omes adhere to multiple leukocyte sub opulations
after exposure to shear flow in whol blood. (A) C nfocal images f ES/TRAIL
liposom s (gre n) bound to human leuk cytes (blue, cell nuclei) after ex-
posure to sh ar flow in whole blo d in a cone-and-plate viscometer at
188 s−1 fo 30 min. Leukocytes have nuclear morphology characteristic of
monocytes (Left), lymphocy es (C nter), and neutrophil (Right). (Scale bar,
5 μm.) (B–G) T ass ss the adhesi n of ES/TRAIL liposomes to leukocyte
s bpopulations, fluorescent ES/TRAIL lip somes were dded to human blood
and expo ed to she r flow in a cone-and-plate viscomet r at a sh ar rate of
188 s−1 f r 30 min. L ukocy es were isolated f om bl od using a Polymorphs
nsity gradient a d labeled with CD3, CD14, CD16, CD19, and CD56, which
is typically expressed n T lymphocy s, monocytes, neutrophils, B-lympho-
cy es, and natural killer cells, respectively. Expression of fluorescent ES/TRAIL
(FL ES/TRAIL) lipos mes on the surface of le kocytes that are CD3+ (B),
CD14+ (C), CD16+ (D), CD19+ (E ), and CD56+ (F ), determined using flow
cytometry. Expression of CD3, CD14, CD16, CD19, and CD56 on the leu-
kocyte surface w s de ermined using isotype controls. No label, unsheared
cells that w re not treated with fluorescent ES/TRAIL lipo mes; ES Block,
cells treate with fluoresce t ES/TRAIL liposomes that were pretreated
with an ES functional blocking antibody; Post-Mix, cells label i
fluor sce t ES/TRAIL liposom s immedi ely fter mixing liposomes in
whole blood. (G) Perc nt of CD3+, CD14+, CD16+, CD19+, and CD56+
leukocyt s ad ed to ES/TRAIL liposo es. n = 3 for all samples. Bars
represent the mean ± SD in each reat ent group. ***P < 0.0001 (one-way
ANOVA with Tuk y posttest).
P3
Viable nsheared !" Viable 
E-selectin
ES + TRAIL
P3
ES +TRAIL
P3
E-selectin
SS
C
 (x
 1
05
) 
FSC (x 106) 
(x
 1
02
) 
ES ES/TRAIL
FSC (x 106) 
Unsheare ES/TRAIL ES  
ES/TRAILUnsheared
5.0 2.5 
0 
1.0 
2.0 
0 
2.5 
10 
5.0 
7.5 
6.0 3.0 
ES 
Vi
ab
le
 c
el
ls
 p
er
5 )
 10 
8 
6 
4 
2 
0 
ES/TRAIL ES Unsheared
COLO 205 PC-3
**********
   
   
   
Vi
ab
le
 
C
O
LO
 2
05
m
L 
bl
oo
d 
(x
 1
0
6.0 3.0 6.0 3.0 
Buffer Blood
40
30
20
10
0
COLO 205 PC-3
%
 V
ia
bl
e 
ce
lls
Pl
as
m
a
Pl
as
m
a00
11
.3
11
.3
22
.5
22
.545 45
 COLO 205 PC-3
Hematocrit (%) Hematocrit (%)
%
 V
ia
bl
e 
ce
lls
0
10
20
30*** ***
*
*
*
*
*
*
*
***
A B
C D
E F
Fig. 3. ES/TRAIL liposome therapeutic effects are enhanced in human blood
under flow in vitro. (A) Flow cytometry of COLO 205 cancer cells after
treatment with ES/TRAIL or ES liposomes in blood under shear flow in a
cone- -plate viscometer at 188 s−1 for 2 h. Unsheared, viable untreated
cancer cell control. (B) Representative flow cytometry histogram showing
the numb r of viable cancer cells collected. (C) Representative micrographs
of COLO 205 cells (white) in blood when treated with ES/TRAIL (Left) and ES
only (Right) liposomes in blood under shear flow. (Scale bar, 50 μm.) (D)
Number of viable COLO 205 and PC-3 cells per volume of blood after
treatment with ES/TRAIL or ES liposomes in blood under shear flow. n = 3 for
all samples. Bars represent the mean ± SD in each treatment group. **P <
0.001, ***P < 0.0001 (unpaired t test). (E) Comparison of fraction of COLO 205
and PC-3 cells that remained viable after treatment with ES/TRAIL liposomes
in buffer versus blood. n = 3 for all samples. Bars represent the mean ± SD in
each treatment group. ***P < 0.0001 (unpaired t test). (F) Fraction of COLO
205 and PC-3 cells that remained viable after treatment with ES/TRAIL lip-
osomes in blood with varying percentages of normal hematocrit. Hematocrit
was varied whereas other blood components remained constant, based on
a normal hematocrit of 45%. Plasma indicates removal of all blood cells. n = 3
for all samples. Bars represent the mean ± SD in each treatment group. *P <
0.05 (one-way ANOVA with Tukey posttest).
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of apoptosis. Mouse lungs were imaged using two-photon mi-
croscopy to determine whether Hoescht-labeled COLO 205 cells
were also positive for Annexin-V labeling. In addition to the de-
creased density of cancer cells lodged in mouse lung (Fig. 6C), we
also found a dramatic increase in apoptosis of the cancer cells
(Fig. 6 B and D) in the ES/TRAIL liposome-treated mice com-
pared with other groups. Soluble TRAIL protein injected into
mice following the same protocol displayed minimal cytotoxic ac-
tivity comparable with control, as expected due to its short circu-
lation half-life (37). Mice injected with ES/TRAIL liposomes
survived for over 2 wk with no loss in body weight (n = 3). These
data suggest that ES/TRAIL treatment serves to decrease the
number of remaining circulating COLO 205 cells lodged in mouse
lung, while increasing the fraction of them that are apoptotic.
Discussion
Natural killer cells, activated by interleukin-2 or other factors,
are induced to present TRAIL protein on their surface. These
cells participate in immunosurveillance against micrometastases
in the body and comprise 10–20% of peripheral blood mono-
nuclear cells (38, 39). Although the liposome-coated leukocytes
described here are not specifically programmed to actively in-
vade tissues and seek out solid tumors, they do have frequent
opportunities for incidental contact with CTCs in the blood-
stream. Interestingly, infiltration of neutrophils and macro-
phages throughout the interior of solid tumor masses has been
found in dynamic, self-seeding tumors, suggesting that some
degree of homing of normally functioning leukocytes to solid
tumors could be expected (40, 41). We find that TRAIL is most
potent when in its natural state—tethered to the surface of leu-
kocytes in shear flow—rather than freely soluble or on untethered
liposomes in the absence of blood. Tethering nanoscale liposomes
to the surface of peripheral blood leukocytes is also beneficial
for increasing liposo e circulation time, by avoiding renal
clearanc mec nisms.
So hy d l ukocyt s coated th ES/TRAIL liposomes have
much igher cyto ox c activit in hear flow, compared with
s lated ES/TRAIL lip somes or soluble TRAIL protein? The
answer ay lie in the compressive force between surfaces. Two
spherical particl s colliding in linear shear flow will experience
a compressive force between them, which scales as Fc ∼ μ*G*a*b,
where μ is the fluid viscosity, G is the shear rate, and a and b are
the radii of the smaller and larger sphere, respectively (42). Thus,
a 10-μm-diameter leukocyte colliding with a cancer c ll will ex-
perience 100 ti es the compressive force of a 100-nm liposome
c lliding with a cancer cell. Compressive forces act to flatten down
any cell-surface glycocalyx composed of biologically inert macro-
m lecul s, thus allowi g TRAIL t come within a reactive dis-
ta ce to the cancer cell ath receptors a d f rm bonds. Th
physics of forc -ind ced flattening and penetration of cell glyco-
calyx o f c litate surface receptor binding to ligands on an op-
posing cell urface has been analyzed in the context of leukocyte
adhesion to the vascular endothelium (43, 44).
Recombina human TRAIL/Apo2L, also known s PRO1762
developed by Amgen/Genentech, has been the subject f nu-
merous Phase 1, 1a, 2, and 3 cli ical tri ls over the past d cade,
with minimal adverse effects reported (45, 46). There re many
intr cellular proteins, such as the inhibitors of apopto is protein
(IAPs) family membe s, that also confer TRAIL resistance to
normal cells (47). Additionally, the dosages of TRAIL used in
this current study ranged from 0.06–0.08 mg/kg, two orders of
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Fig. 5. ES/TRAIL functionalized leukocytes target and kill cancer cells in the
circulation of mice in vivo. (A) Sch matic of in vivo mouse experiment. (B)
Flow cytometry of untreated COLO 205 cancer c lls (Left) and those re-
cover d from cardiac puncture from mice treated with ES (Center) nd ES/
TRAIL liposomes (Right). (C) Number f viable cancer cells r covered per
volume of mouse blood for mice treated with ES/TRAIL liposomes, soluble
TRAIL (sTRAIL), ES liposomes, and buffer injections. n = 3 for all samples. Bars
represent the mean ± SD in each treatment group. *P < 0.01, **P < 0.001,
***P < 0.0001 (one-way ANOVA with Tukey posttest). (D) Representative
micrographs of COLO 205 cells removed from circulation in mice treated
with ES/TRAIL liposomes (Upper Left), sTRAIL (Upper Right), ES liposomes
(Lower Left), and buffer (Lower Right) injections. (Scale bar, 20 μm.) (E)
Leukocytes functionalized with fluorescent ES/TRAIL liposomes (green) upon
removal from mouse circulation 2.5 h after injection. (Scale bar, 50 μm.)
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Fig. 6. Decreased number and increased apoptosis in COLO 205 cells lodged
in mouse lung after treatment with ES/TRAIL liposomes. (A) Schematic of
mouse lung and example two-photon excited fluorescence (2PEF) image stack
from mouse lung where Hoechst-labeled COLO 205 cells (green) are arrested
in lung tissue (visible by autofluorescence, yellow). (Scale bar, 80 μm.) (B) The
2PEF images of Hoescht-labeled COLO 205 cells (green) with Alexa Flour 568-
labeled Annexin-V apoptosis probe (red) for each experimental group. Red
arrows point to apoptotic COLO 205 cells (red and green colocalized), and
blue arrows indicate nonapoptotic COLO 205 cells (green only). White circles
indicate regions of autofluorescence from lung tissue. (Scale bar, 30 μm.) (C)
Density of COLO 205 cells lodged in the lung for each experimental group. (D)
Percentage of lodged COLO 205 cells positive for Annexin-V probe for each
experimental group. Individual data points represent data from one image
stack, with points shown in the same color representing image stacks from
the same animal. Superimposed box plots bound the 25th to 75th percentage
of all data points and the whiskers extend 1.5 times the interquartile range
beyond the boxes. The horizontal lines within the boxplot represent the
median. n = 3 animals for each experimental group. *P < 0.01, **P < 0.0001
(one-way ANOVA with Tukey posttest).
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of apoptosis. Mouse lungs were imaged using two-photon mi-
croscopy to determine wh ther oescht-labeled COLO 205 cells
were also positive for Ann xin-V labeling. In additi to th de-
creased density of cancer cells lodged in m use lung (Fig. 6C), we
also found a dramatic increase in apoptosis of the cancer cells
(Fig. 6 B and D) in the ES/TRAIL liposome-treated mice com-
pared with other groups. Soluble TRAIL protein injected into
mice following the same protocol displayed minimal cytotoxic ac-
tivity comparable with ontrol, as expected due to its short circu-
lation half-life (37). Mice injected with ES/TRAIL liposomes
survived for over 2 wk with no loss in body weight (n = 3). These
data suggest that ES/TRAIL treatment serves to decrease the
number of remaining circulating COLO 205 cells lodged in mouse
lung, while increasing the fraction of them that are apoptotic.
Discussion
Natural killer cells, activated by interleukin-2 or other fa tors,
are induced t present TRAIL protein on their surface. These
cells par icipate in immunosurveillance against micrometastases
in the body and comprise 10–20% of peripheral blood mono-
nuclear cells (38, 39). Although the liposome-coated leukocytes
described here are not specifically programmed to actively in-
vade tissues and seek out solid tumors, they do have frequent
opportuniti s for incidental co tact with CTCs in the blo d-
stream. Interestingly, infiltration of neutrophils and macro-
phages throughout the interior of solid tumor masses has been
found in dynamic, self-seeding tumors, suggesting that some
degree of homing of normally functioning le ko ytes to solid
tumors could be expect d (40, 41). We find that TRAIL is most
potent when i its natural state—tethered to the surface of leu-
kocytes in shear flow—rather than freely soluble or on untethered
liposomes in the absence of blood. Tethering nanoscale liposomes
to the surface of peripheral blood leukocytes is also beneficial
for inc asing l posome circulation time, by avoiding renal
clearance mechanisms.
So why do l ukocytes coated with ES/TRAIL liposomes have
mu h higher cytotoxic activity in shear flow, compared with
isolated ES/TRAIL liposomes or soluble TRAIL protein? The
answer may lie in the compressive force between surfaces. Two
spherical particles colliding in linear shear flow will experience
a compressive force b tween them, w ich scales as Fc ∼ μ*G*a*b,
wh re μ is the fluid viscosity, G is the shear rate, and a and b are
the radii of the smaller and larger sphere, respectiv ly (42). Thus,
a 10-μm-diameter leukocyte colliding with a cancer cell will ex-
perience 100 times the compressive force of a 100-nm liposome
colliding with a cancer cell. Compressiv forces act to flatten down
any cell-surfac glycoc lyx composed of biologically inert macro-
molecules, thus all wing TRAIL to come within a reactive dis-
tance to the cancer cell death receptors and form bonds. The
physics of force-induced flattening and penetration of cell glyco-
lyx to facilitate surface recept r binding to ligands on an op-
posing cell surfac has been analyzed in the context of leukocyte
adhesion to the vascular endothelium (43, 44).
Recombinant human TRAIL/Apo2L, also known as PRO1762
developed by Amgen/Genentech, has been the subject of nu-
merous Phase 1, 1a, 2, and 3 clinical trials over the past decade,
with minimal adverse effects reported (45, 46). There are many
intracellular proteins, such as the inhibitors of apoptosis protein
(IAPs) family members, that also confer TRAIL resistance to
nor al ells (47). Additionally, the dosages of TRAIL used in
this current study ranged from 0.06–0.08 mg/kg, two orders of
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Fig. 5. ES/TRAIL functionalized leukocytes target and kill cancer cells in the
circulation of mice in vivo. (A) Schematic of in vivo mouse experiment. (B)
Flow cytometry of untreated COLO 205 cancer cells (Left) and those re-
covered from cardiac puncture fro ice treated with ES (Center) a d ES/
TRAIL liposom s (Righ ). (C) Number of viable c ncer cells r cov r d per
volum of mouse blood for mice treated with ES/TRAIL liposomes, solubl
TRAIL (sTRAIL), ES liposomes, and buffer inject ons. = 3 for all samples. Bars
represent the mean ± SD in each treatment group. *P < 0.01, **P < 0.001,
***P < 0.0001 (one-way ANOVA with Tukey posttest). (D) Representative
micrographs of COLO 205 cells removed from circulation in mice treated
with ES/TRAIL liposomes (Upper Left), sTRAIL (Upper Right), ES liposomes
(Lower Left), and buffer (Lower Right) injections. (Scale bar, 20 μm.) (E)
Leuko ytes functionalized with fluorescent ES/TRAIL liposomes (green) upon
removal from m use circul tion 2.5 h after injection. (Scale bar, 50 μm.)
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Fig. 6. Decreased number and increased apoptosis in COLO 205 cells lodged
in mouse lung after treatment with ES/TRAIL liposomes. (A) Schematic of
mouse lung and example two-photon excited fluorescence (2PEF) image stack
from mouse lung where Hoechst-labeled COLO 205 cells (green) are arrested
in lung tissue (visible by autofluorescence, yellow). (Scale bar, 80 μm.) (B) The
2PEF images of Hoescht-labeled COLO 205 cells (green) with Alexa Flour 568-
labeled Annexin-V apoptosis probe (red) for each experimental group. Red
arrows point to apoptotic COLO 205 cells (red and green colocalized), and
blue arrows indicate nonapoptotic COLO 205 cells (green only). White circles
indicate regions of autofluorescence from lung tissue. (Scale bar, 30 μm.) (C)
Densi y of COLO 205 cells lodged in the lung for each experimental group. (D)
Percentage of lo ged COLO 205 cells positive for Annexin-V probe for each
experimental group. Individual data points represent data from one image
stack, with points shown in the same color representing image stacks from
the same animal. Superimposed box plots bound the 25th to 75th percentage
of all data points and the whiskers extend 1.5 times the interquartile range
beyond the boxes. The horizontal lines within the boxplot represent the
median. n = 3 animals for each experimental group. *P < 0.01, **P < 0.0001
(one-way ANOVA with Tukey posttest).
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of apoptosis. Mouse lungs were imaged using two-photon mi-
croscopy to determine whether Hoescht-labeled COLO 205 cells
were also positive for Annexin-V labeling. In addition to t e de-
creased density of cancer cells lodged in mous lung (Fig. 6C), we
also found a dramatic increase in poptosis of the cancer cells
(Fig. 6 B and D) in the ES/TRAIL liposome-treate ice com-
pared with other groups. Soluble TRAIL protein injected into
mice following the s me protoc displayed minimal cytotoxic ac-
tivity comparable with control, as expected due to its short circu-
lation half-life (37). Mice injected with ES/TRAIL liposome
survived for over 2 wk with no loss in body weight (n = 3). These
data suggest that ES/TRAIL treatment serv s to dec ease e
number of remaining circulating COLO 205 cells lodg d in mouse
lung, while increasing the fr ction o t m that are apoptotic.
Discussion
Natural killer cells, activated by interleukin-2 or other factors,
are induced to present TRAIL protein on their surface. These
cells participate in immunosurveillance against micrometastases
in the body and comprise 10–20% of peripheral blood mono-
nuclear cells (38, 39). Although the liposome-coated leukocytes
described here are not specifically programmed to actively in-
vade tissues and seek out solid tumors, they do have frequent
opportunities for incidental contact with CTCs in the blood-
stream. Interestingly, infiltration of neutrophils and macro-
phages throughout the interior of solid tumor masses has been
found in dynamic, self-seeding tumors, suggesting that some
degree of homing of normally functioning leukocytes to solid
tumors could be expected (40, 41). We find that TRAIL is most
potent when in its natural state—tethered to the surface of leu-
kocytes in shear flow—rather than freely soluble or on untethered
liposomes in the absence of blood. Tethering nanoscale liposomes
to the surface of peripheral blood leukocytes is also beneficial
for increasing liposome circulation time, by av iding renal
clear nc ch nisms.
So why do leukocy es c ated with ES/TRAIL iposomes have
muc higher cyt t xic activity in shear flow, compared with
isolat d ES/TRAIL lipos mes or soluble TRAIL protein? The
swer m y lie in the c mp essive force between surfaces. Two
pherical particles colliding in linear sh ar flow will experience
compressive force between th m, which scales as Fc ∼ μ*G* *b,
wh re μ is the fluid viscosity, G is the shear r te, a a d b are
th radii of the smaller and larger sphere, respectively (42). Thus,
a 10-μm-diameter l ukocyte coll ding ith a cancer cell will ex-
perience 100 times the compressive force of a 100-nm liposome
c lli ing with a cancer c ll. Compressive f rces act to flatten down
any cell-surf ce glycoc lyx comp sed of bi logic lly iner macro-
molecules thus allowing TRAIL to come within a reactive dis-
tance to the cancer cel death receptor and form bonds. Th
physics of force-induced flattening and penetration of cell glyco-
calyx to facilitate surface receptor binding to ligands on an op-
posing cell surfac has been analyzed in the context of leukocyte
adhesion to the vascular endothelium (43, 44).
Re omb nant human TRAIL/Apo2L, also known as PRO1762
developed by mgen/Ge entech, has been the subject of nu-
merous Phase 1, 1a, 2, and 3 clinical trials over the past decad ,
wi h minimal a ver effects reported (45, 46). There are many
i tracellular proteins, such as the inhibitors of apopto is p otein
(IAPs) family members, that also confer TRAIL resistance to
normal cells (47). Additionally, the dosages of TRAIL us d in
this current study ranged from 0.06–0.08 mg/kg, two orders of
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Fig. 5. ES/TRAIL functionalized leukocytes target and kill canc r cells in the
circulation of mice in vivo. (A) Schem tic f in vivo mous experim nt. (B)
Flow cytometry f untreated COLO 205 ncer c ll (L ft) and those re-
covered from cardiac puncture from mic reated with ES (C ter) and ES/
TRAIL liposomes (Right). (C) Number of v able cancer cells recovered per
volume of mouse blood for mice treated with ES/TRAIL lipos me , soluble
TRAIL (sTRAIL), ES liposomes, and buffer injections. n = 3 for all samples. Bars
represent the mean ± SD in each treatment group. *P < 0.01, **P < 0.001,
***P < 0.0001 (one-way ANOVA with Tukey posttest). (D) Representative
micrographs of COLO 205 cells removed from circulation in mice treated
with ES/TRAIL liposomes (Upper Left), sTRAIL (Upper Right), ES liposomes
(Lower Left), and buffer (Lower Right) injections. (Scale bar, 20 μm.) (E)
Leukocytes functionalized with fluorescent ES/TRAIL liposomes (green) upon
removal from mouse circulation 2.5 h after injection. (Scale bar, 50 μm.)
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Fig. 6. Decreased number and increased apoptosis in COLO 205 cells lodged
in mouse lung after treatment with ES/TRAIL liposomes. (A) Schematic of
mouse lung and example two-photon excited fluorescence (2PEF) image stack
from mouse lung where Hoechst-labeled COLO 205 cells (green) are arrested
in lung tissue (visible by autofluorescence, yellow). (Scale bar, 80 μm.) (B) The
2PEF images of Hoescht-labeled COLO 205 cells (green) with Alexa Flour 568-
labeled Annexin-V apoptosis probe (red) for each experimental group. Red
arrows point to apoptotic COLO 205 cells (red and green colocalized), and
blue arrows indicate nonapoptotic COLO 205 cells (green only). White circles
indicate regions of autofluorescence from lung tissue. (Scale bar, 30 μm.) (C)
Density of COLO 205 cells lodged in the lung for each experimental group. (D)
Percentage of lodged COLO 205 cells positive for Annexin-V probe for each
experimental group. Individual data points represent data from one image
stack, with points shown in the same color representing image stacks from
the same animal. Superimposed box plots bound the 25th to 75th percentage
of all data points and the whiskers extend 1.5 times the interquartile range
beyond the boxes. The horizontal lines within the boxplot represent the
median. n = 3 animals for each experimental group. *P < 0.01, **P < 0.0001
(one-way ANOVA with Tukey posttest).
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of apoptosis. Mouse lungs were imaged using two-photon mi-
croscopy to determine whether Hoescht-labeled COLO 205 cells
were also positive for Annexin-V labeling. In addition to the de-
creased density of cancer cells lodged in mouse lung (Fig. 6C), we
also found a dramatic increase in apoptosis of the cancer cells
(Fig. 6 B and D) in the ES/TRAIL liposome-treated mice com-
pared with other groups. Soluble TRAIL protein injected into
mice following the same protocol displayed minimal cytotoxic ac-
tivity comparable with control, as expected due to its short circu-
lation half-life (37). Mice injected with ES/TRAIL liposomes
survived for over 2 wk with no loss in body weight (n = 3). These
data suggest that ES/TRAIL treatment serves to decrease the
number of remaining circulating COLO 205 cells lodged in mouse
lung, while increasing the fraction of them that are apoptotic.
Discussion
Natural killer cells, activated by interleukin-2 or other factors,
are induced to present TRAIL protein on their surface. These
cells participate in immunosurveillance against micrometastases
in the body and comprise 10–20% of peripheral blood mono-
nuclear cells (38, 39). Although the liposome-coated le kocytes
described here are not specifically programmed to actively in-
vade tissues and seek out solid tumors, they do have frequent
opportunities for incidental contact with CTCs in the blood-
stream. Interestingly, infiltration of neutrophils and macro-
phages throughout the interior of solid tumor masses has been
found in dynamic, self-seeding tumors, suggesting that some
degree of homing of normally functioning leukocytes to solid
tumors could be expected (40, 41). We find that TRAIL is most
potent when in its natural state—tethered to the surface of leu-
kocytes in shear flow—rather than freely soluble or on untethered
liposomes in the absence of blood. Tethering nanoscale liposomes
to the surface of peripheral blood leukocytes is also beneficial
for increasing liposome circulati n time, by voiding renal
clearance mec anisms.
So why do l ocytes coat with ES/TRAIL liposomes have
much higher cyt toxic activity in shear flow, compared with
isolate ES/TRAIL liposomes soluble TRAI protein? The
answer may lie in the compressive force betw en surfac s. Two
spherical particles c lliding in linear shear flow will experience
a compressive force betw en them, which scales as Fc ∼ μ*G*a*b,
where μ is the fluid viscosity, G is the shear rate, and a and b are
the radii of the smaller and larger sphere, respectively (42). Thus,
a 10-μm-diameter leukocyte colliding with a cancer cell will ex-
perience 100 times the compressive force of a 100-nm liposome
colliding with a cancer cell. Compressive forces act to flatten down
any cell-surface glycocalyx c posed of biologically inert macro-
olecules, thus allowing TRAIL to come within a reactive dis-
tance to the ancer cell death eceptor and form bonds. The
phy ics of force-induced flat ening and penetration of cell glyco-
calyx to facilitate surface receptor binding to ligands on an op-
posing cell surface has been analyzed in the context of leukocyte
adhesion to the vascular endothelium (43, 44).
Recombinant hu an TRAIL/Apo2L, also known as PRO1762
develo ed by Amg n/Genentech, has been th subject o nu-
mer us P as 1, 1a, 2, and 3 clinical trials ov r h pa t d cade,
with minimal dverse effects epo ted 45, 46). The ar any
intracellular proteins, such as th in ibitors of ap ptosis prot in
(IAPs) family members, that also confer TRAIL resistance to
normal cells (47). Additionally, the dos ges of TRAIL used in
this current study ra ged from 0.06–0.08 mg/kg, two orders of
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Fig. 5. ES/TRAIL functionalized leukocytes target and kill cancer cel s in t e
circulation of mice in vivo. (A) Schematic of in vivo mouse experiment. (B)
Flow cytometry of u treat COLO 205 cancer cells (Left) and those re-
covered from cardiac puncture from mice treated with ES (Center) and ES/
TRAIL liposomes (Right). (C) Number of viable canc lls recovered p r
volume of mouse blood for mice treated with ES/TRAIL liposomes, soluble
TRAIL (sTRAIL), ES liposomes, and buffer injections. n = 3 for all samples. Bars
represent the mean ± SD in each treatment group. *P < 0.01, **P < 0.001,
***P < 0.0001 (one-way ANOVA with Tukey posttest). (D) Representative
micrographs of COLO 205 cells removed from circulation in mice treated
with ES/TRAIL liposomes (Upper Left), sTRAIL (Upper Right), ES liposomes
(Lower Left), and buffer (Lower Right) injections. (Scale bar, 20 μm.) (E)
Leukocytes functionalized with fluorescent ES/TRAIL liposo es (green) up n
removal from mouse circulation 2.5 h after injection. (Sca e bar, 50 μm.)
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Fig. 6. Decreased number and increased apoptosis in COLO 205 cells lodged
in m us lung af er treatment with ES/TRAIL liposomes. (A) Schematic f
mouse lung and example two-photon excited fluorescenc (2PEF) image stack
from mouse lung where Hoechst-labeled COLO 205 cells (green) are arrested
in lung tissue (visible by autofluorescence, yellow). (Scale bar, 80 μm.) (B) The
2PEF images of H escht-labeled COLO 205 cells (green) with Alexa Flour 568-
labeled Annexin-V apoptosis probe (red) for each experimental group. Red
arrows point to apoptotic COLO 205 cells (red and green colocalized), and
blue arrows indicate nonapoptotic COLO 205 cells (green on y). White circles
indicate regions of autofluorescence from lung tissu . (Scale bar, 30 μm.) (C)
Density of COLO 205 cells lodged in the lung for each experimental group. (D)
Percentage of lodged COLO 205 cells positive for Annexin-V probe for each
experimental group. Individual data points repres n d a from one i age
stack, i points sho n in the sam color representing image stacks fr
th same animal. Superimposed box plot boun th 25th to 75 h per entage
of all data points and the whiskers extend 1.5 times the interquartile range
beyond the boxes. The horizontal lines ithin the boxplot represent the
median. n = 3 animals for each experimental group. *P < 0.01, **P < 0.0001
(one-way ANOVA with Tukey posttest).
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of apoptosis. Mouse lungs were imaged using tw -photon mi-
croscopy to determine whether Hoescht-labeled COLO 205 cells
were also positive for Annexin-V labeling. In addition to the de-
creased density of cancer cells lodged in mouse lung (Fig. 6C), we
also found a dramatic increase in apoptosis of th ca cer cells
(Fig. 6 B and D) in the ES/TRAIL liposom -treated mice com-
pared with other groups. Soluble TRAIL prot in injec ed into
mice following the same protocol displayed minimal cytotoxic ac-
tivity comparable wi h control, as xpected due to i s short circu-
lation half-life (37). Mice injected with ES/TRAIL liposom
survived for over 2 wk with no loss in body weight (n = 3). These
data suggest that ES/TRAIL treatment serves to d crease the
numb r of rema ning c rculating COLO 205 cells lodged in mouse
lung, while increasing the fraction of them th t are apoptotic.
Discussion
Natural ki er cells, activated by interleukin-2 o other factors,
are induced to present TRAIL pr tein on their surface. These
cells rticipate in immunosurv illance aga nst icrom tastases
in the body and comprise 10–20% of peripheral bl od mono-
nuclear cells (38, 39). Although the lipos m -c ated leukocytes
describ d h re are not specifically programmed to actively in-
vad tissue and seek out solid tumors, they do have frequent
opportunities for incidental contact with CTCs in the blood-
stream. Interesti gly, infiltration of neutrophils and macro-
phages throug out the interior of solid tumor mas es has been
found in dynamic, self-seeding tumors, suggesting that some
degree of homi g of normally functioning leukocytes to solid
tumors could be xpected (40, 41). We find that TRAIL is most
potent when in its na ural state—tethered to the sur ace of leu-
kocytes in shear flow—rather than freely s luble or n untethered
liposomes in the absence of blood. Tethering nanoscale liposomes
to the sur ace of peripheral blood leukocytes is also beneficial
for increasing liposome circulation time, by avoiding renal
clearan e mechanisms.
So why d leukocytes coa ed with ES/TRAIL lipos m s hav
much higher cytotoxic activity in shear flow, compared with
isolated ES/TRAIL liposomes or soluble TRAIL protein? The
answer may l in the compressive force betwe n surfaces. Two
spherical partic es colliding in lin shear f ow will xp rience
a compressive for be w en them, which scales as Fc ∼ μ*G*a*b,
where μ is the fluid viscos ty, G is the sh ar rate, a nd b are
the radii of the smaller and larg r spher , respectively (42). Thus,
a 10-μm-diameter leukocyte colliding with a cancer cell will ex-
perience 100 imes the compressive force of a 100-nm liposome
colliding with a cancer cell. Compressiv forces ac to flatten down
any cell surface glycocalyx composed f bio ogically ine t macro-
molecules, thus allowing TRAIL to come within a reactive dis-
ance to th c ncer cell d ath receptors and f rm bonds. The
physics of f rce-induc d fl tte ing and penetration of cell glyco-
calyx to facilitate surface receptor bindin to ligands on an op-
posing cell surface has been analyzed in th context of leukocyte
adhesion to the vascular endothelium (43, 44).
Recombinant human TRAIL/Apo2L, also known as PRO1762
d veloped by Amgen/Genentech, has been th subj ct of u-
merous Phase 1, 1a, 2, and 3 clinical rials over the past decade,
with minim l adverse effects report d (45, 46). T re are m y
intr cellular proteins, uch as the inhibitors of o t sis protein
(IAPs) family members, th t also conf r TRAIL resis ance t
normal cells (47). Additionally, the dosages of TRAIL used in
this current study anged from 0.06–0.08 mg/kg, two orders of
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Fig. 6. Decreased number and increased apoptosis in COLO 205 cells lodged
in mouse lung aft r treatment with ES/TRAIL liposomes. (A) Sc matic of
mouse lung and xample two-pho n exc t d fluorescence (2PEF) image stack
from mouse lung where Hoechst-labeled COLO 205 c lls (green) ar arrested
in l ng tissu (visible by autofluorescence, yellow). (Scale bar, 80 μm.) (B) The
2PEF images of Ho scht-l b led COLO 205 c lls (gre n) with Al xa Fl ur 568-
label d Annexin-V apoptosis probe (r d) for each experimental group. Red
arrows point to apoptotic COLO 205 cells (red and green colocalized), and
blue arrows i dic te nonapoptotic COLO 205 c lls (gre n only). White circles
indic te regions of autofluorescence from l ng tissue. (Scale bar, 30 μm.) (C)
Density of COLO 205 cells lodg d i th lung for each experimental group. (D)
Percentage of lodged COLO 205 cells p sitive for Annexin-V p obe for each
experimental group. Individual da a points repres nt data from one image
s ack, wi h p ints shown in the same color representing image stacks from
the same animal. Su rimpose box plots bound the 2 t 75th pe cen age
of all data points and th whiskers exten 1.5 times the in erquartile range
beyond the boxes. The horizontal lines within the box lot represent the
median. = 3 animals for each experimental group *P < 0.01, **P < 0.0001
(one-way ANOVA with Tukey posttest).
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CHAPTER 2: SHEAR-INDUCED RESISTANCE TO NEUTROPHIL 
ACTIVATION VIA THE FORMYL PEPTIDE RECEPTOR 
 
*This section is adapted from the following publication: M.J. Mitchell and M.R. King. 
Biophysical Journal. 102(8): 1804-1814, 2012. 
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2.1 INTRODUCTION 
 
The adhesion of leukocytes to the luminal surface of the microvasculature 
plays an important role in the inflammatory response and lymphocyte homing to 
lymphatic tissues [176,192,251]. The initial step of the leukocyte adhesion cascade 
involves the capture and rolling of leukocytes on the receptor bearing endothelial cell 
layer, with L-selectin acting as an important mediator on the leukocyte surface [252]. 
Experiments with L-selectin knockout mice show severely impaired leukocyte 
migration into the inflamed endothelial wall, along with virtually no lymphocyte 
migration to lymphatic tissues [253,254]. While E-selectin and P-selectin are cell 
adhesion molecules expressed on activated endothelial cells, L-selectin is 
constitutively expressed on the microvilli tips of neutrophils. In contrast to E-selectin 
and P-selectin, L-selectin is rapidly cleaved from the neutrophil surface due to an 
inflammatory stimulus and cellular activation [255]. In addition, the firm adhesion of 
neutrophils to endothelial cells in the vasculature is mediated via intracellular adhesion 
molecule-1 (ICAM-1) on endothelial cells binding to β2 integrins on neutrophils, such 
as CD11b/CD18 or Mac-1, and CD11a/CD18 or LFA-1 [175,176]. Together, the 
downregulation of L-selectin along with the active conformational change of the αM 
subunit of αMβ2 integrins, leading to increased binding affinity, are key indicators of 
neutrophil activation [256,257]. Stimulus by fMLP, which binds to the formyl peptide 
receptor (FPR) on neutrophils, has shown to lead to β2 integrin conformational 
changes and downregulation of L-selectin [188,189,258,259]. 
65 
FPR, a chemoattractant G-protein coupled receptor (GPCR), exhibits high 
constitutive activity in addition to activity due to agonist binding [260,261]. Under 
static conditions in the absence of fluid shear stress, neutrophils spread their cytoplasm 
and are able to migrate on a glass substrate, in part due to constitutive GPCR activity. 
In the presence of fluid shear stress, neutrophils have shown to rapidly retract 
lamellipodia, assume a round resting state, and decrease GPCR constitutive activity 
[9,90,262]. Neutrophils treated with pertussis toxin, a Gi inhibitor, significantly 
attenuated the fluid shear stress-induced pseudopod retraction response, demonstrating 
the role of GPCR activity changes due to fluid shear stress [90]. Transfection of cDNA 
for FPR into a cell line with very low levels of FPR and low pseudopod activity led to 
the projection of pseudopods, which then retracted following exposure to fluid shear 
stress [90]. FPR depletion via siRNA delivery in differentiated HL60 cells also 
significantly reduced fluid shear stress-induced pseudopod retraction. 
While the ability of activated leukocytes to retract pseudopods in response to 
fluid shear stress has been documented in several papers, a variety of different 
neutrophil morphological responses have been obtained. Circulating leukocytes have 
been shown to undergo significant shape change and morphology disruption after 
exposure to extended periods of fluid shear stress [263]. Leukocytes treated with 
dexamethasone or after centrifugation have shown to reverse their shear stress 
response, and can activate and project pseudopods when exposed to fluid shear stress 
[264,265]. Leukocytes adherent on a glass substrate without any active deformation of 
pseudopods have been shown to become activated and extend pseudopods upon 
sudden application of fluid shear stress [266]. Leukocytes activated specifically by 
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low concentrations of G-protein coupled receptor ligands such as platelet activating 
factor (PAF) and fMLP have been shown to retract pseudopods upon application of 
fluid shear [267]. 
The effect of fluid shear stress on earlier indicators of neutrophil activation, 
such as L-selectin shedding and αMβ2 integrin activation induced by low 
concentrations of fMLP, has not yet been addressed. In this study, I examined the 
quantitative dynamics of the shear stress-dependent response of fMLP-induced L-
selectin shedding and αMβ2 integrin activation in neutrophils. 
 
2.2. MATERIALS AND METHODS 
 
Reagents 
 
FITC conjugated mouse anti-human CD62L specific for human L-selectin, 
FITC conjugated mouse IgG1 isotype control antibody, APC conjugated mouse IgG2b 
isotype control antibody, APC conjugated mouse anti-human CD181 specific for 
CXCR1, APC conjugated mouse IgG1 isotype control antibody, and APC conjugated 
mouse anti-human CD182 specific for CXCR2 were purchased from BD Biosciences 
(San Jose, CA). PE conjugated anti-human CBRM1/5 and PE conjugated mouse IgG1 
isotype control antibody were purchased from Biolegend (San Diego, CA). Primary 
goat anti-human FPR, which binds to the extracellular epitope of FPR, and FITC 
secondary donkey anti-goat IgG antibody were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Formyl-methionyl-leucyl-phenylalanine (fMLP) and 
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Interleukin-8 (IL-8) were purchased from R&D Systems (Minneapolis, MN). Ca2+ and 
Mg2+ free DPBS (Invitrogen, Carlsbad, CA), Ca2+ and Mg2+ free HBSS (Invitrogen), 
endotoxin-free human serum albumin (Sigma Aldrich, St. Louis, MO), calcium 
carbonate (Sigma Aldrich), endotoxin-free water (MO BIO Laboratories, Carlsbad, 
CA), and low endotoxin (1 ng/mg), essentially γ-globulin-free BSA (Sigma-Aldrich) 
were purchased to make buffer solutions for neutrophil isolation and viscometer 
assays. Tumor necrosis factor α (TNF-α) protease inhibitor-0 (TAPI-0; Peptides 
International, Louisville, KY), 1,10-phenanthroline (1,10-Ph; Sigma Aldrich), and 
GM6001 (Chemicon, Temecula, CA) were purchased for protease inhibition studies. 
Quantum simply cellular (QSC) anti-mouse IgG beads were purchased from Bangs 
Laboratories, Inc. (Fisher, IN). 
 
Neutrophil Isolation 
 
Human peripheral blood was obtained via venipuncture from healthy 
consenting blood donors and collected into sterile sodium heparin-containing tubes 
(BD Biosciences) after informed consent. Neutrophils were then isolated by 
centrifugation at 480 X g for 50 min at 23°C in a Marathon 8K centrifuge (Fisher 
Scientific, Pittsburgh, PA) using 1-StepTM Polymorphs (Accurate Chemical & 
Scientific Corporation, Westbury, NY). This centrifugation method creates a density 
gradient to separate blood into visible layers of plasma, mononuclear cells, 
neutrophils, and erythrocytes and platelets. The neutrophils were extracted and washed 
in Mg2+ and Ca2+ free HBSS to remove any remaining polymorph. Any remaining red 
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blood cells in the suspension were lysed hypotonically. Neutrophils were resuspended 
at a concentration of 0.5 x 106 cells/mL in HBSS containing 0.5% HSA, 2 mM Ca2+, 1 
mM Mg2+, and 10 mM HEPES (Invitrogen), buffered to pH 7.4. For protease 
inhibition studies, neutrophils were incubated with 25 µM GM6001, 5 mM 1,10-Ph, or 
35 µM TAPI-0 for 30 min prior to the onset of shear. 
 
Cone-and-Plate Viscometer Assay 
 
To study the shear stress response of neutrophils in a controlled, uniform 
environment, experiments were performed using a cone-and-plate device consisting of 
a stationary plate beneath a rotating cone (0.8° angle) maintained at 23°C or 37°C by a 
circulating water bath (Brookfield, Middleboro, MA). The cone and plate viscometer 
design allows for a uniform shear rate to be applied to the entire sample. The shear 
rate, G, does not depend on the distance from the cone center, and is given by: 
 ! = !tan! 
 
 
where ω is the angular velocity of the cone (rad/s) and θ is the angle of the cone (rad). 
A laminar flow field is expected for all experimental conditions.  
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Under these conditions for a Newtonian fluid, the shear stress, τ, is 
proportional to the shear rate being applied: 
 ! = !!" 
 
 
where µ is the viscosity of the medium. Prior to the experiments, the stationary plate 
and rotating cone were incubated with 5% BSA at room temperature for 1 hour to 
block non-specific adhesion of neutrophils to the cone and plate surfaces. Neutrophil 
suspensions of 500 µL were placed on the plate at a concentration of 0.5 x 106 
cells/mL, and were allowed to equilibrate for 1 min before the onset of shear. Shear 
stress was varied from 0.1-4.0 dyn/cm2 for 1-120 min in duration. To maintain a 
constant shear rate while increasing the shear stress, the medium viscosity was 
increased by adding varying amounts of ultra-high molecular weight dextran polymer 
to the medium (2 x 106 MW; Sigma Aldrich) of neutrophils under both shear and static 
conditions.  Increasing the shear rate alone caused neutrophils to collide more 
frequently and activate (Figure 2.1), most likely due to L-selectin binding to P-selectin 
glycoprotein ligand-1 (PSGL-1). After shearing, aliquots of neutrophils were 
immediately exposed to 0.5 nM fMLP, 5 nM IL-8, or no chemoattractant for a period 
of 10 min. The 10 min incubation period was chosen to observe a measurable amount 
of L-selectin shedding and αMβ2 integrin activation, given the low concentrations of 
chemoattractants that were utilized. 
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Flow Cytometry 
 
After chemoattractant exposure, both sheared and non-sheared neutrophils 
were immediately labeled with FITC-conjugated anti-human CD62L monoclonal 
antibody and PE-conjugated anti-human CBRM1/5 to quantify L-selectin expression 
and activated CD11b subunits of β2 integrins. Sheared and non-sheared control 
samples of neutrophils were labeled with FITC- and PE- conjugated mouse IgG1 
isotype antibodies to distinguish non-specific from specific antibody staining. All 
labeled neutrophil samples were incubated for 30 min at 4°C and then washed twice 
with cold Ca2+ and Mg2+ free DPBS.  Samples were then analyzed using an Accuri C6 
flow cytometer (Accuri Cytometers Incorporated) and flow cytometry plots were 
created with Accuri CFlow Plus and FCS Express V3 (De Novo Software, Thornhill, 
Canada) software. 
 
Brightfield Microscopy and Image Analysis 
 
Unlabeled neutrophils were fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences, Hatfield, PA) in Ca2+ and Mg2+ free DPBS at 4°C for 30 min 
and then washed twice with cold Ca2+ and Mg2+ free DPBS. Cells were then placed on 
coverglass and imaged by bright field and phase contrast microscopy using an 
Olympus IX81 inverted microscope (Olympus America Inc., Center Valley, PA). 
Outlines of neutrophils were created from thresholded images using edge-detection 
functions in Metamorph (Universal Imaging Corp., West Chester, PA). Changes in 
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neutrophil shape were determined using the ‘shape factor’ program in Metamorph, 
where the shape factor is given by: 
 
!ℎ!"#!!"#$%& = 4!"!! ! 
 
 
where P is the perimeter and A is the area of the object (neutrophil). Shape factor 
values close to 1 represent a perfect circle, while values closer to zero represent 
elongated or ruffled shapes. All shape factor data were imported into Microsoft Excel 
2007 (Microsoft Corporation, Redmond, WA). 
 
Surface Receptor Quantification 
 
The average number of FPR, CXCR1, and CXCR2 receptors on the surface of 
neutrophils was determined using flow cytometry with QSC beads. Beads were 
incubated for 45 min with a FITC or APC conjugated antibody specific to the antigen 
on the beads. A mixture of beads with varying numbers of antigen binding capacities 
(ABCs) was run through a flow cytometer. Populations of beads corresponding to 
increasing numbers of ABCs yield increasingly fluorescent peaks in the FITC or APC 
fluorescence channel. The median value of each fluorescence peak was obtained using 
Accuri CFlow Plus software, and was used along with the ABC values reported by the 
manufacturer to generate a calibration curve using QuickCal v2.3 (Bangs Labs, Fisher, 
IN). 
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Immediately following the calibration step, both sheared and non-sheared 
neutrophils were incubated with primary anti-human FPR for 45 min at 4°C. To 
examine the number of IL-8 surface receptors, separate sheared and non-sheared 
neutrophils were labeled with anti-CD181 and anti-CD182 for 30 min at 4°C. All 
neutrophil samples were washed twice with cold Ca2+ and Mg2+ free DPBS, and 
neutrophils labeled with anti-FPR were incubated with an additional secondary IgG-
FITC antibody for 30 min at 4°C. All samples were washed and then analyzed using a 
flow cytometer. The peak fluorescence channel was recorded from each sample, and 
the peak was converted into the number of receptors using the calibration curve in 
QuickCal. 
 
Confocal Microscopy 
 
Neutrophils exposed to either shear or static conditions were fixed with 4% 
paraformaldehyde in Ca2+ and Mg2+ free DPBS at 4°C for 30 min, and then washed 
twice with cold Ca2+ and Mg2+ free DPBS. Neutrophil samples were then distributed 
onto slides using a Shandon CytoSpin III centrifuge (Shandon, Pittsburgh, PA) at 750 
RPM for 5 min. Slides were allowed to dry for 5 min, and were then rehydrated in 
DPBS. Samples were permeabilized in 0.2% Triton X-100 for 5 min, and then 
incubated in 1% BSA for 1h. Slides were incubated in primary anti-human FPR for 12 
h in a humidified chamber, and then washed twice with 0.2% Tween in DPBS for 5 
min each. All samples were incubated with a secondary IgG-FITC antibody for 30 min 
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4°C, washed twice with 0.2% Tween in DPBS, and mounted onto coverslips using 
Vectashield mounting medium (Vector Laboratories, Burlingame, CA). 
Samples were examined with a Zeiss 710 Spectral Confocal Microscope 
System (Carl Zeiss MicroImaging GmbH, Jena, Germany) at 65X magnification with 
a FITC filter. Both individual and Z-stack images were taken and processed using 
Zeiss ZEN software (Carl Zeiss MicroImaging GmbH). Metamorph software was used 
to examine FPR internalization and fluorescence intensities within neutrophils. To 
measure fluorescence intensity within the cell, the cell membrane was thresholded 
using edge detection functions to exclude the fluorescent membrane from calculations 
(Fig. 8C). Fluorescent measurements within the cell were then recorded and averaged 
for 100 neutrophils from each of n=3 donors. 
 
Statistical Analysis 
 
Flow cytometry and shape factor data were plotted and analyzed using Prism 
5.0b for Microsoft (GraphPad software, San Diego, CA). A two-tailed paired t-test 
was used for comparisons between two groups with p  < 0.05 being considered 
significant. 
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2.3 RESULTS 
 
Fluid shear stress reduces fMLP-induced L-selectin shedding and αMβ2 integrin 
activation in neutrophils 
 
We initially studied the fluid shear stress response of neutrophils to L-selectin 
shedding and αMβ2 integrin activation after exposure to a low concentration of fMLP. 
Neutrophil suspensions were exposed to static conditions or 4.0 dyn/cm2 of fluid shear 
stress in a cone-and-plate viscometer for 2 h at 23°C, followed by stimulation with or 
without 0.5 nM fMLP for 10 min. Stimulus from fMLP, an inflammatory mediator, is 
known to lead to a downregulation of L-selectin and conformational change in the αM 
subunit of αMβ2 integrins [188,258,259]. Neutrophils exposed to static conditions 
(Figure 2.2A) and 4.0 dyn/cm2 (Figure 2.2B) of fluid shear stress in the absence of 
fMLP did not show appreciable differences in L-selectin shedding and αMβ2 integrin 
activation as expected. However, neutrophils exposed to fMLP after fluid shear stress 
(Figure 2.2D) showed a measurable reduction in L-selectin shedding and αMβ2 
integrin activation compared to neutrophils exposed to fMLP after exposure to static 
conditions (Figure 2.2C). No significant difference in L-selectin shedding and αMβ2 
integrin activation was found between sheared and nonsheared neutrophils, while a 
significant reduction in fMLP-induced L-selectin shedding (Figure 2.2G) and αMβ2 
integrin activation (Figure 2.2H) was found in sheared neutrophils compared to 
neutrophils under static conditions. Experiments were also conducted at 37°C to 
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compare to 23°C experiments, and similar differences were seen between neutrophils 
under shear and static conditions in terms of L-selectin shedding and αMβ2 integrin 
activation (Figure 2.3). Experiments were performed for 20 min rather than 2 h to 
minimize sample evaporation. 
 
Fluid shear stress does not affect IL-8-induced L-selectin shedding and αMβ2 integrin 
activation 
 
To assess whether fluid shear stress alters L-selectin shedding and αMβ2 
integrin activation via other major neutrophil chemoattractant GPCRs, neutrophils 
were exposed to static conditions or 4.0 dyn/cm2 of fluid shear stress in a cone-and-
plate viscometer for 2 h at 23°C, followed by either stimulation with or without 5 nM 
of IL-8. IL-8, a chemoattractant found on the surface of endothelial cells [268-270], 
binds to G-protein coupled receptors CXCR1 and CXCR2, which are believed to have 
lower constitutive activity in comparison to FPR [260,271-273]. Neutrophils exposed 
to static conditions (Figure 2.2E) or 4.0 dyn/cm2 (Figure 2.2F) of fluid shear stress 
followed by IL-8 treatment did not show significant differences in L-selectin shedding 
(Figure 2.2G) or αMβ2 integrin activation (Figure 2.2H). 
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fMLP-induced L-selectin shedding and αMβ2 integrin activation in neutrophils is dose-
dependent in fluid shear stress magnitude 
 
To study the effect of shear stress magnitude on fMLP-induced activation, 
neutrophils were exposed to varying shear stresses of 0.1-4.0 dyn/cm2 for 2 h. These 
shear stress magnitudes are values typically found in the microcirculation [274]. At 
low shear stresses of 0.10 and 0.25 dyn/cm2, no significant difference in L-selectin 
shedding (Figure 2.4A) or αMβ2 integrin activation (Figure 2.4B) was observed 
between cells exposed to shear followed by fMLP stimulation and cells exposed to no 
shear followed by fMLP stimulation. However, a shear stress of 0.75 dyn/cm2 yielded 
a significant reduction in L-selectin shedding (Figure 2.4A) and αMβ2 integrin 
activation (Figure 2.4B) after exposure to fMLP. Shear stress exposures of 2.5 and 4.0 
dyn/cm2 showed an even greater reduction of L-selectin shedding (Figure 2.4A) and 
αMβ2 integrin activation (Figure 2.4B). 
 
fMLP-induced L-selectin shedding and αMβ2 integrin activation in neutrophils is shear 
stress exposure time-dependent 
 
To assess the kinetics of the FPR mechanosensing phenomenon, neutrophils 
were exposed to a constant shear stress of 4.0 dyn/cm2 at 23°C while increasing the 
fluid shear stress exposure time from 1-120 min, followed by stimulation with 0.5 nM 
fMLP. The exposure time was increased to determine a threshold where the shear-
induced resistance begins to develop. No significant difference in fMLP-induced L-
77 
selectin shedding in neutrophils was found over a shear stress exposure time period of 
1-10 min (Figure 2.5A). However, a significant decrease in fMLP-induced L-selectin 
shedding was found at a threshold shear stress exposure time of 20 min, and was 
found to be significantly less than neutrophils in static conditions for the range of 20-
120 min. fMLP-induced αMβ2 integrin activation in neutrophils showed no significant 
difference in neutrophils exposed to shear and static conditions from 1-30 min (Figure 
2.5B). A threshold value of 60 min was found be required to produce a significant 
difference in αMβ2 integrin activation in neutrophils exposed to shear and static 
conditions, and this response was significant over a range of 60-120 min. 
 
Neutrophils develop a resistance to fMLP-induced L-selectin shedding and αMβ2 
integrin activation with increasing shear stress magnitude and shear stress exposure 
time 
 
Due to the variability in response experienced with primary neutrophils, 
neutrophils exposed to both shear and static conditions from each donor were directly 
compared over varying shear stress magnitudes and shear stress exposure durations. 
Neutrophil resistance responses to L-selectin shedding and αMβ2 integrin activation 
were directly compared using the equation: 
 
%!!"#$#%&'(" = %! "#$%&'ℎ!"#! "#ℎ!"#!!ℎ!"# − ! %! "#$%&'ℎ!"#! "#ℎ!!ℎ!"#%! "#$%&'ℎ!"#! "#ℎ!"#!!ℎ!"# ×100% 
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The resistance equation applies to neutrophils labeled for both L-selectin 
shedding and αMβ2 integrin activation, for varying shear stress magnitudes and shear 
stress durations. 
By varying the shear stress magnitude, it is apparent that shear stress does not 
confer resistance in neutrophils to fMLP-induced L-selectin shedding (Figure 2.6A) 
and αMβ2 integrin activation (Figure 2.6C) at lower shear stress values of 0.10 and 
0.25 dyn/cm2. Resistance to L-selectin shedding and αMβ2 integrin activation is 
achieved at 0.75 dyn/cm2 and maximum shear stress response is conferred at 2.5 
dyn/cm2. No additional increase in response is observed at a higher shear stress of 4.0 
dyn/cm2. No measurable resistance to L-selectin shedding (Figure 2.6A) or αMβ2 
integrin activation (Figure 2.6C) was observed in neutrophils without fMLP 
stimulation. By varying the duration of shear stress exposure, it is apparent that the 
shear-induced resistance to fMLP-induced L-selectin shedding (Figure 2.6B) and αMβ2 
integrin activation (Figure 2.6D) increases with increasing shear stress exposure time. 
Resistance to activation after 1-120 min of fluid shear was not observed in the absence 
of fMLP. 
 
Neutrophils acquire a shear-induced resistance to fMLP-induced morphological 
changes  
 
To assess how fluid shear stress alters neutrophil morphology after fMLP 
stimulation, neutrophils exposed to 4.0 dyn/cm2 or static conditions for 2 h at 23°C 
were fixed with 4% paraformaldehyde and examined for their morphological 
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characteristics. Activated neutrophils project pseudopods after exposure to 
chemoattractants such as fMLP, platelet activating factor (PAF), C5a anaphylotoxin, 
leukotriene B4, and interleukin-8 [275]. To quantify this, neutrophil morphology was 
evaluated using Metamorph by calculating the shape factor of each cell. The shape 
factor approaches 1 for round, unactivated neutrophils and decreases for more 
extended, dendritic shapes. 
No significant difference in the shape factor was found between neutrophils 
exposed to shear and static conditions without exposure to fMLP (Figure 2.7A). 
Neutrophils stimulated with 0.5 nM fMLP showed an average shape factor 
significantly less than 1. Interestingly, a significant difference in shape factor was 
found between sheared and unsheared neutrophils after exposure to 0.5 nM fMLP, as 
the sheared neutrophils exhibiting a shape factor close to unity. Neutrophils assumed a 
round morphology in the absence of fMLP (Figure 2.7B,C), while unsheared 
neutrophils developed a more extended morphology than sheared neutrophils in the 
presence of fMLP (Figure 2.7D,E). 
 
Fluid shear stress reduces FPR surface expression 
 
To investigate the mechanotransduction effects on FPR surface expression, 
neutrophils were exposed to shear stress (4.0 dyn/cm2) and static conditions at 23°C 
for 2 h and immediately labeled with anti-FPR antibodies to be analyzed via flow 
cytometry. Sheared neutrophils displayed a reduction in FPR expression (Figure 
2.8A). In comparison to nonsheared samples, QSC bead analysis indicated a 
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significant difference in FPR receptor count, as sheared neutrophils averaged 14,600 
receptors/cell, while nonsheared samples averaged 20,100 receptors/cell (Figure 
2.8D). Sheared neutrophils did not show a reduction in the expression of the two IL-8 
receptors CXCR1 (Figure 2.8B) and CXCR2 (Figure 2.8C), in comparison to 
nonsheared neutrophils. CXCR1 and CXCR2 receptor counts using QSC beads 
showed no significant differences between sheared and nonsheared neutrophils. 
 
FPR expression levels are unaltered in the presence of protease inhibitors 
 
To assess whether FPR is enzymatically cleaved by proteases derived from the 
neutrophil upon exposure to fluid shear stress, neutrophils were treated with 25 µM 
GM6001, 5 mM 1,10-Ph, or 35 µM TAPI-0 for 30 min prior to fluid shear stress 
exposure. Neutrophils exposed to fluid shear stress (4.0 dyn/cm2) and static conditions 
at 23°C for 2 h were then labeled with anti-FPR antibodies to be analyzed via flow 
cytometry, followed by surface receptor quantification. No significant differences 
were observed in FPR surface expression of neutrophils treated with protease 
inhibitors compared to untreated neutrophils exposed to shear (Figure 2.9), indicating 
that loss of FPR expression is not due to cleavage by neutrophil proteases under fluid 
shear. 
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Neutrophils experience FPR internalization under fluid shear  
 
To examine potential FPR internalization as a possible cause for FPR surface 
expression decrease following fluid shear stress exposure, neutrophils were exposed to 
either fluid shear stress (4.0 dyn/cm2) or static conditions for 2 h, permeabilized and 
then labeled with anti-FPR antibodies for examination via confocal microscopy. 
Images were thresholded (Figure 2.10C) to exclude the cell membrane from 
fluorescence measurements. Immunostaining revealed FPR to be clearly localized 
within the cell in sheared samples (Figure 2.10A), while minimal FPR was shown 
within neutrophils exposed to static conditions (Figure 2.10B). The average pixel 
intensities calculated from within neutrophils showed a significant increase in 
fluorescence intensity in sheared neutrophils, compared to neutrophils exposed to 
static conditions (Figure 2.10D). 
 
2.4 DISCUSSION 
 
The aim of this study was to quantify the shear stress-dependent response of 
fMLP-induced L-selectin shedding and αMβ2 integrin activation in neutrophils via the 
formyl peptide receptor. Resistance was acquired by neutrophils during exposure to 
physiological levels of shear stress in a force- and time-dependent manner, directly 
implicating fluid shear stress in this response. Interestingly, we found this resistance to 
be first manifest at a shear stress magnitude of 0.75 dyn/cm2; this value is close to the 
0.5 dyn/cm2 minimum level of shear stress found to induce pseudopod retraction by 
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Schmid-Schonbein and colleagues, which is also believed to act through the formyl 
peptide receptor [9]. Additionally, a shear stress of greater than 0.4 dyn/cm2 is 
required for L-selectin adhesion to CD34 on vascular tissue [169]. The kinetic studies 
of the shear-induced fMLP resistance showed that measurable effects began in the 5 
min range for both L-selectin shedding and αM integrin conformational change, 
consistent to what was observed in pseudopod retraction experiments [276].  
While neutrophils acquired a resistance to both fMLP-induced L-selectin 
shedding and αMβ2 integrin activation, the number of cells that were resistant to both 
effects varied. The fact that fewer cells developed a resistance to αMβ2 integrin 
activation compared to L-selectin shedding could be due to the fact that the 
extracellular domain of CD18 can be cleaved at physiological shear stresses [277]. 
Cleavage of CD18 on cells due to fluid shear stress may distort the true number of 
cells that are positive or negative for αMβ2 integrin activation, while L-selectin has 
only been found to be cleaved due to fluid shear stress when rolling on carbohydrate 
ligand coated surfaces [278]. 
 In addition to the variations in fMLP-induced L-selectin shedding and αMβ2 
integrin activation in neutrophils, it is also apparent that a subset does not acquire any 
resistance due to fluid shear stress. There is evidence that fluid shear stress on the 
neutrophil membrane can be non-uniform; variations in the shear stress distribution on 
the surface of a neutrophil have been found, due to the geometric shape of the 
membrane [279]. While spherical in shape, neutrophils have villous membrane made 
up of numerous fine foldings [280] that may alter the shear stress exerted on cell 
surface receptors. Despite these two factors, it is notable that a measurable population 
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of neutrophils developed a resistance to fMLP-induced activation. The ranges of the 
neutrophils being examined might also explain the differences in their response to 
fluid shear stress. Recent studies suggest that neutrophil lifespans might be much 
longer than what was previously believed, with neutrophils having a circulatory 
lifespan of up to 5.4 days, compared to the previously, generally accepted short 
lifespan of less than one day [281]. 
 Neutrophils have the ability to enzymatically cleave their surface receptors 
with proteases derived from within the cell upon exposure to fluid shear, including 
adhesion receptors such as L-selectin [278] and CD18 [277]. Cleavage of FPR by 
matrix metalloproteinases (MMPs) has previously been shown by others to alter the 
fluid shear response of neutrophils [282]. However, when neutrophils were treated 
with MMP inhibitors in this present study, no significant changes in FPR surface 
expression was observed when compared to untreated samples exposed to fluid shear. 
This indicates that the loss of FPR surface expression is not due to enzymatic cleavage 
via proteases derived from the neutrophil due to the onset of shear. Cleavage of FPR 
observed by other groups was due to the elevated levels of MMPs within the blood of 
the spontaneously hypertensive rat [282], while neutrophils used in this study were 
taken from normal human donors. 
 Our studies show that FPR surface expression downregulation could be due to 
the observed internalization of FPR by neutrophils upon exposure to fluid shear stress. 
FPR internalization is typically associated with desensitization of the receptor upon 
exposure to fMLP [283]. When FPR is activated due to fMLP, the receptor becomes 
phosphorylated by GPCR kinases, which increases FPR affinity for the cytosolic 
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protein arrestin [284]. Arrestin binding to GPCRs prevents the receptors from 
additional association with G proteins, making arrestins a major component in GPCR 
desensitization. FPR desensitization has also been shown to occur as a form of cross-
desensitization among chemoattractant receptors. HEK293 cells coexpressing fMLP 
and C5a receptors have shown that activation of C5a receptors resulted in cross-
desensitization of Ca2+ mobilization stimulated by FPR, and vice versa [285]. 
Neutrophils expressing combinations of chemoattractant receptors have shown that 
peptide chemoattractants such as fMLP, C5a, and IL-8 desensitized Ca2+ mobilization 
to one another and to PAF [286,287]. Recently, exposure to fluid shear stress has also 
been shown to cause FPR on leukocytes to be internalized into perinuclear 
compartments [279], and similar internalization responses due to shear stress have 
been observed in other cell types [288]. Based on the loss of FPR expression on 
neutrophils after the application of fluid shear stress, FPR internalization due to shear 
forces may also cause another form of desensitization, and thus attenuate the effects of 
fMLP on L-selectin shedding and αM integrin conformational change. Since fMLP is 
known to induce L-selectin shedding and αMβ2 integrin conformational change 
[189,258,259] and FPR was internalized upon exposure to shear stress in this current 
study, a downregulation of FPR on the surface available for receptor-ligand binding 
will contribute to the neutrophil response to activation. While FPR internalization 
could play a major role in the downregulation of FPR on the cell surface, other causes 
for FPR downregulation could also be contributors. For example, it has been 
suggested that fluid shear may change the conformation in the seven transmembrane 
domain region of FPR, which can possibly also cause FPR inactivation [276]. 
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 FPR has been implicated as a sensor for fluid shear stress, however other 
chemoattractant GPCRs such as CXCR1 and CXCR2 did not display unique 
properties while exposed to shear stress in this current study. Differences in their 
response to fluid shear stress could involve differences in their signaling pathways, as 
neutrophil chemotaxis in response to either fMLP or IL-8 are known to display 
different properties. Chemotaxis assays have shown neutrophil migration to IL-8 to be 
dependent on PI3K, however FPR signaling drastically differs, as treatment with Pan-
PI3K inhibitors only delays initial neutrophil migration to fMLP [289-292]. 
Physiologically, FPR surface expression on neutrophils might alter under shear, but 
not CXCR1 and CXCR2, due to the differences in the presentation of fMLP and IL-8 
in tissue compared to within the bloodstream. There is extremely low fMLP 
concentration present within the bloodstream, as fMLP is derived from bacterial 
protein degradation or from mitochondrial proteins upon tissue damage. While 
experiencing higher shear stresses within the bloodstream, FPR might remain 
internalized due to low fMLP concentrations, but once under much lower shear stress 
conditions from interstitial flow within the tissue, FPR could present itself along the 
surface of the neutrophil membrane to enhance migration along the chemotactic 
gradient. Conversely, the differences in IL-8 concentration are not as pronounced. 
Significant amounts of IL-8 are known to line along venular endothelial cells in the 
bloodstream while also being present within the tissue during inflammatory conditions 
[268], necessitating CXCR1 and CXCR2 levels to remain similar both under shear and 
non shear conditions. 
86 
To investigate the importance of FPR internalization in the shear-induced 
resistance to activation, one may attempt to match the number of receptor-ligand 
complexes at equilibrium for sheared and nonsheared neutrophils by increasing the 
fMLP concentration used to stimulate sheared neutrophils. If simple monovalent 
receptor-ligand binding is assumed, a monovalent ligand L binds reversibly to a 
monovalent receptor R to form a receptor-ligand complex C (54). Neglecting ligand 
depletion in the neutrophil suspension and assuming the ligand concentration remains 
constant at its initial value, L0, yields an estimate for the number of receptor ligand 
complexes at equilibrium, Ceq from the equation Ceq=RTL0/KD+L0, where KD is the 
equilibrium dissociation constant (nM) of the receptor ligand interactions, and RT is 
the number of receptors present on the cell surface (#/cell).  
FPR on neutrophils displays a KD in the range of 0.5-1.0 nM [293,294]. With 
the FPR receptor count for sheared neutrophils determined in the present study, one 
can estimate the L0 value necessary to reach the same Ceq found in nonsheared 
neutrophils. Using KD=1.0 nM, we predicted the fMLP concentration needed to elicit 
the same Ceq in sheared neutrophils as in nonsheared ones to be L0=0.8 nM. Equal 
responses of L-selectin shedding and αMβ2 integrin activation in sheared neutrophils 
exposed to 0.8 nM fMLP compared to nonsheared ones exposed to 0.5 nM fMLP 
would suggest that FPR internalization is responsible for the shear-induced resistance. 
Conversely, a lower degree of L-selectin shedding and αMβ2 integrin activation in the 
sheared neutrophils would suggest that FPR internalization, along with other factors, 
combine to contribute to the resistance response. Here, sheared neutrophils stimulated 
with 0.8 nM fMLP showed a reduction in selectin shedding and integrin activation 
87 
compared to nonsheared neutrophils stimulated with 0.5 nM fMLP, but exhibited 
greater selectin shedding and integrin activation than sheared neutrophils stimulated 
with 0.5 nM fMLP (Figure 2.11). This analysis suggests that FPR internalization 
contributes along with other factors in the neutrophil shear-induced resistance to 
activation. However, it should be noted that we have neglected receptor dynamics that 
occur during the 10 min stimulation with fMLP. Taking into account the synthesis, 
intracellular sorting, and differential endocytosis of formyl peptide receptors [295] 
could help further evaluate the impact the effects of FPR downregulation in the 
neutrophil shear-induced resistance to activation. 
 
2.5 CONCLUSION 
 
The results from this study suggest that fluid shear stress has a significant 
effect on the activation of circulating neutrophils. Neutrophils acquired a fluid shear 
stress-induced resistance to activation via FPRs. The resistance was shown to be 
dependent on shear stress magnitude, as the resistance response increased with 
increasing shear stress. The mechanical response was also shown to be dependent on 
shear stress duration, as neutrophils increased their resistance with increased shear 
stress exposure time. A decrease in FPR surface expression was observed under fluid 
shear stress, and high-resolution confocal microscopy revealed that FPR was 
internalized within cells. Although other studies on mechanotransduction in 
neutrophils have mostly focused on morphological changes, this study focused on 
earlier indicators of activation, specifically fMLP-induced L-selectin shedding and 
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αMβ2 integrin activation. The complete signaling pathways of these receptors deserve 
further study, as do the molecules that mediate GPCR internalization. Other receptors 
that have shown high constitutive activity should be investigated to understand their 
contributions to the mechanosensing responses of cells within the vascular 
microenvironment. 
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FIGURE 2.1: LOSS OF NEUTROPHIL L-SELECTIN UNDER VARIOUS 
SHEAR RATES. Neutrophils were exposed to shear rates of 75 s-1, 150 s-1, 225 s-1, or 
450 s-1 in a cone and plate viscometer 2 h at 23°C and were analyzed for L-selectin 
shedding due to shear alone. n = 3 donors for each shear rate value. Error bars 
represent 95% confidence intervals.  
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FIGURE 2.2: FLUID SHEAR STRESS INCREASES NEUTROPHIL 
RESISTANCE TO L-SELECTIN SHEDDING AND αMβ2 INTEGRIN 
ACTIVATION. Neutrophils were exposed to static conditions (A) and 4 dyn/cm2 of 
shear (B) for 2 h, respectively. Neutrophils exposed to static conditions and 4 dyn/cm2 
of shear for 2 h were then immediately exposed to 0.5 nM of fMLP for 10 min (C, D) 
or 5 nM of IL-8 for 10 min (E, F). All conditions were repeated for significance with n 
= 5 donors for L-selectin shedding (G) and αMβ2 integrin activation (H). Upper two 
quadrants of each flow cytometry plot represent positive CBRM1/5 staining, while the 
lower two signify little to no CBRM1/5 staining. The two right quadrants of each plot 
represent positive L-selectin staining, while the two left quadrants represent the 
absence of L-selectin staining. Quadrants determined by labeling neutrophils with 
isotype antibodies corresponding to L-selectin and CBRM1/5 antibodies, which label 
for all nonspecific binding sites on the neutrophil surface. “Low L-selectin” represents 
fluorescence values no greater than isotype values. PE represents the R-Phycoerythrin 
fluorescence channel, while FITC represents the fluorescein isothiocyanate 
fluorescence channel. Error bars represent 95% confidence intervals. *P < 0.05 for all 
measurements, and NS denotes a non-significant difference.  
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FIGURE 2.2: FLUID SHEAR STRESS INCREASES NEUTROPHIL 
RESISTANCE TO L-SELECTIN SHEDDING AND αMβ2 INTEGRIN 
ACTIVATION.  
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FIGURE 2.3: NEUTROPHIL SHEAR-INDUCED RESISTANCE TO 
ACTIVATION AT 23°C AND 37°C. Neutrophils were exposed to either shear (4.0 
dyn/cm2) or static conditions for 20 min at 23°C or 37°C, and then analyzed for L-
selectin shedding (A) and αMβ2 integrin activation (B). A 20 min duration was used to 
minimize sample evaporation. n = 5 donors for each shear stress value. Error bars 
represent 95% confidence intervals. *P < 0.05 for all measurements. NS: not 
significant. 
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FIGURE 2.4: INCREASING FLUID SHEAR STRESS REDUCES FMLP-
INDUCED L-SELECTIN SHEDDING AND αMβ2 INTEGRIN ACTIVATION 
OF NEUTROPHILS. Increasing fluid shear stress reduces fMLP-induced L-selectin 
shedding (A) and αMβ2 integrin activation (B) of neutrophils. Shear stress magnitude 
was varied in separate experiments from 0.1-4.0 dyn/cm2 for 2 h at 23°C, followed by 
stimulation with 0.5 nM of fMLP for 10 min. n = 5 donors for each shear stress value. 
Error bars represent 95% confidence intervals. *P < 0.05 for all measurements.  
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FIGURE 2.5: NEUTROPHIL RESISTANCE TO ACTIVATION INCREASES 
WITH INCREASING FLUID SHEAR STRESS DURATION. The time 
dependence of the mechanical response of neutrophils to fMLP-induced L-selectin 
shedding (A) and αMβ2 integrin activation (B) was determined by increasing the shear 
stress exposure time from 1-120 min at a uniform shear stress of 4.0 dyn/cm2 at 23°C.  
n = 3 donors for each time point. Error bars represent 95% confidence intervals. *P < 
0.05 for all measurements. 
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FIGURE 2.6: NEUTROPHILS DEVELOP RESISTANCE TO FMLP-INDUCED 
L-SELECTIN SHEDDING AND αMβ2 INTEGRIN ACTIVATION WITH 
INCREASING SHEAR STRESS MAGNITUDE AND SHEAR STRESS 
DURATION. Neutrophils develop resistance to fMLP-induced L-selectin shedding 
and αMβ2 integrin activation with increasing shear stress magnitude (A, C) and shear 
stress duration (B, D), respectively. Resistance is plotted as a function of the log10 of 
shear stress (dyn/cm2) or time (min). n = 5 donors for each shear stress point, and n = 
3 donors for each time point. Error bars represent 95% confidence intervals.  
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FIGURE 2.7: FLUID SHEAR STRESS ALTERS FMLP-INDUCED 
NEUTROPHIL MORPHOLOGY. Fluid shear stress alters fMLP-induced 
neutrophil morphology. Shape factor measurements of neutrophils exposed to shear 
stress or static conditions without and with 0.5 nM fMLP stimulation (A). Brightfield 
images of neutrophils exposed to shear stress (B) or static conditions (C) without 
fMLP, and neutrophils exposed to shear stress (D) or static conditions (E) with 0.5 nM 
fMLP. All scale bars = 50 µm. n = 3 donors, with 300 neutrophils analyzed for their 
shape factor for each donor condition. Error bars represent 95% confidence intervals. 
*P < 0.05 for all measurements. 
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FIGURE 2.8: FLUID SHEAR STRESS INDUCES A LOSS OF FPR SURFACE 
EXPRESSION. Fluid shear stress induces a loss of FPR surface expression. Flow 
cytometry plots show FPR expression at 4.0 dyn/cm2 for 2 h (A) compared to 
nonsheared samples, along with IL-8 receptors CXCR1 (B) and CXCR2 (C) 
expression of sheared and nonsheared neutrophils.  Receptor quantification using QSC 
beads was used to determine the surface receptor count of FPR, CXCR1, and CXCR2 
on neutrophils (D). n = 3 donors. Error bars represent 95% confidence intervals. *P < 
0.05 for all measurements. 
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FIGURE 2.9: PROTEASE INHIBITION DOES NOT AFFECT FPR SURFACE 
EXPRESSION UPON EXPOSURE TO FLUID SHEAR STRESS. Untreated 
neutrophils and neutrophils treated GM6001, 1,10-Phenanthroline, or TAPI-0 were 
exposed to static conditions and 4 dyn/cm2 of shear stress for 2 h. Samples were 
analyzed for FPR surface expression via flow cytometry. All conditions were repeated 
for significance with n = 3 donors. Error bars represent 95% confidence intervals. NS: 
not significant. 
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FIGURE 2.10: FLUID SHEAR STRESS INDUCES FPR INTERNALIZATION 
IN NEUTROPHILS. Neutrophils were exposed to 4 dyn/cm2 of fluid shear stress (A) 
or static conditions (B) for 2 h. All samples were permeabilized, labeled with FPR 
antibodies, and examined via confocal microscopy. Images were then thresholded (C) 
to exclude the cell membrane from measurements, and the average fluorescent 
intensity of the inner portion of sheared and non sheared cells (D) was quantified. All 
scale bars = 5 µm. All conditions were repeated for significance with n = 3 donors. 
Error bars represent 95% confidence intervals. *P < 0.05 for all measurements. 
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FIGURE 2.11: CHANGES IN FPR SURFACE EXPRESSION CONTRIBUTE 
TO THE NEUTROPHIL RESISTANCE TO ACTIVATION. Sheared neutrophils 
at 4.0 dyn/cm2 for 2 h were stimulated with 0.8 nM fMLP (A), to approach the Ceq of 
nonsheared neutrophils stimulated with 0.5 nM, based on an assumption of simple 
monovalent receptor-ligand binding. Nonsheared neutrophils stimulated with 0.5 nM 
and 0.8 nM fMLP and sheared neutrophils exposed to both 0.5 nM and 0.8 nM fMLP 
(B) were compared for L-selectin shedding and αMβ2 integrin activation with n=3 
donors. Error bars represent 95% confidence intervals. *P < 0.05 for all 
measurements. 
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CHAPTER 3: FLUID SHEAR STRESS INCREASES NEUTROPHIL 
ACTIVATION VIA PLATELET ACTIVATING FACTOR 
 
*This section is adapted from the following publication: M.J. Mitchell, K.S. Lin, and 
M.R. King. Biophysical Journal. 106(10): 2243-2253, 2014. 
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3.1 INTRODUCTION 
 
The initial recruitment and adhesion of leukocytes to the endothelial cell wall 
is a critical event in inflammation and lymphocyte homing to lymphatic tissues 
[168,296]. In the initial phase of recruitment, free flowing leukocytes in postcapillary 
venules can be captured under the presence of hemodynamic shear forces as low as 
~0.4-0.5 dyn/cm2 [168,169], and subsequently exhibit rolling adhesion on the 
receptor-bearing endothelial cell wall.  Rolling adhesion is mediated by rapid, force-
dependent selectin-selectin ligand interactions between leukocytes and the 
endothelium, which can transition to firm adhesion and subsequent leukocyte 
transmigration into inflamed tissues [192,297]. L-selectin, an important mediator on 
the leukocyte surface and constitutively expressed on the tips of microvilli, can initiate 
capture and rolling adhesion via binding to P-selectin glycoprotein ligand-1 (PSGL-1) 
on the endothelium [296,298,299]. Mouse knockdown experiments using L-selectin-
deficient mice show impaired neutrophil, lymphocyte, and monocyte migration into 
inflamed tissues [253], demonstrating the importance of L-selectin in inflammation 
and leukocyte homing. After initial tethering to the blood vessel wall, L-selectin can 
be rapidly cleaved from the cell surface by metalloprotease ADAM17, in a process 
known as “shedding” [300], to regulate cell rolling velocity and thus the rate of firm 
adhesion to the endothelium [278]. In addition to L-selectin, β2 integrins on the 
surface of leukocytes bind with intercellular adhesion molecule-1 (ICAM-1) on the 
endothelium. Integrins such as macrophage-1 antigen (Mac-1), also known as 
CD11b/CD18 or integrin αMβ2, and lymphocyte function-associated antigen-1 (LFA
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1), also known as CD11a/CD18 or αLβ2, are constitutively expressed on neutrophils 
and initially bind to ICAM-1 in an intermediate affinity state, which can result in slow 
rolling adhesion under low physiological shear forces [297]. In response to increased 
signaling by chemotactic factors, the integrin molecules Mac-1 and LFA-1 undergo 
further conformational changes to achieve full activation, leading to firm adhesion. 
Together, the shedding of L-selectin and conformational activation of β2 integrins are 
key events that characterize neutrophil activation. One such chemotactic factor that 
induces neutrophil activation is platelet-activating factor (PAF) [301], which has been 
shown to lead to a decrease in L-selectin expression and activation of αMβ2 integrins 
on the neutrophil surface [167,302]. 
Hemodynamic fluid shear stresses have the ability to regulate the neutrophil 
activation response observed during inflammation. Human neutrophils exposed to 
static conditions, either in the presence or absence of chemoattractants, spread their 
cytoplasm, project pseudopods, and migrate on glass substrates [9,267]. Upon the 
application of fluid shear stress, neutrophils have been observed to retract pseudopods, 
assume a round resting state, and detach from glass substrates [9,267]. Conversely, 
leukocytes exposed to centrifugation or treated with dexamethasone can reverse their 
response to shear stress, and can project pseudopods upon fluid shear stress exposure 
[264,265]. Additionally, extended exposure to fluid shear stress can cause leukocyte 
membrane disruption [263].  
G-protein coupled receptors (GPCRs) have been hypothesized to serve as 
molecular mechanosensors on the neutrophil surface. HL60 cells differentiated into 
neutrophils using DMSO decreased GPCR constitutive activity in the presence of fluid 
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shear stress, in addition to retraction of lamellipodia, and returned to a round resting 
state [90,279]. Treatment with Gi inhibitor pertussis toxin or depletion of the GPCR 
formyl peptide receptor (FPR) via siRNA delivery significantly reduced shear-induced 
neutrophil pseudopod retraction [90]. cDNA FPR transfection into undifferentiated 
HL60 cells with low FPR expression led to the projection of pseudopods, which 
quickly retracted in response to fluid shear stress exposure. Recently, fluid shear stress 
pre-exposure was shown to suppress neutrophil activation to formyl-methionyl-leucyl-
phenylalanine (fMLP), which binds to FPR on the neutrophil surface during 
inflammation. fMLP is a chemotactic peptide derived from bacterial protein 
degradation and mitochondrial proteins upon tissue damage [303,304], and is present 
in low concentrations in the bloodstream during inflammation.  Exposure to fluid 
shear stress in a cone-and-plate viscometer (0.1-4.0 dyn/cm2) prior to fMLP treatment 
significantly reduced fMLP-induced αMβ2 integrin activation, L-selectin shedding, and 
pseudopod projection [91]. Neutrophils increased their resistance to fMLP-induced 
activation in a fluid shear stress magnitude- and exposure time-dependent manner. 
Interestingly, fluid shear stress did not alter the neutrophil activation response to 
interleukin-8 (IL-8), which binds to GPCRs CXCR1 and CXCR2 on the neutrophil 
surface. 
In addition to exposure to fMLP and IL-8 during inflammation, neutrophils can 
be exposed to platelet-activating factor (PAF), a phospholipid inflammatory mediator 
synthesized by monocytes, platelets, neutrophils, and endothelial cells [305]. PAF can 
then activate platelets, neutrophils, and other leukocytes in the bloodstream, 
particularly during inflammation and allergy [306]. Recognition by these cells occurs 
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via the PAF receptor (PAFR), a GPCR on the neutrophil surface, which leads to 
neutrophil migration through intercellular junctions in the endothelium to ameliorate 
tissue injury [307,308]. After synthesis via endothelial cells, PAF is translocated to the 
cell surface rather than secreted into the bloodstream, where it is available for binding 
to blood cells [306]. This is in contrast to fMLP, which is released from bacterial and 
mitochondrial proteins released from tissues. Upon recognition via interaction with 
PAF receptors on the surface of neutrophils, PAF induces cell adhesion and cell 
polarization, enhanced motility, priming of granular enzyme release, and redistribution 
of surface adhesion ligands in neutrophils [302]. These physiological effects occur 
while PAF remains associated with the endothelial membrane, showing that PAF 
commonly acts by juxtacrine signaling, which is necessary for tightly localized 
neutrophil recruitment [309]. Additionally, differences in functional response have 
been observed with PAF and fMLP. For example, neutrophils stimulated by fMLP can 
produce superoxide ions, while minimal ions are produced in neutrophils stimulated 
by PAF [310]. The different physiological responses to inflammation suggest that 
different intracellular pathways are utilized by PAFR and FPR, and that the response 
depends on the type of chemoattractant present (i.e., PAF or fMLP). 
The effect of hemodynamic shear forces on early indicators of PAF-induced 
neutrophil activation remains unknown. In this study, I quantified the effects of fluid 
shear stress pretreatment on PAF-induced neutrophil activation. 
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3.2 MATERIALS AND METHODS 
 
Reagents 
 
APC-conjugated mouse anti-human CD62L specific for human L-selectin, 
APC-conjugated mouse IgG1 isotype control antibody, and FITC-conjugated mouse 
IgG1 isotype control antibody were purchased from BD Biosciences (San Jose, CA). 
FITC-conjugated mouse anti-human CBRM1/5, which binds to the activation epitope 
of CD11b, was purchased from eBioscience (San Diego, CA). Platelet-activating 
factor (PAF) was purchased from Millipore (Billerica, MA). Primary goat anti-human 
PAF-R antibody, which binds to the extracellular N-terminus of the PAF receptor, and 
FITC-conjugated secondary donkey anti-goat IgG antibody were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Tumor necrosis factor-α protease 
inhibitor-0 (TAPI-0) and p38 mitogen-activated protein (MAP) kinase inhibitor 
SB203580 were purchased from Peptides International (Louisville, Kentucky) and 
Millipore, respectively. Human TruStain FcX Fc receptor blocking solution was 
purchased from Biolegend (San Diego, CA). Ca2+ and Mg2+ free Hank’s balanced salt 
solution (HBSS) and Dulbecco’s phosphate buffered saline (DPBS) were purchased 
from Invitrogen (Carlsbad, CA). Endotoxin-free water was purchased from MO Bio 
(Carlsbad, CA). Endotoxin-free human serum albumin (HSA) HEPES, low-endotoxin 
and essentially globulin-free bovine serum albumin (BSA) were purchased from 
Sigma Aldrich (St. Louis, MO). 
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Neutrophil Isolation 
 
Primary human neutrophils were isolated as described previously [83,209]. 
Whole peripheral blood was obtained via venous needle injection from healthy human 
donors after informed consent. Neutrophils were separated by centrifugation at 480 x g 
at 23°C for 50 min in a Marathon 8K centrifuge (Fischer Scientific; Pittsburgh, PA) 
using 1-Step Polymorphs (Accurate Chemical and Scientific Corporation; Westbury, 
NY) and resuspended in Mg2+ and Ca2+ free HBSS to remove excess polymorph 
solution. Remaining red blood cells were lysed hypotonically, and purified neutrophils 
were resuspended in Mg2+ free HBSS buffer with 0.5% HSA, 10 mM HEPES, and 2 
mM Ca2+ at a pH of 7.4 at a concentration of 0.5 x 106 cells/mL. Isolation protocols 
were approved by the Institutional Review Board (IRB) of Cornell University. 
 
Cone-and-Plate Viscometer Assay 
 
Cells were exposed to uniform fluid shear stress in a cone-and-plate DV-II+ 
pro digital viscometer (Brookfield Engineering Laboratories; Middleboro, MA) as 
previously described [82,86,91]. Neutrophils were placed in a plate underneath a cone 
angled at 0.8°. Shear rate, G, is known to be a function of cone angle and independent 
of distance from the center by the following equation: 
 
 θ
ω
tan
=G
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where ω is the angular velocity of the cone (rad/s) and θ is the cone angle (rad) [91]. 
To achieve a desired shear stress, τ, assuming Newtonian fluid behavior, the shear rate 
was varied according to the equation:  
 
 
 
where µ is the viscosity of the buffer solution (Pa·s)[86]. Prior to fluid shear stress 
exposure, the cone and plate were incubated with 5% bovine serum albumin (BSA) for 
1 hour to prevent non-specific adherence of neutrophils to the steel surfaces. 
Neutrophils suspensions were then placed onto the plate at a concentration of 0.5 x 106 
cells/mL. Neutrophils were exposed to fluid shear stress (0.1 – 2.75 dyn/cm2) for 1-
120 min at 23°C. Cells were then immediately incubated with 1 µM PAF for 10 min at 
room temperature (RT). Cells were washed and prepared for antibody labeling, or 
fixed in paraformaldehyde and prepared for morphology analysis. For L-selectin 
inhibition studies, neutrophils were treated with 25 µM TAPI-0, an inhibitor of the L-
selectin sheddase ADAM-17, or 1 µM SB203580, an inhibitor of p38 MAP kinase, for 
60 min prior to fluid shear stress exposure. Neutrophil viability levels of >95%, before 
and after cone-and-plate assays, were confirmed using a trypan blue exclusion dye.   
 
Flow Cytometry 
 
 Untreated and PAF-treated neutrophils were incubated with APC-conjugated 
mouse anti-human CD62L and FITC-conjugated mouse anti-human CBRM1/5 
Gµτ =
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antibodies after PAF treatment. Control samples to measure nonspecific binding were 
incubated with APC-conjugated and FITC-conjugated mouse IgG1 isotype control 
antibodies. All samples were incubated at 4°C for 35 minutes and washed twice with 
cold Ca2+ free and Mg2+ free DPBS. Data were collected and analyzed using an Accuri 
C6 Flow Cytometer (BD Biosciences; San Jose, CA) and FCS Express V3 (De Novo 
Software; Thornville, Ontario, Canada) software. 
 
Brightfield Microscopy and Imaging Analysis 
 
 Neutrophils were prepared for morphology analysis via fixation with 4% 
paraformaldehyde (Electron Microscopy Sciences; Hatfield, PA) for 30 min at 4°C. 
Cells were washed and placed in a 24-well plate, and imaged via bright field and 
phase contrast microscopy using an Olympus IX81 Inverted System Microscope 
(Olympus America; Center Valley, PA). Metamorph Software (Molecular Devices; 
Sunnyvale, CA) was used to threshold outlines of neutrophils. Neutrophil circularity 
was quantified by calculating the shape factor, defined by the following equation:  
 
 
 
where A = area (µm2) and P = perimeter (µm) [91]. A shape factor of 1 defines a 
perfect circle. All shape factor data were imported into Microsoft Excel (Microsoft 
Corporation, Redmond, WA) for analysis. 
2
4
P
AFactorShape π=
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PAF Receptor Expression 
 
 Neutrophil surface expression of PAF receptor (PAF-R) was detected using 
flow cytometry. Cells were incubated in Human TruStain FcX for 10 min at RT, to 
block nonspecific binding between Fc regions of antibodies and Fc receptors on the 
cell surface. Neutrophils were then labeled with PAF-R antibody (N-17) and incubated 
for 1 h at 4°C. After washing twice with cold Ca2+ free and Mg2+ free DPBS, samples 
were incubated with FITC-conjugated secondary IgG antibody for 30 min at 4°C. 
Samples were washed twice and analyzed using a flow cytometer. To measure PAF 
receptor density of neutrophils exposed to static conditions and fluid shear stress, PAF 
receptor fluorescence intensity measurements were compared to the fluorescence of 
standard microspheres with known levels of fluorescence. Quantum FITC-5 molecules 
of equivalent soluble fluorochrome kits (MESF; Bangs Laboratories Inc.), consisting 
of four types of microspheres with increasing levels of FITC fluorochrome and one 
blank microsphere population, were used to create a fluorescence calibration curve 
according to the manufacturer’s instructions. Quantum FITC-5 MESF beads were 
analyzed for fluorescence intensity using a flow cytometer to create a standard 
fluorescence curve. Neutrophils exposed to static and sheared conditions, which were 
labeled with PAF receptor and FITC-conjugated secondary antibodies, were then 
analyzed for fluorescence intensity using a flow cytometer. PAF receptor density was 
estimated using the standard fluorescence curve. 
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Statistical Analysis 
 
 Shape factor and flow cytometry data were plotted using GraphPad Prism 5 
(GraphPad Software; La Jolla, CA). Statistical two-tailed paired t-tests were 
performed to test for significant differences between data sets, with p<0.05 being 
considered significant. 
 
3.3 RESULTS 
 
Fluid shear stress increases neutrophil PAF-induced L-selectin shedding and αMβ2 
integrin activation 
 
 We initially examined the response of neutrophils to PAF under fluid shear 
stress conditions in terms of L-selectin shedding and αMβ2 integrin activation using a 
cone a plate viscometer, which has been previously used by our lab to examine fluid 
shear stress effects on neutrophils and cancer cells [86,91,159]. Neutrophils were in 
static conditions or exposed to a fluid shear stress of 1.0 dyn/cm2 for 2 h and 
subsequently treated with 1 µM PAF for 10 min at 23°C. PAF, a phospholipid 
produced by endothelial cells that acts as a mediator of the inflammatory response 
[302], is known to increase L-selectin shedding and induce structural changes in αMβ2 
integrins to an activated conformation [311]. Negligible neutrophil L-selectin 
shedding and αMβ2 integrin activation was observed in samples exposed to static 
conditions (Figure 3.1A), while fluid shear stress exposure induced a moderate 
 112 
increase in both indicators of activation (Figure 3.1B). However, in response to PAF 
neutrophils showed a greater degree of L-selectin shedding and αMβ2 integrin 
activation after fluid shear stress pre-exposure (Figure 3.1D), compared to pre-
exposure to static conditions (Figure 3.1C). While trends indicate that shear stress 
exposure alone does induce an increase in neutrophil L-selectin shedding and αMβ2 
integrin activation, these changes were found to be not significant (Figure 3.1E,F). In 
the presence of PAF, the average percentage of neutrophils that shed L-selectin 
increased significantly after shear stress exposure, from approximately 35% for cells 
under static conditions to over 70% for cells exposed to fluid shear stress (Figure 
3.1E). Similarly, the average percentage of neutrophils expressing the activated αMβ2 
integrin subunit increased in PAF-treated samples, from approximately 15% for cells 
under static conditions to approximately 60% for cells exposed to fluid shear stress 
(Figure 3.1F). These results suggest that fluid shear stress pre-exposure and PAF can 
both act to increase neutrophil activation. 
 
PAF activation of neutrophils increases with fluid shear stress magnitude 
 
 To assess the effect of fluid shear stress magnitude on neutrophil PAF-induced 
activation, cells were exposed to shear stresses ranging from 0.1—2.75 dyn/cm2 in a 
cone-and-plate viscometer for 30 min, followed by treatment with 1 µM PAF for 10 
min at 23°C. The range of shear stress includes that typically found in the venular 
microcirculation [312], which is the primary site of leukocyte interactions with the 
endothelium [170,274]. No differences in L-selectin shedding or αMβ2 integrin 
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activation were seen after exposure to low fluid shear stresses of 0.1 dyn/cm2 (Figure 
3.2A,B). However, a significant increase in neutrophil PAF-induced L-selectin 
shedding was observed after exposure to shear stresses of 1.0 dyn/cm2 and 2.75 
dyn/cm2, compared to static conditions (Figure 3.2A). Fluid shear stress induced a 
similar increase in activation in terms of the activated αMβ2 integrin epitope, when 
compared to neutrophils stimulated with PAF under static conditions (Figure 3.2B).  
 To identify the increase in shedding of L-selectin and activated αMβ2 integrin 
subunit expression with respect to fluid shear stress, the neutrophil sensitization 
responses to L-selectin shedding and αMβ2 integrin activation were calculated using 
the following equation:  
 !%!PAF!Activation!Increase = %!!"##$!"#$% ! %!!"##$!"#"$%%!!!""#!"#"$% !X!100%       
 
When shear stress magnitude was varied, it was found that the PAF activation increase 
in neutrophils increased with increasing magnitude of fluid shear stress pre-exposure 
(Fig 1C).  
 
Neutrophil PAF activation is dependent on fluid shear stress exposure time 
 
To study the kinetics of the neutrophil PAF activation in the presence of fluid 
shear stress, neutrophils were sheared at 1.0 dyn/cm2 for durations ranging from 5 to 
120 min at 23°C, followed by stimulation with 1 µM PAF. While no significant 
differences in L-selectin shedding were observed after 10 min shear stress exposure, 
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L-selectin shedding significantly increased after shear stress exposure for 30 min 
(Figure 3.3A). A significant increase in PAF-induced αMβ2 integrin activation was also 
observed after 30 min of exposure to shear stress conditions (Figure 3.3B). The 
percent PAF increase equation used to calculate the shear stress dose response plot 
was also used to quantify the increase in neutrophil PAF activation over shear stress 
exposure time.  With increasing durations of shear stress pre-exposure, neutrophils 
stimulated with PAF increased their level of activation (Figure 3.3C). By 30 min, the 
percent increase in L-selectin shedding and αMβ2 integrin activation reached ~95% and 
45%, respectively.  
 
Fluid shear stress increases PAF-induced neutrophil morphological changes 
 
In addition to L-selectin shedding and αMβ2 integrin activation, cell 
polarization is among the responses exhibited in activated neutrophils after PAF 
stimulation [302]. During this phenomenon, neutrophils extend pseudopods to enable 
cell motility, allowing neutrophils to effectively extravasate through the blood vessel 
wall and migrate to inflamed tissue during the immune response [275]. To assess the 
effect of fluid shear stress on cell polarization, neutrophils were exposed to 1.0 
dyn/cm2 shear stress for 30 min, followed by stimulation with PAF. Cells were then 
fixed with 4% paraformaldehyde and examined for morphological changes. 
Qualitative evaluation of neutrophil morphology in the absence of PAF under either 
static conditions or 1.0 dyn/cm2 fluid shear stress showed similar round morphologies 
(Figure 3.4A,B) characteristic of resting neutrophils. Upon stimulation with PAF, 
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neutrophils assumed a notably more elongated form with extended pseudopods 
(Figure 3.4C), while cells exposed to shear prior to PAF stimulation displayed more 
exaggerated features than those under static conditions (Figure 3.4D). To calculate 
neutrophil shape factor, images were thresholded to select the outline of the cells to be 
measured (Figure 3.4E). Neutrophils exposed to static and shear conditions in the 
absence of PAF stimulation both exhibited shape factors close to 1 and were not 
significantly different from each other (Figure 3.4F), consistent with empirical 
observations. While neutrophils stimulated with PAF after exposure to static and shear 
conditions displayed shape factor values significantly less than those in the absence of 
PAF, PAF-treated neutrophils exposed to shear stress showed significantly lower 
average shape factor than those exposed to static conditions (Figure 3.4F). These 
results indicate that fluid shear stress enhances changes in neutrophil morphology in 
response to PAF.  
 
Neutrophil PAF surface receptor expression is unaltered in response to fluid shear 
stress 
 
Previous studies showed that neutrophil response to fluid shear stress can 
result in changes in chemoattractant surface receptor expression [91]. To investigate 
whether neutrophil response to fluid shear stress alters the expression of the PAF 
receptor (PAFR) on the cell surface, neutrophils were exposed to fluid shear stress (1.0 
dyn/cm2) for 30 min, labeled with fluorescent anti-PAFR antibodies, and analyzed via 
flow cytometry. The distribution of PAFR surface expression among the neutrophil 
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population remained unchanged between static and shear conditions (Figure 3.5A). 
PAFR surface expression was quantified in terms of percent of neutrophils expressing 
PAF receptor, and results show no significant change in expression between 
neutrophils under static and shear conditions (Figure 3.5B). To measure PAF receptor 
densities of neutrophils exposed to shear and static conditions, quantum MESF beads 
were used to generate a fluorescence standard curve to estimate the number of PAF 
receptors per neutrophil. No significant differences in the number of PAF receptors 
per neutrophil were found, as neutrophils exposed to either shear or static conditions 
averaged ~9000 PAF receptors/cell (Figure 3.5C). 
 
Shear stress and PAF-induced neutrophil L-selectin shedding is ADAM-17 and p38 
MAP kinase-dependent 
 
Neutrophil shedding of L-selectin is dependent on the p38 mitogen-activated 
protein kinase pathway [313].  This pathway subsequently leads to activation of 
ADAM-17, a protease involved in TNF-α activation and known to regulate L-selectin 
shedding [314]. To shed light upon the mechanism by which L-selectin is shed in the 
presence of shear stress pre-exposure followed by PAF stimulation, neutrophils were 
treated with 25 µM TAPI-0 (Figure 3.6C) and 1 µM SB203580 (Figure 3.6D), 
inhibitors of p38 MAP kinase and ADAM-17 sheddase, respectively, for 60 min prior 
to shear stress exposure. Untreated and PAF-treated neutrophils maintained in static 
conditions (Figure 3.6A,C,E,G) or fluid shear stress (Figure 3.6B,D,F,H) were then 
labeled with fluorescent anti-L-selectin antibodies. Expression of L-selectin on 
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inhibitor-treated cells was then compared to uninhibited cells with and without PAF 
treatment. Consistent with previous work, static neutrophils treated with TAPI-0 or 
SB203580 and subsequently stimulated with PAF showed minimal L-selectin 
shedding, relative to untreated neutrophils (Figure 3.6I). After shear stress exposure, 
sensitization to PAF-induced L-selectin shedding was attenuated in TAPI-0 and 
SB203580-treated neutrophils (Figure 3.6E-I), supporting the idea that fluid shear 
stress and PAF-induced L-selectin shedding is ADAM-17 and p38 MAP kinase-
dependent. 
 
3.4 DISCUSSION 
 
The goal of this study was to characterize the effect of fluid shear stress on 
PAF-induced L-selectin shedding, αMβ2 integrin activation, and morphological 
changes in neutrophils. Our results show that neutrophil PAF activation is 
significantly increased after fluid shear stress pre-exposure of magnitude as low as 1.0 
dyn/cm2, consistent with previous studies. Marschel et. al., observed rapid pseudopod 
retraction of neutrophils adhering via β2 integrins on a glass substrate upon fluid shear 
stress exposure at 1.0 dyn/cm2 [315]. In terms of initial rolling adhesion, Finger et. al. 
reported that a minimal wall shear stress of 0.4 dyn/cm2 is required for stable tethering 
and rolling of neutrophils via L-selectin on peripheral lymph node addressin (PNAd), 
with a maximal number of neutrophils rolling at 1.0 dyn/cm2 [169]. Sundd et. al. 
reported that fluid shear stresses greater than 0.5 dyn/cm2 are required for neutrophil 
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rolling on P-selectin. Such adhesion is a necessary precursor interaction to binding 
with PAF on endothelial cells during the onset of inflammation [168]. 
Interestingly, our previous study characterizing the effect of fluid shear stress 
on fMLP-induced L-selectin shedding and αMβ2 integrin activation in neutrophils 
showed that, in stark contrast to our current findings, neutrophils display a resistance 
instead of a sensitization to chemoattractant stimulation [91]. fMLP is a peptide 
chemoattractant released by certain bacteria and mitochondria at a site of tissue 
infection and/or injury, and activates neutrophils by interacting with the formyl 
peptide receptor on the neutrophil surface (Figure 3.7) [316]. In humans, fMLP 
present only at very low concentrations in the bloodstream, compared to sites of tissue 
infection and/or injury. Sustained activation to fMLP stimuli in the bloodstream could 
hinder the neutrophil response to infection by promoting pseudopod projection, 
increasing neutrophil transit time in blood, and enhancing neutrophil retention in the 
microvasculature [317,318]. Thus, if neutrophils pre-exposed to hemodynamic shear 
forces in the bloodstream increased fMLP-induced activation, neutrophils would be 
fully activated in the bloodstream and less efficient at transmigrating into localized 
tissues. Additionally, activation of neutrophils via fMLP also induces production of 
reactive oxygen species (ROS) [319], and thus shear-induced resistance to fMLP can 
reduce ROS-induced damage to healthy blood vessels. By developing a resistance to 
fMLP-induced activation when exposed to shear in the bloodstream, neutrophils avoid 
unnecessary activation in the bloodstream, facilitating extravasation and subsequent 
migration in tissues. In contrast, PAF-induced activation of neutrophils in the 
bloodstream is physiologically important (Figure 3.7). 
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PAF is a unique chemotactic factor in that it triggers both thrombotic and acute 
inflammatory responses after stimulation by chemical mediators found in the blood, 
such as thrombin and histamines, and thus links the hemostatic and innate immune 
responses [320]. For platelets, exposure to PAF is important for activation and 
aggregation at sites of vascular injury. For neutrophils, it primes the release of 
granular factors, which play a role in coagulation [302]. Because it is secreted by 
various leukocytes in the fluid phase, PAF is thought to have endocrine and paracrine 
signaling roles as well, which may also necessitate its presence in the vascular system 
for its use as a means of transport [302]. The increase in neutrophil PAF activation in 
the presence of fluid shear stress primes neutrophils for activation in the bloodstream, 
allowing them to respond to vascular injury [320]. The differences in PAF and fMLP-
induced activation after shear stress pretreatment suggest that there is an underlying 
mechanism for neutrophils to optimize their response to their local fluid shear stress 
microenvironment (Figure 3.7).  
While the observed sensitization response was not coupled with a shear stress-
induced change in PAF receptor density on the neutrophil surface, sensitization to L-
selectin shedding was shown to be p38 MAP kinase (MAPK)-dependent. The 
molecular mechanisms underlying αMβ2 integrin activation were not probed, as they 
remain poorly understood and is the subject of ongoing research [321,322]. While this 
study focused on mechanical force-induced increases to PAF-induced activation, 
increases in neutrophil PAF activation have previously been induced by chemical 
exposure. Human recombinant granulocyte-macrophage colony-stimulating factor 
(GM-CSF) was shown to prime arachidonic acid release and intracellular calcium 
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fluxes in neutrophils after PAF stimulation [323]. One proposed hypothesis for this 
phenomenon is that GM-CSF remodels the lipid profile of the neutrophil plasma 
membrane, causing receptors on the neutrophil surface to become more accessible to 
substrates [323]. This hypothesis may also explain the observed increases in PAF 
activation; shear forces may act on the neutrophil membrane to readily expose the 
PAFR for easier access by immobilized PAF, without changing receptor density. 
Ginkgolide B (GKB), a bioactive component of the Ginkgo biloba leaf extract 761, is 
another chemical found to prime neutrophils for activation. GKB primes fMLP- and 
zymosan-induced respiratory burst in neutrophils by acting through the PAF receptor. 
Although this mechanism remains unknown, it is hypothesized that this priming effect 
may involve phosphorylation or some conformational change of PAFR to a more 
activated form. It has been suggested by a number of studies in response to 
observations of heterogeneous low- and high-affinity binding of PAFR to PAF that 
PAFR may exist in various conformational states and requires activation in order to 
achieve high-affinity binding [324,325].  Mutations of the Ala230 and Leu231 
residues on the third intracellular loop of the receptor to Glu230 and Arg231, 
respectively, have been shown to lead to inactive and constitutively active PAFR 
states [326]. This finding suggests the possibility that fluid shear stress may affect the 
PAF receptor directly, and future work could probe conformational changes or 
clustering of the receptor in response to shear. 
In response to PAF stimulation, PAFR, much like other GPCRs, can 
internalize into cells with their respective PAF ligands to cause either desensitization 
or resensitization of the receptor [284,327,328]. Immediately after PAF binding, 
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PAFR uncouples from G-proteins, and are rapidly phosphorylated by different 
kinases. During densensitization, PAFR can undergo endocytosis into endosomes and 
be targeted for degradation via ubiquitination [328]. This can lead to an overall down 
regulation of PAFR, and thus desensitization in the presence of PAF ligands. 
Conversely, resensitization to PAF can occur, in a process where PAFR is thought to 
move into early endosomes and recycle to the cell membrane. Previous work by our 
group showed that FPR can internalize within neutrophils upon exposure to fluid shear 
stress, in the absence of fMLP stimulation [91]. In this study, there were no 
differences found in PAFR expression on the neutrophil surface after fluid shear stress 
exposure, thus suggesting that the fluid shear stress pre-exposure does not desensitize 
neutrophils to PAF stimulation. However, it is possible that fluid shear stress pre-
exposure could affect PAFR internalization in the presence of the agonist, perhaps by 
enhancing recycling of PAFR, which would explain the increase in neutrophil PAF 
activation. 
Neutrophil p38 MAPK signaling may also be influenced by fluid shear stress 
exposure. Killock et. al. showed that stimulation of resting leukocytes with calcyculin 
A or cantharidin led to increased levels of phosphorylated p38 MAPK, which triggers 
increased phosphorylation of the cytoplasmic tails of TNF-α-converting enzyme 
(TACE) and its subsequent expression on the cell surface, which likely caused the 
simultaneous increase of L-selectin shedding [329]. Fluid shear stress may increase 
phosphorylation of p38 MAPK in a similar manner, to induce the sensitized L-selectin 
shedding response observed in our study. To explore this possible mechanism, future 
efforts could compare the surface expression of TACE or radioactively labeled 
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phosphorylated p38 MAPK pre- and post-shear stress exposure. Downstream of PAFR 
signaling, PAF, like fMLP, is known to strongly activate MAP kinase kinase-3 
(MKK3). Unlike fMLP, PAF minimally activates MAP ERK kinase kinase-1 
(MEKK1), Raf, and the p42/44 (ERK) MAP kinases, all of which are pathways that 
are strongly activated by fMLP [310]. Fluid shear stress could act to increase 
activation of these pathways to enhance neutrophil PAF-induced activation.  
One important difference between the experimental conditions of this study 
and the physiological conditions of the human body is the presentation of PAF. 
Physiologically, while PAF is secreted by many leukocytes in a fluid-phase form, in 
the inflammatory response it is most commonly synthesized by endothelial cells and is 
translocated onto the cell surface, where it primarily acts through a juxtacrine 
signaling mechanism. The main advantage to the cell-associated form of 
communication is to allow for spatial regulation of signaling and only permit localized 
activation, thus preventing activation of PMNs in free-flowing blood [330]. Because 
unregulated secretion of PAF has been shown to induce anaphylactic or septic shock 
and trauma [320], the body has adopted various mechanisms to regulate plasma PAF 
concentrations. One method of control is by PAF acetylhydrolase, which degrades 
PAF and limits its half-life to no more than a few minutes in the blood stream [302]. 
The half-life of PAF in a study involving patients with acute allergic reactions was 
found to be ~13.6 minutes in serum with the lowest PAF acetylhydrolase activity, ~6.0 
minutes in serum with intermediate PAF acetylhydrolase activity, and ~3.8 minutes in 
serum with the highest PAF acetylhydrolase activity [331]. Our experiments were 
conducted in the absence of PAF acetylhydrolase, and neutrophils were treated with 
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PAF for a duration of 10 minutes. Thus, we expect there to be less neutrophil 
activation than that reported in our results in individuals with intermediate to high 
PAF acetylhydrolase activity. In addition to limiting the actions of PAF in the 
bloodstream, the body also has mechanisms to facilitate neutrophil recognition of 
PAF. One example of this involves granule membrane protein-140 (GMP-140), a 
membrane glycoprotein in the granules of platelets and endothelial cells that is 
translocated to the cell surface along with PAF upon stimulation by histamine or 
thrombin. It is found to act cooperatively with PAF in facilitating recruitment of β2 
integrins on neutrophils in an indirect manner – it initiates tethering of neutrophils to 
endothelial cells, bringing the otherwise inaccessible and immobilized PAF in 
proximity to its receptor on neutrophils [332]. In comparison, the fluid phase form of 
the chemoattractant in our study may make PAF more accessible to neutrophils and 
heighten the response. While the discrepancy between the experimental conditions of 
our study and those of in vivo conditions may cause differences in the degree of 
neutrophil activation, our reported findings still hold –fluid shear stress sensitizes 
PAF-induced L-selectin shedding, αMβ2 integrin activation, and morphological 
changes of neutrophils during the inflammatory response. Future work that explores 
the role of other enzymes in the p38 MAPK pathway downstream of PAFR, potential 
cross-talk mechanisms between integrins, and the possibility of different 
conformational states in the receptor itself may bring a greater understanding of the 
molecular details of the role of fluid shear stress in the innate immune response. 
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FIGURE 3.1: FLUID SHEAR STRESS EXPOSURE AND PLATELET 
ACTIVATING FACTOR INCREASE NEUTROPHIL ACTIVATION. 
Neutrophils exposed to (A) static and (B) shear conditions at 1.0 dyn/cm2 for 2 h. 
PAF-treated samples were exposed to 1 µM PAF for 10 min (C, D) and analyzed for 
activation. Upper 2 quadrants signify activated αMβ2 integrin subunit expression. Two 
right-hand quadrants show L-selectin expression. Gating was determined using 
fluorescence intensities of isotype controls. Bar graph representation of (E) L-selectin 
shedding and (F) αMβ2 integrin activation. “Low L-selectin” denotes neutrophils that 
have shed L-selectin from their surface, and have fluorescence intensities no greater 
than that of isotype controls. Conditions were repeated for 3 donors (n = 3). Error bars 
signify 95% confidence intervals. *P < 0.05. NS: not significant. 
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FIGURE 3.1: FLUID SHEAR STRESS EXPOSURE AND PLATELET 
ACTIVATING FACTOR INCREASE NEUTROPHIL ACTIVATION.  
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FIGURE 3.2: PAF ACTIVATION OF NEUTROPHILS IS FLUID SHEAR 
STRESS MAGNITUDE-DEPENDENT. Cells were exposed to a range of shear 
stress (0.1-2.75 dyn/cm2) for 30 min at 23°C, followed by immediate treatment with 1 
µM PAF for 10 min. Quantification of (A) L-selectin shedding and (B) activated αMβ2 
integrin expression on neutrophils after exposure to increasing shear stress. (C) 
Percent platelet activating factor (PAF) activation increase, in terms of L-selectin 
shedding and αMβ2 integrin activation, plotted as a function of the log10 of shear stress.  
*P < 0.05, ** P < 0.01. 
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FIGURE 3.2: PAF ACTIVATION OF NEUTROPHILS IS FLUID SHEAR 
STRESS MAGNITUDE-DEPENDENT.  
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FIGURE 3.3: INCREASED NEUTROPHIL PAF ACTIVATION IS FLUID 
SHEAR STRESS TIME-DEPENDENT.  Cells were sheared (1.0 dyn/cm2) for a 
duration of 5-120 min at 23°C and immediately incubated in 1 µM PAF for 10 min. 
Quantification of (A) L-selectin shedding and (B) activated αMβ2 integrin expression 
of neutrophils over time. (C) Percent platelet activating factor (PAF) activation 
increase, in terms of L-selectin shedding and αMβ2 integrin activation, plotted as a 
function of the log10 of time. *P < 0.05, **P < 0.01. 
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FIGURE 3.3: INCREASED NEUTROPHIL PAF ACTIVATION IS FLUID 
SHEAR STRESS TIME-DEPENDENT.  
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FIGURE 3.4: FLUID SHEAR STRESS INCREASES NEUTROPHIL 
MORPHOLOGICAL CHANGES IN THE PRESENCE OF PAF. Representative 
brightfield images of untreated neutrophils after exposure to (A) static and (B) shear 
conditions (1.0 dyn/cm2) for 30 min, compared to cells stimulated with 1 µM PAF 
after exposure to (C) static and (D) shear conditions. Scale bar = 50 µm. (E) Shape 
factor data of neutrophils exposed to static (1.0 dyn/cm2) or shear conditions, with and 
without 1 µM PAF stimulation. (E) Inset: images were thresholded to calculate shape 
factor of cells (scale bar = 5 µm). n = 3 donors, with 100 neutrophils from each donor 
analyzed for shape factor. 
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FIGURE 3.5: FLUID SHEAR STRESS DOES NOT ALTER PAF RECEPTOR 
EXPRESSION. Neutrophils were exposed to fluid shear stress (1.0 dyn/cm2) for 30 
min at 23°C. Flow cytometry histograms (A) and mean fluorescence intensities (B) of 
PAF receptor expression in sheared and nonsheared neutrophil samples. (C) PAF 
receptor density of neutrophils exposed to static conditions and fluid shear stress (1.0 
dyn/cm2) for 30 min at 23°C. NS: not significant. 
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FIGURE 3.5: FLUID SHEAR STRESS DOES NOT ALTER PAF RECEPTOR 
EXPRESSION.  
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FIGURE 3.6: SHEAR AND PAF-INDUCED L-SELECTIN SHEDDING IS 
ADAM-17 AND P38 MAP KINASE-DEPENDENT. L-selectin expression as a 
function of forward scatter of nonsheared and sheared (1.0 dyn/cm2) neutrophils in the 
absence of PAF (A,B) after treatment with PAF (C,D), and PAF-stimulated cells 
treated with TAPI-0 (E,F) and SB203580 (G,H). Gate determined using fluorescence 
of isotype controls. (I) Quantification of L-selectin shedding in all samples. n = 3 
separate donors. *P < 0.05. NS: not significant. 
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FIGURE 3.6: SHEAR AND PAF-INDUCED L-SELECTIN SHEDDING IS 
ADAM-17 AND P38 MAP KINASE-DEPENDENT.  
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FIGURE 3.7: COMPARISON OF FLUID SHEAR STRESS EFFECTS ON 
NEUTROPHIL ACTIVATION VIA PAF AND FMLP. Comparison of fluid shear 
stress effects on neutrophil activation via PAF (A) and fMLP (B). Shear stress 
exposure in the microvasculature increases neutrophil activation via PAF (A), while 
activation is be suppressed upon exposure to fMLP (B). FSS: fluid shear stress. PAF: 
platelet-activating factor. PAFR: platelet-activating factor receptor. FPR: formyl 
peptide receptor. 
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FIGURE 3.7: COMPARISON OF FLUID SHEAR STRESS EFFECTS ON 
NEUTROPHIL ACTIVATION VIA PAF AND FMLP.  
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CHAPTER 4: FLUID SHEAR STRESS SENSITIZES CANCER CELLS TO 
RECEPTOR-MEDIATED APOPTOSIS VIA TRIMERIC DEATH 
RECEPTORS 
 
*This section is adapted from the following publication: M.J. Mitchell and M.R. King. 
New Journal of Physics. 15(015008): 1-18, 2013. 
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4.1 INTRODUCTION 
 
Approximately 90% of human cancer-related deaths are due to cancer metastasis 
[1], which consists of a series of discrete steps that allow cancer cell migration from a 
primary site to a distal location. For hematogenous metastasis to occur, cancer cells 
must detach from the primary tumor, invade surrounding tissue, and intravasate into 
the circulation as circulating tumor cells (CTCs) [51]. Once in the circulation, CTCs 
are believed to adhere to the luminal surface of the microvasculature in a manner 
similar to the leukocyte adhesion cascade [176]. The process consists of adhesive 
interactions with the receptor-bearing endothelial cell wall, including selectin-
mediated cell tethering and rolling along the endothelium, followed by firm adhesion 
or arrest [52,176]. Once firmly adhered, CTCs may extravasate into a distal site and 
proliferate to form secondary tumors [333,334]. Radiation therapy, chemotherapy and 
surgery are generally successful in the treatment of primary tumors, however the 
treatment of metastases is challenging due to its systemic nature, and typically signals 
a poor prognosis [335]. The targeting and treatment of CTCs within the circulation are 
a potential solution to reduce the probability of metastasis. Several approaches have 
been developed to isolate patient CTCs from whole blood [336,337], along with novel 
strategies to target and treat CTCs with therapeutics under physiological flow [82,85]. 
One therapeutic that has displayed potential for the treatment of CTCs is tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL), a type 2 transmembrane 
protein of the tumor necrosis factor family [338]. TRAIL binds to death receptors 
(DR4 and DR5) expressed on the surface of a range of cancer cells, which can induce 
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cell apoptosis [84]. TRAIL also binds to three decoy receptors (DcR1, DcR2, DcR3) 
expressed on the surface of cells, which do not signal apoptosis and can act as 
competitive inhibitors to apoptosis [339]. Additionally, TRAIL does not exert 
apoptotic effects on most normal cells [87]. Natural killer (NK) cells, which are 
believed to play a physiological role in natural protection against tumor formation 
[340], can express TRAIL on the NK cell membrane. NK cell subpopulations in adult 
mouse liver constitutively expressed TRAIL in an interferon ϒ- dependent manner, 
and played a role in the suppression of tumor initiation and metastasis [341,342]. 
Interferon ϒ-dependent TRAIL expression on NK cells also plays a role in interferon 
ϒ-dependent tumor prevention effects of interleukin-12 (IL-12) and α-
galactosylceramide (α-GalCer) [343]. In addition to its therapeutic effects as a soluble 
ligand, TRAIL can play a role in NK cell surveillance of CTCs and tumors [342].  
The microenvironments of tumors and CTCs are remarkably different, with fluid 
shear forces being one factor that is dramatically altered once cancer cells enter the 
vascular microenvironment. In the tumor microenvironment, cancer cells are exposed 
to shear stresses created by interstitial flows, which range from 0.1 to 1.0 µm/s in 
normal tissues and higher values in the tumor microenvironment [12,18]. Such flows 
cause an upregulation of transforming growth factor beta (TGFβ) in fibroblasts, which 
can lead to myofibroblast differentiation, along with TGFβ-dependent alignment and 
stiffening of the extracellular matrix [34]. Interstitial flows can also upregulate matrix 
metalloproteinase expression to enhance glioma cell invasion [97]. Surface shear 
stress estimates for cancer cells exposed to interstitial flow are difficult to measure, 
but are estimated to be relatively low in comparison to those experienced in the 
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vasculature. For interstitial flow rates of 1 µm/s, one study estimated a fluid shear 
stress range of 0.007-0.015 dyn/cm2 [20]. This is in contrast to shear stresses in the 
circulation, which range from approximately 0.5 to 4.0 dyn/cm2 in the venous 
circulation and 4.0 to 30.0 dyn/cm2 in the arterial circulation, with the maximum shear 
stress experienced at the vessel wall [46]. Increases in fluid shear forces could affect 
cancer cell survival, as only a small portion of CTCs survive the circulation to 
generate metastases [344]. Conversely, fluid shear forces can aid CTCs in binding to 
the vascular endothelium via selectin-mediated tethering and rolling, followed by firm 
adhesion to the endothelium [345]. While previous studies have investigated the role 
of fluid shear forces in CTC adhesion to the microvasculature, little is known about 
the effects of fluid shear forces on the viability and proliferation of CTCs [6]. 
The role of hemodynamic shear forces in altering receptor-mediated apoptosis of 
cancer cells has not yet been investigated. In this study, I investigated the role of 
physiological shear forces in sensitizing cancer cells to TRAIL-mediated apoptosis. 
 
4.2 MATERIALS AND METHODS 
 
Cell culture 
 
Colorectal adenocarcinoma cell line COLO 205 (ATCC #CCL-222) and 
prostate adenocarcinoma cell line PC-3 (ATCC #CRL-1435) were purchased from 
American Type Culture Collection (Manassas, VA, USA). COLO 205 and PC-3 cells 
were cultured in RPMI 1640 and F-12K cell culture medium from Invitrogen (Grand 
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Island, NY, USA). Complete media was supplemented with 10% (v/v) fetal bovine 
serum and 1% (v/v) PenStrep, all purchased from Invitrogen. COLO 205 and PC-3 
cells were incubated under humidified conditions at 37°C and 5% CO2, and were not 
allowed to exceed 90% confluence. 
 
Preparation of cell for fluid shear stress studies 
 
COLO 205 and PC-3 cells were washed in Ca2+ and Mg2+ free Hank’s 
balanced salt solution (HBSS) (Invitrogen, Carlsbad, CA, USA) and then treated with 
Accutase (Sigma Aldrich, St. Louis, MO, USA) for 5-10 min at 37°C before handling. 
COLO 205 and PC-3 cells were washed with Ca2+ and Mg2+ free Dulbecco’s 
phosphate buffered saline (DPBS) (Invitrogen) at 300 X g for 5 min at 23°C. Cells 
were resuspended in media at a concentration of 0.5 x 106 cells/mL. Prior to 
performing fluid shear stress studies, 99% cell viability was confirmed using a trypan 
blue exclusion stain (Gibco, Grand Island, NY, USA).  
For TRAIL studies, cells were treated with 0.1 µg/mL recombinant human 
TRAIL (R&D Systems, Minneapolis, MN, USA) prior to the application of fluid shear 
stress. For caspase inhibition studies, cells were treated with 50 µM of pan-caspase 
inhibitor Z-VAD-FMK or negative control compound Z-FA-FMK (R&D Systems) for 
4 hours at 37°C prior to TRAIL treatment. For doxorubicin (DOX) studies, COLO 205 
cells were treated with doxorubicin hydrochloride (Sigma Aldrich) at a concentration 
of 20 µM, which has previously been shown to induce COLO 205 cell death, prior to 
the onset of fluid shear stress [82]. 
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Cone-and-plate viscometer assay 
 
To study the fluid shear stress response of cancer cells in a controlled, uniform 
environment, studies were conducted using a cone-and-plate viscometer consisting of 
a stationary plate underneath a rotating cone maintained at 37°C by a circulating water 
bath (Brookfield, Middleboro, MA) as described previously [91]. The design of the 
cone-and-plate device allows a uniform shear rate to be applied to the cancer cell 
suspension. The shear rate (G), does not depend on distance from the center of the 
cone, and is given by:  
 ! = !tan! 
 
 
where ω is the cone angular velocity (rad/s) and θ is the cone angle (rad). Under all 
experimental conditions, a laminar flow field is expected. For a Newtonian fluid under 
these conditions, the shear stress, τ, is proportional to the shear rate being applied:  
 ! = !!"!
!
where µ is the viscosity of the medium. Prior to fluid shear stress experiments, the 
stationary plate and rotating cone were washed thoroughly with 70% ethanol. TRAIL 
or doxorubicin-treated cancer cell suspensions were introduced to the plate at a 
concentration of 0.5 x 106 cells/mL, and were allowed to equilibrate for 1 min prior to 
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the onset of fluid shear stress. To identify a shear stress threshold required for cancer 
cell sensitization to TRAIL, cells were exposed to shear stresses ranging from 0.05-2.0 
dyn/cm2 for a duration of 120 min. To determine the shear stress exposure time 
required for TRAIL sensitization, cells were exposed to a shear stress of 2.0 dyn/cm2 
for increasing time intervals of 1-120 min. COLO 205 sensitization responses were 
determined by comparing samples exposed to shear and static conditions using the 
following equation:  
 
%!!"#$%&%'(&%)# = %!!"##$, !ℎ!"#!!"#$%&%"#' − ! %!!"##$, !"#"$%!!"#$%&%"#!%!!"##$, !"#"$%!!"#$%&%"#' ×100% 
 
 
The sensitization equation applies to COLO 205 cells labeled for apoptosis and 
necrosis, for both TRAIL-treated and untreated samples, at all shear stress magnitudes 
and exposure times. 
After exposure to shear stress, cells were washed thoroughly in PBS and analyzed 
for cell death using an Annexin-V assay. For doxorubicin studies, cells were washed 
and incubated overnight prior to apoptosis analysis, as a longer incubation time was 
required for cells to undergo doxorubicin-induced apoptosis. 
 
Annexin-V apoptosis assay 
 
A FITC-conjugated Annexin-V assay (Trevigen, Gaithersburg, MD, USA) was 
used to assess cell apoptosis and necrosis. Due to the intrinsic fluorescence of 
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doxorubicin, all doxorubicin treated cells were analyzed using an APC-conjugated 
Annexin-V assay (BD Pharmingen, San Diego, CA, USA). The manufacturer’s 
instructions were followed to prepare samples for flow cytometric analysis. Viable 
cells were identified as being negative for both Annexin-V and propidium iodide (PI), 
early apoptotic cells were positive for Annexin-V only, late apoptotic cells were 
positive for both Annexin-V and PI, and necrotic cells were positive for PI only. 
 
Flow cytometry 
 
Cells were incubated with Annexin-V reagents for 15 min at room temperature in 
the absence of light, and immediately analyzed using an Accuri C6 flow cytometer 
(Accuri Cytometers Incorporated, Ann Arbor, MI, USA). Flow cytometry plots were 
generated using Accuri CFlow Plus and FCS Express V3 software (De Novo 
Software, Thornhill, Canada). The following control samples were used to calibrate 
the instrument: unlabeled cell samples to evaluate the level of autofluorescence and 
adjust the instrument accordingly, and cell samples labeled individually with Annexin-
V and PI to define the boundaries of each cell population. 
 
Brightfield and phase contrast microscopy 
 
Cell samples were placed into 6 well plates and incubated at 37°C for 60 min to 
allow cells to adhere to the plate surface. Cells were then imaged by brightfield and 
phase contrast microscopy using an Olympus IX81 inverted microscope (Olympus 
 145 
America Inc., Center Valley, PA) to observe the presence of viable cells and 
membrane blebbing, which is characteristic of cells undergoing apoptosis. All images 
were processed using ImageJ software (U.S. National Institutes of Health, Bethesda, 
MD, USA). 
 
Death receptor quantification 
 
The average number of death receptors on the surface of cancer cells was 
determined using flow cytometry calibration with Quantum simply cellular (QSC) 
anti-mouse IgG beads (Bangs Laboratories, Inc., Fisher, IN, USA). QSC beads were 
incubated for 45 min at 4°C with a phycoerythrin (PE)-conjugated antibody specific to 
the antigen on the beads. A mixture of antibody-conjugated beads with a range of 
antigen binding capacities (ABCs) was run through a flow cytometer. Bead 
populations corresponding to increasing numbers of ABCs yield increasingly 
fluorescent peaks in the PE fluorescence channel. Median values of each fluorescence 
peak were obtained using Accuri CFlow Plus software. Fluorescence data and ABC 
values reported by the manufacturer were used to generate a calibration curve using 
QuickCal v2.3 (Bangs Labs, Fisher, IN). 
Following the calibration step, surface expression of death receptors DR4 and DR5 
on cancer cells was determined using flow cytometry. COLO 205 cells were exposed 
to static conditions or fluid shear stress (2.0 dyn/cm2) in a cone-and-plate viscometer 
for 120 min, followed by immediate incubation with either a PE-conjugated isotype or 
PE-conjugated DR4 and DR5 antibodies (Biolegend, San Diego, CA, USA) for 45 
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min at 4°C. Cells were then washed and analyzed for death receptor expression using 
flow cytometry. Median values of each fluorescence peak were recorded from each 
sample, and the fluorescence data was converted into the number of receptors using 
the calibration curve in QuickCal. 
 
Statistical analysis 
 
Data sets were plotted and analyzed using Prism 5.0b for Mac OS X (GraphPad 
software, San Diego, CA, USA). A two-tailed paired t-test was used for comparisons 
between two groups with p < 0.05 considered significant. 
 
4.3 RESULTS 
 
Fluid shear stress increases TRAIL-induced cancer cell apoptosis 
 
We first characterized the effect of fluid shear stress on TRAIL-treated cancer 
cells in terms of cell viability. COLO 205 cells were treated with TRAIL (0.1 µg/mL) 
and then exposed to either static conditions or 2.0 dyn/cm2 of fluid shear stress in a 
cone-and-plate viscometer for 120 min at 37°C. TRAIL binds to death receptors DR4 
(TRAIL-R1) and DR5 (TRAIL-R2) on the cell surface, which signal apoptosis [339]. 
Both death receptors are expressed on the surface of COLO 205 cells [346]. COLO 
205 cells exposed to static conditions (Figure 4.1A) or 2.0 dyn/cm2 of fluid shear 
stress (Figure 4.1B) for 120 min maintained high cell viability (>94%), with minimal 
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apoptosis observed in the absence of TRAIL (<6%). As expected, COLO 205 cells 
treated with TRAIL exposed to static conditions for 120 min reduced cell viability by 
~25%, with >22% of the cell population becoming apoptotic (Figure 4.1C). However, 
cells exposed to the same dosage of TRAIL followed by exposure to fluid shear stress 
(Figure 4.1D) induced a greater decrease in cell viability (>53%) and more than 
doubled the amount of apoptotic cells (>47%), compared to TRAIL-treated samples 
exposed to static conditions. Experiments performed in triplicate revealed that fluid 
shear stress alone did not affect cell viability (Figure 4.1E) or apoptosis (Figure 4.1F), 
yet induced a significant decrease in cell viability and increase in apoptosis in the 
presence of TRAIL. Similar effects on cell viability (Figure 4.1G) and apoptosis 
(Figure 4.1H) were also found in experiments performed with prostate 
adenocarcinoma cell line PC-3. Brightfield microscopy images revealed that COLO 
205 cells remained viable and retained their characteristic morphology when exposed 
to static conditions (Figure 4.2A) or 2.0 dyn/cm2 of fluid shear stress (Figure 4.2B). A 
greater number of viable cells was observed in TRAIL-treated COLO 205 samples 
exposed to static conditions (Figure 4.2C) compared to TRAIL-treated samples 
exposed to 2.0 dyn/cm2 of fluid shear stress (Figure 4.2D), with fewer viable cells and 
a greater degree of membrane blebbing, characteristic of cell apoptosis. PC-3 cells 
also remained healthy under static (Figure 4.2E) and shear  (Figure 4.2F) conditions, 
while a greater number of apoptotic cells was observed in TRAIL-treated samples 
exposed to shear (Figure 4.2H) compared to TRAIL-treated samples exposed to static 
conditions (Figure 4.2G). 
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Fluid shear stress does not alter TRAIL-induced cancer cell necrosis 
 
To assess whether fluid shear stress sensitizes cancer cells to TRAIL-induced 
necrosis, another form of cell death, cells treated with 0.1 µg/mL TRAIL followed by 
shear stress exposure were stained with propidium iodide (PI) dye and characterized 
using flow cytometry. Cells positive for PI labeling but negative for Annexin-V were 
determined to be necrotic, as the cytoplasmic membrane is compromised but lacks the 
membrane flipping of phosphatidylserine (PS), which is characteristic of apoptosis. 
Untreated COLO 205 (Figure 4.3A) and PC-3 (Figure 4.3B) cells exposed to static 
conditions or fluid shear stress did not show significant differences in necrotic cell 
death. Treatment with 0.1 µg/mL TRAIL increased COLO 205 and PC-3 necrotic cell 
death, compared to untreated samples. However, fluid shear stress did not induce 
significant differences in TRAIL-mediated COLO 205 and PC-3 necrotic cell death, 
compared to samples exposed to static conditions. These results indicate that the shear 
stress sensitization response is TRAIL-mediated apoptosis-specific. 
 
Cancer cell sensitization to TRAIL-induced apoptosis is fluid shear stress dose-
dependent 
 
The effect of increasing shear force on cancer cell sensitization to TRAIL-
mediated apoptosis was evaluated by exposing TRAIL-treated COLO 205 cells to a 
range of shear stress from 0.05 to 2.0 dyn/cm2, for an exposure period of 120 min. The 
shear stress range is representative of shear stress values experienced in the 
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microcirculation [274], and was used to identify a shear stress threshold that induces 
sensitization to apoptosis. At shear stresses of 0.05 and 0.1 dyn/cm2, no significant 
differences in cell viability or apoptosis were found in TRAIL-treated COLO 205 
cells, compared to samples exposed to static conditions. Interestingly, a shear stress of 
0.4 dyn/cm2 significantly decreased cell viability (Figure 4.4A) and increased 
apoptosis (Figure 4.4B), compared to TRAIL-treated cells exposed to static 
conditions. A shear stress range of 1.0-2.0 dyn/cm2 induced a more pronounced 
decrease in cell viability and increase in cell apoptosis, indicating that the sensitization 
to apoptosis is fluid shear stress dose-dependent. 
 
Cancer cell sensitization to TRAIL-induced apoptosis is fluid shear stress time-
dependent 
 
To assess the kinetics of the sensitization response, TRAIL-treated COLO 205 
cells were exposed to a shear stress of 2.0 dyn/cm2, while the fluid shear stress 
exposure time was increased in parallel experiments from 10 to 120 min. The 
exposure time was increased to determine a threshold exposure time needed to induce 
cancer cell sensitization to TRAIL. No significant differences in cell viability (Figure 
4.5A) and apoptosis (Figure 4.5B) were observed in TRAIL-treated COLO 205 cells 
exposed to fluid shear stress for 10-30 min, compared to samples exposed to static 
conditions for the same duration. Exposure to fluid shear stress for 60 min 
significantly decreased COLO 205 cell viability (Figure 4.5A) and increased apoptosis 
(Figure 4.5B), compared to TRAIL-treated cells exposed to static conditions. Shear 
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stress exposure times of 90-120 min caused a further decrease in cell viability and 
increase in COLO 205 apoptosis, providing evidence that the sensitization to TRAIL-
induced apoptosis is fluid shear stress time-dependent. 
 
Cancer cells develop an increased sensitization to TRAIL-induced apoptosis with 
increasing shear stress magnitude and shear stress exposure time 
 
Sensitization to TRAIL was quantified by determining the relative difference 
in COLO 205 cell death for sheared and nonsheared samples, over a range of shear 
stress magnitudes and exposure times. By varying the magnitude of fluid shear stress, 
it is apparent that shear stress values of 0.05-0.10 dyn/cm2 induce minimal 
sensitization of COLO 205 cells to TRAIL (Figure 4.6A) as measured by apoptosis, 
necrosis, and overall cell death. COLO 205 sensitization to TRAIL is readily apparent 
at a shear stress value of 0.4 dyn/cm2, as cells are sensitized to overall cell death and 
apoptosis, but not necrosis. Interestingly, sensitization plots also showed that the 
average percent sensitization to TRAIL-mediated cell death and apoptosis increased 
with each increasing shear stress, from 0.4-2.0 dyn/cm2 (Figure 4.6A). Untreated 
control samples do not show sensitization to apoptosis, necrosis, and overall cell death 
across the range of shear stresses. 
By varying the exposure time of cells to a fluid shear stress of 2.0 dyn/cm2, a 
similar trend is observed where short shear stress exposure times of 10 and 30 min do 
not induce cancer cell sensitization to TRAIL (Figure 4.6B). After 60 min of shear 
stress exposure, COLO 205 cells develop a sensitization to cell death and apoptosis, 
 151 
but not necrosis. From there, sensitization increased linearly with increasing exposure 
time (Figure 4.6B). As expected, untreated control samples do not show sensitization 
to apoptosis, necrosis, or overall cell death due to fluid shear stress exposure over the 
time intervals studied. 
 
Fluid shear stress does not sensitize cancer cells to doxorubicin-mediated apoptosis 
 
To assess the effect of fluid shear stress on the cancer cell response to other 
therapeutics that induce apoptosis, cancer cells were also treated with doxorubicin 
prior to the onset of fluid shear stress. While TRAIL binds to death receptors on the 
surface of the cancer cell membrane to signal cell death, doxorubicin induces cell 
death via inhibition of topo-isomerase II and DNA intercalation [88,89]. COLO 205 
cells analyzed using an APC-conjugated Annexin-V assay showed that untreated 
COLO 205 cells exposed to static conditions (Figure 4.7A) or fluid shear stress 
(Figure 4.7B) do not show measurable differences in apoptotic cell death. 
Doxorubicin-treated COLO 205 cells experienced an increase in cell apoptosis (22-
23%), however minimal differences were found between doxorubicin treated COLO 
205 cells exposed to static conditions (Figure 4.7C) and fluid shear stress (Figure 
4.7D). Experiments performed in triplicate revealed no significant differences in 
untreated cells exposed to static and shear conditions (Figure 4.7E), and doxorubicin-
treated cells showed no significant differences in apoptosis. Sensitization plots over 
varying shear stress magnitudes (Figure 4.7F) and exposure times (Figure 4.7G) show 
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that while a shear-induced sensitization to TRAIL is apparent, COLO 205 cells are not 
sensitized to doxorubicin treatment upon exposure to fluid shear stress. 
 
Cancer cell shear-induced sensitization to TRAIL occurs via caspase-dependent 
apoptosis 
 
To assess whether shear-induced sensitization to apoptosis is caspase-
dependent, COLO 205 cells were incubated with the pan caspase inhibitor Z-VAD-
FMK before treatment with TRAIL, followed by exposure to fluid shear stress. The 
binding of TRAIL to death receptors on the cancer cell surface can activate caspases 
that initiate the caspase cascade, which triggers cell apoptosis. Z-VAD-FMK is a 
general caspase inhibitor that irreversibly binds to the catalytic site of caspase 
proteases, which inhibit apoptosis [347]. FITC-conjugated Annexin-V analysis 
revealed that untreated COLO 205 cells exposed to static conditions (Figure 4.8A) or 
fluid shear stress undergo minimal cell death, while cells treated with TRAIL showed 
characteristic sensitization to apoptosis when exposed to fluid shear stress (Figure 
4.8D), compared to exposure to static conditions (Figure 4.8C). While the negative 
control inhibitor Z-FA-FMK did not affect the sensitization response to TRAIL 
(Figure 4.8E,F), treatment with general caspase inhibitor Z-VAD-FMK abolished the 
sensitization response (Figure 4.8G,H), as the differences in apoptosis between TRAIL 
treated samples exposed to shear and static conditions were not significant (Figure 
4.8I). These results indicate the shear-induced sensitization to TRAIL is caspase-
dependent. 
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Fluid shear stress does not alter death receptor expression on the cancer cell surface 
 
To investigate fluid shear stress effects on DR4 and DR5 surface expression, 
COLO 205 cells were exposed to shear stress (2.0 dyn/cm2) and static conditions at 
37°C for 120 min and immediately labeled with anti-DR4 and anti-DR5 antibodies for 
flow cytometric analysis. COLO 205 cells exposed to either static conditions or fluid 
shear stress did not show measurable differences in DR4 (Figure 4.9A) or DR5 surface 
expression (Figure 4.9B).  QSC bead analysis did not show significant differences in 
COLO 205 DR4 surface expression, with sheared and nonsheared samples averaging 
approximately 30,000 receptors/cell (Figure 4.9C). COLO 205 cells also did not show 
significant differences in DR5 surface expression, with sheared and nonsheared 
samples averaging approximately 150,000 receptors/cell.   
 
4.4 DISCUSSION 
 
The aim of this study was to quantify the role of fluid shear stress in altering 
the cancer cell response to receptor-mediated apoptosis. TRAIL-treated colon and 
prostate cancer cells were sensitized to receptor-mediated apoptosis under the 
presence of physiological fluid shear stresses (Figures 4.1,4.2). Previous studies have 
shown that cancer cells can become chemically sensitized to TRAIL therapy. TRAIL 
resistant LNCaP cells treated with aspirin have been sensitized to TRAIL treatment 
via downregulation of NF-κB, a regulator of antiapoptotic proteins [348]. Combined 
treatment of the demethylating agent 5-Aza-20-deoxycytidine (5-dAzaC) and 
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interferon-ϒ (IFN-ϒ) sensitize neuroblastoma and medulloblastoma cells to TRAIL-
induced apoptosis via upregulation of caspase-8 expression [349]. Second 
mitochondria-derived activator of caspase (SMAC) synthetic peptides sensitized 
multiple tumor cell types to TRAIL in vitro and enhanced the antitumor effect of 
TRAIL in vivo in a human glioma xenograft model [350]. Our results show that rather 
than by chemical sensitization, fluid shear forces alone sensitize cancer cells to 
TRAIL-induced apoptosis. 
While fluid shear stress sensitized cancer cells to apoptosis via TRAIL, fluid 
shear forces did not alter TRAIL-induced cell necrosis (Figure 4.3). TRAIL can 
induce apoptosis, necrosis, or a combination of both in a variety of cancer cell lines. 
TRAIL has been shown to induce cell death in prostate adenocarcinoma TRAMP-C2 
and Jurkat cell lines via necrosis [351,352]. In particular, TRAMP-C2 cell death was 
via necrosis only, as cells lacked apoptotic characteristics such as an annexin V+/PI- 
population, SAPK/JNK phosphorylation, caspase activation, or cytochrome c release 
[351]. Recently, acidic extracellular pH has been shown to alter the form of TRAIL-
induced cell death, from apoptosis to receptor interacting protein kinase 1 (RIPK1)-
dependent regulated necrosis in colon adenocarcinoma HT29 and hepatocarcinoma 
HepG2 cell lines [353,354]. Shear-induced sensitization to TRAIL did not show a shift 
from TRAIL-induced apoptosis to TRAIL-induced necrosis, indicating that the 
sensitization response is apoptosis-specific. 
Cancer cells developed a shear-induced sensitization to TRAIL-induced 
apoptosis in a fluid shear stress force- and time-dependent manner, directly 
implicating fluid shear stress in this response (Figures 4.4,4.5,4.6). While low shear 
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forces representative of those generated by interstitial flows did not sensitize cancer 
cells to TRAIL, a minimum shear stress of 0.4 dyn/cm2 induced a significant increase 
in TRAIL-induced apoptosis. In the tumor microenvironment, cancer cells are exposed 
to slow interstitial flows in and around the tumor tissue [355]. The mechanisms behind 
how cancer cells sense interstitial flow are not well understood, however shear stress 
values have been estimated in 3D in vitro matrices [20]. For flow rates of 1 µm/s, cell 
surface shear stress estimates are extremely low, ranging from 0.007-0.015 dyn/cm2 
[20]. Cancer cells are exposed to greater fluid shear forces upon entering the 
circulation, and such conditions may play a role in sensitization to TRAIL-induced 
apoptosis. It is interesting to note that the cone-and-plate viscometer shear 
experiments were designed so that fluid shear forces alone would not induce 
significant cancer cell death, compared to cancer cells exposed to static conditions. 
Thus, we were able to isolate fluid shear stress effects on receptor-mediated apoptosis, 
implicating shear-induced sensitization to TRAIL as a synergistic response. 
While fluid shear stress sensitized cancer cells to TRAIL-induced apoptosis, 
cancer cells did not show an increase in doxorubicin-induced apoptosis under the 
presence of fluid shear forces (Figure 4.7). Much like TRAIL, chemical sensitization 
to doxorubicin has been investigated previously. Gliotoxin, MG132, and Sulfasalazine 
sensitized typically resistant pancreatic carcinoma Capan-1 and A818-4 cell lines to 
doxorubicin-induced apoptosis via inhibition of NF-κB [356]. Selenium treatment 
combined with doxorubicin was successful in enhancing apoptosis in MCF-7 breast 
cancer cells, a doxorubicin-resistant cell line, via depression of Akt phosphorylation 
[357]. Small molecule inhibitors of the Hdm2:p53 complex, allowing for activation of 
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tumor suppressor p53, exerted synergistic effects with doxorubicin in an A375 
melanoma cell line xenograft model to decrease tumor growth [358]. Due to the fact 
that shear stress-induced sensitization to apoptosis was not observed with doxorubicin 
treatment, it is possible that the fluid shear stress effects originate at the cell surface 
receptor level, where TRAIL ligand binds to death receptors DR4 and DR5 while 
exposed to fluid shear stress. This is in direct contrast to doxorubicin, which interacts 
with DNA within the cell to exert its apoptotic effects. 
Treatment with Z-VAD-FMK revealed that shear-induced sensitization to 
TRAIL-induced apoptosis is caspase-dependent (Figure 4.8). Caspase activation is a 
critical step in the apoptotic pathway, induced by TRAIL binding to death receptors 
[359]. In contrast to extrinsic apoptosis pathways such as TRAIL-mediated apoptosis, 
intrinsic pathways are initiated by DNA and cellular damage, along with the 
permeabilization of mitochondria [360]. During this process, mitochondrial factors 
including cytochrome c, AIF (apoptosis-inducing factor), and SMAC are released, 
with AIF-induced apoptosis occurring via a caspase-independent process [361]. DNA-
damaging agents have previously shown to sensitize hepatic carcinoma cell lines to 
TRAIL, due to ATM kinase activation [362]. ATM kinase activity in turn leads to a 
downregulation of antiapoptotic protein cFLIP, and subsequent sensitization to 
TRAIL. Since our sensitization process is caspase-dependent, it is likely that the 
shear-induced sensitization is not due to DNA-damaging events, providing further 
support that the sensitization phenomena may occur at the cell surface. Inhibition of 
WEE1, a cell cycle checkpoint regulator, has been shown to sensitize a variety of 
basal breast cancer cell lines to TRAIL-induced apoptosis due to increased surface 
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expression of death receptors and increased caspase activation [363]. Our results show 
that COLO 205 surface expression of death receptors DR4 and DR5 is not altered after 
exposure to fluid shear stress (Figure 4.9), and thus sensitization to TRAIL-induced 
apoptosis is not likely due to shear-induced changes in receptor expression. It is likely 
that a combination of fluid shear stress effects along with TRAIL stimulation, rather 
than fluid shear stress alone, cause changes in death receptor trimerization and 
signaling. Death receptors, upon binding to TRAIL, are known to trimerize and recruit 
adaptor proteins to form a signaling complex required for TRAIL-induced apoptosis 
[364]. It is possible that mechanical shear forces could enhance death receptor 
trimerization in the presence of TRAIL, and assist in the formation of signaling 
complexes for TRAIL-induced apoptosis. The effects of fluid shear stress on death 
receptor trimerization upon binding to TRAIL could lead to further insight into the 
mechanistic basis of shear stress-induced TRAIL sensitization. 
 
4.5 CONCLUSION 
 
Results from this study indicate that hemodynamic shear forces have a 
significant effect on receptor-mediated apoptosis of cancer cells in the presence of 
TRAIL. Fluid shear stress was found to sensitize both colon and prostate cancer cell 
lines to TRAIL-mediated apoptosis. Cancer cells were not sensitized to TRAIL-
mediated necrosis upon exposure to fluid shear stress. TRAIL sensitization was shown 
to be shear stress dose-dependent, as sensitization was found to increase with 
increasing fluid shear stress. TRAIL sensitization was also fluid shear stress time-
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dependent, as sensitization to apoptosis was enhanced with increasing fluid shear 
stress exposure time. The response was TRAIL-specific, as shear stress did not 
sensitize cancer cells to doxorubicin treatment over varying shear stress magnitudes 
and exposure times. Caspase inhibition assays revealed the sensitization response to be 
caspase-dependent. These results shed new light on the cancer cell response to soluble 
apoptotic agents within the circulation. The effects of fluid shear stress on 
mechanosensing death receptors on the cancer cell surface, along with their signaling 
pathways, can reveal new strategies for treating circulating cancer cells and reducing 
the likelihood of metastasis. 
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FIGURE 4.1: FLUID SHEAR STRESS SENSITIZES CANCER CELLS TO 
TRAIL. COLO 205 cancer cells exposed to static conditions (A) and 2.0 dyn/cm2 of 
fluid shear stress (B) for 120 min at 37°C, respectively. COLO 205 cells treated with 
0.1 µg/mL TRAIL and then exposed to static conditions (C) and 2.0 dyn/cm2 of fluid 
shear stress (D) for 120 min at 37°C. Percent viable (E) and apoptotic (F) COLO 205 
cells after treatment with 0.1 µg/mL TRAIL followed by exposure to static conditions 
and 2.0 dyn/cm2 of fluid shear stress (n = 3). Percent viable (G) and apoptotic (H) PC-
3 cells after treatment with 0.1 µg/mL TRAIL followed by exposure to static 
conditions and 2.0 dyn/cm2 of fluid shear stress (n = 3). Lower lefthand and righthand 
quadrants of each flow cytometry plot represent viable and early apoptotic cells, 
respectively. Upper lefthand and righthand quadrants of each flow cytometry plot 
represent necrotic and late apoptotic cells, respectively. PI: propidium iodide. FITC: 
Fluorescein isothiocyanate. Error bars represent 95% confidence intervals. *P < 0.05. 
**P < 0.01. NS: non-significant.  
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FIGURE 4.2: BRIGHTFIELD MICROSCOPY IMAGES OF COLO 205 CELLS 
EXPOSED TO STATIC CONDITIONS AND 2.0 DYN/CM2 OF FLUID SHEAR 
STRESS BOTH IN THE ABSENCE AND PRESENCE OF TRAIL. Brightfield 
microscopy images of untreated COLO 205 cells exposed to static conditions (A) and 
2.0 dyn/cm2 of fluid shear stress (B) for 120 min at 37°C. COLO 205 cells treated with 
0.1 µg/mL TRAIL and then exposed to static conditions (C) and 2.0 dyn/cm2 of fluid 
shear stress (D) for 120 min at 37°C. Untreated PC-3 cells exposed to static conditions 
(E) and 2.0 dyn/cm2 of fluid shear stress (F) for 120 min at 37°C. PC-3 cells treated 
with 0.1 µg/mL TRAIL and then exposed to static conditions (G) and 2.0 dyn/cm2 of 
fluid shear stress (H) for 120 min at 37°C. Scale bars = 30 µm. 
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FIGURE 4.2: BRIGHTFIELD MICROSCOPY IMAGES OF COLO 205 CELLS 
EXPOSED TO STATIC CONDITIONS AND 2.0 DYN/CM2 OF FLUID SHEAR 
STRESS BOTH IN THE ABSENCE AND PRESENCE OF TRAIL. 
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FIGURE 4.3: PERCENT NECROTIC COLO 205 AND PC-3 CELLS AFTER 
TREATMENT WITH TRAIL UNDER STATIC AND SHEAR STRESS 
CONDITIONS. Percent necrotic COLO 205 cells (A) after treatment with 0.1 µg/mL 
TRAIL followed by exposure to static conditions and 2.0 dyn/cm2 of fluid shear stress 
(n = 3) 120 min at 37°C. Percent necrotic PC-3 cells (B) after treatment with 0.1 
µg/mL TRAIL followed by exposure to static conditions and 2.0 dyn/cm2 of fluid 
shear stress (n = 3) 120 min at 37°C. Error bars represent 95% confidence intervals. 
NS: non-significant.  
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FIGURE 4.4: INCREASED FLUID SHEAR STRESS SENSITIZES CANCER 
CELLS TO TRAIL. Percent viable (A) and apoptotic (B) COLO 205 cells (n = 3). 
Shear stress magnitude was varied in separate experiments from 0.05 - 2.0 dyn/cm2 for 
120 min at 37°C. COLO 205 cells were treated with 0.1 µg/mL TRAIL prior to the 
onset of fluid shear stress. Error bars represent 95% confidence intervals. *P < 0.05 
for all measurements.  
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FIGURE 4.5: SHEAR-INDUCED SENSITIZATION TO TRAIL INCREASES 
WITH INCREASING FLUID SHEAR STRESS EXPOSURE TIME. Percent 
viable (A) and apoptotic (B) COLO 205 cells (n = 3). Time dependence of shear-
induced sensitization was determined by increasing the fluid shear stress exposure 
time from 10 - 120 min at a uniform shear stress of 2.0 dyn/cm2 at 37°C. COLO 205 
cells were treated with 0.1 µg/mL TRAIL prior to the onset of fluid shear stress. Error 
bars represent 95% confidence intervals. *P < 0.05 for all measurements. 
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FIGURE 4.6: CANCER CELLS DEVELOP SENSITIZATION TO TRAIL-
MEDIATED APOPTOSIS WITH INCREASING SHEAR STRESS 
MAGNITUDE AND EXPOSURE TIME. Cancer cells develop sensitization to 
TRAIL-mediated apoptosis with increasing shear stress magnitude (A) and exposure 
time (B) (n = 3). Resistance is plotted as a function of the log10 of shear stress 
(dyn/cm2) or log10 of time (min). Error bars represent 95% confidence intervals. 
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FIGURE 4.7: FLUID SHEAR STRESS DOES NOT SENSITIZE CANCER 
CELLS TO DOXORUBICIN. COLO 205 cells exposed to static conditions (A) and 
2.0 dyn/cm2 of fluid shear stress (B) for 120 min at 37°C. COLO 205 cells treated with 
20 µM doxorubicin and then exposed to static conditions (C) and 2.0 dyn/cm2 of fluid 
shear stress (D) for 120 min at 37°C. Percent apoptotic (E) COLO 205 cells after 
treatment with 20 µM doxorubicin followed by exposure to static conditions and 2.0 
dyn/cm2 of fluid shear stress (n = 3). Comparison of cancer cell shear-induced 
sensitization to TRAIL and doxorubicin with increasing shear stress magnitude (F) 
and exposure time (G) (n = 3). Resistance is plotted as a function of the log10 of shear 
stress (dyn/cm2) or log10 of time (min). Error bars represent 95% confidence intervals. 
Gated region of flow cytometry histograms represent apoptotic COLO 205 cells. Gates 
determined by labeling viable COLO 205 control samples with Annexin-V APC 
staining. APC: allophycocyanin. NS: non-significant.  
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FIGURE 4.7: FLUID SHEAR STRESS DOES NOT SENSITIZE CANCER 
CELLS TO DOXORUBICIN.  
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FIGURE 4.8: FLUID SHEAR STRESS SENSITIZATION TO TRAIL-
MEDIATED APOPTOSIS IS CASPASE-DEPENDENT. COLO 205 cells (A,B) 
treated with 0.1 µg/mL TRAIL (C,D), negative control inhibitor Z-FA-FMK followed 
by 0.1 µg/mL TRAIL (E,F), and pan caspase inhibitor Z-VAD-FMK followed by 0.1 
µg/mL TRAIL (G,H), exposed to static conditions and 2.0 dyn/cm2 of fluid shear 
stress for 120 min at 37°C, respectively. Percent apoptotic COLO 205 cells (n = 3) 
after exposure to various treatments (I). Gated region of flow cytometry histograms 
represent apoptotic COLO 205 cells. Gates determined by labeling viable COLO 205 
control samples with Annexin-V FITC staining. FITC: fluorescein isothiocyanate. NS: 
non-significant.  
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FIGURE 4.8: FLUID SHEAR STRESS SENSITIZATION TO TRAIL-
MEDIATED APOPTOSIS IS CASPASE-DEPENDENT.  
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FIGURE 4.9: FLUID SHEAR STRESS DOES NOT ALTER DEATH 
RECEPTOR SURFACE EXPRESSION.  COLO 205 cells exposed to static 
conditions and 2.0 dyn/cm2 of fluid shear stress for 120 min at 37°C were labeled with 
anti-DR4 (A) and anti-DR5 (B) antibodies, respectively. (C) QSC receptor 
quantification of DR4 and DR5 on the surface of COLO 205 cells exposed to static 
conditions and fluid shear stress (n = 3). NS: non-significant.  
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CHAPTER 5: E-SELECTIN LIPOSOMAL AND NANOTUBE-TARGETED 
DELIVERY OF DOXORUBICIN TO CIRCULATING TUMOR CELLS 
 
*This section is adapted from the following publication: M.J. Mitchell, C.S. Chen, V. 
Ponmudi, A.D. Hughes, and M.R. King. Journal of Controlled Release. 160(3): 609-
617, 2012. 
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5.1 INTRODUCTION 
 
Cancer is one of the leading causes of death, as approximately 90% of human 
cancer deaths are attributed to cancer metastasis [1,333]. The process of metastasis can 
involve the presence of circulating tumor cells (CTCs), which are believed to undergo 
an adhesion cascade similar to leukocytes. This process consists of a discrete sequence 
of steps involving tethering, rolling, and firm adhesion between cells and the inflamed 
endothelial lining of the vasculature [51,52]. Cells from the primary tumor detach, 
invade the surrounding tissue, and intravasate into the blood or lymphatic circulation 
as CTCs [1,51,365,366]. Following intravasation, CTCs interact with the vasculature 
by selectin-mediated rolling and cell arrest, where a fraction of cells are presumed to 
extravasate into the tissue of a distant organ and proliferate to form a secondary tumor 
[1,51,52]. Although metastasis is an inefficient process with only about 0.01% of 
CTCs surviving the pathway [334,367], the development of metastases remains as the 
primary cause of cancer-related mortality. 
Doxorubicin (DXR), an adriamyacin anthracycline antibiotic, is a common 
chemotherapy agent that has been used in treating a variety of cancers, including 
metastatic breast cancer, Kaposi’s sarcoma, acute leukemia, Hodgkin’s Disease and 
other lymphomas and sarcomas [88].  The drug’s potent antineoplastic ability stems 
from its function in DNA-intercalation, inhibition of topo-isomerase II, and formation 
of free radicals [88,89,368]. However, the non-specific activity of DXR can lead to 
systemic toxicity, tissue necrosis, neutropenia, and side effects including 
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cardiomyopathy, myelosuppression, alopecia, mucositis, nausea and vomiting 
[88,369,370].   
To increase delivery efficiency and reduce toxicity of doxorubicin, a number 
of delivery systems such as polymers, dendrimers, liposomes, and nanoparticles have 
been developed [369,371]. In particular, liposomal doxorubicin (L-DXR) has been 
shown to improve the drug’s efficacy by altering its pharmacokinetics, greatly 
increasing its circulation time in blood, reducing drug accumulation in organs, and 
dampening toxic side effects [372-376].  Furthermore, the addition of polyethylene 
glycol (PEG) coupled to the liposomal surface provides steric stabilization, reducing 
drug clearance, protein interactions, and opsonization by the reticulo-endothelial 
system [377-379]. Known as “stealth” liposomes, PEG-conjugated nanoparticles 
further extend the circulation time of the drug, which due to enhanced permeability 
and retention effects, aids in tumor uptake [380,381]. The success of liposomal 
doxorubicin has been shown in pre-clinical and clinical studies as evidenced by 
Doxil®, a commercially available L-DXR formulation that has been approved by the 
FDA for use in treating Kaposi’s sarcoma, and Myocet®, a non-PEGylated L-DXR 
for the treatment of metastatic breast cancer [382]. 
While PEGylated L-DXR is effective in treating tumors, the drug vehicle 
remains limited in its ability to target specific cells. Many CTCs express sialylated 
carbohydrate ligands on their surface, which adhere to selectin proteins along the 
inflamed endothelium during metastasis [48-50,383,384]. Targeting of CTCs in the 
bloodstream via selectin bonds could reduce the probability of metastasis. In this 
study, targeted L-DXR particles were developed by functionalizing the liposome 
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surface with a combination of PEG and recombinant human E-selectin. I then 
investigated the targeting, capture, and killing of model CTCs using targeted L-DXR 
(1) immobilized within a microtube device while exposed to physiologically relevant 
shear stresses, and (2) in a dilute suspension under shear flow in a cone-and-plate 
viscometer. Naturally-occurring halloysite nanotubes (HNT), which have recently 
been shown to enhance cell capture under shear flow, were used as a nanostructured 
surface coating within microtubes to enhance targeted DXR delivery [385].  
 
5.2 MATERIALS AND METHODS 
 
Cell lines and cell culture 
 
Colorectal adenocarcinoma cell line COLO 205 (ATCC # CCL-222) and acute 
promyelocytic leukemic cell line KG-1a (ATCC # CCL-246.1) were purchased from 
American Type Culture Collection (Manassas, VA, USA). Cells were cultured in 
RPMI 1640 cell culture medium with 10% (v/v) fetal bovine serum and 1% (v/v) 
PenStrep, all purchased from Invitrogen (Grand Island, NY, USA), and incubated 
under humidified conditions at 37°C and 5% CO2 (complete media). COLO 205 cells 
were not allowed to exceed 90% confluence, and KG-1a cells were maintained at less 
than 1x106 cells/mL. 
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Liposomal doxorubicin preparation 
 
Multilamellar liposomes (Figure 5.1) were prepared using a thin lipid film 
hydration method [386,387] with 125 mM ammonium sulfate (Sigma-Aldrich, St. 
Louis, MO, USA) followed by 10 freeze-thaw cycles and then extrusion as previously 
described [388] to prepare empty liposomes (EL). To prepare L-DXR, DXR HCL 
(Sigma-Aldrich) was encapsulated within ELs using the ammonium sulfate remote 
loading method as described previously [387] at a doxorubicin-to-lipid ratio of 0.2:1 
(w/w). Non-encapsulated DXR was removed using gel-exclusion chromatography 
with Sephadex G-50 (Sigma-Aldrich). The liposomal doxorubicin concentration was 
determined by spectrophotometry (λ=490 nm), and the loading efficiency of 
doxorubicin was determined to be >95%. 
 
Preparation of targeted liposomes 
 
Recombinant human E-selectin/Fc chimera (rhE/Fc) (R&D Systems, 
Minneapolis, MN) was conjugated to 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-Maleimide 2000 (DSPE-PEG2000 maleimide) (Avanti Polar 
Lipids, Alabaster, AL, USA) via thiolation, and conjuguates were covalently attached 
to diluted EL or L-DXR as previously described [388] to make two forms of targeted 
liposomes, E-selectin-PEG-conjugated liposomal doxorubicin (ES-PEG L-DXR) and 
E-selectin-PEG-conjugated empty liposomes (ES-PEG EL). The volume ratio of EL 
or L-DXR in phosphate-buffered saline (PBS) and rhE/Fc-DSPE-PEG2000 maleimide to 
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the diluted liposomes was 1:1 and 1:12, respectively. All liposomes were stored at 4°C 
for no more than one week until usage. 
Liposomes were freshly prepared and diluted with phosphate-buffered saline 
(PBS), and the mean particle diameter and zeta potential were measured by dynamic 
light scattering using a Malvern Zetasizer nano ZS (Malvern Instruments Ltd., 
Worcestershire, UK), according to the manufacturer’s protocols. To confirm that E-
selectin was successfully conjugated to the liposome surface, 10 μL of fluorescently 
tagged liposomes were mixed with 490 μL COLO 205 or KG-1a cells (106 cells/mL) 
and sheared in a cone and plate viscometer at 2.0 dyn/cm2 for 10 min. All cells were 
analyzed for fluorescent liposomes conjugated to the surface using an Accuri C6 flow 
cytometer (Accuri Cytometers, Inc., Ann Arbor, MI, USA). Adhesion of fluorescent 
liposomes to the cell surface was confirmed via confocal microscopy. 
 
Doxorubicin encapsulation and leakage studies 
 
A 5 µL sample of L-DXR was treated with or without 20 µL of 10% Triton X-
100. Samples of EL, L-DXR, PEG L-DXR, and ES-PEG L-DXR (30 µL) were used 
for the leakage study. PBS was added to all solutions to achieve a total volume of 200 
µL. Fluorescence intensity of DXR in 200 µL solutions was measured in fluorescence 
units (fu) using a spectrophotometer (SmartSpec Plus; Bio-Rad Laboratories, 
Philadelphia, PA, USA). To assess DXR leakage, fluorescence readings were recorded 
over a span of 39 days. 
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Static experiments 
 
COLO 205 and KG-1a cells were cultured in complete media at a 
concentration of 1x105 cells/mL and 3x106 cells/mL, respectively, on 24-well plates 
(Becton Dickinson, Franklin Lakes, NJ, USA). Cells were treated with ES-PEG L-
DXR, naked L-DXR, soluble DXR (20 µM), or naked EL at volumes of 0, 0.001, 
0.01, 0.1, 0.5, 1, 2, and 5 µL for 18 hours. Adherent COLO 205 cells were then treated 
with Accutase (Sigma-Aldrich) for 5 min at 37°C to remove cells from the surface. 
Both COLO 205 and KG-1a cells were then washed with 1x PBS at 1000 rpm in a 
refrigerated centrifuge (Allegra XX-22R Centrifuge; Beckman Coulter, Brea, CA, 
USA) and resuspended in fresh media. After 4 days, cell viability was evaluated on a 
hemocytometer (Hausser Scientific, Horcham, PA, USA) using trypan blue exclusion 
dye (Lonza, Wilkersville, MD, USA). The percentage of dead cells was determined by 
comparing the number of viable cells for treated and untreated cells. For treatment of 
0.5 µL liposomes on COLO 205 cells, cell viability was assessed each day for 4 days. 
Brightfield images were taken of COLO 205 cells at day 4 using an inverted 
microscope (IX-81; Olympus America Inc., Melville, NY, USA) coupled to a CCD 
camera (Hitachi) and processed using ImageJ software (U.S. National Institutes of 
Health, Bethesda, MD, USA).  
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Preparation of cells for capture experiments 
 
COLO 205 cells were treated with Accutase for 5 min at 37°C before handling. 
KG-1a and COLO 205 cells were washed with 1x PBS at 1000 rpm and resuspended 
in flow buffer at a concentration of 1x106 cells/mL. The assay buffer consisted of PBS 
saturated with Ca2+ and Mg2+, which activated recombinant human E-selectin 
receptors to facilitate cell capture. Prior to performing capture experiments, 95% cell 
viability was confirmed by using trypan blue. 
To prepare blood cells for capture experiments, Human peripheral blood was 
obtained via venipuncture from healthy consenting blood donors and collected into 
sterile sodium heparin-containing tubes (BD Biosciences) after informed consent. 
Mononuclear cells (MNCs) and red blood cells (RBCs) were isolated by centrifugation 
at 480 X g for 50 min at 23°C in a Marathon 8K centrifuge (Fisher Scientific, 
Pittsburgh, PA) using 1-Step™ Polymorphs (Accurate Chemical & Scientific 
Corporation, Westbury, NY). This centrifugation method creates a density gradient to 
separate blood into visible layers of plasma, mononuclear cells, neutrophils, and 
erythrocytes and platelets. MNCs and RBCs were extracted separately and washed in 
Mg2+ and Ca2+ free HBSS to remove any remaining Polymorphs. The MNC sample 
was further purified from remaining red blood cells in the suspension by hypotonic 
lysis. RBC and MNC samples were resuspended at a concentration of 1.0 x 106 
cells/mL in HBSS containing 0.5% HSA, 2 mM Ca2+, 1 mM Mg2+, and 10 mM 
HEPES (Invitrogen), buffered to pH 7.4. 
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Preparation of microtube surfaces 
 
Microrenathane tubing (Braintree Scientific, Braintree, MA, USA) of 300 µm 
inner diameter was cut to 55 cm in length and washed with 75% ethanol. HNT-coated 
surfaces were prepared as previously described [385].  Briefly, HNT solution (6.6% by 
weight) (NaturalNano Rochester, NY, USA) was treated via sonication and then 
filtration. Microtubes were then washed with distilled water followed by a 5-minute 
incubation with 2:8 poly-L-lysine (0.1% w/v in water) (Sigma-Aldrich) and a 3-
minute incubation with treated HNTs. Excess HNTs were removed with distilled 
water and microtubes were incubated overnight at RT. Immobilization of E-selectin 
targeted liposomes (ES-PEG L-DXR or ES-PEG EL) onto the surface of both HNT-
coated and smooth tubes was achieved by incubation with liposomes for 2.5 hours. 
Surfaces were then blocked for 1 hour with 5% bovine serum albumin (BSA) (Sigma-
Aldrich), in PBS (v/v) for smooth tubes and 5% milk protein in PBS for HNT-coated 
tubes. Blotting grade blocker nonfat dry milk was obtained from Bio-Rad Laboratories 
(Hercules, CA, USA). All incubations were preceded and followed by PBS washes. 
Control tubes were incubated with 5% BSA or 5% milk protein for 3.5 hours. To 
activate immobilized E-selectin proteins, microtubes were incubated with calcium-
enriched flow buffer prior to beginning cell capture experiments. All steps were 
performed at RT or 4°C. 
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Cell capture experiments 
 
Microtubes were fastened onto the stage of an Olympus IX81 motorized 
inverted microscope following surface functionalization. Perfusion of cells suspended 
in flow buffer through microtubes was controlled via a motorized syringe pump (KDS 
230; IITC Life Science, Woodland Hills, CA, USA). Cells were initially perfused 
through microtubes at a rate of 0.008 mL/min (wall shear stress of 0.5 dynes/cm2) for 
15 minutes, and then 0.04 mL/min (wall shear stress of 2.5 dynes/cm2) for 2 hours. 
Captured cells were collected by perfusion of flow buffer and air embolism at 0.1 
mL/min (wall shear stress ≥ 10 dynes/cm2). Cells were cultured in 24-well plates in 
complete media and analyzed for cell viability at day 4 via trypan blue exclusion. 
 
Cone-and-plate shear assay 
 
COLO 205 and KG-1a cells were washed and resuspended in 490 µL of 
Hank’s buffered salt solution (HBSS) (Invitrogen) saturated with Ca2+ (HBSS+) at a 
concentration of 1x106 cells/mL. Samples of ES-PEG L-DXR, naked L-DXR, or ES-
PEG EL (10 µL) were then added to the cell suspension to produce a total volume of 
500 µL.  Dilute suspensions of both cancer cells and liposomes were then sheared in a 
LVDV-II+ Pro cone-and-plate viscometer (Brookfield Engineering Laboratories, Inc., 
Middleboro, MA, USA) for 2 hours at 2 dynes/cm2. Collected cells were placed in 
culture and analyzed for cell viability at day 4 via trypan blue exclusion. 
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Fluorescence microscopy 
 
To assess cellular internalization of L-DXR and ES-PEG L-DXR in static 
experiments, KG-1a and COLO 205 cells were incubated with 0.5 µL of L-DXR for 2 
hours at 37°C and then washed twice with PBS to remove free liposomes from the cell 
suspension. To determine successful immobilization of ES-PEG L-DXR onto the 
inner surface of the microtube, surfaces were prepared as previously described and 
visualized prior to performing capture experiments. Images of intrinsic DXR 
fluorescence were taken using an Olympus IX81 microscope.  
To determine cellular adhesion and uptake of liposomes following shearing 
and capture experiments, cells were treated with fluorescent ES-PEG EL for both 
experiments. Fluorescent liposomes were constructed by replacing ovine wool 
cholesterol with BODIPY-cholesterol (Avanti Polar Lipids). Cell nuclei were 
visualized by staining with 2 µL of 10 mg/mL trihydrochloride trihydrate (Hoechst 
33342) (Invitrogen, Carlsbad, CA, USA) for 15 minutes. Cells were washed twice 
with PBS and then placed on a glass slide and visualized with either a Zeiss 710 
Spectral Confocal Microscope System (Carl Zeiss MicroImaging GmbH, Jena, 
Germany), or a Leica TCS SP2 system (Leica Microsystems Heidelberg GmbH, 
Mannheim, Germany) at 65X magnification with FITC and DAPI filters. Both 
individual and Z-stack images were taken and processed using Zen 2009 light edition 
software (Carl Zeiss MicroImaging GmbH) or LCS software (Leica Microsystems 
Heidelberg GmbH). 
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Statistical Analysis 
 
Results were reported as mean ± standard error of the mean and statistical 
significance was calculated using GraphPad Prism Software (San Diego, CA, USA). 
Paired two-tailed P-value t-tests were performed for static and cell capture 
experiments, and unpaired t-tests were performed for cone-and-plate experiments. P-
values less than 0.05 were considered significant. 
 
5.3 RESULTS 
 
Characterization of targeted liposomes 
 
The physical characteristics of the liposomes are summarized in Table 5.1. The 
diameters of L-DXR and PEG L-DXR were similar, while ES-PEG L-DXR was 35–
40 nm larger in diameter than non-targeting liposomes. The zeta potential of L-DXR 
was reduced by PEG surface modification from -24.56 mV to -8.49 mV, compared to 
the zeta potential of naked liposomes. Attachment of ES-PEG showed a slight increase 
in the zeta potential compared to PEG modified liposomes, but remained lower than 
the naked liposome zeta potential.  
To assess whether functional E-selectin was successfully conjugated to the 
surface, fluorescently tagged liposomes were sheared with COLO 205 and KG-1a 
cells in a cone-and-plate viscometer for 10 min at a shear stress of 2.0 dyn/cm2. 
Liposomes lacking E-selectin showed negligible adhesion to the cells, due to the lack 
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of E-selectin interactions with E-selectin ligands on the cell surface. Cells sheared 
with ES-PEG L-DXR showed nearly 99.9% adherence to fluorescent liposomes 
(Figure 5.2A). A nearly identical percentage of cells adhered to ES-PEG EL, 
suggesting that the fluorescence was due to E-selectin adhesion, rather than 
fluorescence due to DXR drug release. The 10 min shear duration was sufficient for 
complete adhesion to all cell surfaces with negligible time for significant liposome 
internalization to occur (Figure 5.2B). 
 
Encapsulation with minimal leakage of DXR from liposomes 
 
To evaluate encapsulation efficacy of DXR, the fluorescence intensity of 
intrinsically fluorescent DXR in the presence or absence of Triton X-100 was 
measured, and showed that DXR was successfully encapsulated into liposomes 
(Figure 5.3A). The fluorescence intensity of both samples was compared to 1 µM 
soluble DXR in PBS, which revealed 3-fold greater fluorescence intensity compared 
to the sample without Triton X-100. The leakage profile of DXR from L-DXR 
demonstrates minimal release of the drug over time, regardless of E-selectin and/or 
PEG conjugation to the liposome surface (Figure 5.3B). 
  
Cellular uptake and toxicity of L-DXR 
 
COLO 205 and KG-1a cancer cell lines were treated with 0.001 – 5 µL of L-
DXR, EL, soluble DXR, or ES-PEG L-DXR for 18 h and assessed for cell viability at 
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day 4. The dose response curves for both KG-1a (Figure 5.4A) and COLO 205 (Figure 
5.4B) cells showed a significant decrease in cell viability with all treatment doses of 
L-DXR and ES-PEG L-DXR when compared to untreated cells. Fluorescence from 
DXR was visible within the cell, indicating liposome internalization (Figure 5.5). 
Conjugation of ES-PEG to the liposome surface did not decrease the effectiveness of 
the liposome formulation, as treatment of cancer cells with L-DXR and ES-PEG 
showed no significant difference in static conditions, and maximum efficacy was 
observed at 0.5 µL. Neither KG-1a (Figure 5.4A) nor COLO 205 (Figure 5.4B) cells 
were affected by treatment with EL. The growth curve of COLO 205 cells treated with 
0.5 µL of EL over 4 days was not significantly different from that of untreated cells 
(Figure 5.6), further implying that liposomes themselves do not negatively affect cell 
viability. The difference in treatment responses is readily seen in brightfield images 
taken at day 4 (Figure 5.7). 
 
Microtubes coated with ES-PEG L-DXR capture and kill cancer cells under flow   
 
Previously, we demonstrated that E-selectin could be absorbed onto the inner 
surface of microrenathane tubes and cause rolling adhesion of cells expressing E-
selectin ligand [84,385]. Microrenathane tubes, which were previously demonstrated 
as a vascular shunt prototype in rats to successfully capture CD34+ hematopoietic 
stem and progenitor cells from the circulation [389], as well as for use in multiple in 
vitro studies examining leukocyte adhesion [278,390] and cancer cell adhesion 
[84,391] along the inflamed endothelium, were used as a model of human vasculature 
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in our experiments. To ensure that ES-PEG L-DXR was successfully immobilized 
onto the inner surface of microtubes, fluorescence microscopy was used to detect the 
intrinsic fluorescence of DXR from liposomes in the coated tubes. Tubes coated with 
ES-PEG L-DXR displayed a uniform amount of fluorescence throughout the tube 
(Figure 5.8B), while control tubes showed minimal auto-fluorescence (Figure 5.8A). 
Untreated control tubes were coated with BSA to prevent non-specific binding. After 
targeted liposomes were immobilized onto the surface of the microtube, KG-1a or 
COLO 205 cells were perfused through coated microtubes at physiological shear 
stresses to mimic the behavior of CTCs in the vasculature. COLO 205 and KG-1a 
were chosen as model CTCs for these experiments because they are cancer cell lines 
that express sialylated carbohydrate ligands and have been shown to exhibit rolling 
adhesion along immobilized selectin proteins [84,385], characteristics that leukocytes 
use for the initial steps in diapedesis [178,392,393]. Both KG-1a cells and COLO 205 
cells were captured by ES-PEG liposomes (Figure 5.8C). No rolling, tethering, or 
adhesion was observed in control tubes, indicating that cells were specifically captured 
by ES-PEG liposomes in microtubes (Figure 5.8D).  
After perfusion, captured cells were collected and placed in culture. Of 
captured KG-1a cells, there was a significant reduction in cell viability of 
approximately 20% for cells captured with ES-PEG L-DXR compared to untreated 
cells and those captured with ES-PEG EL (Figure 5.9A). Viability of COLO 205 cells 
was also reduced by ~30% when captured and treated with ES-PEG L-DXR (Figure 
5.9A). For both cell lines, cell viability was not significantly affected when captured 
with ES-PEG EL.  
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The cytotoxic effects of the targeting mechanism on healthy blood cells was 
assessed using red blood cells and mononuclear white blood cells from healthy human 
donors. RBCs are not targeted by this mechanism, as they did not display significant 
adhesion to ES-PEG liposome coated surfaces compared to BSA coated surfaces 
(Figure 5.9B). MNCs only experienced ~16% decrease in cell viability after perfusion 
through the device (Figure 5.9C). 
 
ES-PEG L-DXR enhances cancer cell death in a dilute suspension under flow 
 
To assess the effectiveness of targeted liposomes in suspension under flow, 
KG-1a and COLO 205 cells were exposed to liposomes in a dilute suspension and 
sheared in a cone-and-plate viscometer for 2 hours. The cone-and-plate assay mimics 
targeted liposomes freely circulating in the bloodstream to target CTCs, as an 
injectable, alternative method to liposomes immobilized along a microtube platform. 
Confocal microscopy images taken of KG-1a (Figure 5.10A) and COLO 205 (Figure 
5.10B) cells illustrate the adhesion and internalization of targeted liposomes to cells 
following shearing experiments. Green and blue fluorescence represents liposomes 
and the cell nuclei, respectively. 
KG-1a cells treated with ES-PEG L-DXR experienced a nearly 75% decrease 
in cell viability compared to EL and untreated controls (Figure 5.11). When compared 
to naked L-DXR, ES-PEG L-DXR also significantly reduced cell viability by nearly 
65%, indicating targeted liposomes are more effective than naked liposomes in 
adhering to and killing cancer cells expressing E-selectin ligands. Similarly, viability 
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of COLO 205 cells treated with ES-PEG L-DXR experienced a 90% decrease in cell 
viability compared to untreated cells. Taken together, these results suggest that 
increased interaction between cells and liposomes are necessary for improved targeted 
delivery of liposomal doxorubicin. 
 
HNTs promote the delivery and cytotoxic potential of immobilized ES-PEG L-DXR to 
cancer cells under flow 
 
A nanostructured surface coating of HNTs was applied to the microtube 
surfaces to enhance the adhesion of cancer cells to E-selectin liposomes, and thus 
improve their uptake into cancer cells (Figure 5.12). For COLO 205 and KG-1a cells 
treated with ES-PEG L-DXR coated on HNT-coated microtubes, cell viability 
decreased by over 87% and nearly 35% respectively, when compared to that on 
smooth tubes and decreased by approximately 96% and 45% respectively, when 
compared to control HNT-coated microtubes (Figure 5.13A,B). For both cell lines, 
cell viability was not negatively affected by control HNT-coated microtubes and either 
smooth or HNT-coated tube treated with ES-PEG EL. Confocal microscopy images 
taken of COLO 205 cells following perfusion over targeted liposomes coated on 
smooth (Figure 5.14A) and HNT-coated (Figure 5.14B) tubes illustrate the location of 
liposomes on the cell surface. 
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5.4 DISCUSSION 
 
The capture and killing of cancer cells was successfully achieved using a 
combination of E-selectin functionalized L-DXR immobilized along the inner surface 
of a blood-compatible microfluidic device. Preliminary results on the use of L-DXR in 
our study suggest that liposomes were satisfactory for cytotoxic evaluation and 
effective in killing cancer cells. Over the course of several weeks, L-DXR maintained 
its retention of the drug, even without the addition of PEG (Figure 5.3). This was 
consistent with previous results [387,394] and can be attributed to two factors: the 
lipid composition and method of DXR loading. The cholesterol formulation for L-
DXR exhibits resistance to strong shear forces, which aid in withstanding forces 
applied during the extrusion process [387]; thus, providing liposomal stability when 
encapsulating DXR. Remote loading of DXR was facilitated using an ammonium 
sulfate gradient, which lies between the basic outer phase and the acidic inner phase of 
the liposome, and drives DXR inside and ammonium ions out of the vesicle [395]. 
DXR precipitates as it is driven into liposomes, enhancing drug retention.  
In treating model CTCs, L-DXR nanoparticles demonstrated great potential in 
their cytotoxicity to cancer cells. With over 95% of cells killed, a treatment dosage 0.5 
µL of liposomal doxorubicin was shown to have a maximum therapeutic efficacy in 
both KG-1a and COLO 205 cancer cell lines (Figure 5.4A,B), despite physiological 
differences between the cell lineages. This high cell death rate can be attributed to 
DXR alone. For both cell lines, empty liposomes tended to have either little or no 
effect following internalization of the liposomes, which occurs within 2 hours of 
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treatment for KG-1a and COLO 205 cells (Figure 5.5). Moreover, free DXR and 
liposomes were removed from the media with multiple washes, suggesting that DXR 
released from L-DXR inside the cells was responsible for triggering cell death.  
Cytotoxic potential to CTCs was shown to be equally or more effective with 
the functionalization of L-DXR using E-selectin. E-selectin, an adhesion molecule that 
mediates tumor cell dissemination [50,396], was chosen to decorate the surface of 
liposomes for target-specificity and DXR delivery to cancer cells expressing E-
selectin ligands. The addition of PEG was used to provide stability and charge 
neutralization of liposomes. To incorporate both E-selectin and PEG to the surface of 
the liposomes, E-selectin was attached to PEG via a maleimide group [397]. Using 
COLO 205 and KG-1a cells as model CTCs, static experiments confirmed that ES-
PEG L-DXR was no less effective than L-DXR, making them a good candidate for 
targeting under flow conditions. Cell capture experiments demonstrated that CTCs 
could be captured and killed under flow conditions, while leukocytes only experienced 
a minimal decrease in cell viability. While both CTCs and leukocytes express ligands 
for E-selectin on their surface, metastatic cancer cells typically have very high 
expression of E-selectin ligands [179,398-400]. Thus, more liposomes are likely to be 
adhering to cancer cells than leukocytes, which could explain the differences in cell 
death. Red blood cells do not possess E-selectin ligands, and thus experienced 
negligible adhesion and cell death using this novel targeting mechanism. 
Under shear flow in a cone-and-plate viscometer, improved cytotoxicity of 
targeted liposomes was evident from a substantial increase in cell death compared to 
delivery using liposome-coated microtubes. The dynamic environment of the 
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viscometer mimics sustained flow through a closed system, and in contrast to static 
conditions, allows for an increased number of collisions between the cells and 
nanoparticles, thus delivering more L-DXR to the cells. Although naked L-DXR 
contributes considerably to cell death, the bond between E-selectin and its ligands 
expressed by cells is strong and remains so even after several washes, as evidenced by 
a light red pellet following centrifugation of the sample. This further supports the 
conclusion that the target-specificity of ES-PEG L-DXR is a strong improvement over 
naked L-DXR and in general, confirms the demonstrated improvement of ligand-
targeted liposomes described in previous studies [396,401]. However in the 
bloodstream, suspension liposomes could have less opportunity to adhere to CTCs in 
the complex milieu of blood, which would necessitate high concentrations of 
chemotherapeutics that could cause undesired side effects. An immobilized platform 
along a microtube would adhesively interact only with cells that circulate along the 
near-wall region of blood vessel. Here, margination elevates the local concentration of 
leukocytes and CTC above those in the systemic circulation by several-fold, allowing 
more opportunities for an immobilized platform to interact with CTCs. The 
nanostructured coating of HNTs along the microtube surface enhanced the CTC 
capture and killing of the microtube platform to similar levels as the cone and plate 
assay, providing potential that an immobilized platform of targeted chemotherapeutic 
can be used to capture and kill CTCs, and possibly decrease the probability of 
metastasis. 
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5.5 CONCLUSION 
 
In this study, we demonstrated the efficacy of targeting, capturing, and killing 
model CTCs using a novel combination of E-selectin functionalized L-DXR and a 
biomimetic microtube device. Targeted ES- PEG L-DXR was shown to increase 
cancer cell killing in both static and dynamic environments. The cone-and-plate shear 
experiments demonstrated the effectiveness of target-specific nanoparticles in 
solution, which can aid in the development of drugs intended for systemic delivery. 
Furthermore, by immobilizing liposomes onto HNT- coated microtubes, capture and 
kill rates of cells in flow were significantly increased. One advantage of this device for 
capturing and killing of CTCs is that by immobilizing liposomes onto the microtube 
surface, the potential distribution of targeted L-DXR into circulation is reduced and a 
lower dose of the drug is necessary. The proposed device demonstrates potential 
application of HNT-coated microtubes for reducing the probability of metastasis, and 
suggests new strategies for enhancing targeted delivery of chemotherapeutics to CTCs. 
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FIGURE 5.1: SCHEMATIC OF E-SELECTIN-TARGETED PEGYLATED 
LIPOSOME SYNTHESIS.  DXR: doxorubicin, ES: E-selectin, PEG: polyethylene 
glycol.  
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TABLE 5.1: HYDRODYNAMIC RADIUS AND ZETA POTENTIAL OF 
LIPOSOME FORMULATIONS. DXR: doxorubicin, ES: E-selectin, PEG: 
polyethylene glycol, nm: nanometers, mV: millivolts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
evaluated on a hemocytometer (Hausser Scientiﬁc, Horcham, PA, USA)
using trypan blue exclusion dye (Lonza, Wilkersville, MD, USA). The
percentage of dead cells was determined by comparing the number of
viable cells for treated and untreated cells. For treatment of 0.5 μL
liposomes on COLO 205 cells, cell viability was assessed each day for
4 days. Brightﬁeld images were taken of COLO 205 cells at day 4 using
an inverted microscope (IX-81; Olympus America Inc., Melville, NY,
USA) coupled to a CCD camera (Hitachi) and processed using ImageJ
software (U.S. National Institutes of Health, Bethesda, MD, USA).
2.6. Preparation of cells for capture experiments
COLO 205 cells were treated with Accutase for 5 min at 37 °C be-
fore handling. KG-1a and COLO 205 cells were washed with 1× PBS
at 1000 rpm and resuspended in ﬂow buffer at a concentration of
1×106 cells/mL. The assay buffer consisted of PBS saturated with
Ca2+ and Mg2+, which activated recombinant human E-selectin re-
ceptors to facilitate cell capture. Prior to performing capture experi-
ments, 95% cell viability was conﬁrmed by trypan blue assay.
To prepare blood cells for capture experiments, Human peripheral
blood was obtained via venipuncture from healthy blood donors and
collected into sterile sodium heparin-containing tubes (BD Biosci-
ences) after informed consent. Mononuclear cells (MNCs) and red
blood cells (RBCs) were isolated by centrifugation at 480×g for
50 min at 23 °C in a Marathon 8 K centrifuge (Fisher Scientiﬁc, Pitts-
burgh, PA) using 1-Step™ Polymorphs (Accurate Chemical & Scientif-
ic Corporation, Westbury, NY). This centrifugation method creates a
density gradient to separate blood into visible layers of plasma, mono-
nuclear cells, neutrophils, and erythrocytes and platelets. MNCs and
RBCs were extracted separately and washed in Mg2+ and Ca2+ free
HBSS to remove any remaining Polymorphs. The MNC sample was fur-
ther puriﬁed from remaining red blood cells in the suspension by hypo-
tonic lysis. RBC andMNC samples were resuspended at a concentration
of 1.0×106 cells/mL in HBSS containing 0.5% HSA, 2 mM Ca2+,
1 mMMg2+, and 10 mM HEPES (Invitrogen), buffered to pH 7.4.
2.7. Preparation of microtube surfaces
Microrenathane tubing (Braintree Scientiﬁc, Braintree, MA, USA)
of 300 μm inner diameter was cut to 55 cm in length and washed
with 75% ethanol. HNT-coated surfaces were prepared as previously
described [31]. Brieﬂy, HNT solution (6.6% by weight) (NaturalNano
Rochester, NY, USA) was treated via sonication and then ﬁltration.
Microtubes were then washed with distilled water followed by a 5-
min incubation with 2:8 poly-L-lysine (0.1% w/v in water) (Sigma-Al-
drich) and a 3-min incubation with treated HNTs. Excess HNTs were
removed with distilled water and microtubes were incubated
overnight at RT. Immobilization of E-selectin targeted liposomes
(ES-PEG L-DXR or ES-PEG EL) onto the surface of both HNT-coated
and smooth tubes was achieved by incubation with liposomes for
2.5 hours. Surfaces were then blocked for 1 hour with 5% bovine
serum albumin (BSA) (Sigma-Aldrich), in PBS (v/v) for smooth
tubes and 5% milk protein in PBS for HNT-coated tubes. Blotting
grade blocker nonfat dry milk was obtained from Bio-Rad Laborato-
ries (Hercules, CA, USA). All incubations were preceded and followed
by PBS washes. Control tubes were incubated with 5% BSA or 5% milk
protein for 3.5 h. To activate immobilized E-selectin proteins, microtubes
were incubatedwith calcium-enrichedﬂowbuffer prior to beginning cell
capture experiments. All steps were performed at RT or 4 °C.
2.8. Cell capture experiments
Microtubes were fastened onto the stage of an Olympus IX81 mo-
torized inverted microscope following surface functionalization. Per-
fusion of cells suspended in ﬂow buffer through microtubes was
controlled via a motorized syringe pump (KDS 230; IITC Life Science,
Woodland Hills, CA, USA). Cells were initially perfused through
microtubes at a rate of 0.008 mL/min (wall shear stress of 0.5 dyn/
cm2) for 15 min, and then 0.04 mL/min (wall shear stress of
2.5 dyn/cm2) for 2 h. Captured cells were collected by perfusion of
ﬂow buffer and air embolism at 0.1 mL/min (wall shear stress≥10 -
dyn/cm2). Cells were cultured in 24-well plates in complete media
and analyzed for cell viability at day 4 via trypan blue exclusion.
2.9. Cone-and-plate shear assay
COLO 205 and KG-1a cells were washed and resuspended in
490 μL of Hank's buffered salt solution (HBSS) (Invitrogen) saturated
with Ca2+ (HBSS+) at a concentration of 1×106 cells/mL. Samples of
ES-PEG L-DXR, naked L-DXR, or ES-PEG EL (10 μL) were then added to
the cell suspension to produce a total volume of 500 μL. Dilute sus-
pensions of both cancer cells and liposomes were then sheared in a
LVDV-II+Pro cone-and-plate viscometer (Brookﬁeld Engineering
Table 1
Characterization of liposomes.
L-DXR PEG L-DXR ES-PEG L-DXR
Particle size (nm) 106.3+/−5.9 111.5+/−6.4 143.7+/−11.2
Zeta potential (mV) −24.56+/−6.34 −8.49+/−5.85 −13.12+/−6.28
Data are mean+/−standard deviation of three independent measurements.
A
B
Fig. 2. (A) Percent of COLO 205 and KG-1a cells with liposomes adhered to the surface.
Data presented as mean±SEM (n=3). (B) Representative COLO 205 cell (blue = cell
nuclei) with ﬂuorescent ES-PEG liposomes (green) adhered to the surface. Scale
bar=10 μm.
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FIGURE 5.2: E-SELECTIN CONJUGATED LIPOSOME ADHESION TO THE 
CANCER CELL SURFACE. (A) Percent of COLO 205 and KG-1a cells with 
liposomes adhered to the surface. Data presented as mean ± SEM (n=3). (B) 
Representative COLO 205 cell (blue = cell nuclei) with fluorescent ES-PEG 
liposomes (green) adhered to the surface. Scale bar = 10 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
evaluated on a hemocytometer (Hausser Scientiﬁc, Horcham, PA, USA)
using trypan blue exclusion dye (Lonza, Wilkersville, MD, USA). The
percentage of dead cells was determined by comparing the number of
viable cells for treated and untreated cells. For treatment of 0.5 μL
liposomes on COLO 205 cells, cell viability was assessed each day for
4 days. Brightﬁeld images were taken of COLO 205 cells at day 4 using
an inverted microscope (IX-81; Olympus America Inc., Melville, NY,
USA) coupled to a CCD camera (Hitachi) and processed using ImageJ
software (U.S. National Institutes of Health, Bethesda, MD, USA).
2.6. Preparation of cells for capture experiments
COLO 205 cells were treated with Accutase for 5 min at 37 °C be-
fore handling. KG-1a and COLO 205 cells were washed with 1× PBS
at 1000 rpm and resuspended in ﬂow buffer at a concentration of
1×106 cells/mL. The assay buffer consisted of PBS saturated with
Ca2+ and Mg2+, which activated recombinant human E-selectin re-
ceptors to facilitate cell capture. Prior to performing capture experi-
ments, 95% cell viability was conﬁrmed by trypan blue assay.
To prepare blood cells for capture experiments, Human peripheral
blood was obtained via venipuncture from healthy blood donors and
collected into sterile sodium heparin-containing tubes (BD Biosci-
ences) after informed consent. Mononuclear cells (MNCs) and red
blood cells (RBCs) were isolated by centrifugation at 480×g for
50 min at 23 °C in a Marathon 8 K centrifuge (Fisher Scientiﬁc, Pitts-
burgh, PA) using 1-Step™ Polymorphs (Accurate Chemical & Scientif-
ic Corporation, Westbury, NY). This centrifugation method creates a
density gradient to separate blood into visible layers of plasma, mono-
nuclear cells, neutrophils, and erythrocytes and platelets. MNCs and
RBCs were extracted separately and washed in Mg2+ and Ca2+ free
HBSS to remove any remaining Polymorphs. The MNC sample was fur-
ther puriﬁed from remaining red blood cells in the suspension by hypo-
tonic lysis. RBC andMNC samples were resuspended at a concentration
of 1.0×106 cells/mL in HBSS containing 0.5% HSA, 2 mM Ca2+,
1 mMMg2+, and 10 mM HEPES (Invitrogen), buffered to pH 7.4.
2.7. Preparation of microtube surfaces
Microrenathane tubing (Braintree Scientiﬁc, Braintree, MA, USA)
of 300 μm inner diameter was cut to 55 cm in length and washed
with 75% ethanol. HNT-coated surfaces were prepared as previously
described [31]. Brieﬂy, HNT solution (6.6% by weight) (NaturalNano
Rochester, NY, USA) was treated via sonication and then ﬁltration.
Microtubes were then washed with distilled water followed by a 5-
min incubation with 2:8 poly-L-lysine (0.1% w/v in water) (Sigma-Al-
drich) and a 3-min incubation with treated HNTs. Excess HNTs were
removed with distilled water and microtubes were incubated
overnight at RT. Immobilization of E-selectin targeted liposomes
(ES-PEG L-DXR or ES-PEG EL) onto the surface of both HNT-coated
and smooth tubes was achieved by incubation with liposomes for
2.5 hours. Surfaces were then blocked for 1 hour with 5% bovine
serum albumin (BSA) (Sigma-Aldrich), in PBS (v/v) for smooth
tubes and 5% milk protein in PBS for HNT-coated tubes. Blotting
grade blocker nonfat dry milk was obtained from Bio-Rad Laborato-
ries (Hercules, CA, USA). All incubations were preceded and followed
by PBS washes. Control tubes were incubated with 5% BSA or 5% milk
protein for 3.5 h. To activate immobilized E-selectin proteins, microtubes
were incubatedwith calcium-enrichedﬂowbuffer prior to beginning cell
capture experiments. All steps were performed at RT or 4 °C.
2.8. Cell capture experiments
Microtubes were fastened onto the stage of an Olympus IX81 mo-
torized inverted microscope following surface functionalization. Per-
fusion of cells suspended in ﬂow buffer through microtubes was
controlled via a motorized syringe pump (KDS 230; IITC Life Science,
Woodland Hills, CA, USA). Cells were initially perfused through
microtubes at a rate of 0.008 mL/min (wall shear stress of 0.5 dyn/
cm2) for 15 min, and then 0.04 mL/min (wall shear stress of
2.5 dyn/cm2) for 2 h. Captured cells were collected by perfusion of
ﬂow buffer and air embolism at 0.1 mL/min (wall shear stress≥10 -
dyn/cm2). Cells were cultured in 24-well plates in complete media
and analyzed for cell viability at day 4 via trypan blue exclusion.
2.9. Cone-and-plate shear assay
COLO 205 and KG-1a cells were washed and resuspended in
490 μL of Hank's buffer d salt solution (HBSS) (Invitrogen) saturated
with Ca2+ (HBSS+) at a concentration of 1×106 cells/mL. Samples of
ES-PEG L-DXR, naked L-DXR, or ES-PEG EL (10 μL) were then added to
the cell suspension to produce a total volume of 500 μL. Dilute sus-
pensions of both cancer cells and liposomes were then sheared in a
LVDV-II+Pro cone-and-plate viscometer (Brookﬁeld Engineering
Table 1
Characterization of liposomes.
L-DXR PEG L-DXR ES-PEG L-DXR
Particle size (nm) 106.3+/−5.9 111.5+/−6.4 143.7+/−11.2
Zeta potential (mV) −24.56+/−6.34 −8.49+/−5.85 −13.12+/−6.28
Data are mean+/−standard deviation of three independent measurements.
A
B
Fig. 2. (A) Percent of COLO 205 and KG-1a cells with liposomes adhered to the surface.
Data presented as mean±SEM (n=3). (B) Representative COLO 205 cell (blue = cell
nuclei) with ﬂuorescent ES-PEG liposomes (green) adhered to the surface. Scale
bar=10 μm.
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FIGURE 5.3: DOXORUBICIN ENCAPSULATION AND LEAKAGE FROM 
LIPOSOMES. (A) Fluorescence intensity of soluble DXR (1 µM) and 5 µL L-DXR 
in the presence or absence of 10% Triton X-100. Results expressed in fluorescence 
units (fu). (B) Leakage profile of 30 µL liposomes over time as measured by 
fluorescence intensity. Data presented as mean ± SEM (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratories, Inc., Middleboro, MA, USA) for 2 h at 2 dyn/cm2. Collected
cells were placed in culture and analyzed for cell viability at day 4 via
trypan blue exclusion.
2.10. Fluorescence microscopy
To assess cellular internalization of L-DXR and ES-PEG L-DXR in
static experiments, KG-1a and COLO 205 cells were incubated with
0.5 μL of L-DXR for 2 h at 37 °C and then washed twice with PBS to re-
move free liposomes from the cell suspension. To determine success-
ful immobilization of ES-PEG L-DXR onto the inner surface of the
microtube, surfaces were prepared as previously described and visu-
alized prior to performing capture experiments. Images of intrinsic
DXR ﬂuorescence were taken using an Olympus IX81 microscope.
To determine cellular adhesion and uptake of liposomes following
shearing and capture experiments, cells were treated with ﬂuores-
cent ES-PEG EL for both experiments. Fluorescent liposomes were
constructed by replacing ovine wool cholesterol with BODIPY-
cholesterol (Avanti Polar Lipids). Cell nuclei were visualized by stain-
ing with 2 μL of 10 mg/mL trihydrochloride trihydrate (Hoechst
33342) (Invitrogen, Carlsbad, CA, USA) for 15 min. Cells were washed
twice with PBS and then placed on a glass slide and visualized with
either a Zeiss 710 Spectral Confocal Microscope System (Carl Zeiss
MicroImaging GmbH, Jena, Germany), or a Leica TCS SP2 system
(Leica Microsystems Heidelberg GmbH, Mannheim, Germany) at
65× magniﬁcation with FITC and DAPI ﬁlters. Both individual and Z-
stack images were taken and processed using Zen 2009 light edition
software (Carl Zeiss MicroImaging GmbH) or LCS software (Leica
Microsystems Heidelberg GmbH).
2.11. Statistical analysis
Results were reported as mean±standard error of the mean and
statistical signiﬁcance was calculated using GraphPad Prism Software
(San Diego, CA, USA). Paired two-tailed P-value t-tests were per-
formed for static and cell capture experiments, and unpaired t-tests
were performed for cone-and-plate experiments. P-values less than
0.05 were considered signiﬁcant.
3. Results
3.1. Characterization of targeted liposomes
The physical characteristics of the liposomes are summarized in
Table 1. The diameters of L-DXR and PEG L-DXR were similar, while
ES-PEG L-DXR was 35–40 nm larger in diameter than non-targeting
liposomes. The zeta potential of L-DXR was reduced by PEG surface
modiﬁcation from −24.56 mV to −8.49 mV, compared to the zeta
potential of naked liposomes. Attachment of ES-PEG showed a slight
A
B
Fig. 3. (A) Fluorescence intensity of soluble DXR (1 μM) and 5 μL L-DXR in the presence or
absence of 10% TritonX-100. Results expressed inﬂuorescence units (fu). (B) Leakagepro-
ﬁle of 30 μL liposomes over time asmeasured by ﬂuorescence intensity. Data presented as
mean±SEM (n=3).
Fig. 4. Liposome uptake and cytotoxic potential on cancer cells under static conditions.
KG-1a cells (A) and COLO 205 cells (B) were placed in static conditions for 4 days and
evaluated for viability using trypan-blue. (A,B) Dose response curves relating the volume
of L-DXR, EL, ES-PEGL-DXRor solubleDXR treatment and viability of cells. All data are pre-
sented as mean±SEM (n=3). *** denotes Pb0.001.
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FIGURE 5.4:  LIPOSOME UPTAKE AND CYTOTOXIC POTENTIAL ON 
CANCER CELLS UNDER STATIC CONDITIONS.   KG-1a cells (A) and COLO 
205 cells (B) were placed in static conditions for 4 days and evaluated for viability 
using trypan-blue. (A,B) Dose response curves relating the volume of L-DXR, EL, 
ES-PEG L-DXR or soluble DXR treatment and viability of cells. All data presented as 
mean ± SEM (n=3). *** denotes P < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratories, Inc., Middleboro, MA, USA) for 2 h at 2 dyn/cm2. Collected
cells were placed in culture and analyzed for cell viability at day 4 via
trypan blue exclusion.
2.10. Fluorescence microscopy
To assess cellular internalization of L-DXR and ES-PEG L-DXR in
static experiments, KG-1a and COLO 205 cells were incubated with
0.5 μL of L-DXR for 2 h at 37 °C and then washed twice with PBS to re-
move free liposomes from the cell suspension. To determine success-
ful immobilization of ES-PEG L-DXR onto the inner surface of the
microtube, surfaces were prepared as previously described and visu-
alized prior to performing capture experiments. Images of intrinsic
DXR ﬂuorescence were taken using an Olympus IX81 microscope.
To determine cellular adhesion and uptake of liposomes following
shearing and capture experiments, cells were treated with ﬂuores-
cent ES-PEG EL for both experiments. Fluorescent liposomes were
constructed by replacing ovine wool cholesterol with BODIPY-
cholesterol (Avanti Polar Lipids). Cell nuclei were visualized by stain-
ing with 2 μL of 10 mg/mL trihydrochloride trihydrate (Hoechst
33342) (Invitrogen, Carlsbad, CA, USA) for 15 min. Cells were washed
twice with PBS and then placed on a glass slide and visualized with
either a Zeiss 710 Spectral Confocal Microscope System (Carl Zeiss
MicroImaging GmbH, Jena, Germany), or a Leica TCS SP2 system
(Leica Microsystems Heidelberg GmbH, Mannheim, Germany) at
65× magniﬁcation with FITC and DAPI ﬁlters. Both individual and Z-
stack images were taken and processed using Zen 2009 light edition
software (Carl Zeiss MicroImaging GmbH) or LCS software (Leica
Microsystems Heidelberg GmbH).
2.11. Statistical analysis
Results were reported as mean±standard error of the mean and
statistical signiﬁcance was calculated using GraphPad Prism Software
(San Diego, CA, USA). Paired two-tailed P-value t-tests were per-
formed for static and cell capture experiments, and unpaired t-tests
were performed for cone-and-plate experiments. P-values less than
0.05 were considered signiﬁcant.
3. Results
3.1. Characterization of targeted liposomes
The physical characteristics of the liposomes are summarized in
Table 1. The diameters of L-DXR and PEG L-DXR were similar, while
ES-PEG L-DXR was 35–40 nm larger in diameter than non-targeting
liposomes. The zeta potential of L-DXR was reduced by PEG surface
modiﬁcation from −24.56 mV to −8.49 mV, compared to the zeta
potential of naked liposomes. Attachment of ES-PEG showed a slight
A
B
Fig. 3. (A) Fluorescence intensity of soluble DXR (1 μM) and 5 μL L-DXR in the presence or
absence of 10% TritonX-100. Results expressed inﬂuorescence units (fu). (B) Leakagepro-
ﬁle of 30 μL liposomes over time asmeasured by ﬂuorescence intensity. Data presented as
mean±SEM (n=3).
Fig. 4. Liposome uptake and cytotoxic potential on cancer cells under static conditions.
KG-1a cells (A) and COLO 205 cells (B) were placed in static conditions for 4 days and
evaluated for viability using trypan-blue. (A,B) Dose response curves relating the volume
of L-DXR, EL, ES-PEGL-DXRor solubleDXR treatment and viability of cells. All data are pre-
sented as mean±SEM (n=3). *** denotes Pb0.001.
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FIGURE 5.5:  E-SELECTIN CONJUGATED LIPOSOMAL DOXORUBICIN 
INTERNALIZATION WITHIN CANCER CELLS.  Fluorescent images of L-DXR 
internalization by KG-1a cells (A,B) and COLO 205 cells (C, D) after treatment with 
L-DXR (A,C) and ES-PEG L-DXR (B,D). Scale bar = 30 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
increase in the zeta potential compared to PEG modiﬁed liposomes,
but remained lower than the naked liposome zeta potential.
To assess whether functional E-selectin was successfully conjugat-
ed to the surface, ﬂuorescently tagged liposomes were sheared with
COLO 205 and KG-1a cells in a cone-and-plate viscometer for
10 min at a shear stress of 2 dyn/cm2. Liposomes lacking E-selectin
showed negligible adhesion to the cells, due to the lack of E-selectin
interactions with E-selectin ligands on the cell surface. Cells sheared
with ES-PEG L-DXR showed nearly 99.9% adherence to ﬂuorescent li-
posomes (Fig. 2A). A nearly identical percentage of cells adhered to ES-
PEG EL, suggesting that the ﬂuorescence was due to E-selectin adhesion,
rather than ﬂuorescence due to DXRdrug release. The 10 min shear dura-
tion was sufﬁcient for complete adhesion to all cell surfaces with negligi-
ble time for signiﬁcant liposome internalization to occur (Fig. 2B).
3.2. Encapsulation with minimal leakage of DXR from liposomes
To evaluate encapsulation efﬁcacy of DXR, the ﬂuorescence inten-
sity of intrinsically ﬂuorescent DXR in the presence or absence of
Triton X-100 was measured, and showed that DXR was successfully
encapsulated into liposomes (Fig. 3A). The ﬂuorescence intensity of
both samples was compared to 1 μM soluble DXR in PBS, which
revealed 3-fold greater ﬂuorescence intensity compared to the sam-
ple without Triton X-100. The leakage proﬁle of DXR from L-DXR
demonstrates minimal release of the drug over time, regardless of
E-selectin and/or PEG conjugation to the liposome surface (Fig. 3B).
3.3. Cellular uptake and cytotoxicity of L-DXR
COLO 205 and KG-1a cancer cell lines were treatedwith 0.001–5 μL of
L-DXR, EL, soluble DXR, or ES-PEG L-DXR for 18 h and assessed for cell vi-
ability at day 4. The dose response curves for both KG-1a (Fig. 4A) and
COLO 205 (Fig. 4B) cells showed a signiﬁcant decrease in cell viability
with all treatment doses of L-DXR and ES-PEG L-DXR when compared
to untreated cells. Fluorescence from DXR was visible within the cell, in-
dicating liposome internalization (Fig. 5). Conjugation of ES-PEG to the li-
posome surface did not decrease the effectiveness of the liposome
formulation, as treatment of cancer cells with L-DXR and ES-PEG showed
no signiﬁcant difference in static conditions, and maximum efﬁcacy was
observed at 0.5 μL. Neither KG-1a (Fig. 4A) nor COLO 205 (Fig. 4B) cells
were affected by treatment with EL. The growth curve of COLO 205 cells
treated with 0.5 μL of EL over 4 days was not signiﬁcantly different from
that of untreated cells (Fig. 6), further implying that liposomes
themselves do not negatively affect cell viability. The difference in treat-
ment responses is readily seen in brightﬁeld images taken at day 4
(Fig. 7).
3.4. Microtubes coated with ES-PEG L-DXR capture and kill cancer cells
under ﬂow
Previously, we demonstrated that E-selectin could be absorbed
onto the inner surface of microrenathane tubes and cause rolling ad-
hesion of cells expressing E-selectin ligand [31,35]. Microrenathane
tubes, which were previously demonstrated as a vascular shunt pro-
totype in rats to successfully capture CD34+ hematopoietic stem
and progenitor cells from the circulation [36], as well as for use in
multiple in vitro studies examining leukocyte adhesion [37,38] and
cancer cell adhesion [35,39] along the inﬂamed endothelium, were
used as a model of human vasculature in our experiments. To ensure
that ES-PEG L-DXR was successfully immobilized onto the inner sur-
face of microtubes, ﬂuorescence microscopy was used to detect the
intrinsic ﬂuorescence of DXR from liposomes in the coated tubes.
Tubes coated with ES-PEG L-DXR displayed a uniform amount of ﬂuo-
rescence throughout the tube (Fig. 8B), while control tubes showed
minimal auto-ﬂuorescence (Fig. 8A). Untreated control tubes were
coated with BSA to prevent non-speciﬁc binding. After targeted lipo-
somes were immobilized onto the surface of the microtube, KG-1a or
COLO 205 cells were perfused through coated microtubes at
A B
C D
Fig. 7. Brightﬁeld images of COLO 205 cells (A) untreated or treated with 0.5 uL of (B) EL,
(C) naked L-DXR, or (D) ES-PEG L-DXR taken 4 days after treatment. Scale bar=50 μm.
A B
C D
Fig. 5. Fluorescent images of L-DXR internalization by KG-1a cells (A,B) and COLO 205
cells (C, D) after treatment with L-DXR (A,C) and ES-PEG L-DXR (B,D). Scale bar=30 μm.
Fig. 6. Viability of COLO 205 cells over 4 days after treatmentwith 0.5 μL of ES-PEG L-DXR,
naked L-DXR, or naked EL. All data presented as mean±SEM (n=3). * denotes Pb0.05,
and ** denotes Pb0.01.
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FIGURE 5.6: GROWTH CURVES OF CANCER CELLS AFTER 
TREATMENT WITH E-SELECTIN CONJUGATED LIPOSOMAL 
DOXORUBICIN.  Viability of COLO 205 cells over 4 days after treatment with 0.5 
µL of ES-PEG L-DXR, naked L-DXR, or naked EL. All data presented as mean ± 
SEM (n=3). * denotes P < 0.05, and ** denotes P < 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
increase in the zeta potential compared to PEG modiﬁed liposomes,
but remained lower than the naked liposome zeta potential.
To assess whether functional E-selectin was successfully conjugat-
ed to the surface, ﬂuorescently tagged liposomes were sheared with
COLO 205 and KG-1a cells in a cone-and-plate viscometer for
10 min at a shear stress of 2 dyn/cm2. Liposomes lacking E-selectin
showed negligible adhesion to the cells, due to the lack of E-selectin
interactions with E-selectin ligands on the cell surface. Cells sheared
with ES-PEG L-DXR showed nearly 99.9% adherence to ﬂuorescent li-
posomes (Fig. 2A). A nearly identical percentage of cells adhered to ES-
PEG EL, suggesting that the ﬂuorescence was due to E-selectin adhesion,
rather than ﬂuorescence due to DXRdrug release. The 10 min shear dura-
tion was sufﬁcient for complete adhesion to all cell surfaces with negligi-
ble time for signiﬁcant liposome internalization to occur (Fig. 2B).
3.2. Encapsulation with minimal leakage of DXR from liposomes
To evaluate encapsulation efﬁcacy of DXR, the ﬂuorescence inten-
sity of intrinsically ﬂuorescent DXR in the presence or absence of
Triton X-100 was measured, and showed that DXR was successfully
encapsulated into liposomes (Fig. 3A). The ﬂuorescence intensity of
both samples was compared to 1 μM soluble DXR in PBS, which
revealed 3-fold greater ﬂuorescence intensity compared to the sam-
ple without Triton X-100. The leakage proﬁle of DXR from L-DXR
demonstrates minimal release of the drug over time, regardless of
E-selectin and/or PEG conjugation to the liposome surface (Fig. 3B).
3.3. Cellular uptake and cytotoxicity of L-DXR
COLO 205 and KG-1a cancer cell lines were treatedwith 0.001–5 μL of
L-DXR, EL, soluble DXR, or ES-PEG L-DXR for 18 h and assessed for cell vi-
ability at day 4. The dose response curves for both KG-1a (Fig. 4A) and
COLO 205 (Fig. 4B) cells showed a signiﬁcant decrease in cell viability
with all treatment doses of L-DXR and ES-PEG L-DXR when compared
to untreated cells. Fluorescence from DXR was visible within the cell, in-
dicating liposome internalization (Fig. 5). Conjugation of ES-PEG to the li-
posome surface did not decrease the effectiveness of the liposome
formulation, as treatment of cancer cells with L-DXR and ES-PEG showed
no signiﬁcant difference in static conditions, and maximum efﬁcacy was
observed at 0.5 μL. Neither KG-1a (Fig. 4A) nor COLO 205 (Fig. 4B) cells
were affected by treatment with EL. The growth curve of COLO 205 cells
treated with 0.5 μL of EL over 4 days was not signiﬁcantly different from
that of untreated cells (Fig. 6), further implying that liposomes
themselves do not negatively affect cell viability. The difference in treat-
ment responses is readily seen in brightﬁeld images taken at day 4
(Fig. 7).
3.4. Microtubes coated with ES-PEG L-DXR capture and kill cancer cells
under ﬂow
Previously, we demonstrated that E-selectin could be absorbed
onto the inner surface of microrenathane tubes and cause rolling ad-
hesion of cells expressing E-selectin ligand [31,35]. Microrenathane
tubes, which were previously demonstrated as a vascular shunt pro-
totype in rats to successfully capture CD34+ hematopoietic stem
and progenitor cells from the circulation [36], as well as for use in
multiple in vitro studies examining leukocyte adhesion [37,38] and
cancer cell adhesion [35,39] along the inﬂamed endothelium, were
used as a model of human vasculature in our experiments. To ensure
that ES-PEG L-DXR was successfully immobilized onto the inner sur-
face of microtubes, ﬂuorescence microscopy was used to detect the
intrinsic ﬂuorescence of DXR from liposomes in the coated tubes.
Tubes coated with ES-PEG L-DXR displayed a uniform amount of ﬂuo-
rescence throughout the tube (Fig. 8B), while control tubes showed
minimal auto-ﬂuorescence (Fig. 8A). Untreated control tubes were
coated with BSA to prevent non-speciﬁc binding. After targeted lipo-
somes were immobilized onto the surface of the microtube, KG-1a or
COLO 205 cells were perfused through coated microtubes at
A B
C D
Fig. 7. Brightﬁeld images of COLO 205 cells (A) untreated or treated with 0.5 uL of (B) EL,
(C) naked L-DXR, or (D) ES-PEG L-DXR taken 4 days after treatment. Scale bar=50 μm.
A B
C D
Fig. 5. Fluorescent images of L-DXR internalization by KG-1a cells (A,B) and COLO 205
cells (C, D) after treatment with L-DXR (A,C) and ES-PEG L-DXR (B,D). Scale bar=30 μm.
Fig. 6. Viability of COLO 205 cells over 4 days after treatmentwith 0.5 μL of ES-PEG L-DXR,
naked L-DXR, or naked EL. All data presented as mean±SEM (n=3). * denotes Pb0.05,
and ** denotes Pb0.01.
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FIGURE 5.7: CANCER CELL MORPHOLOGY AFTER TREATMENT WITH 
E-SELECTIN CONJUGATED LIPOSOMAL DOXORUBICIN. Brightfield 
images of COLO 205 cells (A) untreated or treated with 0.5 uL of (B) EL, (C) naked 
L-DXR, or (D) ES-PEG L-DXR taken 4 days after treatment. Scale bar = 50 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
increase in the zeta potential compared to PEG modiﬁed liposomes,
but remained lower than the naked liposome zeta potential.
To assess whether functional E-selectin was successfully conjugat-
ed to the surface, ﬂuorescently tagged liposomes were sheared with
COLO 205 and KG-1a cells in a cone-and-plate viscometer for
10 min at a shear stress of 2 dyn/cm2. Liposomes lacking E-selectin
showed negligible adhesion to the cells, due to the lack of E-selectin
interactions with E-selectin ligands on the cell surface. Cells sheared
with ES-PEG L-DXR showed nearly 99.9% adherence to ﬂuorescent li-
posomes (Fig. 2A). A nearly identical percentage of cells adhered to ES-
PEG EL, suggesting that the ﬂuorescence was due to E-selectin adhesion,
rather than ﬂuorescence due to DXRdrug release. The 10 min shear dura-
tion was sufﬁcient for complete adhesion to all cell surfaces with negligi-
ble time for signiﬁcant liposome internalization to occur (Fig. 2B).
3.2. Encapsulation with minimal leakage of DXR from liposomes
To evaluate encapsulation efﬁcacy of DXR, the ﬂuorescence inten-
sity of intrinsically ﬂuorescent DXR in the presence or absence of
Triton X-100 was measured, and showed that DXR was successfully
encapsulated into liposomes (Fig. 3A). The ﬂuorescence intensity of
both samples was compared to 1 μM soluble DXR in PBS, which
revealed 3-fold greater ﬂuorescence intensity compared to the sam-
ple without Triton X-100. The leakage proﬁle of DXR from L-DXR
demonstrates minimal release of the drug over time, regardless of
E-selectin and/or PEG conjugation to the liposome surface (Fig. 3B).
3.3. Cellular uptake and cytotoxicity of L-DXR
COLO 205 and KG-1a cancer cell lines were treatedwith 0.001–5 μL of
L-DXR, EL, soluble DXR, or ES-PEG L-DXR for 18 h and assessed for cell vi-
ability at day 4. The dose response curves for both KG-1a (Fig. 4A) and
COLO 205 (Fig. 4B) cells showed a signiﬁcant decrease in cell viability
with all treatment doses of L-DXR and ES-PEG L-DXR when compared
to untreated cells. Fluorescence from DXR was visible within the cell, in-
dicating liposome internalization (Fig. 5). Conjugation of ES-PEG to the li-
posome surface did not decrease the effectiveness of the liposome
formulation, as treatment of cancer cells with L-DXR and ES-PEG showed
no signiﬁcant difference in static conditions, and maximum efﬁcacy was
observed at 0.5 μL. Neither KG-1a (Fig. 4A) nor COLO 205 (Fig. 4B) cells
were affected by treatment with EL. The growth curve of COLO 205 cells
treated with 0.5 μL of EL over 4 days was not signiﬁcantly different from
that of untreated cells (Fig. 6), further implying that liposomes
themselves do not negatively affect cell viability. The difference in treat-
ment responses is readily seen in brightﬁeld images taken at day 4
(Fig. 7).
3.4. Microtubes coated with ES-PEG L-DXR capture and kill cancer cells
under ﬂow
Previously, we demonstrated that E-selectin could be absorbed
onto the inner surface of microrenathane tubes and cause rolling ad-
hesion of cells expressing E-selectin ligand [31,35]. Microrenathane
tubes, which were previously demonstrated as a vascular shunt pro-
totype in rats to successfully capture CD34+ hematopoietic stem
and progenitor cells from the circulation [36], as well as for use in
multiple in vitro studies examining leukocyte adhesion [37,38] and
cancer cell adhesion [35,39] along the inﬂamed endothelium, were
used as a model of human vasculature in our experiments. To ensure
that ES-PEG L-DXR was successfully immobilized onto the inner sur-
face of microtubes, ﬂuorescence microscopy was used to detect the
intrinsic ﬂuorescence of DXR from liposomes in the coated tubes.
Tubes coated with ES-PEG L-DXR displayed a uniform amount of ﬂuo-
rescence throughout the tube (Fig. 8B), while control tubes showed
minimal auto-ﬂuorescence (Fig. 8A). Untreated control tubes were
coated with BSA to prevent non-speciﬁc binding. After targeted lipo-
somes were immobilized onto the surface of the microtube, KG-1a or
COLO 205 cells were perfused through coated microtubes at
A B
C D
Fig. 7. Brightﬁeld images of COLO 205 cells (A) untreated or treated with 0.5 uL of (B) EL,
(C) naked L-DXR, or (D) ES-PEG L-DXR taken 4 days after treatment. Scale bar=50 μm.
A B
C D
Fig. 5. Fluorescent images of L-DXR internalization by KG-1a cells (A,B) and COLO 205
cells (C, D) after treatment with L-DXR (A,C) and ES-PEG L-DXR (B,D). Scale bar=30 μm.
Fig. 6. Viability of COLO 205 cells over 4 days after treatmentwith 0.5 μL of ES-PEG L-DXR,
naked L-DXR, or naked EL. All data presented as mean±SEM (n=3). * denotes Pb0.05,
and ** denotes Pb0.01.
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FIGURE 5.8: E-SELECTIN CONJUGATED LIPOSOMAL DOXORUBICIN 
IMMOBILIZATION TO MICROTUBE SURFACE. Fluorescent images of a (A) 
control tube and (B) tube coated with ES-PEG L-DXR. Video frames of COLO 205 
cells perfusing through a (C) ES-PEG L-DXR coated tube and (D) BSA-coated 
control tube. Scale bar = 100 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
physiological shear stresses to mimic the behavior of CTCs in the vas-
culature. COLO 205 and KG-1a were chosen as model CTCs for these
experiments because they are cancer cell lines that express sialylated
carbohydrate ligands and have been shown to exhibit rolling adhe-
sion along immobilized selectin proteins [31,35], characteristics that
leukocytes use for the initial steps in diapedesis [4,28,40–42]. Both
KG-1a cells (not shown) and COLO 205 cells were captured by ES-
PEG liposomes (Fig. 8C, Supplemental video 1). No rolling, tethering,
or adhesion was observed in control tubes, indicating that cells
were speciﬁcally captured by ES-PEG liposomes in microtubes
(Fig. 8D, Supplemental video 2).
After perfusion, captured cells were collected and placed in cul-
ture. Of captured KG-1a cells, there was a signiﬁcant reduction in
cell viability of approximately 20% for cells captured with ES-PEG
L-DXR compared to untreated cells and those captured with ES-PEG
EL (Fig. 9A). Viability of COLO 205 cells was also reduced by ~30%
when captured and treated with ES-PEG L-DXR (Fig. 9A). For both
cell lines, cell viability was not signiﬁcantly affected when captured
with ES-PEG EL.
The cytotoxic effects of the targeting mechanism on healthy blood
cells was assessed using red blood cells and mononuclear white
blood cells from healthy human donors. RBCs are not targeted by
this mechanism, as they did not display signiﬁcant adhesion to ES-
PEG liposome coated surfaces compared to BSA coated surfaces
(Fig. 9B). MNCs only experienced ~16% decrease in cell viability
after perfusion through the device (Fig. 9C).
3.5. ES-PEG L-DXR enhances cancer cell death in a dilute suspension
under ﬂow
To assess the effectiveness of targeted liposomes in suspension
under ﬂow, KG-1a and COLO 205 cells were exposed to liposomes in
a dilute suspension and sheared in a cone-and-plate viscometer for
2 h. The cone-and-plate assay mimics targeted liposomes freely circu-
lating in the bloodstream to target CTCs, as an injectable, alternative
method to liposomes immobilized along a microtube platform. Confo-
cal microscopy images taken of KG-1a (Fig. 10A) and COLO 205
(Fig. 10B) cells illustrate the adhesion and internalization of targeted
liposomes to cells following shearing experiments. Green and blue
ﬂuorescence represents liposomes and the cell nuclei, respectively.
KG-1a cells treated with ES-PEG L-DXR experienced a nearly 75%
decrease in cell viability compared to EL and untreated controls
(Fig. 11). When compared to naked L-DXR, ES-PEG L-DXR also signif-
icantly reduced cell viability by nearly 65%, indicating targeted
liposomes are more effective than naked liposomes in adhering to
and killing cancer cells expressing E-selectin ligands. Similarly, viabil-
ity of COLO 205 cells treated with ES-PEG L-DXR experienced a 90%
decrease in cell viability compared to untreated cells. Taken together,
these results suggest that increased interaction between cells and
liposomes are necessary for improved targeted delivery of liposomal
doxorubicin.
Fig. 9. (A) Comparison of viability of COLO 205 and KG-1a cells following perfusion through
control tubes (BSA-coated or 20 μMDXR) or tubes coated with ES-PEG L-DXR or ES-PEG EL.
Viability of KG-1a andCOLO205 cellswere taken at day 4 (n=3). (B) Percent of nonadhered,
ﬂowing RBCs recovered following perfusion through device. (C) Viability of MNCs following
perfusion through control tubes or tubes coated with liposomes. Data presented as mean±
SEM. * denotes Pb0.05. NS denotes not signiﬁcant.
A B
Fig. 10. Overlay of brightﬁeld and ﬂuorescence microscopy images taken of KG-1a
(A) and COLO 205 (B) cells after 2 h of shearing in a dilute suspension. Scale
bars=10 μm. Green ﬂuorescence labels liposomes and the blue ﬂuorescence labels
DNA.
A B
C D
Fig. 8. Fluorescent images of a (A) control tube and (B) tube coated with ES-PEG L-DXR.
Video frames of COLO 205 cells perfused through a (C) ES-PEG L-DXR coated tube
and (D) BSA-coated control tube. Scale bar=100 μm.
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FIGURE 5.9: VIABILITY AND RECOVERY OF FLOWING CANCER 
CELLS, ERYTHROCYTES, AND LEUKOCYTES AFTER EXPOSED TO 
IMMOBILIZED E-SELECTIN FUNCTIONALIZED LIPOSOMAL 
DOXORUBICIN. (A) Comparison of viability of COLO 205 and KG-1a cells 
following perfusion through control tubes (BSA-coated or 20 μM DXR) or tubes 
coated with ES-PEG L-DXR or ES-PEG EL. Viability of KG-1a and COLO 205 cells 
were taken at day 4 (n=3). (B) Percent of nonadhered, flowing RBCs recovered 
following perfusion through device. (C) Viability of MNCs following perfusion 
through control tubes or tubes coated with liposomes. Data presented as mean ± 
SEM.* denotes P < 0.05. NS denotes not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
physiological shear stresses to mimic the behavior of CTCs in the vas-
culature. COLO 205 and KG-1a were chosen as model CTCs for these
experiments because they are cancer cell lines that express sialylated
carbohydrate ligands and have been shown to exhibit rolling adhe-
sion along immobilized selectin proteins [31,35], characteristics that
leukocytes use for the initial steps in diapedesis [4,28,40–42]. Both
KG-1a cells (not shown) and COLO 205 cells were captured by ES-
PEG liposomes (Fig. 8C, Supplemental video 1). No rolling, tethering,
or adhesion was observed in control tubes, indicating that cells
were speciﬁcally captured by ES-PEG liposomes in microtubes
(Fig. 8D, Supplemental video 2).
After perfusion, captured cells were collected and placed in cul-
ture. Of captured KG-1a cells, there was a signiﬁcant reduction in
cell viability of approximately 20% for cells captured with ES-PEG
L-DXR compared to untreated cells and those captured with ES-PEG
EL (Fig. 9A). Viability of COLO 205 cells was also reduced by ~30%
when captured and treated with ES-PEG L-DXR (Fig. 9A). For both
cell lines, cell viability was not signiﬁcantly affected when captured
with ES-PEG EL.
The cytotoxic effects of the targeting mechanism on healthy blood
cells was assessed using red blood cells and mononuclear white
blood cells from healthy human donors. RBCs are not targeted by
this mechanism, as they did not display signiﬁcant adhesion to ES-
PEG liposome coated surfaces compared to BSA coated surfaces
(Fig. 9B). MNCs only experienced ~16% decrease in cell viability
after perfusion through the device (Fig. 9C).
3.5. ES-PEG L-DXR enhances cancer cell death in a dilute suspension
under ﬂow
To assess the effectiveness of targeted liposomes in suspension
under ﬂow, KG-1a and COLO 205 cells were exposed to liposomes in
a dilute suspension and sheared in a cone-and-plate viscometer for
2 h. The cone-and-plate assay mimics targeted liposomes freely circu-
lating in the bloodstream to target CTCs, as an injectable, alternative
method to liposomes immobilized along a microtube platform. Confo-
cal microscopy images taken of KG-1a (Fig. 10A) and COLO 205
(Fig. 10B) cells illustrate the adhesion and internalization of targeted
liposomes to cells following shearing experiments. Green and blue
ﬂuorescence represents liposomes and the cell nuclei, respectively.
KG-1a cells treated with ES-PEG L-DXR experienced a nearly 75%
decrease in cell viability compared to EL and untreated controls
(Fig. 11). When compared to naked L-DXR, ES-PEG L-DXR also signif-
icantly reduced cell viability by nearly 65%, indicating targeted
liposomes are more effective than naked liposomes in adhering to
and killing cancer cells expressing E-selectin ligands. Similarly, viabil-
ity of COLO 205 cells treated with ES-PEG L-DXR experienced a 90%
decrease in cell viability compared to untreated cells. Taken together,
these results suggest that increased interaction between cells and
liposomes are necessary for improved targeted delivery of liposomal
doxorubicin.
Fig. 9. (A) Comparison of viability of COLO 205 and KG-1a cells following perfusion through
control tubes (BSA-coated or 20 μMDXR) or tubes coated with ES-PEG L-DXR or ES-PEG EL.
Viability of KG-1a andCOLO205 cellswere taken at day 4 (n=3). (B) Percent of nonadhered,
ﬂowing RBCs recovered following perfusion through device. (C) Viability of MNCs following
perfusion through control tubes or tubes coated with liposomes. Data presented as mean±
SEM. * denotes Pb0.05. NS denotes not signiﬁcant.
A B
Fig. 10. Overlay of brightﬁeld and ﬂuorescence microscopy images taken of KG-1a
(A) and COLO 205 (B) cells after 2 h of shearing in a dilute suspension. Scale
bars=10 μm. Green ﬂuorescence labels liposomes and the blue ﬂuorescence labels
DNA.
A B
C D
Fig. 8. Fluorescent images of a (A) control tube and (B) tube coated with ES-PEG L-DXR.
Video frames of COLO 205 cells perfused through a (C) ES-PEG L-DXR coated tube
and (D) BSA-coated control tube. Scale bar=100 μm.
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FIGURE 5.10: CONFOCAL MICROGRAPHS OF E-SELECTIN 
FUNCTIONALIZED LIPOSOMAL DOXORUBICIN ADHERED TO THE 
SURFACE OF KG-1A AND COLO 205 CELLS AFTER EXPOSURE TO 
SHEAR FLOW. Overlay of brightfield and fluorescence microscopy images taken of 
KG-1a (A) and COLO 205 (B) cells after 2 hrs of shearing in a dilute suspension. 
Scale bars = 10 µm. Green fluorescence labels liposomes and the blue fluorescence 
labels DNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
physiological shear stresses to mimic the behavior of CTCs in the vas-
culature. COLO 205 and KG-1a were chosen as model CTCs for these
experiments because they are cancer cell lines that express sialylated
carbohydrate ligands and have been shown to exhibit rolling adhe-
sion along immobilized selectin proteins [31,35], characteristics that
leukocytes use for the initial steps in diapedesis [4,28,40–42]. Both
KG-1a cells (not shown) and COLO 205 cells were captured by ES-
PEG liposomes (Fig. 8C, Supplemental video 1). No rolling, tethering,
or adhesion was observed in control tubes, indicating that cells
were speciﬁcally captured by ES-PEG liposomes in microtubes
(Fig. 8D, Supplemental video 2).
After perfusion, captured cells were collected and placed in cul-
ture. Of captured KG-1a cells, there was a signiﬁcant reduction in
cell viability of approximately 20% for cells captured with ES-PEG
L-DXR compared to untreated cells and those captured with ES-PEG
EL (Fig. 9A). Viability of COLO 205 cells was also reduced by ~30%
when captured and treated with ES-PEG L-DXR (Fig. 9A). For both
cell lines, cell viability was not signiﬁcantly affected when captured
with ES-PEG EL.
The cytotoxic effects of the targeting mechanism on healthy blood
cells was assessed using red blood cells and mononuclear white
blood cells from healthy human donors. RBCs are not targeted by
this mechanism, as they did not display signiﬁcant adhesion to ES-
PEG liposome coated surfaces compared to BSA coated surfaces
(Fig. 9B). MNCs only experienced ~16% decrease in cell viability
after perfusion through the device (Fig. 9C).
3.5. ES-PEG L-DXR enhances cancer cell death in a dilute suspension
under ﬂow
To assess the effectiveness of targeted liposomes in suspension
under ﬂow, KG-1a and COLO 205 cells were exposed to liposomes in
a dilute suspension and sheared in a cone-and-plate viscometer for
2 h. The cone-and-plate assay mimics targeted liposomes freely circu-
lating in the bloodstream to target CTCs, as an injectable, alternative
method to liposomes immobilized along a microtube platform. Confo-
cal microscopy images taken of KG-1a (Fig. 10A) and COLO 205
(Fig. 10B) cells illustrate the adhesion and internalization of targeted
liposomes to cells following shearing experiments. Green and blue
ﬂuorescence represents liposomes and the cell nuclei, respectively.
KG-1a cells treated with ES-PEG L-DXR experienced a nearly 75%
decrease in cell viability compared to EL and untreated controls
(Fig. 11). When compared to naked L-DXR, ES-PEG L-DXR also signif-
icantly reduced cell viability by nearly 65%, indicating targeted
liposomes are more effective than naked liposomes in adhering to
and killing cancer cells expressing E-selectin ligands. Similarly, viabil-
ity of COLO 205 cells treated with ES-PEG L-DXR experienced a 90%
decrease in cell viability compared to untreated cells. Taken together,
these results suggest that increased interaction between cells and
liposomes are necessary for improved targeted delivery of liposomal
doxorubicin.
Fig. 9. (A) Comparison of viability of COLO 205 and KG-1a cells following perfusion through
control tubes (BSA-coated or 20 μMDXR) or tubes coated with ES-PEG L-DXR or ES-PEG EL.
Viability of KG-1a andCOLO205 cellswere taken at day 4 (n=3). (B) Percent of nonadhered,
ﬂowing RBCs recovered following perfusion through device. (C) Viability of MNCs following
perfusion through control tubes or tubes coated with liposomes. Data presented as mean±
SEM. * denotes Pb0.05. NS denotes not signiﬁcant.
A B
Fig. 10. Overlay of brightﬁeld and ﬂuorescence microscopy images taken of KG-1a
(A) and COLO 205 (B) cells after 2 h of shearing in a dilute suspension. Scale
bars=10 μm. Green ﬂuorescence labels liposomes and the blue ﬂuorescence labels
DNA.
A B
C D
Fig. 8. Fluorescent images of a (A) control tube and (B) tube coated with ES-PEG L-DXR.
Video frames of COLO 205 cells perfused through a (C) ES-PEG L-DXR coated tube
and (D) BSA-coated control tube. Scale bar=100 μm.
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FIGURE 5.11: VIABILITY OF KG-1A AND COLO 205 CELLS AT DAY 4 
FOLLOWING TREATMENT WITH TARGETED L-DXR UNDER SHEAR IN 
A DILUTE SUSPENSION.  Data presented as mean ± SEM (n=3). *** denotes P < 
0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6. HNTs promote the delivery and cytotoxic potential of immobilized
ES-PEG L-DXR to cancer cells under ﬂow
A nanostructured surface coating of HNTs was applied to the micro-
tube surfaces to enhance the adhesion of cancer cells to E-selectin
liposomes, and thus improve their uptake into cancer cells (Fig. 12).
For COLO 205 and KG-1a cells treated with ES-PEG L-DXR coated on
HNT-coated microtubes, cell viability decreased by over 87% and nearly
35% respectively, when compared to that on smooth tubes and
decreased by approximately 96% and 45% respectively, when compared
to control HNT-coated microtubes (Fig. 13A,B). For both cell lines, cell
viability was not negatively affected by control HNT-coated microtubes
and either smooth or HNT-coated tubes treated with ES-PEG EL. Confo-
cal microscopy images taken of COLO 205 cells following perfusion over
targeted liposomes coated on smooth (Fig. 14A) and HNT-coated
(Fig. 14B) tubes illustrate the location of liposomes on the cell surface.
4. Discussion
The capture and killing of cancer cells was successfully achieved
using a combination of E-selectin functionalized L-DXR immobilized
along the inner surface of a blood-compatible microﬂuidic device. Re-
sults on the use of L-DXR in our study suggest that liposomes were sat-
isfactory for cytotoxic evaluation and effective in killing cancer cells.
Over the course of several weeks, L-DXR maintained its retention of
the drug, even without the addition of PEG (Fig. 3). This was consistent
with previous results [33,43] and can be attributed to two factors: the
lipid composition andmethod of DXR loading. The cholesterol formula-
tion for L-DXR exhibits resistance to strong shear forces, which aid in
withstanding forces applied during the extrusion process [33]; thus,
providing liposomal stability when encapsulating DXR. Remote loading
of DXR was facilitated using an ammonium sulfate gradient, which lies
between the basic outer phase and the acidic inner phase of the lipo-
some, and drives DXR inside and ammonium ions out of the vesicle
[44]. DXR precipitates as it is driven into liposomes, enhancing drug re-
tention [22].
In treating model CTCs, L-DXR nanoparticles demonstrated great
potential in their cytotoxicity to cancer cells. With over 95% of
cells killed, a treatment dosage 0.5 μL of liposomal doxorubicin was
shown to have a maximum therapeutic efﬁcacy in both KG-1a and
COLO 205 cancer cell lines (Fig. 4A,B), despite physiological differ-
ences between the cell lineages. This high cell death rate can be at-
tributed to DXR alone. For both cell lines, empty liposomes tended
to have either little or no effect following internalization of the lipo-
somes, which occurs within 2 hours of treatment for KG-1a and
COLO 205 cells (Fig. 5). Moreover, free DXR and liposomes were
removed from the media with multiple washes, suggesting that DXR
released from L-DXR inside the cells was responsible for triggering
cell death.
Fig. 12. Schematic of halloysite nanotube (HNT)-coated microtube device with immo-
bilized targeted L-DXR to enhance capture and killing of tumor cells under ﬂow.
Fig. 11. Viability of KG-1a and COLO 205 cells at day 4 following treatment with tar-
geted L-DXR under shear in a dilute suspension. Data presented as mean±SEM
(n=3). *** denotes Pb0.001.
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Fig. 13. Comparison of smooth and HNT-coated tube with immobilized liposomes on
cell viability of (A) KG-1a and (B) COLO 205 after perfusion through microtubes. Cell
viability of KG-1a and COLO 205 cells were taken at day 4 (n=3), respectively. Data
presented as mean±SEM. * denotes Pb0.05, ** denotes Pb0.01.
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Fig. 14. Overlay of brightﬁeld and ﬂuorescence microscopy images of COLO 205 cells
following perfusion through a (A) smooth tube and (B) HNT-coated tube incubated
with ﬂuorescently-tagged ES-PEG EL. Scale bar=30 μm.
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FIGURE 5.12: SCHEMATIC OF HALLOYSITE NANOTUBE (HNT)-COATED 
MICROTUBE DEVICE WITH IMMOBILIZED TARGETED L-DXR TO 
ENHANCE CAPTURE AND KILLING OF TUMOR CELLS UNDER FLOW.  
ES-PEG L-DXR: E-selectin functionalized liposomal doxorubicin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6. HNTs promote the delivery and cytotoxic potential of immobilized
ES-PEG L-DXR to cancer cells under ﬂow
A nanostructured surface coating of HNTs was applied to the micro-
tube surfaces to enhance the adhesion of cancer cells to E-selectin
liposomes, and thus improve their uptake into cancer cells (Fig. 12).
For COLO 205 and KG-1a cells treated with ES-PEG L-DXR coated on
HNT-coated microtubes, cell viability decreased by over 87% and nearly
35% respectively, when compared to that on smooth tubes and
decreased by approximately 96% and 45% respectively, when compared
to control HNT-coated microtubes (Fig. 13A,B). For both cell lines, cell
viability was not negatively affected by control HNT-coated microtubes
and either smooth or HNT-coated tubes treated with ES-PEG EL. Confo-
cal microscopy images taken of COLO 205 cells following perfusion over
targeted liposomes coated on smooth (Fig. 14A) and HNT-coated
(Fig. 14B) tubes illustrate the location of liposomes on the cell surface.
4. Discussion
The capture and killing of cancer cells was successfully achieved
using a combination of E-selectin functionalized L-DXR immobilized
along the inner surface of a blood-compatible microﬂuidic device. Re-
sults on the use of L-DXR in our study suggest that liposomes were sat-
isfactory for cytotoxic evaluation and effective in killing cancer cells.
Over the course of several weeks, L-DXR maintained its retention of
the drug, even without the addition of PEG (Fig. 3). This was consistent
with previous results [33,43] and can be attributed to two factors: the
lipid composition andmethod of DXR loading. The cholesterol formula-
tion for L-DXR exhibits resistance to strong shear forces, which aid in
withstanding forces applied during the extrusion process [33]; thus,
providing liposomal stability when encapsulating DXR. Remote loading
of DXR was facilitated using an ammonium sulfate gradient, which lies
between the basic outer phase and the acidic inner phase of the lipo-
some, and drives DXR inside and ammonium ions out of the vesicle
[44]. DXR precipitates as it is driven into liposomes, enhancing drug re-
tention [22].
In treating model CTCs, L-DXR nanoparticles demonstrated great
potential in their cytotoxicity to cancer cells. With over 95% of
cells killed, a treatment dosage 0.5 μL of liposomal doxorubicin was
shown to have a maximum therapeutic efﬁcacy in both KG-1a and
COLO 205 cancer cell lines (Fig. 4A,B), despite physiological differ-
ences between the cell lineages. This high cell death rate can be at-
tributed to DXR alone. For both cell lines, empty liposomes tended
to have either little or no effect following internalization of the lipo-
somes, which occurs within 2 hours of treatment for KG-1a and
COLO 205 cells (Fig. 5). Moreover, free DXR and liposomes were
removed from the media with multiple washes, suggesting that DXR
released from L-DXR inside the cells was responsible for triggering
cell death.
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Fig. 13. Comparison of smooth and HNT-coated tube with immobilized liposomes on
cell viability of (A) KG-1a and (B) COLO 205 after perfusion through microtubes. Cell
viability of KG-1a and COLO 205 cells were taken at day 4 (n=3), respectively. Data
presented as mean±SEM. * denotes Pb0.05, ** denotes Pb0.01.
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Fig. 14. Overlay of brightﬁeld and ﬂuorescence microscopy images of COLO 205 cells
following perfusion through a (A) smooth tube and (B) HNT-coated tube incubated
with ﬂuorescently-tagged ES-PEG EL. Scale bar=30 μm.
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FIGURE 5.13: COMPARISON OF SMOOTH AND HNT-COATED TUBE 
WITH IMMOBILIZED E-SELECTIN CONJUGATED LIPOSOMAL 
DOXORUBICIN ON CANCER CELL VIABILITY AFTER PERFUSION 
THROUGH MICROTUBES. Comparison of smooth and HNT-coated tube with 
immobilized E-selectin conjugated liposomal doxorubicin on cell viability of (A) KG-
1a and (B) COLO 205 after perfusion through microtubes. Cell viability of KG-1a and 
COLO 205 cells were taken at day 4 (n=3), respectively. Data presented as mean ± 
SEM. * denotes P < 0.05, ** denotes P < 0.01. 
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FIGURE 5.14: E-SELECTIN FUNCTIONALIZED LIPOSOMAL 
DOXORUBICIN ADHESION TO CANCER CELLS AFTER EXPOSURE TO 
HNT-COATED MICROTUBES. Overlay of brightfield and fluorescence 
microscopy images of COLO 205 cells following perfusion through a (A) smooth tube 
and (B) HNT-coated tube incubated with fluorescently-tagged ES-PEG EL. Scale bar 
= 30 µm. 
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CHAPTER 6: NANOSTRUCTURED SURFACES TO TARGET AND KILL 
CIRCULATING TUMOR CELLS WHILE REPELLING LEUKOCYTES 
 
*This section is adapted from the following publication: M.J. Mitchell, C.A. 
Castellanos, and M.R. King. Journal of Nanomaterials. 2012(5): 1-10, 2012. 
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6.1 INTRODUCTION 
 
Hematogenous metastasis typically signals a poor patient prognosis, with over 
90% of cancer deaths attributed to the metastatic spread [1]. For metastasis to occur, 
cancer cells detach from the primary tumor, invade through the basement membrane, 
and intravasate into the peripheral circulation as circulating tumor cells (CTCs) [8]. 
CTCs that express sialylated carbohydrate ligands on their surface can adhesively 
interact with selectin proteins on the inflamed endothelial cell wall, leading to selectin-
mediated CTC tethering and rolling on the endothelium, followed by firm adhesion 
and arrest [1,52]. CTCs can then extravasate to the tissue of a distal organ to form 
secondary metastases, and while the percentage of CTCs that survive this pathway is 
small (<0.01%), the formation of such metastases remains the primary cause of 
cancer-related deaths [8,334,367].  
Several chemotherapeutics are currently in use for the treatment of cancers, 
including doxorubicin, which is in use for the treatment of Kaposi’s sarcoma, acute 
leukemia, metastatic breast cancer and other lymphomas and sarcomas [88]. 
Doxorubicin is an adriamyacin anthracycline antibiotic that can induce cancer cell 
death via DNA intercalation, inhibition of topo-isomerase II, and formation of free 
radicals [89,368]. However, the non-specific effects of doxorubicin are numerous, and 
include systemic toxicity, tissue necrosis, neutropenia, and cardiomyopathy [369,370]. 
Nanobiotechnology has contributed to the development of novel drug delivery 
vehicles to both enhance the efficiency of doxorubicin while reducing its toxic effects, 
such as polymers, dendrimers, and liposomes [371]. Liposomal doxorubicin (L-DXR) 
 209 
in particular has been shown to enhance overall drug efficacy by altering 
pharmacokinetics, increasing circulation time, and reducing non-specific toxic effects 
[372,373,379]. Polyethylene glycol (PEG) conjugation to the liposome surface 
provides steric stabilization and increased circulation time of the drug, and can also 
aid in tumor uptake due to enhanced permeability and retention effects [379,381]. The 
efficacy of L-DXR has been shown clinically as evidenced by Doxil®, which has been 
approved by the FDA for use in treating Kaposi’s sarcoma [382]. However, current L-
DXR formulations lack the targeting mechanisms to treat individual CTCs in 
bloodstream, due to the rarity of CTCs amongst healthy circulating blood cells. The 
concentration of CTCs in the bloodstream of patients is approximately one in a million 
leukocytes [238], or one in a billion of all healthy blood cells [42]. 
Cell adhesion molecules known as selectins hold promise in targeting drug 
delivery vehicles to CTCs under physiological shear flow, due to their rapid, force-
dependent binding kinetics [171,335]. Sialylated carbohydrate ligands are expressed 
on the surface of many CTCs, which have the ability to bind to selectin proteins on the 
inflamed endothelium during metastasis [48,50,384]. Targeting of CTCs in the 
bloodstream via selectin-mediated adhesion could reduce the probability of metastasis. 
However, healthy circulating leukocytes are also known to express sialylated 
carbohydrate ligands on their surface [176]. Thus, strategies to reduce healthy blood 
cell adhesion are required for selectin-mediated targeting of therapies to CTCs. 
The development of nanostructured surfaces to enhance the capture of CTCs for 
chemotherapeutic delivery while preventing healthy cell adhesion has not yet been 
investigated. Here, I assessed the application of a nanostructured surface consisting of 
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halloysite nanotubes and nanoscale L-DXR to increase cancer cell recruitment while 
preventing leukocyte adhesion. 
 
6.2 MATERIALS AND METHODS 
 
Cell culture 
 
Colorectal adenocarcinoma cell line COLO 205 (ATCC #CCL-222) and breast 
adenocarcinoma cell line MCF7 (ATCC #HTB-22) were purchased from American 
Type Culture Collection (Manassas, VA, USA). COLO 205 cells were cultured in 
RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) 
PenStrep, all purchased from Invitrogen (Grand Island, NY, USA). MCF7 cells were 
cultured in Eagle's Minimum Essential Medium (EMEM) supplemented with 0.01 
mg/ml bovine insulin, 10% (v/v) fetal bovine serum, and 1% (v/v) PenStrep, all 
purchased from Invitrogen. All cancer cell lines were incubated under humidified 
conditions at 37°C and 5% CO2, and were not allowed to exceed 90% confluence. 
 
Neutrophil isolation 
 
Neutrophils were isolated as previously described [91]. Briefly, human 
peripheral blood was obtained from healthy blood donors after informed consent via 
venipuncture, and collected using sterile sodium heparin-containing tubes (BD 
Biosciences, San Jose, CA). Neutrophils were isolated from blood by centrifugation at 
 211 
480 X g for 50 min at 23°C, in a Marathon 8K centrifuge (Fisher Scientific, 
Pittsburgh, PA) using 1-StepTM Polymorphs (Accurate Chemical & Scientific 
Corporation, Westbury, NY). Neutrophils were extracted and washed in Mg2+ and 
Ca2+ free Hank’s balanced salt solution (HBSS), and all remaining red blood cells in 
the suspension were lysed hypotonically. Neutrophils were resuspended at a 
concentration of 1.0 x 106 cells/mL in HBSS containing 0.5% HSA, 2 mM Ca2+, and 
10 mM HEPES (Invitrogen), buffered to pH 7.4. 
 
Liposomal doxorubicin synthesis 
 
Nanoscale liposomes were synthesized as described previously [82]. Briefly, 
lipids were dried overnight, and rehydrated using a thin lipid film hydration method 
[386,387] with 125 mM ammonium sulfate (Sigma-Aldrich, St. Louis, MO, USA). 
Lipids were then subjected to 10 freeze-thaw cycles and extruded to prepare empty 
liposomes (EL). Doxorubicin hydrochloride (Sigma-Aldrich) was encapsulated within 
ELs using an ammonium sulfate remote loading method, at a doxorubicin-to-lipid 
ratio of 0.2:1 (w/w). Excess DXR was removed using gel-exclusion chromatography 
with Sephadex G-50 (Sigma-Aldrich). Liposomal doxorubicin concentration was 
determined by spectrophotometry (λ=490 nm). The loading efficiency of doxorubicin 
was determined to be >95%. 
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Targeted liposome preparation 
 
E-selectin functionalized L-DXR (ES-PEG L-DXR) and E-selectin functionalized 
empty liposomes (ES-PEG EL) were prepared using a post-insertion technique [402]. 
Recombinant human E-selectin/Fc chimera (rhE/Fc) (R&D Systems, Minneapolis, 
MN) was thiolated and conjugated to 1,2-Distearoyl-sn-Glycero-3-
Phosphoethanolamine-N-Maleimide 2000 (DSPE-PEG2000 maleimide) (Avanti Polar 
Lipids, Alabaster, AL, USA). To incorporate ES-polyethylene glycol (ES-PEG) 
conjuguates into the lipid bilayer, ES-PEG was incubated with liposomes at 50°C for 
30 min. Liposomes were stored at 4°C for <1 week until usage. 
The mean particle diameter and zeta potential of the liposome formulations were 
measured by dynamic light scattering, using a Malvern Zetasizer nano ZS (Malvern 
Instruments Ltd., Worcestershire, UK) according to the manufacturer’s protocols. 
Mean particle diameter and zeta potential measurements of the liposome formulations 
were similar to values previously reported [82]. To determine successful E-selectin 
conjugation to liposome surface, 10 µL of fluorescently tagged liposomes were mixed 
with 490 µL of MCF7 cells (106 cells/mL) and exposed to a shear flow in a cone and 
plate viscometer at 2.0 dyn/cm2 for 10 min. Fluorescent liposomes adhered to the cell 
surface were measured using an Accuri C6 flow cytometer (Accuri Cytometers, Inc., 
Ann Arbor, MI, USA). To assess fluorescent liposome adhesion and internalization to 
MCF7 cells, sheared samples were incubated for 60 min at 37°C and then imaged 
using confocal microscopy. 
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Confocal microscopy 
 
Fluorescent ES-conjugated liposomes were used to verify selectin-mediated 
adhesion to cancer cells. Fluorescent lipids were synthesized using fluorescent 
BODIPY-cholesterol (Avanti Polar Lipids). Cells were incubated with 2 µL of 10 
mg/mL trihydrochloride trihydrate (Hoechst 33342) (Invitrogen, Carlsbad, CA, USA) 
for 15 minutes to image cell nuclei. Cells were then placed on glass coverslips and 
visualized with a Zeiss 710 Spectral Confocal Microscope System (Carl Zeiss 
MicroImaging GmbH, Jena, Germany) at 65X magnification with FITC and DAPI 
filters. Images were processed using Zen 2009 light edition software (Carl Zeiss 
MicroImaging GmbH). 
 
MCF7 breast cancer cell static assays 
 
MCF7 cells were cultured in complete media at a concentration of 1x105 
cells/mL on 12-well plates (Becton Dickinson, Franklin Lakes, NJ, USA). Cells were 
treated with ES-PEG L-DXR, L-DXR, or EL at volumes of 0 to 5 µL for 18 hours. 
MCF7 cells were treated with Accutase (Sigma-Aldrich) for 5 min at 37°C, to remove 
adherent cells from the surface. Cells were then washed with phosphate buffered 
saline (PBS) at 1000 rpm in a refrigerated centrifuge (Allegra XX-22R Centrifuge; 
Beckman Coulter, Brea, CA, USA) and resuspended in fresh media. After 4 days, cell 
viability was evaluated on a hemocytometer (Hausser Scientific, Horcham, PA, USA) 
using a trypan blue exclusion assay (Lonza, Wilkersville, MD, USA). Cells were also 
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treated with 0.5 µL of liposome solution and assessed for viability over a period of 1-4 
days. Cell morphology and uptake of doxorubicin were imaged using brightfield and 
fluorescence microscopy, respectively. 
 
Cancer cell and neutrophil preparation for capture experiments 
 
MCF7 and COLO 205 cells were treated with Accutase (Sigma, St. Louis, 
MO) for 5-10 min before handling.  MCF7 and COLO 205 cells were washed in PBS 
and resuspended at a concentration of 1.0 x 106 cells/mL, in a flow buffer of HBSS 
containing 0.5% HSA, 2 mM Ca2+, and 10 mM HEPES (Invitrogen), buffered to pH 
7.4. For neutrophil capture experiments, freshly isolated neutrophils were resuspended 
in flow buffer at a concentration of 1.0 X 106 cells/mL. For combined cell capture 
assays, MCF7 or COLO 205 cells were resuspended in flow buffer with neutrophils at 
a 1:1 cancer cell to neutrophil ratio, at a concentration of 1.0 X 106 cells/mL. 
 
Halloysite nanotube-liposome immobilization to microtube surface 
 
Microrenathane microtubing (Braintree Scientific, Braintree, MA, USA) of 
inner diameter 300 µm was cut to 55 cm in length and washed with 75% ethanol. To 
prepare HNT-coated microtube surfaces, a 6.6% by weight HNT solution 
(NaturalNano Rochester, NY, USA) was treated via sonication, followed by filtration 
[82]. Microtubes were washed using distilled water, followed by incubation with 2:8 
poly-L-lysine (0.1% w/v, Sigma) for 5 min and then incubation with treated HNT 
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solution for 3 min. Microtubes were washed thoroughly with distilled water to remove 
excess HNTs in solution, and incubated overnight at RT. Surface immobilization of 
liposomes was achieved by incubating E-selectin functionalized liposome solution 
(ES-PEG L-DXR or ES-PEG EL) for 2.5 hours within HNT-coated microtubes. 
Smooth microtubes were prepared by immobilizing liposomes on the surface in the 
absence of HNTs. All surfaces were blocked for non-specific adhesion for 1 h with 5% 
bovine serum albumin (BSA) (Sigma-Aldrich) in PBS (w/v). All incubation steps 
were preceded and followed by thorough washes with PBS. Immobilized E-selectin 
proteins were activated prior to cell capture experiments via perfusion of calcium-
enriched flow buffer. 
 
Cell capture experiments 
 
To visualize cell adhesion and capture, functionalized microtubes were secured 
onto the stage of an Olympus IX81 motorized inverted microscope (Olympus, Center 
Valley, PA, USA). A motorized syringe pump (KDS 230; IITC Life Science, 
Woodland Hills, CA, USA) was used to perfuse cell suspensions through microtubes 
at physiologically relevant flow rates. Cancer cells and combined cell solutions were 
initially perfused through microtubes at a rate of 0.008 mL/min (wall shear stress of 
0.5 dynes/cm2) for 30 min, and then 0.04 mL/min (wall shear stress of 2.5 dynes/cm2) 
for another 30 min. Isolated neutrophils were perfused at 0.04 mL/min for 60 min. 
Microtubes were washed with calcium-enriched PBS at 1.0 dyn/cm2 to remove all 
non-adherent cells. Accutase was gently perfused into the microtube and allowed to 
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incubate for 10 min to detach adherent cells, followed by perfusion of medium for cell 
collection. For combined cell assays, neutrophils were separated from cancer cells by 
centrifugation using 1-Step Polymorphs after cell collection. Cells were cultured in 6-
well plates in complete media, and analyzed for cell viability at day 4 via trypan blue 
exclusion.  
 
Data acquisition 
 
Videos of cell capture experiments were recorded using a microscope-linked 
Hitachi CCD camera KP-M1AN (Hitachi, Japan) and a Sony DVD Recorder DVO-
1000MD (Sony Electronics Inc., San Diego, California, USA). Video frames were 
utilized to determine the number of captured cells per 100,000 µm2. For combined cell 
experiments, cancer cell and neutrophil capture measurements were determined based 
on differences in cell diameter. 
 
Shape factor analysis 
 
Brightfield images of neutrophils captured in smooth and HNT-coated tubes were 
analyzed for morphological changes using a shape factor analysis. Outlines of 
neutrophils were created from thresholded brightfield images using edge-detection 
functions in Metamorph software (Universal Imaging Corp., West Chester, PA). 
Neutrophil morphological changes were determined using a shape factor program in 
Metamorph, where shape factor is determined by:  
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where P is the perimeter and A is the area of the object (neutrophil). Shape factor 
values close to 1 correspond to a circle, while values approaching 0 represent spindly 
or dendritic shapes. 
  
Statistical analysis 
 
Data sets were plotted and analyzed using Prism 5.0b for Mac OS X 
(GraphPad software, San Diego, CA, USA). All results were reported as the mean +/- 
standard error of the mean. A two-tailed paired t-test was used for comparisons 
between two groups. P-values less than 0.05 were considered significant. 
 
6.3 RESULTS AND DISCUSSION 
 
ES-PEG L-DXR targets and induces breast cancer cell death 
 
To assess the functionality of E-selectin conjugated to the liposome surface, 
fluorescently tagged ES-PEG L-DXR was incubated with human breast cancer MCF7 
cells and sheared in a cone-and-plate viscometer for 10 min at 2.0 dyn/cm2. MCF7 
cells have previously been shown to roll on ES-coated surfaces, a process that is 
mediated by CD24 expressed on the MCF7 cell surface [181]. MCF7 cells sheared 
with fluorescent ES-PEG L-DXR increased in fluorescence by >99.9%, compared to 
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MCF7 cells sheared with fluorescent liposomes lacking E-selectin (Figure 6.1A). 
Confocal microscopy revealed that ES-PEG L-DXR not only binds to the cancer cell 
surface but also internalizes within the cell over time (Figure 6.1B), making this 
targeting mechanism well suited for the internalization of ES-PEG L-DXR within 
cancer cells. Static assays verified cellular uptake and cytotoxicity of ES-PEG L-DXR 
at levels comparable to L-DXR (Figure 6.1C,D). MCF7 cells treated with either L-
DXR (Figure 6.1G) or ES-PEG L-DXR (Figure 6.1H) had observable membrane 
blebbing and were non-adherent, characteristic of MCF7 cell death. MCF7 cells 
treated with EL (Figure 6.1F) were adherent, and displayed a morphology similar to 
healthy, untreated MCF7 cells (Figure 6.1E). Fluorescence microscopy confirmed 
comparable doxorubicin uptake in MCF7 cells treated with L-DXR (Figure 6.1K) and 
ES-PEG L-DXR (Figure 6.1L), compared to control samples in the absence of 
doxorubicin (Figure 6.1I,J). It is apparent from these images that E-selectin adhesion 
to the cell surface does not hinder internalization and cytotoxic effects of L-DXR on 
MCF7 cells, making this targeting mechanism suitable for MCF7 treatment under 
physiological flow. 
 
Nanostructured surfaces enhance breast and colon cancer cell adhesion to 
immobilized ES-PEG L-DXR 
 
Our lab has previously demonstrated that selectin proteins and selectin-coated 
nanoparticles can be immobilized on the inner surfaces of microtubes for the capture 
of circulating cells [388], as well as for use as in vitro models of the microvasculature 
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to examine the rolling adhesion of leukocytes [278] and cancer cells [391].  In this 
study, smooth microtubes were coated with only ES-PEG L-DXR. HNT-liposome 
coated microtubes were coated with HNTs, followed by ES-PEG L-DXR 
immobilization. MCF7 or COLO 205 cells were perfused through microtubes at shear 
stresses (0.5-2.5 dyn/cm2) observed in the microvasculature in vivo [274]. Both cell 
lines were chosen as model CTCs because they express sialylated carbohydrate 
ligands and exhibit rolling adhesion properties on immobilized E-selectin surfaces 
[85,181]. MCF7 cells were captured from flow in both smooth (Figure 6.2A) and 
HNT-liposome coated microtubes (Figure 6.2B). However, an increase in the number 
of MCF7 cells captured was observed on HNT-liposome surfaces, compared to 
smooth surfaces. A significant three-fold increase in MCF7 (Figure 6.2C) and two-
fold increase in COLO 205 cell capture (Figure 6.2D) per 100,000 µm2 were observed 
on HNT-liposome coated surfaces, compared to smooth surfaces coated with ES-PEG 
L-DXR. HNT-coated microtubes have been previously shown to increase the 
adsorption of selectin proteins [385], compared to the adsorption of selectins within 
microtubes in the absence of HNTs. It is likely that HNT coatings can also enhance 
the deposition of ES-PEG L-DXR, which could increase the recruitment of flowing 
cancer cells. 
 
Nanostructured surfaces reduce neutrophil adhesion to ES-PEG L-DXR 
 
While HNT-coated surfaces can enhance the delivery of chemotherapeutics to 
CTCs via selectin-mediated adhesion, it is also important to examine the effects of 
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such surface interactions with healthy blood cells. Leukocytes, which express 
sialylated carbohydrate ligands, outnumber CTCs by roughly one million to one in 
patients, on average [337]. Thus, leukocytes could potentially uptake the majority, if 
not all of the encapsulated chemotherapeutic being delivered. However, capture assays 
revealed that the number of neutrophils adhered to HNT-liposome coated surfaces 
(Figure 6.3B) was largely diminished compared to smooth surfaces (Figure 6.3A), the 
opposite of the trend observed in cancer cell capture studies. Similar trends were also 
observed in the isolation of CTCs from a suspension of mononuclear cells [336]. A 
significant >94% reduction of neutrophils captured per 100,000 µm2 was confirmed in 
HNT-liposome coated microtubes, compared to smooth microtubes coated with ES-
PEG L-DXR (Figure 6.3C).  
Cytoskeletal projections known as pseudopods were observed consistently on 
neutrophils adhered to smooth surfaces, characteristic of firmly adhered and activated 
neutrophils (Figure 6.3A) [176]. Neutrophils on HNT-liposome coated surfaces 
displayed a rounder morphology, characteristic of weaker adhesion of resting 
neutrophils (Figure 6.3B). Shape factor analysis has previously been utilized to assess 
neutrophil morphological changes [82], and was performed in this study to determine 
the effect of adhesion to HNT-liposome coated surfaces on morphological changes. 
On a scale of 0 (elongated shapes) to 1 (circularity), shape factor analysis verified a 
significantly higher shape factor in neutrophils adhered to HNT-liposome coated 
surfaces (Figure 6.3D) compared to those adhered to smooth surfaces, adding further 
support that neutrophils display weaker adhesion on HNT-liposome coated surfaces. 
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To examine if the reduction in neutrophil adhesion and capture is due to 
prevention of ES-PEG L-DXR adsorption, ES-PEG L-DXR was fluorescently tagged 
and immobilized on smooth and HNT-coated microtubes. However, fluorescence 
microscopy confirmed that ES-PEG L-DXR immobilized within both smooth (Figure 
6.4B) and HNT-coated microtubes (Figure 6.4C), compared to control microtubes in 
the absence of fluorescent ES-PEG L-DXR (Figure 6.4A). Thus, the reduction in 
neutrophil adhesion could not be caused by prevention of ES-PEG L-DXR adsorption. 
 
Halloysite nanotube-liposome surfaces capture cancer cells and repel neutrophils 
under flow from a mixture containing both cell types 
 
The use of HNT-liposome coated surfaces for CTC capture from a combined 
cell suspension was assessed via perfusion of a 1:1 mixture of cancer cells and 
neutrophils over liposome-coated surfaces. Neutrophils and MCF7 cells were 
identified based on size; cells 15 µm in diameter or less were identified as neutrophils, 
while cells greater than 15 µm were identified as MCF7 or COLO 205 cells. Upon 
perfusion of neutrophils and MCF7 cells, the number of neutrophils captured 
decreased on HNT-liposome coated surfaces (Figure 6.5B) compared to smooth 
surfaces (Figure 6.5A). Simultaneously, an increase in MCF7 cell capture was 
observed on HNT-liposome coated surfaces (Figure 6.5B) compared to smooth 
surfaces (Figure 6.5A). The number of both MCF7 (Figure 6.5C) and COLO 205 
(Figure 6.5D) cells captured was significantly increased on HNT-liposome coated 
surfaces, with significant reductions in neutrophil capture (Figure 6.5E). 
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Halloysite nanotube-liposome surfaces specifically induce cancer cell death under 
flow from a mixture containing both neutrophils and cancer cells 
 
The ability to successfully deliver doxorubicin to cancer cells within a 
combined cell suspension was assessed by the removal and collection of captured cells 
from surfaces, separation of cancer cells from neutrophils, and placement into culture 
for viability tests. Neutrophils, which have a short lifespan in vivo and typically 
undergo cell death in vitro within 18-28 hours post-isolation [403], showed negligible 
differences in viability whether captured within microtubes or placed directly into 
culture upon isolation. After a 4-day incubation, brightfield microscopy confirmed that 
MCF7 cells captured on smooth surfaces were adherent and displayed healthy 
morphology (Figure 6.6A). However, MCF7 cells captured on HNT-liposome coated 
surfaces were non-adherent and displayed significant membrane blebbing, 
characteristic of apoptosis (Figure 6.6B). MCF7 cells captured on smooth surfaces 
exhibited minimal doxorubicin uptake based on fluorescence images (Figure 6.6C), 
while MCF7 cells captured on HNT-liposome coated surfaces displayed increased 
doxorubicin uptake (Figure 6.6D). Cell viability assays confirmed doxorubicin-
induced cell death, with a significant decrease in MCF7 (Figure 6.6E) and COLO 205 
cell viability (Figure 6.6F) when captured on smooth tubes coated with ES-PEG L-
DXR, compared to control smooth surfaces coated with ES-PEG EL. However, the 
number of viable MCF7 and COLO 205 cells captured on HNT-liposome coated 
surfaces was significantly reduced, compared to the number of viable cells captured on 
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smooth surfaces. Similar trends were observed previously in KG-1a and COLO 205 
cells captured from a solution consisting only of cancer cells [82]. These results 
demonstrate that a combined surface of HNTs and ES-PEG L-DXR can serve a dual 
role in: (1) delivering chemotherapeutics to CTCs, and (2) reducing leukocyte 
adhesion and interaction with chemotherapeutics, and thus reducing toxic side effects 
on healthy blood cells. 
 
6.4 CONCLUSION 
 
Here, we have demonstrated a technique utilizing cell adhesion molecules to 
deliver therapeutics to CTCs while actively preventing blood cell adhesion. ES-PEG 
L-DXR was shown to adhesively interact with MCF7 breast cancer cells and induce 
cell death. Under physiological flow rates, HNT-liposome coated surfaces 
significantly increased the number of captured MCF7 and COLO 205 cancer cells, 
compared to smooth surfaces coated with ES-PEG L-DXR. The opposite trend 
occurred with healthy blood cells, as perfusion of neutrophils over HNT-liposome 
coated surfaces significantly reduced the number of captured cells. In a combined 
solution of cancer cells and neutrophils, HNT-liposome coated surfaces 
simultaneously increased the number of MCF7 and COLO 205 cells captured, while 
significantly reducing neutrophil capture to minimal levels. Liposomal doxorubicin 
was successfully delivered to MCF7 and COLO 205 cells in flow assays with a 
combined solution of cancer cells and neutrophils. The application of HNT-liposome 
surfaces can enhance chemotherapeutic delivery to CTCs and reduce the probability of 
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metastasis. Additionally, the unique ability of such surfaces to prevent normal blood 
cell interactions can reduce toxic non-specific effects and dramatically reduce 
chemotherapeutic dosages required for CTC treatment. 
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FIGURE 6.1: E-SELECTIN TARGETED LIPOSOMES ADHESIVELY BIND 
AND DELIVER DOXORUBICIN TO MCF7 BREAST CANCER CELLS. (A) 
Flow cytometry fluorescence histograms of MCF7 cells adhered to fluorescently-
tagged (FL) liposomes and fluorescent E-selectin targeted liposomes (FL ES-PEG) 
after exposure to fluid shear stress in a cone-and-plate viscometer. FITC: Fluorescein 
isothiocyanate. (B) Confocal microscopy image of FL ES-PEG (green) bound to 
MCF7 cells after fluid shear stress exposure. Cell nucleus = blue. Scale bar = 10 µm. 
(C) Number of viable MCF7 cells after treatment with empty liposomes (EL), 
liposomal doxorubicin (L-DXR) or E-selectin targeted L-DXR (ES-PEG L-DXR) 
under static conditions for a period of 1-4 days. (D) Dose response of MCF7 cells after 
treatment with liposomes over a 4 day period. (E-H) Brightfield microscopy images of 
untreated MCF7 cells (E) and those treated with EL (F), L-DXR (G), and ES-PEG L-
DXR (H) after a 4 day period. Scale bars = 100 µm. (I-L) Fluorescence microscopy 
images of doxorubicin uptake (red) of untreated MCF7 cells (I) and those treated with 
EL (J), L-DXR (K), and ES-PEG L-DXR (L) after a 4 day period.  
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FIGURE 6.1: E-SELECTIN TARGETED LIPOSOMES ADHESIVELY BIND 
AND DELIVER DOXORUBICIN TO MCF7 BREAST CANCER CELLS.  
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FIGURE 6.2: HNT-LIPOSOME COATED SURFACES ENHANCE MCF7 AND 
COLO 205 CELL CAPTURE.  (A) MCF7 breast cancer cells adhered to a smooth 
microtube coated with ES-PEG L-DXR. Scale bar = 100 µm. (B) MCF7 cells adhered 
to an HNT-coated microtube with ES-PEG L-DXR. Scale bar = 100 µm. (C) Number 
of MCF7 cells adhered to smooth and HNT-coated microtubes per 100,000 µm2. (D) 
Number of COLO 205 cells adhered to smooth and HNT-coated microtubes per 
100,000 µm2. * P < 0.01. ** P < 0.001. 
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FIGURE 6.3: HNT-LIPOSOME COATED SURFACES REDUCE AND 
WEAKEN NEUTROPHIL ADHESION. (A) Neutrophils adhered to a smooth 
microtube coated with ES-PEG L-DXR. Scale bar = 100 µm. (B) Neutrophils adhered 
to an HNT-coated microtube with ES-PEG L-DXR. Scale bar = 100 µm. Insets show 
representative cell shapes at higher magnification (approximately 20x20 um). (C) 
Number of neutrophils adhered to smooth and HNT-coated microtubes per 100,000 
µm2. (D) Shape factor analysis of neutrophils adhered to smooth and HNT-coated 
microtubes. ** P < 0.001. 
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FIGURE 6.4: E-SELECTIN TARGETED LIPOSOMES IMMOBILIZE ON 
BOTH SMOOTH AND HNT-COATED MICROTUBE SURFACES. (A-C) 
Fluorescence microscopy images of microtubes coated with BSA (A), smooth 
microtubes coated with fluorescent ES-PEG L-DXR (B), and HNT-coated microtubes 
with immobilized fluorescent ES-PEG L-DXR (C). Scale bar = 100 µm. 
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FIGURE 6.5: HNT-LIPOSOME SURFACES SIMULTANEOUSLY ENHANCE 
MCF7 AND COLO 205 CELL ADHESION AND REDUCE NEUTROPHIL 
ADHESION FROM A COMBINED SUSPENSION OF CANCER CELLS AND 
NEUTROPHILS. (A) MCF7 (red arrow) and neutrophils (yellow arrow) adhered to a 
smooth microtube coated with ES-PEG L-DXR. Scale bar = 100 µm. (B) MCF7 (red 
arrow) and neutrophils (yellow arrow) adhered to an HNT-coated microtube with 
immobilized ES-PEG L-DXR. Scale bar = 100 µm. (C) Number of MCF7 cells 
adhered to smooth and HNT-coated microtubes per 100,000 µm2. (D) Number of 
COLO 205 cells adhered to smooth and HNT-coated microtubes per 100,000 µm2. (E) 
Number of neutrophils adhered to smooth and HNT-coated microtubes per 100,000 
µm2.  * P < 0.01. 
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FIGURE 6.5: HNT-LIPOSOME SURFACES SIMULTANEOUSLY ENHANCE 
MCF7 AND COLO 205 CELL ADHESION AND REDUCE NEUTROPHIL 
ADHESION FROM A COMBINED SUSPENSION OF CANCER CELLS AND 
NEUTROPHILS.  
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FIGURE 6.6: HNT-LIPOSOME COATED SURFACES SUCCESSFULLY 
DELIVER DOXORUBICIN TO CANCER CELLS FROM A COMBINED 
SOLUTION OF CANCER CELLS AND NEUTROPHILS.  Brightfield images of 
MCF7 cells captured on a smooth surface (A) and an HNT-liposome coated surface 
(B), from a combined solution of cancer cells and neutrophils. Internalization of 
doxorubicin (red) in MCF7 cells captured on a smooth surface (C) and an HNT-
liposome coated surface (D), from a combined solution of cancer cells and 
neutrophils. All images were taken after a 4-day incubation at 37°C. Scale bar = 100 
µm. Number of viable MCF7 (E) and COLO 205 (F) cells after capture on smooth and 
HNT-liposome coated surfaces. Control samples represent viable cells captured by 
ES-PEG EL. * P < 0.01. ** P < 0.001. 
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CHAPTER 7:  UNNATURAL KILLER CELLS. TRAIL-COATED 
LEUKOCYTES THAT KILL CANCER CELLS IN THE CIRCULATION 
 
*This section is adapted from the following publication: M.J. Mitchell, E. Wayne, K. 
Rana, C.B. Schaffer, and M.R. King. Proceedings of the National Academy of 
Sciences. 111(3): 930-935, 2014. 
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7.1 INTRODUCTION 
 
Over 90% of cancer-related deaths are due to cancer metastasis, the spread of 
cancer cells from a primary tumor to anatomically distant organs [1]. In many types of 
cancer, cancer cells from the primary tumor can intravasate into the peripheral 
circulation as circulating tumor cells (CTCs) [42,404]. These CTCs can then interact 
with the receptor-bearing endothelial cell wall under flow in other organs, in a manner 
similar to leukocyte extravasation during inflammation and lymphocyte homing to 
lymphatic tissues [52]. Recent studies have shown that CTCs from many types of 
primary tumors express sialylated carbohydrate ligands similar to leukocytes, which 
mediate interactions with selectins on the endothelium [177,178]. Selectins possess 
rapid, force-dependent binding kinetics, which can trigger the rolling adhesion of 
CTCs along the blood vessel wall [49,405]. CTCs can subsequently transition from 
rolling to firm adhesion, allowing for transendothelial migration into tissues and 
eventual formation of micrometastases [185]. Surgery and radiation has proven 
effective at treating primary tumors that do not invade the basement membrane, 
however the difficulty of detecting distant micrometastases has made the majority of 
metastatic cancer treatments unsuccessful.  
The development of technologies to directly target CTCs in vivo holds promise 
in reducing both the metastatic load and the formation of new tumors. While studies 
have reported that as many as 1 x 106 cancer cells detach from the primary tumor (per 
gram) of patients per day [406,407], CTCs are difficult to detect due to their sparse 
concentrations in the bloodstream, as low as 1-100 cells/mL [42,238]. Additionally, 
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there are approximately 1 x 106 leukocytes or 1 x 109 erythrocytes per single CTC in 
blood [43]. Despite the difference in numbers, both leukocytes and CTCs share similar 
characteristics in terms of their migration within the bloodstream. Highly deformable 
erythrocytes experience a drift velocity away from the vessel wall and collect in the 
center region, displacing less deformable leukocytes and CTCs to the near-wall region 
in a mechanism termed margination [163]. Such margination phenomena can 
effectively surround CTCs within the circulating leukocyte population, thus making 
leukocytes a potentially attractive carrier of treatments to CTCs by exploiting their 
numerous adhesion receptors. 
The utilization of leukocytes to treat CTCs directly within the bloodstream has 
not previously been explored. Here, I describe a therapeutic approach to target and kill 
circulating cancer cells in the bloodstream by functionalizing leukocytes with the 
apoptosis-inducing ligand TRAIL, and the adhesion receptor E-selectin directly within 
blood under shear flow. The functionalization of leukocytes under flow, effectively 
creating a form of “unnatural killer cells” within the bloodstream, is shown to be 
highly effective at treating circulating cancer cells in flowing human blood in vitro, 
and in the peripheral circulation of mice in vivo. 
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7.2 MATERIALS AND METHODS 
 
Reagents and antibodies 
 
Human serum albumin (HSA), bovine serum albumin (BSA), Accutase™, 
HEPES, DMSO, NaCl, MgCl2, CaCO3 and chloroform (ACS grade with 0.5 – 1% 
ethanol added as stabilizer) were all obtained from Sigma-Aldrich (St Louis, MO). 
RPMI 1640 cell culture media, fetal bovine serum (FBS), Hank’s balanced salt 
solution (HBSS), penicillin-streptomycin (PenStrep) and Dulbecco’s phosphate 
buffered saline (DPBS) were all obtained from Invitrogen (Grand Island, NY). His-
tagged recombinant human tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), his-tagged recombinant human E-selectin-IgG chimera (ES) and Annexin-V 
FITC Apoptosis Detection Kit were purchased from R&D Systems (Minneapolis, 
MN). BCECF AM solution and trypsin-EDTA solution were obtained from Invitrogen 
(Carlsbad, CA). PBS-based enzyme-free cell dissociation media was purchased from 
Millipore (Billerica, MA).  L-α-lysophosphatidylcholine from egg (Egg PC), 
sphingomyelin from egg (Egg SM), ovine wool cholesterol (Chol), 1,2-dioleoyl-sn-
glycero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt) 
(DOGS NTA-Ni) and 23-(dipyrrometheneboron difluoride)-24-norcholesterol (Bdp-
Chol, Ex/Em 490 nm/504 nm) either dissolved in chloroform (Egg PC, Egg SM, Chol, 
DOGS NTA-Ni) or in powder form (Bdp-Chol) were purchased from Avanti Polar 
Lipids (Alabaster, AL). Rat anti-human CD62E (E-selectin) antibody was purchased 
from Abcam (Cambridge, MA). Anti human CD3, CD14, CD16, CD19 and CD56 
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conjugated with Pacific Blue™, APC Cy7™, PERCP-Cy5.5, APC, and PE 
respectively along with corresponding isotypes were all purchased from BD 
Biosciences (San Jose, CA). 
 
Cell lines and cell culture 
 
Colon cancer cell line COLO 205 (ATCC number CCL-222) was obtained 
from ATCC (Manassas, VA) and cultured in RPMI 1640 supplemented with 2 mM L-
Glutamine, 25 mM HEPES, 10% v/v FBS and 100 U/mL PenStrep (complete media) 
under humidified conditions at 37˚C and 5% CO2. Prostate cancer cell line PC-3 
(ATCC number CRL-1435) was obtained from ATCC and cultured in F-12K medium 
supplemented with 10% v/v FBS and 100U/mL PenStrep. Human umbilical vein 
endothelial cells (HUVEC) were purchased from Cascade Biologics (Portland, OR) 
and maintained in Medium 200 (Cascade Biologics) supplemented with low-serum 
growth supplement (Cascade Biologics) and 5% fetal bovine serum (Invitrogen). 
HUVECs were utilized from passages 2-5 for experiments. For all experiments,  >95% 
viability was assessed by trypan blue exclusion dye. 
 
Preparation of liposomes 
 
Multilamellar liposomes, composed of egg L-α-lysophosphatidylcholine (Egg 
PC), egg sphingomyelin (Egg SM), ovine wool cholesterol (Chol), 1,2-dioleoyl-sn-
glycero-3-[(N-(5-amino-1-carboxypentyl) iminodiacetic acid) succinyl] (nickel salt) 
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(DOGS NTA-Ni) at weight ratios 60-50%:30%:10%:0-10% (Egg PC/Egg 
SM/Chol/DOGS NTA-Ni), were prepared by thin lipid film method [388]. DOGS-
NTA-Ni is a lipid conjugated to nickel-nitrilotriacetic acid (Ni-NTA) that allows for 
attachment to his-tagged proteins. Briefly, stock solutions of all lipids were prepared 
by dissolving powdered lipids in chloroform to produce a final concentration of 5 
mg/mL Egg PC, 20 mg/mL Egg SM, 5 mg/mL Chol and 20 mg/mL DOGS-NTA-Ni in 
glass containers and stored at -20°C. Appropriate volumes of the lipids were taken 
from the stock solution to make lipids with varying concentrations of DOGS NTA-Ni 
in a glass tube and gently dried under nitrogen. To ensure complete removal of 
chloroform, the lipids were left under vacuum for an additional 12 h. With increasing 
amounts of DOGS NTA-Ni, the corresponding amount of Egg PC was decreased 
(Table 7.1). The lipid film was hydrated with a liposome buffer composed of 150 mM 
NaCl, 10 mM HEPES and 1 mM MgCl2 dissolved in nuclease-free water to create 
multilamellar liposomes. The resulting multilamellar liposomes were sized by 
repeated thawing and freezing, and then subjected to 15 extrusion cycles at 60ºC 
through two different pore size (200 and 100 nm) polycarbonate membranes 
(Nucleopore, Whatman, NJ, USA) to produce unilamellar nanoscale liposomes. 
Recombinant human ES and TRAIL were dissolved in nuclease-free sterile water to a 
final concentration of 1 mg/mL and 100 µg/mL. Aliquots of stock solutions were 
stored at –20 ºC and used as needed within 60 days. Freshly prepared nanoscale 
liposomes were then incubated with ES (final concentration 71.43 nM) and TRAIL 
(250 nM final concentration) for 30 min at 37ºC and then overnight at 4ºC, to ensure 
maximum protein binding via the interaction between his-tag and Ni-
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approximations for ligand density on liposomes suggested in previous work by Huang 
and Mason [408], there were approximately 65 TRAIL and 19 E-selectin proteins 
present on the surface of each liposome, assuming a unilamellar liposome diameter of 
100 nm. To remove unbound TRAIL and ES, liposomes were diluted 1:6 with 
liposome buffer and subjected to ultracentrifugation at 100000g for 3 h at 4ºC. The 
supernatant with unbound TRAIL and ES was carefully removed and collected for 
further evaluation, and the remaining liposomes were gently resuspended in buffer. A 
similar procedure was used to create fluorescent conjugated liposomes by replacing 
ovine wool cholesterol with 23-(dipyrrometheneboron difluoride)-24-norcholesterol. 
Freshly prepared nanoscale liposomes were diluted in buffer, and the mean particle 
diameter and surface charge (zeta potential) were measured by dynamic light 
scattering using a Malvern Zetasizer nano ZS (Malvern Instruments Ltd., 
Worcestershire, UK), according to the manufacturer’s protocols. Conjugated 
liposomes were measured to be 117.8 ± 10.3 nm in diameter, with a zeta potential of -
5.7 ± 4.6 mV.  
 
Static experiments 
 
COLO 205 cells were seeded in multiwell plates at a seeding density of 
300,000 cells/mL, 1 day prior to experimentation to ensure that the cells were in the 
linear phase of the growth cycle. Media was changed prior to experimentation. Cells 
were incubated with either the supernatant from ultracentrifugation or 10 µL of 
conjugated and purified liposomes. The cells were maintained in culture conditions 
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with the supernatant or nanoscale lipids for 24 h and later analyzed by an Annexin-V 
assay to quantify the proportion of viable cells. 
 
Uniform shear flow experiments  
 
To simulate the shear stress conditions of blood flow, cancer cells were 
subjected to uniform shear in a cone-and-plate viscometer [86,91]. Cancer cells seeded 
one day prior to the experiment were gently detached from the surface using PBS-
based enzyme-free cell detachment solution or accutase. Cells were then washed twice 
in 1X DPBS and resuspended in buffer at a concentration of 1 x 106 cells/mL. 10 µL 
of lipids was added to 490 µL of cell suspension (at 106 cells/mL) and immediately 
added to the cone-and-plate viscometer. Shear rate was set to 188 s-1 for 2 h. All 
samples were exposed to shear flow at RT, to prevent potential sample evaporation 
and/or drying in the cone-and-plate viscometer over prolonged periods of shear. After 
2 h, the cells were removed and washed twice in resuspension buffer at 200g for 5 
min. Cells were resuspended in complete media and cultured for 24 h. In the case of 
fluorescent lipids, an aliquot was taken for visual inspection on an inverted 
microscope (Olympus America Inc, Melville, NY) equipped with fluorescence and an 
intensified CCD digital camera (Cooke Corporation, Romulus, MI) to record images. 
For spiking experiments, peripheral blood was collected into Vacutainer tubes 
containing heparin and allowed to equilibrate to RT before use. 1 x 106 COLO 205 or 
PC-3 cells were tagged fluorescently with 3 µM BCECF AM solution for 15 min at 
37°C, washed twice and collected via centrifugation at 200g for 5 min. The 
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supernatant was discarded, and the collected cells were resuspended in 1 mL of whole 
blood. 10 µL of lipid was then added to 490 µL of spiked blood and immediately 
added to a cone-and-plate viscometer previously coated with 5% BSA. Spiked blood 
was subjected to a uniform shear rate of 188 s-1 for 2 h. As an additional comparison 
for spiking experiments, identical experiments were performed in buffer instead of 
whole blood. In leukocyte functionalization experiments, 10 µL of lipid was added to 
490 µL human blood, sheared in a cone-and-plate viscometer at a uniform shear rate 
of 188 s-1 for 2 h, and subsequently centrifuged to remove the plasma containing 
unbound liposomes. The removed plasma was replaced with freshly isolated plasma, 
and the blood samples were used for identical spiking experiments mentioned above. 
After shearing, the blood sample was collected from the device and carefully layered 
over 1.5 mL of Ficoll and centrifuged at 480g for 50 min at RT. The buffy coat 
containing MNCs and cancer cells was recovered and washed twice in resuspension 
buffer, collected, cultured for 24 h, and analyzed for viable fluorescent cancer cells 
using flow cytometry. To evaluate the effect of hematocrit, the number of RBCs was 
varied by removal via centrifugation. Volumes of RBCs were replaced with excess 
plasma from the same blood donor. Cancer cells were spiked into blood samples as 
mentioned earlier, at a concentration of 1 x 106 cells/mL. 10 µL of liposome solution 
was added to 490 µL of blood and sheared for 2 h at 188 s-1. Samples were collected, 
incubated, and analyzed for viability on a flow cytometer as described above. In some 
experiments, 490 µL of whole blood was sheared with 10 µL of liposome solution, and 
the plasma and any remaining unbound liposomes and/or liposome fragments were 
separated by centrifugation. To determine the effects of remaining unbound liposomes 
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and/or liposome fragments on cancer cell viability, the recovered plasma was 
incubated with 500,000 COLO 205 cells for 24 h at 37°C and analyzed for cell 
viability using flow cytometry. 
 
Polymorphonuclear (PMN) and mononuclear cell (MNC) isolation 
 
All human subject protocols were approved by the Institutional Review Board 
for Human Participants of Cornell University. Peripheral blood was collected from 
healthy, willing donors after informed consent into Vacutainer tubes containing 
heparin and allowed to equilibrate at room temperature (RT) before use [91,390]. 3 
mL of blood diluted with resuspension buffer was carefully layered over 3 mL of 1-
Step™ Polymorphs (Accurate Chemical & Scientific Corporation, Westbury, NY) and 
centrifuged at 480g for 50 min at RT. Two separate layers of MNCs and PMNs were 
collected and washed twice with resuspension buffer. 
 
Leukocyte functionalization with ES/TRAIL liposomes in whole blood 
 
To assess the adhesion of ES/TRAIL liposomes to leukocytes in whole blood 
under flow, 490 µL of whole blood was sheared with 10 µL of fluorescent ES/TRAIL 
liposome solution for 30 min in a cone-and-plate viscometer at a shear rate of 188 s-1. 
Leukocytes were then separated using 1-Step™ Polymorphs and assessed for adherent 
ES/TRAIL liposomes using confocal microscopy. To assess the fraction of leukocyte 
subpopulations that adhere to ES/TRAIL liposomes, leukocytes were labeled with 
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anti-human CD3, CD14, CD16, CD19 and CD56, along with corresponding isotype 
controls, and analyzed for adherent ES/TRAIL liposomes using flow cytometry. To 
assess the specificity of the ES interaction with leukocytes, liposomes were incubated 
with a functional blocking anti-human E-selectin antibody prior to shearing in whole 
blood. To assess the fraction of leukocytes in blood adhered to ES/TRAIL liposomes 
before shear, fluorescent ES/TRAIL liposomes were added to whole blood and then 
separated using 1-Step™ Polymorphs. 
 
Endothelial cell viability assay 
 
40 mm diameter circular glass coverslips (Thermo Scientific, Waltham, MA) 
were plasma treated (Harrick Plasma Cleaner, Ossining, NY) for 2 min and 
subsequently incubated in 1% polyethylenemine (PEI) at room temperature for 10 
min. Coverslips were then washed in water 3 times and treated with 0.1% 
glutaraldehyde (Sigma-Aldrich, St. Louis, MO) in PBS at room temperature for 30 
min. Coverslips were washed in water 3 times, dried, and treated with 0.1 mg/mL of 
type I rat-tail collagen (Becton Dickinson, Franklin Lakes, NJ) in HEPES (pH 8.0, 
Sigma-Aldrich, St. Louis, MO) for 2 h at 4°C. Coverslips were placed in petri dishes 
(60 mm x 15 mm; Sigma-Aldrich), washed 3 times in PBS, and briefly sterilized via 
UV exposure for 15 min. HUVECs were plated on coverslips, at a density of 500,000 
cells per coverslip, in Medium 200 supplemented with low-serum growth supplement 
(Cascade Biologics), 5% fetal bovine serum (Invitrogen), and 100U/mL PenStrep. 
HUVECs were cultured for 4 days on coverslips prior to experiments, and then 
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adhered to the plate of a cone-and-plate viscometer using vacuum grease. HUVECs 
were then treated with 2.94 mL of human blood and 60 µL of PBS, ES/TRAIL 
(TRAIL final concentration: 0.3 µg/mL), or soluble TRAIL in PBS (TRAIL final 
concentration: 0.3 µg/mL) for 4 h at 37°C in a humidified cone-and-plate viscometer 
at a shear rate of 188 s-1. As a positive control, HUVECs were treated with a high 
concentration of soluble TRAIL (15 µg/mL). Coverslips were removed from the 
viscometer, gently washed in PBS, and placed in Medium 200 supplemented with 
low-serum growth supplement, 5% fetal bovine serum (Invitrogen), and 100U/mL 
PenStrep. HUVEC morphology was assessed using brightfield and phase contrast 
microscopy. HUVECs were immediately placed into culture for 8 h, maintained at 
37°C and 5% CO2. HUVECs were then treated with 0.25% Trypsin-EDTA solution 
(Gibco) for 2 min at 37°C, followed by treatment with an equal volume of trypsin 
neutralizer solution (Gibco). HUVECs were collected from coverslips, washed twice 
in PBS, and assessed for viability using an Annexin-V assay. 
 
Liposome and COLO 205 cell injection in mice 
 
C57BL/6J mice aged 16-20 weeks (both sexes), weighing 25-32 g, were 
obtained from The Jackson Laboratory. Mice were anesthetized using isoflurane (5%) 
for all procedures. Either 120 µL of saline, sTRAIL (15 µg/mL; TRAIL plasma 
concentration ~ 1.0 µg/mL), ES/TRAIL (TRAIL injection concentration: 15 µg/mL; 
TRAIL plasma concentration ~ 1.0 µg/mL) liposomes or ES liposomes suspended in 
saline were injected retro-orbitally using a 30-G needle and animals were removed 
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from anesthesia. Three mice were used in each group. Thirty minutes later, animals 
were re-anesthetized and ~2x106 COLO 205 cells, labeled by 2 µg/mL Hoescht 
(#H1399, Invitrogen) or 3 µM BCECF AM suspended in saline were injected into the 
tail vein. Animals were removed from anesthesia and the cancer cells were allowed to 
circulate for 2 h. All animal procedures were approved by the Cornell University 
Institutional Animal Care and Use Committee.  
 
Analysis of circulating COLO 205 cancer cells 
 
Animals were euthanized with a lethal dose of pentobarbital. Blood was 
removed from the heart via cardiac puncture and collected into sodium heparin-coated 
tubes. Leukocytes and circulating COLO 205 cells were separated using Ficoll-Paque 
PLUS™. After centrifugation, the MNC buffy coat was collected, washed in buffer 
containing Ca2+ and cultured for 2-3 h in multiwell plates. Cell viability was assessed 
using flow cytometry. 
 
Two-photon imaging of lung tissue 
 
Animals were anesthetized and received injections of saline, sTRAIL, 
ES/TRAIL liposomes or ES liposomes, followed by an injection of Hoescht-labeled 
cancer cells, as described above. After two hours of cancer cell circulation, an Alexa 
Fluor 568 labeled Annexin-V probe (#A13202, Invitrogen) was injected retro-orbitally 
and allowed to circulate for 2 h to ensure maximum detection of apoptotic cells. 
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Animals were then given a lethal dose of pentobarbital. After euthanasia, intact lungs 
were resected and immediately imaged via two-photon excited fluorescence 
microscopy. Two-photon imaging was conducted on a locally-designed microscope 
using a train of 800-nm, 87-MHz, 100-fs pulses from a Ti:sapphire laser oscillator 
(MIRA HP, pumped by a Verdi-V18, Coherent) for excitation.  Laser scanning and 
data acquisition were controlled by ScanImage software. For high-resolution imaging 
of COLO 205 Hoechst-labeled nuclei and Annexin V labeling a 20X (numerical 
aperture: 0.95) water-immersion objective (Olympus) was used. Fluorescence was 
detected using emission filters with 460-nm and 645-nm center wavelength with 65-
nm bandwidth to image Hoescht and Alexa Fluor 568 (Invitrogen), respectively. 
Spectrally-broad autofluorescence from the lung tissue was visible in both channels. 
 
Counting and viability scoring of COLO 205 cells in lung 
 
Hoechst-labeled COLO 205 cells were manually counted from ~10 
representative two-photon image stacks taken from the lung in each mouse using 
Image J (NIH) cell counting software. The Hoechst signal was of similar magnitude to 
the background lung autofluorescence in the 460-nm channel. To aid in identifying 
nuclei, the Hoechst channel was compared with the 645-nm channel, where 
autofluorescence was also visible, but Hoescht was not and Alexa Fluor 568 signal 
was significantly brighter than autofluorescence. In addition, attributes such as size 
and shape to distinguish the labeled COLO 205 cells were used. Each imaged volume 
was about 0.022 mm3. The total number of cells in the lung was estimated by scaling 
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the imaged volumes to the total lung volume, which was measured via a volume 
displacement method. Counts were recorded by two different observers, each blinded 
to the treatment received, and averaged. To determine which COLO 205 cells were 
apoptotic, we determined whether Alexa Fluor 568 Annexin V labeling was present at 
each of the COLO 205 cell nuclei we identified. 
 
Flow cytometry  
 
Mode of cell death was analyzed using an Annexin-V apoptosis assay on an 
Accuri C6 flow cytometer. Samples were prepared for as per the manufacturer’s 
instructions. Briefly, cells were classified into four categories based on dye uptake: 
viable cells (negative for Annexin-V and propidium iodide (PI)), early apoptotic cells 
(positive for Annexin-V only), late apoptotic cells (positive for Annexin-V and PI) and 
necrotic cells (positive for PI only). For blood spiking experiments, fluorescent 
untreated cancer cells and liposome treated samples were assessed for viability using a 
flow cytometer. A gate was set based on a viable, untreated cancer cell control. Equal 
volumes from all samples were used for analysis. Cell viability was determined by 
measuring the amount of cells positive for fluorescent BCECF staining. For in vivo 
animal experiments, 100 µL of each sample was processed. A gate denoting viable, 
BCECF AM-labeled cancer cells was established by processing a viable, fluorescent 
sample of COLO 205 cells in buffer. COLO 205 cells recovered from mouse blood 
were differentiated based on size and fluorescence using flow cytometry. The number 
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of cancer cells per milliliter of mouse blood was determined based on the amount of 
mouse blood recovered from each animal. 
 
Statistical analysis 
 
Where appropriate, student’s t-test and one-way ANOVA with Tukey post test 
comparing all means were employed at a significance level of α = 0.05. All statistical 
analyses were performed using GraphPad Prism 5.0c for Mac OS X GraphPad 
software (San Diego, CA USA) and Kaleidagraph (Synergy) software. 
 
7.3 RESULTS 
 
ES/TRAIL liposomes adhesively interact and induce apoptotic cancer cell death under 
shear flow 
 
Many types of circulating tumor cells (CTC), and cancer cell lines derived 
from colon, breast, prostate, and pancreas are known to display glycosylated ligands 
that allow them to adhesively interact with E-selectin (ES) under physiological shear 
flow [50]. This has been proposed to explain why some cancers home to tissue 
specific capillary beds such as the bone marrow and liver [48,53]. In an attempt to 
target and kill cancer cells of this form, nanoscale liposomes conjugated with a 
mixture of recombinant human E-selectin (ES) protein and tumor necrosis factor 
(TNF)-related apoptosis inducing ligand were developed (TRAIL; Figures 7.1A, 7.2 
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and Table 7.1). TRAIL binds to death receptors 4 and 5 on the surface of cancer cells 
to induce apoptosis through the intrinsic and extrinsic pathways [232,233].  ES/TRAIL 
liposomes consisting of a 10% weight ratio of DOGS-Ni-NTA, utilized to conjugate 
ES and TRAIL to the liposome surface, were found to be most effective at inducing 
apoptotic cell death in a colorectal adenocarcinoma (COLO 205) cell line under static 
conditions (Figure 7.3), as determined using an Annexin-V apoptosis assay. 
In the post-capillary venules where selectin-mediated adhesion and cell 
extravasation into tissues typically occur, moderate shear rates can initiate flowing cell 
interactions with the endothelial cell wall [159,274]. To recreate these physical forces 
in vitro, a cone-and-plate shear assay was developed to probe the interactions of 
cancer cells and ES/TRAIL liposomes under venular shear rates. After exposure to 
shear flow (shear rate: 188 s-1) for 2 h, COLO 205 cells exposed to ES liposomes 
displayed their normal morphology, while substantial membrane blebbing was 
observed in those exposed to ES/TRAIL liposomes, characteristic of cells undergoing 
apoptosis (Figure 7.1B). Annexin-V assay revealed that exposure to shear flow for 2 h 
induced minimal COLO 205 cell apoptosis in untreated controls (Figure 7.1C), in 
addition to treatment with liposomes in the absence of conjugated protein (Figure 
7.1D) or conjugated solely with ES (Figure 7.1E) or TRAIL (Figure 7.1F). However, a 
combination of ES/TRAIL conjugated to the liposome surface induced a significant 
decrease in COLO 205 viability following exposure to shear flow (Figure 7.1G, H). 
To investigate the adhesive characteristics of ES/TRAIL liposomes to cancer 
cells under flow, COLO 205 cells were exposed to ES/TRAIL liposomes consisting of 
fluorescent cholesterol and exposed to shear flow as in previous in vitro shear assays. 
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Flow cytometry revealed that >99.9% of the COLO 205 cell population was adhered 
to ES/TRAIL liposomes after exposure to shear flow (Figure 7.4A,B). Fluorescent 
micrographs and brightfield overlay images clearly displayed ES/TRAIL liposomes 
adhered to the surface of COLO 205 cells (Figure 7.4C,D). These data suggest that the 
presence of the ES adhesion receptor enhances the effect of TRAIL by promoting 
tighter contacts with the cancer cell membrane. 
 
ES/TRAIL liposomes functionalize leukocytes in whole blood under shear flow in vitro 
  
In addition to CTCs, circulating leukocytes also possess ligands for E-selectin, 
which are necessary in the inflammatory response and lymphocyte homing to 
lymphatic tissues [1,176]. To assess the potential to functionalize leukocytes with 
ES/TRAIL to target and kill CTC, we treated whole human blood with fluorescent 
ES/TRAIL liposomes under shear flow in a cone-and-plate viscometer. Upon exposure 
to shear (shear rate: 188 s-1), ES/TRAIL liposomes readily bind to leukocytes via 
selectin ligands on the leukocyte surface (Figure 7.5A). 
To quantify leukocyte subpopulations that adhere to ES/TRAIL liposomes 
under flow, leukocytes were separated from whole blood and analyzed for both 
leukocyte marker expression and adherent ES/TRAIL liposomes using flow 
cytometry. Functionalized leukocytes were labeled with CD3, CD14, CD16, CD19, 
and CD56 antibodies, as such markers are commonly expressed on most T-
lymphocytes, monocytes, neutrophils, B-lymphocytes, and natural killer (NK) cells, 
respectively [409]. Minimal adhesion of ES/TRAIL liposomes to leukocytes in blood 
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was observed in the presence of a functional blocking ES antibody (Figure 7.5B-G). 
Minimal ES/TRAIL liposome adhesion was also observed immediately after treatment 
with whole blood. However, after exposure to shear flow, flow cytometry analysis 
revealed that leukocyte subpopulations positive for CD3 (Figure 7.5B), CD14 (Figure 
7.5C), CD16 (Figure 7.5D), CD19 (Figure 7.5E), and CD56 (Figure 7.5F) adhered to 
ES/TRAIL liposomes to varying degrees (Figure 7.5G). Adhesion was also observed 
on populations of lymphocytes, which suggests that some cytotoxic patrolling of the 
lymphatic system may also occur in vivo. Leukocyte subpopulations can vary in their 
E-selectin ligand expression [410] and thus could explain the variations in the number 
of bound ES/TRAIL liposomes.  
 
ES/TRAIL functionalization does not induce significant leukocyte or endothelial cell 
death 
 
To assess the effects of ES/TRAIL functionalization on leukocyte viability, 
mononuclear leukocytes isolated from human blood were treated with ES/TRAIL 
liposomes under both static and shear flow conditions. Annexin-V assays revealed no 
significant differences in leukocyte viability when leukocytes were incubated with ES 
(Figure 7.6B) or ES/TRAIL (Figure 7.6C) liposomes under static conditions for 24 h, 
compared to untreated leukocyte controls (Figure 7.6A,D). Upon functionalization 
with liposomes under shear flow for 2 h (shear rate: 188 s-1), no significant decreases 
were found in ES (Figure 7.6F) or ES/TRAIL (Figure 7.6G) functionalized leukocytes, 
compared to untreated leukocyte controls (Figure 7.6E,H). Our data suggest that 
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ES/TRAIL liposomes can functionalize leukocytes under flow to target and kill cancer 
cells, while exerting negligible cytotoxic effects on leukocytes. It is important to note 
that individual subpopulations of leukocytes have shown apoptotic effects in the 
presence of TRAIL [411], however this study focused on the overall effects of 
ES/TRAIL liposomes on bloodborne leukocytes. 
To assess the effects of ES/TRAIL functionalization on endothelial cell 
viability, human umbilical vein endothelial cells (HUVEC) were treated with 
ES/TRAIL liposomes in human blood under shear flow conditions in vitro. Treatment 
with ES/TRAIL liposomes or an equivalent concentration of soluble TRAIL in human 
blood under shear flow for 4 h induced no significant differences in HUVEC viability, 
compared to untreated HUVEC exposed to shear in human blood (Figure 7.7). Our 
data suggest that ES/TRAIL-functionalized leukocytes exert negligible toxic effects on 
human endothelial cells under blood flow conditions. 
 
Apoptotic effects of ES/TRAIL therapy are enhanced in human blood under flow 
 
Clinically, CTCs are sparsely distributed in the complex milieu of whole 
blood, at concentrations as low as 1-100 cells/mL [42,238]. To examine whether 
ES/TRAIL liposomes would effectively target cancer cells in the presence of blood 
cells and serum under flow conditions, we fluorescently labeled colorectal COLO 205 
and prostate PC-3 cancer cell lines and spiked them into human peripheral blood. 
Surprisingly, under identical shear flow conditions ES/TRAIL therapy was even more 
effective at killing cancer cells in the presence of human blood (Figure 7.8A–D), 
 253 
compared to shearing COLO 205 or PC-3 cells alone in buffer (Figure 7.8E), with 
<5% of the fluorescent, viable cancer cell populations remaining after ES/TRAIL 
treatment (Figure 7.8E). These results suggest that ES/TRAIL therapy is effective at 
targeting circulating cancer cells derived from multiple organs in human blood.  
To evaluate the impact of blood cells on the efficacy of ES/TRAIL treatment, 
fluorescent COLO 205 and PC-3 cells were spiked in human blood of varying 
hematocrit percentages. All additional blood cell components were maintained, while 
the volume of removed erythrocytes was replaced with plasma from the same blood 
donor. Interestingly, the apoptotic effects were hematocrit-dependent, as higher 
hematocrit significantly decreased the number of viable COLO 205 and PC-3 cells 
after ES/TRAIL treatment (Figure 7.8F). The enhanced apoptotic effect suggests that 
blood cell collisions under flow can promote the apoptotic effects of ES/TRAIL 
liposomes and agrees with our intuitive understanding of blood rheology, as the 
presence of erythrocytes is known to create erratic cell paths with frequent cross-
streamline displacements [412] and increase the lifetime of colliding doublets to 
promote aggregate formation [413]. 
To assess the mechanism by which leukocytes act as a pervading carrier 
surface for functional TRAIL, blood was pretreated with ES/TRAIL liposomes under 
shear flow, with blood cells subsequently separated from unbound ES/TRAIL via 
centrifugation and replaced with fresh blood plasma. ES/TRAIL therapeutic effects 
under shear flow remained nearly identical, as COLO 205 and PC-3 cells spiked into a 
suspension of blood with washed, pretreated blood cells were killed at roughly the 
same rate as unwashed blood (Figure 7.9A-C). Thus, upon addition of the ES/TRAIL 
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liposomes to cancer cell-spiked blood, liposomes attach to the surface of leukocytes, 
and are available for inducing apoptosis in cancer cells that they come into contact 
with (Figure 7.9D,E). As an indicator of unbound ES/TRAIL liposomes and/or 
liposome fragments remaining in human blood after shearing pretreatment, the toxicity 
of supernatant collected from pretreated blood was tested in COLO 205 culture. An 
Annexin-V assay showed minimal COLO 205 cell death after treatment with a 
supernatant of human plasma and unbound ES/TRAIL, compared to cells treated with 
plasma supernatant alone (Figure 7.10). These data suggest that ES/TRAIL liposomes 
readily bind to the surface of leukocytes, with minimal unbound liposomes remaining, 
to target and kill cancer cells under flow. 
 
ES/TRAIL functionalized leukocytes reduce number of viable cancer cells in mouse 
circulation in vivo 
 
To assess and compare the cytotoxic effects in vivo to our previous results in 
vitro, ES/TRAIL liposomes were also tested for their ability to kill cancer cells 
flowing in the peripheral circulation of mice. Two million fluorescently labeled COLO 
205 cells were injected into the tail vein of immunocompetent C57BL/6J mice, 30 min 
after injection of 120 µL of either ES/TRAIL liposomes, ES liposomes, or soluble 
TRAIL (Figure 7.11A).  Tail vein injection was utilized to model leukocyte/CTC 
interactions in mouse circulation, as this technique has been an accepted and widely 
used model of lung metastasis [239-242] since the pioneering work of Fidler et al. 
[243-245]. For these studies, the use of recombinant human E-selectin was continued 
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because of its ability to bind both human COLO 205 cancer cells and mouse 
neutrophils, which were previously shown to have cross reactivity and roll on E-
selectin [414]. Mice were sacrificed 2.5 h after the initial injection, and cancer cells 
were recovered from the circulation via cardiac puncture. Cancer cells were placed 
back into culture for 2-3 h before the number of viable cells were quantified.  
Using flow cytometry, we measured ~130,000 cancer cells/mL blood for mice 
injected with control ES liposomes, compared to <2,000 cancer cells/mL blood 
surviving from ES/TRAIL treated mice (Figure 7.11B,C). Mice injected with buffer or 
soluble TRAIL had intermediate numbers of cells (Figure 7.11C) compared to ES and 
ES/TRAIL-treated samples, likely indicating that ES functionalized liposomes help to 
retain cancer cells in the circulation by blocking selectin-mediated interaction of the 
COLO 205 cells with the endothelium. Brightfield micrographs of COLO 205 cells 
exposed to buffer and soluble TRAIL showed characteristic cancer cell morphology 
(Figure 7.11D).  Micrographs of COLO 205 cells exposed to ES revealed adherent 
leukocytes on the COLO 205 cell surface without significant morphological change, 
while, whereas the cancer cells from ES/TRAIL-treated mice showed notable 
membrane blebbing of COLO 205 cells in the proximity of leukocytes (Figure 7.11D). 
To assess the adhesion of ES/TRAIL liposomes to leukocytes in mouse circulation, 
mice were injected with ES/TRAIL liposomes tagged with fluorescent cholesterol, and 
were allowed to circulate for 2.5 h. Brightfield overlay micrographs showed that 
leukocytes recovered from the mouse circulation were functionalized with ES/TRAIL 
liposomes (Figure 7.11E), suggesting that ES/TRAIL remains functionalized to 
leukocytes, which can exert cytotoxic effects onto cancer cells in mouse circulation. 
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ES/TRAIL treatment reduces number and increases apoptosis of remaining circulating 
COLO 205 cells lodged in vivo in mouse lung 
 
Previous studies have shown that more than 90% of tumor cells that enter the 
vasculature via tail vein injection lodge into lung vasculature within the first two hours 
[415]. To assess the viability of the remaining circulating cancer cells lodged within 
mice, fluorescent COLO 205 cells lodged within the lungs of mice were identified 
using two-photon excited fluorescence microscopy (Figure 7.12A,B). Immediately 
following euthanasia, the lungs were resected, and two-photon images were acquired 
in three regions of the lung that were identical for each animal, to obtain an accurate 
estimate of cell counts (Figure 7.12A).  Roughly twice as many cells were found in the 
ES, sTRAIL, and buffer treated animals as the ES/TRAIL treated animals (Figure 
7.12C), suggesting many COLO 205 cells had already died and degenerated. The 
cancer cell density found in lung suggests about 1.4 million cancer cells were lodged 
in the lung for buffer treated animals (assuming a lung volume of ~0.4 mL), 
representing the bulk of the two million COLO 205 cells injected. 
We then evaluated the apoptotic effects of ES/TRAIL liposomes on cancer 
cells that have already lodged into the lungs of mice. After the injections of liposomes 
and COLO 205 at previously used time points (Figure 7.12A), we injected a solution 
of Annexin-V tagged with a fluorescent Alexa 594 dye to assess for 
phosphatidylserine flipping on the COLO 205 cell membrane, characteristic of 
apoptosis. Mouse lungs were imaged using two-photon microscopy to determine 
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whether Hoescht-labeled COLO 205 cells were also positive for Annexin-V labeling. 
In addition to the decreased density of cancer cells lodged in mouse lung (Figure 
7.12C), we also found a dramatic increase in apoptosis of the cancer cells (Figure 
7.12B,D) in the ES/TRAIL liposome treated mice as compared with other groups. 
Soluble TRAIL protein injected into mice following the same protocol displayed 
minimal cytotoxic activity comparable to control, as expected due to its short 
circulation half-life [416]. Mice injected with ES/TRAIL liposomes survived for over 
two weeks with no loss in body weight (n = 3). These data suggests that ES/TRAIL 
treatment serves to decrease the number of remaining circulating COLO 205 cells 
lodged in mouse lung, while increasing the fraction of them that are apoptotic. 
 
7.4 DISCUSSION 
 
Natural killer cells, activated by interleukin-2 or other factors, are induced to 
present TRAIL protein on their surface. These cells participate in immunosurveillance 
against micrometastases in the body, and comprise 10-20% of peripheral blood 
mononuclear cells [417,418]. While the liposome-coated leukocytes described here are 
not specifically programmed to actively invade tissues and seek out solid tumors, they 
do have frequent opportunities for incidental contact with CTCs in the bloodstream. 
Interestingly, infiltration of neutrophils and macrophages throughout the interior of 
solid tumor masses has been found in dynamic, self-seeding tumors, suggesting that 
some degree of homing of normally-functioning leukocytes to solid tumors could be 
expected [419,420]. I find that TRAIL is most potent when in its natural state – 
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tethered to the surface of leukocytes in shear flow – rather than freely soluble or on 
untethered liposomes in the absence of blood. Tethering nanoscale liposomes to the 
surface of peripheral blood leukocytes is also beneficial for increasing liposome 
circulation time, by avoiding renal clearance mechanisms. 
So why do leukocytes coated with ES/TRAIL liposomes have much higher 
cytotoxic activity in shear flow, compared to isolated ES/TRAIL liposomes or soluble 
TRAIL protein? The answer may lie in the compressive force between surfaces. Two 
spherical particles colliding in linear shear flow will experience a compressive force 
between them which scales as Fc ~ µ*G*a*b, where µ is the fluid viscosity, G is the 
shear rate, and a and b are the radii of the smaller and larger sphere, respectively 
[421]. Thus, a 10 µm diameter leukocyte colliding with a cancer cell will experience 
100 times the compressive force of a 100 nm liposome colliding with a cancer cell. 
Compressive forces act to flatten down any cell surface glycocalyx composed of 
biologically inert macromolecules, thus allowing TRAIL to come within a reactive 
distance to the cancer cell death receptors and form bonds. The physics of force-
induced flattening and penetration of cell glycocalyx to facilitate surface receptor 
binding to ligands on an opposing cell surface has been analyzed in the context of 
leukocyte adhesion to the vascular endothelium [422,423]. 
Recombinant human TRAIL/Apo2L, also known as PRO1762 developed by 
Amgen/Genentech, has been the subject of numerous Phase 1, 1a, 2, and 3 clinical 
trials over the past decade, with minimal adverse effects reported [247,248]. There are 
many intracellular proteins, such the inhibitors of apoptosis protein (IAPs) family 
members that also confer TRAIL resistance to normal cells [236]. Additionally, the 
 259 
dosages of TRAIL used in this current study ranged from 0.06 – 0.08 mg/kg, two 
orders of magnitude lower than the clinical dosages of 1 – 30 mg/kg used in human 
clinical trials. While different types of cancer cells show different levels of sensitivity 
to TRAIL-induced apoptosis, it has been well documented that there is a wide range of 
agents known to sensitize cancer cells to TRAIL-mediated apoptosis, including 
conventional chemotherapeutics (camptothecin, cisplatin, doxorubicin, 5-fluorouracil, 
irinotecan, paclitaxel, gemcitabine), proteasome inhibitors, Bcl-2 inhibitors, IAP 
antagonists, HDAC inhibitors, CD20 antibodies, irradiation, synthetic triterpenolds, 
Sorafenib, aspirin, and natural products such as curcumin and piperlongumine [232]. 
What remains to be seen is whether ES/TRAIL liposomes can successfully 
prevent the formation of metastatic tumors; future work should focus on addressing 
this question. Additionally, human hepatocytes have shown sensitivity to TRAIL 
[424], though ES/TRAIL liposome adhesion to the leukocyte surface could reduce 
TRAIL uptake by the reticulo-endothelial system in the liver. The present study, 
however, represents an important first step towards the targeting of CTCs in the 
bloodstream as a means to prevent cancer metastasis. Clinically, for instance, one 
could envision using these liposomes as a preventive measure upon diagnosis of 
highly metastatic hematogenous cancers such as those originating in breast, prostate, 
and lung. 
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FIGURE 7.1: ES/TRAIL LIPOSOMES ADHESIVELY INTERACT WITH AND 
KILL CANCER CELLS UNDER UNIFORM SHEAR FLOW. (A) Synthesis of 
ES, TRAIL, and ES/TRAIL unilamellar liposomes using a thin film hydration method. 
Briefly, lipids in chloroform were dried overnight to form a thin lipid film. Lipids 
were then hydrated and subjected to freeze-thaw cycles to form multilamellar 
liposomes, which were extruded through membranes to form unilamellar liposomes. 
ES, TRAIL, or a combination of ES and TRAIL were then conjugated to Ni-NTA on 
the liposome surface. To assess the ability of ES/TRAIL liposomes to target and kill 
cancer cells under flow, ES/TRAIL liposomes were added to a suspension of COLO 
205 cancer cells and exposed to shear flow in a cone-and-plate viscometer at a shear 
rate of 188 s-1 for 2 h. Cells were then removed, washed, placed into culture for 24 h, 
and assessed for cell viability. (B) COLO 205 morphology after treatment with ES 
(top) and ES/TRAIL (bottom) liposomes under shear flow. Scale bar = 20 µm. (C-G) 
Representative propidium iodide/Annexin-V flow cytometry plots of unsheared cancer 
cells (C) and cells sheared with naked (D), TRAIL-bound (E), ES-bound (F), and 
ES/TRAIL-bound liposomes (G) under shear flow. Cells were classified into four 
categories based on dye uptake: viable cells (negative for Annexin-V and propidium 
iodide (PI)), early apoptotic cells (positive for Annexin-V only), late apoptotic cells 
(positive for Annexin-V and PI) and necrotic cells (positive for PI only). (H) Percent 
of viable cells after treatment for each group. n = 3 for all samples. Bars represent the 
mean ± SD in each treatment group. ***P <0.0001 (one-way ANOVA with Tukey 
post test). 
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FIGURE 7.1: ES/TRAIL LIPOSOMES ADHESIVELY INTERACT WITH AND 
KILL CANCER CELLS UNDER UNIFORM SHEAR FLOW.  
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FIGURE 7.2: INCORPORATION OF NI-NTA CONJUGATED LIPIDS ON 
LIPOSOMES MAXIMIZES PROTEIN CONJUGATION TO THE LIPOSOME 
SURFACE. To determine how much Ni-NTA conjugated lipid is required to bind 
TRAIL and ES to the liposome surface, COLO 205 cells were incubated with 
supernatant left after liposome preparation and assayed for cell viability. Increased cell 
death is indicative of more unbound TRAIL protein in solution. (A-D) Annexin-V 
apoptosis assay of COLO 205 cell viability after incubation with supernatant of 
liposomes conjugated to 0% (A), 1% (B), 5% (C), and 10% Ni-NTA (D) post-
ultracentrifugation, with varying amounts of Ni-NTA conjugated to the liposome 
surface. Cells were classified into four categories based on dye uptake: viable cells 
(negative for Annexin-V and propidium iodide (PI)), early apoptotic cells (positive for 
Annexin-V only), late apoptotic cells (positive for Annexin-V and PI) and necrotic 
cells (positive for PI only). (E) COLO 205 cell viability after treatment with unbound 
TRAIL and ES in liposome supernatant. n = 3 for all samples. Bars represent the mean 
± SD in each treatment group. (F) Representative micrographs of untreated COLO 205 
cells (top) and those treated with the supernatant of liposomes conjugated to 0% 
(middle) and 10% Ni-NTA (bottom). 10% Ni-NTA conjugated lipid on the liposome 
leads to nearly complete incorporation onto the liposome surface. Scale bar = 50 µm. 
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FIGURE 7.2: INCORPORATION OF NI-NTA CONJUGATED LIPIDS ON 
LIPOSOMES MAXIMIZES PROTEIN CONJUGATION TO THE LIPOSOME 
SURFACE.  
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TABLE 7.1: WEIGHT RATIOS OF LIPOSOME FORMULATIONS. With 
increasing amounts of Ni-NTA conjugated lipid, the corresponding amount of Egg PC 
lipid was decreased. 
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FIGURE 7.3: ES/TRAIL LIPOSOMES ARE SOMEWHAT EFFECTIVE IN 
TARGETING AND KILLING COLO 205 CELLS UNDER STATIC 
CONDITIONS. (A-D) Annexin-V apoptosis plots of COLO 205 cells treated with 
ES/TRAIL liposomes consisting of 0% (A), 1% (B), 5% (C), and 10% Ni-NTA (D) 
for 24 h. (E) Representative micrographs showing COLO 205 cells after 24 h 
incubation with liposomes. Scale bar = 50 µm. (F) COLO 205 cell viability following 
incubation with liposomes with varying amounts of Ni-NTA on the liposome surface. 
n = 3 for all samples. Bars represent the mean ± SEM in each treatment group. 
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FIGURE 7.4: ES/TRAIL LIPOSOMES ADHESIVELY INTERACT WITH 
CANCER CELLS. (A) Flow cytometry plots of cancer cells positive for 
fluorescently tagged ES/TRAIL liposomes (green). Grey population represents 
fluorescence of COLO 205 cells in the absence of fluorescent ES/TRAIL liposomes. 
(B) Percent of COLO 205 cells adhered to liposomes following shear flow at a shear 
rate of 188s-1. n = 3 for all samples. Bars represent the mean ± SEM in each treatment 
group. (C,D) Representative fluorescent (left) and brightfield overlay (right) 
micrographs of COLO 205 cells adhered to fluorescently tagged liposomes following 
shear flow. Scale bar = 20 µm.  
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FIGURE 7.5: ES/TRAIL LIPOSOMES ADHERE TO MULTIPLE 
LEUKOCYTE SUBPOPULATIONS AFTER EXPOSURE TO SHEAR FLOW 
IN WHOLE BLOOD. (A) Confocal images of ES/TRAIL liposomes (green) bound 
to human leukocytes (blue = cell nuclei) after exposure to shear flow in whole blood 
in a cone-and-plate viscometer at 188 s-1 for 30 min. Leukocytes have nuclear 
morphology characteristic of monocytes (left), lymphocytes (middle), and neutrophils 
(right). Scale bar  = 5 µm. (B-G) To assess which leukocyte subpopulations 
ES/TRAIL liposomes adhesively interact with, fluorescent ES/TRAIL liposomes were 
added to human blood and exposed to shear flow in a cone-and-plate viscometer at a 
shear rate of 188 s-1 for 30 min. Leukocytes were isolated from blood using a 
Polymorphs density gradient, and labeled with CD3, CD14, CD16, CD19, and CD56, 
which is typically expressed on T-lymphocytes, monocytes, neutrophils, B-
lymphocytes, and natural killer cells, respectively. Expression of fluorescent 
ES/TRAIL (FL ES/TRAIL) liposomes on the surface of leukocytes that are CD3+ (B), 
CD14+ (C), CD16+ (D), CD19+ (E), and CD56+ (F), determined using flow 
cytometry. Expression of CD3, CD14, CD16, CD19, and CD56 on the leukocyte 
surface was determined using isotype controls. No label: unsheared cells that were not 
treated with fluorescent ES/TRAIL liposomes. ES block: cells treated with fluorescent 
ES/TRAIL liposomes that were pretreated with an ES functional blocking antibody. 
Post-mix: cells labeled with fluorescent ES/TRAIL liposomes immediately after 
mixing liposomes in whole blood.  (G) Percent of CD3+, CD14+, CD16+, CD19+, 
and CD56+ leukocytes adhered to ES/TRAIL liposomes. n = 3 for all samples. Bars 
represent the mean ± SD in each treatment group. ***P <0.0001 (one-way ANOVA 
with Tukey post test). 
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FIGURE 7.5: ES/TRAIL LIPOSOMES ADHERE TO MULTIPLE 
LEUKOCYTE SUBPOPULATIONS AFTER EXPOSURE TO SHEAR FLOW 
IN WHOLE BLOOD.  
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FIGURE 7.6: LEUKOCYTE FUNCTIONALIZATION WITH ES/TRAIL DOES 
NOT INDUCE SIGNIFICANT LEUKOCYTE DEATH. (A-C) Representative 
propidium iodide/Annexin-V flow cytometry plots of untreated mononuclear cells (A) 
and those treated with ES (B) and ES/TRAIL (C) liposomes under static conditions for 
24 h. (D) Viability of mononuclear cells following incubation with liposomes for 24 h. 
n = 3 for all samples. Bars represent the mean ± SEM in each treatment group. NS: not 
significant (one-way ANOVA with Tukey post test). (E-G) Representative propidium 
iodide/Annexin-V flow cytometry plots of untreated mononuclear cells (E) and those 
treated with ES (F) and ES/TRAIL (G) liposomes under shear flow (shear rate: 188 s-
1) for 2 h.  (H) Viability of MNCs treated with liposomes under shear flow for 2 h. n = 
3 for all samples. Bars represent the mean ± SD in each treatment group. NS: not 
significant (one-way ANOVA with Tukey post test). 
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FIGURE 7.7: LEUKOCYTE FUNCTIONALIZATION WITH ES/TRAIL DOES 
NOT INDUCE SIGNIFICANT ENDOTHELIAL CELL DEATH. (A) 
Representative images of HUVECs immobilized on coverslips immediately after 
treatment in human blood, with various drug treatments, under shear flow (shear rate: 
188 s-1) for 4 h at 37°C. Scale bar = 100 µm. (B-D) Representative propidium 
iodide/Annexin-V flow cytometry plots of untreated HUVECs (B) and those treated 
with ES/TRAIL (C; TRAIL concentration: 0.3 µg/mL) or soluble TRAIL (D; TRAIL 
concentration: 0.3 µg/mL) in human blood under shear flow for 4 h at 37°C. (E) As a 
positive control, HUVECs were treated with a high dosage of TRAIL (15 µg/mL) in 
human blood under shear flow for 4 h at 37°C. HUVECs were classified into four 
categories based on dye uptake: viable cells (negative for Annexin-V and propidium 
iodide (PI)), early apoptotic cells (positive for Annexin-V only), late apoptotic cells 
(positive for Annexin-V and PI) and necrotic cells (positive for PI only). (F) Percent 
viability of HUVECs after various drug treatments in human blood under shear flow 
for 4 h at 37°C. n = 3 for all samples. Bars represent the mean ± SD in each treatment 
group. **P <0.001.  NS: not significant (one-way ANOVA with Tukey post test). 
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FIGURE 7.7: LEUKOCYTE FUNCTIONALIZATION WITH ES/TRAIL DOES 
NOT INDUCE SIGNIFICANT ENDOTHELIAL CELL DEATH.  
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FIGURE 7.8: ES/TRAIL LIPOSOME THERAPEUTIC EFFECTS ARE 
ENHANCED IN HUMAN BLOOD UNDER FLOW IN VITRO. (A) Flow 
cytometry of COLO 205 cancer cells after treatment with ES/TRAIL or ES liposomes 
in blood under shear flow in a cone-and-plate viscometer at 188 s-1 for 2 h. Unsheared: 
viable untreated cancer cell control. (B) Representative flow cytometry histogram 
showing the number of viable cancer cells collected. (C) Representative micrographs 
of COLO 205 cells (white) in blood when treated with ES/TRAIL (left) and ES only 
(right) liposomes in blood under shear flow. Scale bar = 50 µm. (D) Number of viable 
COLO 205 and PC-3 cells per volume of blood after treatment with ES/TRAIL or ES 
liposomes in blood under shear flow. n = 3 for all samples. Bars represent the mean ± 
SD in each treatment group. **P <0.001, ***P <0.0001 (unpaired t-test). (E) 
Comparison of fraction of COLO 205 and PC-3 cells that remained viable after 
treatment with ES/TRAIL liposomes in buffer versus blood. n = 3 for all samples. 
Bars represent the mean ± SD in each treatment group. ***P <0.0001 (unpaired t-test). 
(F) Fraction of COLO 205 and PC-3 cells that remained viable after treatment with 
ES/TRAIL liposomes in blood with varying percentages of normal hematocrit. 
Hematocrit was varied while other blood components remained constant, based on a 
normal hematocrit of 45%. Plasma indicates removal of all blood cells. n = 3 for all 
samples. Bars represent the mean ± SD in each treatment group. *P <0.05 (one-way 
ANOVA with Tukey post test). 
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FIGURE 7.8: ES/TRAIL LIPOSOME THERAPEUTIC EFFECTS ARE 
ENHANCED IN HUMAN BLOOD UNDER FLOW IN VITRO.  
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FIGURE 7.9: ES/TRAIL LIPOSOMES FUNCTIONALIZE LEUKOCYTES 
UNDER SHEAR FLOW IN VITRO TO TARGET AND KILL CANCER 
CELLS. (A) Flow cytometry plots of COLO 205 cells in untreated samples (left) and 
when treated in human blood with ES (middle) or ES/TRAIL (right) functionalized 
leukocytes (but no unbound liposomes) under shear flow. (B,C) Number of viable 
COLO 205 (B) and PC-3 (C) cells per volume of blood after treatment with leukocytes 
functionalized with ES/TRAIL or ES liposomes, but with no unbound liposomes, in 
human blood (Washed), or after treatment with ES or ES/TRAIL liposomes in blood 
(Unwashed). n = 3 for all samples. Bars represent the mean ± SD in each treatment 
group. **P <0.001, ***P <0.0001 (unpaired t-test). (D,E) Schematic of the two-step 
mechanism involving decoration of leukocytes with liposomes (D), which then contact 
circulating cancer cells and activate the death receptor (E).  
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FIGURE 7.9: ES/TRAIL LIPOSOMES FUNCTIONALIZE LEUKOCYTES 
UNDER SHEAR FLOW IN VITRO TO TARGET AND KILL CANCER 
CELLS.  
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FIGURE 7.10: LOW TOXICITY OF BLOOD PLASMA AFTER TREATMENT 
WITH ES/TRAIL LIPOSOMES.  (A) Viability of COLO 205 cells after treatment 
with plasma from normal healthy blood for 24 h. (B) Viability of COLO 205 cells 
after treatment with plasma extracted from blood that had been sheared with 
ES/TRAIL liposomes for 30 min. Cells were incubated with plasma and any 
remaining unbound ES/TRAIL liposomes and/or liposome fragments in the plasma for 
24 h, and analyzed for cell viability. 
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FIGURE 7.11: ES/TRAIL FUNCTIONALIZED LEUKOCYTES TARGET AND 
KILL CANCER CELLS IN THE CIRCULATION OF MICE IN VIVO.  (A) 
Schematic of in vivo mouse experiment. (B) Flow cytometry of untreated COLO 205 
cancer cells (left) and those recovered from cardiac puncture from mice treated with 
ES (middle) and ES/TRAIL liposomes (right). (C) Number of viable cancer cells 
recovered per volume of mouse blood for mice treated with ES/TRAIL liposomes, 
soluble TRAIL (sTRAIL), ES liposomes, and buffer injections. n = 3 for all samples. 
Bars represent the mean ± SD in each treatment group. *P <0.01, **P <0.001, ***P 
<0.0001 (one-way ANOVA with Tukey post test). (D) Representative micrographs of 
COLO 205 cells removed from circulation in mice treated with ES/TRAIL liposomes 
(top left), sTRAIL (top right), ES liposomes (bottom left), and buffer (bottom right) 
injections. Scale bar = 20 µm. (E) Leukocytes functionalized with fluorescent 
ES/TRAIL liposomes (green) upon removal from mouse circulation 2.5 h after 
injection. Scale bar = 50 µm. 
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FIGURE 7.11: ES/TRAIL FUNCTIONALIZED LEUKOCYTES TARGET AND 
KILL CANCER CELLS IN THE CIRCULATION OF MICE IN VIVO.  
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FIGURE 7.12: DECREASED NUMBER AND INCREASED APOPTOSIS IN 
COLO 205 CELLS LODGED IN MOUSE LUNG AFTER TREATMENT WITH 
ES/TRAIL LIPOSOMES. (A) Schematic of mouse lung and example two-photon 
excited fluorescence (2PEF) image stack from mouse lung where Hoechst-labeled 
COLO 205 cells (green) are arrested in lung tissue (visible by autofluorescence, 
yellow). Scale bar = 80 µm. (B) 2PEF images of Hoescht-labeled COLO 205 cells 
(green) with Alexa Flour 568 labeled Annexin V apoptosis probe (red) for each 
experimental group. Red arrows point to apoptotic COLO 205 cells (red and green 
colocalized), blue arrows indicate non-apoptotic COLO 205 cells (green only). White 
circles indicate regions of autofluorescence from lung tissue. Scale bar = 30 µm. (C) 
Density of COLO 205 cells lodged in the lung for each experimental group. (D) 
Percentage of lodged COLO 205 cells positive for Annexin-V probe for each 
experimental group. Individual data points represent data from one image stack, with 
points shown in the same color representing image stacks from the same animal. 
Superimposed box plots bound the 25th to 75th percentage of all data points and the 
whiskers extend 1.5 times the interquartile range beyond the boxes. The horizontal 
lines within the boxplot represent the median. n = 3 animals for each experimental 
group. *P <0.01, **P <0.0001  (one-way ANOVA with Tukey post test). 
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FIGURE 7.12: DECREASED NUMBER AND INCREASED APOPTOSIS IN 
COLO 205 CELLS LODGED IN MOUSE LUNG AFTER TREATMENT WITH 
ES/TRAIL LIPOSOMES. 
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CHAPTER 8: AN NSF GK-12 EXPERIENCE. FABRICATION OF JELL-O 
MILLI-FLUIDIC CHIPS FOR INQUIRY-BASED EDUCATION OF 
HEMODYNAMICS AND BLOOD CELL ADHESION 
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8.1 INTRODUCTION AND SCIENCE CONTENT FOR TEACHERS 
 
The forces generated by blood flow in small blood vessels known as post-
capillary venules play a crucial role in the adhesion of a variety of types of circulating 
cells to the blood vessel wall. The adhesion of blood cells to the blood vessel walls 
(known as the endothelium) play a critical role in how the human body responds to 
infection (known as inflammation), and also the process which causes bleeding to stop 
(known as hemostasis). While blood cell adhesion is important physiologically, it can 
also promote the progression of various human diseases, including arthritis, 
thrombosis, and cancer. 
One class of white blood cells, known as neutrophils, can adhere to blood 
vessel walls under inflammatory conditions, and can act as “first-responders” in 
fighting off infection. Under normal conditions, neutrophils can freely circulate 
throughout the bloodstream. However, in the case of inflammation, neutrophils can 
adhere to the blood vessel wall via receptor-ligand interactions (Figure 1.6B). During 
inflammation, endothelial cells will express adhesion receptors on their surface, one of 
which is E-selectin. Neutrophils possess ligands for E-selectin, which allow them to 
form bonds with the endothelial cells that make up the blood vessel wall. The bonds 
that neutrophils initially form with the blood vessel have rapid, force-dependent 
binding kinetics. These bonds are short lived however, as neutrophils eventually 
detach from these bonds, while forming new selectin-mediated bonds with E-selectin 
receptors further downstream. This process is known as cell rolling adhesion. Rolling 
adhesion of neutrophils can continue on the endothelial cell wall until they come into 
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contact with intercellular adhesion molecule-1 (ICAM-1), which allows the neutrophil 
to become firmly adhered to the cell wall via adhesion molecules known as integrins. 
Once firmly adhered, neutrophils can “squeeze” through the vessel wall, and migrate 
to the site of infection to engulf and kill bacteria. 
Conversely, a similar process is also used in the spread of cancer throughout 
the body, known as metastasis. Metastasis, the spread of cancer cells from a primary 
tumor to a secondary site, is the cause of over 90% of cancer related deaths. When 
cancer cells remain within the primary tumor, the tumor is typically treatable via 
surgery. However, tumor cells can migrate from the primary tumor into the 
bloodstream in a process called intravasation, and circulate through the bloodstream as 
circulating tumor cells (CTCs). Once in the bloodstream, CTCs can adhere to blood 
vessels in different organs of the body, in a manner very similar to white blood cells 
(Figure 1.6B). CTCs can also express selectin ligands, which allow CTCs to roll and 
subsequently adhere to the blood vessel wall. From there, tumor cells can migrate to 
different parts of the body to form secondary tumors. This process leads to a poor 
patient prognosis, as new tumors (known as micrometastases) are very small and hard 
to detect in time to develop effective treatments for the patient. 
Advances in microfluidics have allowed for the development of devices that 
can recreate the complex microenvironment of the bloodstream. In particular, our lab 
has recently developed microscale flow devices that mimic postcapillary venules to 
study the basic mechanisms of cancer metastasis [391] and inflammation [390,425]. 
Such devices have also been adapted to kill cancer cells in the bloodstream [82], and 
isolate circulating tumor cells from patient blood [336]. As the clinical benefits of 
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microfluidics are becoming apparent, it is essential to educate young students on basic 
fluidic principles and their potential impact on human disease diagnosis and treatment. 
A simple fabrication technique was demonstrated using Jell-O to teach high school 
students the essential components of blood flow, and its subsequent effects on cell 
adhesion in inflammation and cancer. 
 
8.2 MATERIALS AND METHODS 
 
Model milli-fluidic devices were fabricated using a soft lithography technique 
consisting of foam plates, coffee stirrers, single- and double-sided tape, and Jell-O. 
Briefly, coffee stirrers were cut, connected, and arranged in various formations and 
adhered to foam plates using double-sided tape. Single-sided tape was placed on top of 
the coffee stirrers to create a smooth surface. A Jell-O liquid was prepared as per 
manufacturer’s instructions, poured onto molds, and left to cure inside a refrigerator 
for 2 days. Jell-O chips were then peeled from molds and placed onto aluminum 
plates. Inlets and outlets were created within the chips, and liquid was perfused 
through the device using disposable transfer pipets. For model blood cell adhesion 
experiments, glass slides were incubated with a solution of 2:8 (0.02 wt%) poly-l-
lysine (Sigma-Aldrich) for 10 mins prior to placing chips onto glass slides. As a model 
of cell adhesion, a 1:10 dilution in distilled water of the original negatively charged, 
90 µm polymeric microspheres solution (Polysciences, Cat # 07315) was perfused 
through the device, and were allowed to adhere to the positively charged poly-l-lysine 
functionalized surface. 
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8.3 CLASSROOM PROCEDURE 
 
Day 1 
 
Students will begin the fabrication their own Jell-O devices in what will be a 
two-day process (Figure 8.1, Figure 8.2). Initially, students will have to use a foam 
plate and coffee stirrers to create their own model of a microfluidic network. To make 
the “negative mold”, students can cut, connect, and shape coffee stirrers, which they 
can then adhere to the foam plate using double-sided tape. To smooth the top surface 
of the stirrer, students can use single-sided tape on the top surfaces of the adhered 
stirrers (Figure 8.1). Students can be encouraged to make sure that all stirrer junctions 
are smooth, to facilitate fluid flow in later portions of the experiment. The negative 
mold can then be sprayed with cooking oil, to allow the Jell-O mold to be easily 
removed from the negative mold. 
Once the negative mold is complete, students can then mix together Jell-O 
powder and gelatin together in hot water, as directed in the Jell-O manufacturer’s 
instructions (NOTE: Jell-O mixture should be mixed with half the amount of liquid 
recommended by the manufacturer, in order to make a stable Jell-O mold). Students 
should be careful to pour the hot Jell-O mixture over the mold, to ensure that there are 
minimal air bubbles, while also ensuring that the coffee stirrers remain adhered to the 
foam plate. Teachers can then place the Jell-O devices in a refrigerator overnight to 
allow the molds to form (NOTE: for optional day 3 activity, extra Jell-O molds should 
be made and incubated overnight). 
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Day 2 
 
By day 2, the Jell-O mold should be formed, and students can carefully remove 
the mold from the plate. Students can do this by gently using their fingers or by 
maneuvering a coffee stirrer under the edge of the mold and peeling it off. The mold 
should be placed channel side down, on a smooth aluminum surface (plate or foil). 
Jell-O mold should be pressed down gently to ensure a good seal.   
Students can then carefully punch inlet and outlet holes at either end of the 
channels using a straw. Using syringes and/or transfer pipets, students can perfuse 
colored water through the device, and record how much fluid is drawn into the syringe 
in Table 8.1. The syringe can then be placed perpendicular to the flow of the chip, and 
students can begin to push the fluid into the chip at a constant rate, and start the timer 
as soon as they start pushing. Students should also time how long it takes to 
completely empty the syringe.  Record this time in table 1.  To record the velocity of 
the fluid, students should measure how long it takes the fluid to travel a given distance 
within their device, and record the measurement (in meters per second (m/s)) in figure 
1. Students can calculate the Reynolds Number of chip by using the following 
equation Re = udp/v, where u is the velocity in m/s, d is the diameter of the tube (in 
this case, we will estimate using the width of the channel, since it is rectangular), p is 
the density of the fluid, and v is the viscosity of the fluid. 
Record this data in Table 8.1. Students can then compare their numbers to 
corresponding flow conditions in Table 8.2 (NOTE: for optional day 3 activity, equal 
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numbers of glass slides should be incubated with either 2:8 (0.02 wt%) poly-l-lysine 
solution or distilled water overnight in a refrigerator). 
 
Day 3 (Optional): 
 
NOTE: For this activity, teachers should use extra molds made in day 1 to adhere onto 
glass slides incubated in poly-l-lysine solution or distilled water after day 2. 
 
In this optional activity, students can develop an understanding of the basic 
mechanisms of cell adhesion in the bloodstream by developing an assay that is free of 
potentially harmful biological materials. Teachers will distribute Jell-O devices that 
have been incubated with poly-l-lysine solution. Students can rinse their devices of 
excess NaL solution with distilled water, and place their devices on an inverted light 
microscope. Students can then draw a 1:10 dilution of polymer microspheres into a 
transfer pipet and perfuse the microspheres through the device. After a period of 10 
minutes, students can then rinse the device of unbound microspheres with distilled 
water. Using the light microscope, students can count the number of remaining 
microspheres adhered within the Jell-O device (on the glass slide preferably, where 
NaL solution has been incubated). Students should write down the number of spheres 
adhered into Table 8.3. 
Teachers will then give students Jell-O devices that have been incubated with 
water. Students can rinse their devices with distilled water, and place their devices on 
an inverted light microscope. Students can then draw the same solution of polymer 
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microspheres into a transfer pipet and perfuse the microspheres through the device. 
After a rinse of the device with distilled water, students can count the number of 
microspheres adhered within the Jell-O device via a light microscope. Students should 
write down the number of spheres adhered into Table 8.3. Students can then be 
introduced to the idea of the negatively charged spheres binding to the positively 
charged glass surface (due to incubation with poly-l-lysine solution). Meanwhile, little 
to no microsphere binding will be seen in the device coated with water, as the 
negatively charged microspheres will not be attracted to the glass surface in the 
absence of the negatively charged surfactant. Microsphere adhesion can be used as a 
model of actual cell adhesion in microfluidic devices, where cells can bind via 
receptor:ligand interactions. 
 
8.4 ASSESSMENT 
 
A rubric (Table 8.4) can be used to assess students during each part of the 
activity. The term “expectations” here refers to the content, process and attitudinal 
goals for this activity. Evidence for understanding may be in the form of oral as well 
as written communication, both with the teacher as well as observed communication 
with other students. Specifics are listed in Table 8.4. 
iClickers can also be used to administer a pre and post-assessment of students’ 
understand of the laboratory. Below are examples of questions that can be asked 
before and after the laboratory: 
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1. What does a high Reynolds number usually indicate? 
A. Laminar flow 
B. Turbulent flow 
C.  Intermediate flow 
D.  Cladistic flow 
 
2.  What benefits can a microfluidic chip provide? 
A. Quick diagnosis 
B. They are very easy to produce 
C. They can model several different animals at one time 
D. The chips can provide quick drug delivery when implanted 
 
3.   What enables white blood cells to exhibit different types of movement? 
A. The cells have different DNA 
B.  The cells can change the way their mitochondria function 
C.  The cells can express different surface proteins 
D.  The cells have multiple cell membranes 
 
4. What is viscosity? 
A. How thin a liquid is 
B.  How much a fluid resists flow 
C.  The average Reynolds number of a fluid 
D.  The median flow rate of a fluid 
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5.  Which is NOT a function of immune cells? 
A. To engulf invading cells 
B. To identify invading cells 
C. They migrate to sites of injury 
D. They secrete hormones to identify pathogens 
 
6. Why is the shape of a protein so important? 
A.  Proteins need a specific shape to fit through the capillary wall 
B.  Proteins that are improperly shaped will never be degraded 
C.  The shape of a protein is directly related to its function 
D.  Each protein must be slightly different to avoid autolysis 
 
7. Why must white blood cells be activated in the bloodstream? 
A.  They must be activated in order to leave the bloodstream 
B.  If they are not activated, they will never circulate in the blood. 
C.  The cells must only be activated to destroy bacteria 
D.  The cells will not duplicate if they are not activated first. 
 
8. How do some white blood cells find a site of infection? 
A.  They always migrate toward blood 
B.  Many bacteria have shapes that are similar to white blood cells 
C.  The cells can migrate toward chemical signals 
D.  The cells polarize and use their flagella to sense inflammation 
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9. How can various parts of the blood be separated in the lab? 
A.  Using electrophoresis 
B.  By centrifugation 
C.  By adding white blood cells to capture other blood components 
D.  Using a small pipette to separate the layers 
 
10. Which of the choices can influence how white blood cells are activated? 
A.  The shape of the blood vessel 
B.  The DNA of the white blood cells 
C.  The application of shear stress on the cells 
D.  The location of the cell in the body 
 
Finally, students can be asked the following essay questions to assess their understand 
of the laboratory: 
 
QUESTION 1:  Compare your Reynolds Number with that of a few other students.  
Were they the same or different?  Can you find a pattern? 
 
QUESTION 2:  Describe a use for a microfluidic device where it might be beneficial 
to have laminar flow. 
 
QUESTION 3:  Describe a use for a microfluidic device where it might be beneficial 
to have turbulent flow. 
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QUESTION 4:  There are several uses for microfluidic devices.  One such use is a 
“lab on a chip.”  What this means is that instead of using a large volume of a sample 
(such as blood), doctors might be able to use just a few drops and perform their tests 
on a very small scale.  Explain at least two benefits and two detriments of such a 
system in the space below.   
 
QUESTION 5:  Microfluidic devices might also be used for personalizing medicines.  
For example, cells could be collected from various organs in a patient’s body, placed 
in a microfluidic device, and then blood with a particular medicine could be profused 
through the device.  What benefits might this have for the patient? 
 
8.5 RESULTS AND DISCUSSION 
 
High school students successfully fabricated model milli-fluidic devices 
consisting of varying fluidic networks (Figure 8.1). Comparisons of Jell-O chip versus 
polydimethylsiloxane (PDMS) microfluidic chip fabrication in biomedical research 
were highlighted throughout the fabrication process. The concept of pressure-driven 
flow was demonstrated using Jell-O chips in the absence of an outlet, as fluid could 
not flow due to air present in the channel, which could not escape due to the absence 
of an outlet. High school students calculated flow rate by measuring the flow of a set 
volume of fluid through the device over time (Figure 8.3). The concept of laminar 
flow was demonstrated to students via perfusion of both a light and a dark-colored 
fluid through a Y-shaped Jell-O chip, as fluids perfused through channels 
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simultaneously did not mix. Jell-O chips were also used to demonstrate a model of cell 
adhesion, as poly-l-lysine coated devices successfully induced polymeric microsphere 
adhesion.  
 
8.6 CONCLUSION 
 
I have shown that simple, inexpensive Jell-O microfluidic devices can 
successfully demonstrate the basic principles of blood flow in a hands-on high school 
laboratory setting. The fabrication and use of devices can benefit students by 
introducing them to current biomedical technologies and applications, and encourage 
the pursuit of engineering and science degrees at the university level. 
 
 
 
 
 
 
 
 
 
 
 
 294 
FIGURE 8.1: SCHEMATIC TO FABRICATE JELL-O CHIPS USING SOFT 
LITHOGRAPHY. (A) Top view of a negative mold consisting of coffee stirrers and 
a foam plate. (B) Side view of coffee stirrers adhered to foam plate using tape. (C) 
Liquid Jell-O is poured onto the mold. (D) Chip is solidified over using refrigeration 
and then peeled from plate. (E) Chip is adhered to aluminum plate or foil for use.   
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FIGURE 8.2: MATERIALS NEEDED FOR OUTREACH ACTIVITY 
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TABLE 8.1: DATA FOR CALCULATION OF REYNOLDS NUMBER.   
 
Amount of fluid in syringe/ Time to 
empty syringe 
 
 
Velocity of fluid   
Reynolds Number   
Laminar, transitional or turbulent 
flow? 
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TABLE 8.2: REYNOLDS NUMBERS THAT INDICATE VARIOUS FLOW 
CONDITIONS. 
 
Condition Reynolds Number 
Laminar  Less than 2300 
Transitional 2300-4000 
Turbulent More than 4000 
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TABLE 8.3: NUMBER OF MICROSPHERES ADHERED TO JELL-O 
DEVICES.  
 
 
Number of spheres adhered, 
device 1 
 
 
Number of sphered adhered, 
device 2 
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TABLE 8.4:  RUBRIC TO ASSESS STUDENTS DURING OUTREACH 
ACTIVITY. 
 
 Engage Explore Explain Expand/Synthesis 
1     
2     
3     
4     
 
1= exceeds expectations  
2= meets expectations consistently  
3= meets expectations occasionally  
4= not meeting expectations 
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FIGURE 8.3: PERFUSION OF FLUID THROUGH A JELL-O MILLI-
FLUIDIC CHIP. 
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CHAPTER 9: CONCLUSIONS AND FUTURE WORK 
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9.1 INTRODUCTION 
 
 Collectively, I have demonstrated the fluid shear stress plays a critical role in 
the mechanotransduction and therapeutic targeting of cells in the circulation. Fluid 
shear stress exposure can both sensitize and desensitize leukocyte activation in the 
bloodstream, in the presence of various chemoattractants, and thus affect the 
inflammatory response. Cancer cells exposed to fluid stress can be sensitized to the 
apoptosis-inducing ligand TRAIL, but not traditional chemotherapeutics such as 
doxorubicin, suggesting that perhaps TRAIL is well suited for systemic delivery to 
circulating tumor cells. Utilizing this newly discovered knowledge of TRAIL 
mechanotransduction, novel selectin-based therapeutic approaches were developed to 
specifically target and kill circulating circulating cells via TRAIL-mediated apoptosis. 
Specifically, E-selectin functionalized liposomes were developed to target cancer cells 
in the circulation. Demonstrating the feasibility of such an approach, immobilized E-
selectin functionalized liposomes rapidly adhered to flowing cancer cells, due to the 
rapid, force-dependent binding kinetics of selectins, to deliver therapeutic cargo and 
induce cancer cell death in vitro. In combination with immobilized halloysite 
nanotubes, this liposome-based approach was successful at repelling leukocytes, 
which also possess ligands for E-selectin while delivering therapeutics to cancer cells. 
A combination of both E-selectin and TRAIL were then both functionalized to the 
surface of liposomes to target and kill cancer cells in the circulation in vivo. This novel 
therapeutic approach was found to be highly ineffective in human blood in vitro and in 
the peripheral circulation of mice in vivo. 
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9.2 FLUID SHEAR STRESS DIFFERENTIALLY ALTERS NEUTROPHIL 
ACTIVATION IN THE PRESENCE OF CHEMOATTRACTANTS 
 
The results from Chapter 2 suggest that fluid shear stress has a significant 
effect on the activation of circulating neutrophils in the presence of the 
chemoattractant fMLP. Neutrophils acquired a fluid shear stress-induced resistance to 
activation via FPR, the receptor for fMLP. The resistance was shown to be dependent 
on shear stress magnitude, as the resistance response increased with increasing shear 
stress. The mechanical response was also shown to be dependent on shear stress 
duration, as neutrophils increased their resistance with increased shear stress exposure 
time. A decrease in FPR surface expression was observed under fluid shear stress, and 
high-resolution confocal microscopy revealed that FPR was internalized within the 
cells. While other studies on mechanotransduction in neutrophils have mostly focused 
on morphological changes, the present study demonstrated that fluid shear stress has a 
significant effect on the earliest stages of neutrophil activation, specifically fMLP-
induced L-selectin shedding and αMβ2 integrin activation.  
Conversely, results from Chapter 3 showed that human neutrophil pre-
exposure to fluid shear stress can increase, rather than decrease, neutrophil activation 
in the presence of different inflammatory mediator platelet-activating factor (PAF). 
Fluid shear stress exposure increased PAF-induced neutrophil activation in terms of L-
selectin shedding, αMβ2 integrin activation, and morphological changes. Neutrophil 
activation via PAF was found to correlate with fluid shear stress exposure, as 
neutrophil activation increased in a shear stress magnitude- and time-dependent 
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manner. These results indicate that fluid shear stress exposure increases neutrophil 
activation to PAF, and, taken together with previous observations, differentially 
controls how neutrophils respond to chemoattractants. fMLP is a peptide 
chemoattractant released by certain bacteria and mitochondria at a site of tissue 
infection and/or injury, and activates neutrophils by interacting with the formyl 
peptide receptor on the neutrophil surface [316]. In humans, fMLP is present only at 
very low concentrations in the bloodstream, compared to sites of tissue infection 
and/or injury. Sustained activation to fMLP stimuli in the bloodstream could hinder 
the neutrophil response to infection by promoting pseudopod projection, increasing 
neutrophil transit time in blood, and enhancing neutrophil retention in the 
microvasculature [317,318]. Thus, if neutrophils pre-exposed to hemodynamic shear 
forces in the bloodstream increased fMLP-induced activation, neutrophils would be 
fully activated in the bloodstream and less efficient at transmigrating into localized 
tissues. Additionally, activation of neutrophils via fMLP also induces production of 
reactive oxygen species (ROS) [319], and thus shear-induced resistance to fMLP can 
reduce ROS-induced damage to healthy blood vessels. By developing a resistance to 
fMLP-induced activation when exposed to shear in the bloodstream, neutrophils avoid 
unnecessary activation in the bloodstream, facilitating extravasation and subsequent 
migration in tissues. In contrast, PAF-induced activation of neutrophils in the 
bloodstream is physiologically important. 
Taken together, these results indicate that the complete signaling pathways of 
these receptors deserve further study, along with the molecules that mediate GPCR 
internalization. Other receptors that have shown high constitutive activity should be 
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investigated to understand their contributions to the mechanosensing response of cells 
within the vascular microenvironment. 
 
9.3 FLUID SHEAR STRESS ENHANCES TRAIL-MEDIATED APOPTOSIS 
OF CIRCULATING CANCER CELLS 
 
The results from Chapter 4 indicate that hemodynamic shear forces have a 
significant effect on receptor-mediated apoptosis of cancer cells in the presence of 
TRAIL. Fluid shear stress was found to sensitize both colon and prostate cancer cell 
lines to TRAIL-mediated apoptosis. Cancer cells were not sensitized to TRAIL-
mediated necrosis upon exposure to fluid shear stress. TRAIL sensitization was shown 
to be shear stress dose-dependent, as sensitization was found to increase with 
increasing fluid shear stress. TRAIL sensitization was also fluid shear stress time-
dependent, as sensitization to apoptosis was enhanced with increasing fluid shear 
stress exposure time. The response was TRAIL-specific, as shear stress did not 
sensitize cancer cells to doxorubicin treatment over varying shear stress magnitudes 
and exposure times. Caspase inhibition assays revealed the sensitization response to be 
caspase-dependent. These results shed new light on the cancer cell response to soluble 
apoptotic agents within the circulation. The effects of fluid shear stress on 
mechanosensing death receptors on the cancer cell surface, along with their signaling 
pathways, can reveal new strategies for treating circulating cancer cells and reducing 
the likelihood of metastasis. Taken as is, the results from this study provide evidence 
that TRAIL is well suited for systemic deliver to therapeutically target circulating 
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tumor cells, compared to traditional therapeutics such as doxorubicin, which do not 
enact their therapeutic effect via receptors on the cancer cell surface. 
 
9.4 E-SELECTIN FUNCTIONALIZED LIPOSOMES TO TARGET CANCER 
CELLS AND DELIVER THERAPEUTIC CARGO UNDER FLOW 
 
In Chapter 5, I demonstrated the efficacy of targeting, capturing, and killing 
model CTCs using immobilized E-selectin functionalized liposomal doxorubicin 
within a biomimetic microtube flow device. Due to its rapid, force-dependent binding 
kinetics, E-selectin functionalized liposomal doxorubicin was shown to enhance 
cancer cell killing in both static conditions and conditions mimicking the 
microcirculation. Cone-and-plate shear experiments demonstrated the effectiveness of 
target-specific nanoparticles in solution, which can aid in the development of drugs 
intended for systemic delivery. Taken together, these results demonstrate that E-
selectin is an effective targeting agent for cancer cell under flow conditions typically 
observed in the microcirculation. 
Since it is challenging to deliver E-selectin functionalized nanoparticles while 
avoiding adhesion to healthy blood cells, as many possess ligands that adhesively 
interact with selectins, I expanded on this nanoparticle platform in Chapter 6 to create 
a nanostructured surface to capture flowing cancer cells while preventing human 
neutrophil adhesion. Microtube surfaces with immobilized halloysite nanotubes 
(HNTs) and E-selectin functionalized liposomal doxorubicin (ES-PEG L-DXR) 
significantly increased the number of breast adenocarcinoma MCF7 cells captured 
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from flow, yet also significantly reduced the number of captured neutrophils. 
Neutrophils firmly adhered and projected pseudopods on surfaces coated only with 
liposomes, while neutrophils adhered to HNT-liposome surfaces maintained a round 
morphology. Perfusion of both MCF7 cells and neutrophils resulted in primarily 
cancer cell adhesion to the HNT-liposome surface, and induced significant cancer cell 
death. This work demonstrates that nanostructured surfaces consisting of HNTs and 
ES-PEG L-DXR can increase CTC recruitment for chemotherapeutic delivery, while 
also preventing healthy cell adhesion and uptake of therapeutic intended for CTCs. 
One advantage of this device for capturing and killing of CTCs is that by 
immobilizing liposomes onto the microtube surface, the potential distribution of 
targeted L-DXR into circulation is reduced and a lower dose of the drug is necessary. 
The proposed device, which can be implemented as a vascular stent or arteriovenous 
shunt, can potentially be utilized for reducing the probability of metastasis, and 
suggests new strategies for enhancing targeted delivery of chemotherapeutics to CTCs. 
 
9.5 TRAIL-COATED LEUKOCYTES TARGET AND KILL CANCER CELLS 
IN FLOWING HUMAN BLOOD IN VITRO AND IN THE PERIPHERAL 
CIRCULATION OF MICE IN VIVO 
 
In Chapter 7, I utilized liposomes functionalized with a combination of E-
selectin and TRAIL to rapidly target and kill CTCs in the circulation in vivo. CTCs are 
essentially surrounded by white blood cells in the circulation, as deformable red blood 
cells tend to flow towards the center of the blood vessel while white blood cells and 
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CTCs are pushed towards the vessel wall during a process known as margination 
[162]. With this in mind, I developed a reverse approach, utilizing the surface of the 
body’s white blood cells to create “Unnatural Killer Cells” (UnKs) to target and 
deliver a cell death signal to CTCs in blood [209]. 
Since both white blood cells and CTCs adhere to ES in blood, I developed 
nanoscale liposomes conjugated with ES, to mediate interactions between both cell 
types, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a 
therapeutic that induces cell death in numerous cancer cell types while exerting 
minimal toxic effects on normal cells [236]. In vitro, liposomes functionalized with ES 
and TRAIL (ES/TRAIL) were generally effective at targeting cancer cells and 
inducing apoptosis under both static conditions and flow conditions mimicking the 
circulatory system. Additionally, ES/TRAIL liposomes were found to adhere to a 
range of white blood cells isolated from human blood under flow conditions in vitro, 
demonstrating that UnKs could target CTCs in a complex fluid such as blood. The 
results were surprising and unexpected, however, as human blood enhanced the 
therapeutic effect of ES/TRAIL, with minimal live cancer cells remaining in human 
blood after exposure to flow conditions for as little as two hours in vitro. 
The presence of whole blood enhanced the therapeutic effect of ES/TRAIL in 
two ways: (i) the presence of red blood cells, and (ii) the formation of UnKs after 
treatment with ES/TRAIL liposomes under flow. By simply increasing the number of 
red blood cells from low levels to normal hematocrit levels found in blood, the 
therapeutic effect of ES/TRAIL exerted on cancer cells significantly increased. 
Perhaps most interesting, however, was utilizing UnKs alone to target cancer cells 
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under blood flow conditions. By adhering ES/TRAIL liposomes to the surface of 
white blood cells and removing unbound ES/TRAIL liposomes from blood, the 
maximal therapeutic effect was still achieved, demonstrating UnKs as the essential 
component for killing circulating cancer cells.  
UnKs have numerous benefits for targeting CTCs in the circulation in vivo. 
From a biophysical perspective, the collisions between CTCs and white blood cells 
can act to flatten the matrix of biological molecules that make up the CTC glycocalyx 
[237], allowing for exposure of TRAIL death receptors that would not be possible to 
target using nanoparticles alone. Additionally, while TRAIL alone is not effective 
means to target CTCs due to its short half life in vivo [416], the formation of UnKs in 
the circulation acts to increase TRAIL circulation time, effectively avoiding renal 
clearance mechanisms to enhance the therapeutic effects on CTCs in vivo. 
Initial in vivo experiments to target CTCs in the circulation have proven to be 
similarly promising. ES/TRAIL liposomes were injected into the peripheral circulation 
of mice for 30 min, allowing for UnKs to form in blood. As a straightforward and 
widely-used model of lung metastasis in vivo [240], fluorescently labeled cancer cells 
were injected via tail vein and allowed to circulate for 2 hours, after which the mice 
were sacrificed and cancer cells were recovered from blood via cardiac puncture. 
Interestingly, mice with UnKs showed >98% less cancer cells in blood than control 
mice that only displayed ES on the white blood cell surface. Injection with the soluble 
TRAIL alone was ineffective, due to its short half-life in the circulation. In this model 
of lung metastasis, it is known that cancer cells also lodge within the blood vessels of 
the lung. Thus, we utilized multiphoton microscopy to assess the number and viability 
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of cancer cells lodged within the lung. Interestingly, fewer cancer cells were found in 
mice with UnKs, indicating that most cancer cells underwent apoptosis and 
dissociated by the time of imaging. Of the cancer cells remaining in UnK mice, the 
majority of the cells stained positive for the apoptosis marker Annexin-V, while a 
minimal number of cells in control mice were apoptotic. Thus, the formation of UnKs 
in mice suggests that cancer cells within the circulation can be targeted and killed, 
before they are able to form new micrometastases. 
The use of UnKs to target and kill bloodborne cancer cells has to potential to 
be translated into the clinic, as Amgen/Genentech’s recombinant human 
TRAIL/Apo2L (also known as PRO1762), has undergone Phase 1, 1a, 2, and 3 clinical 
trials over the past decade, with minimal adverse effects reported [248]. Given that 
this new therapeutic approach is focused on the vascular microenvironment, we also 
validated that cells that comprise the circulation such as leukocytes and endothelial 
cells remain unharmed by this approach [209]. In fact, most normal cells in the body 
are protected from TRAIL-induced cell death through intracellular proteins such as the 
class of inhibitors of apoptosis proteins (IAPs) [236]. For CTCs that exhibit reduced 
sensitivity to the effects of TRAIL, the approach may also be combined in regimens 
with other low cytotoxic agents, such as aspirin or the turmeric spice compound 
curcumin [85,426], to synergistically kill CTCs. 
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9.6 FUTURE WORK 
 
If introduced at the appropriate time points, unnatural killer cells may serve as 
a means to target and kill CTCs before they are able to form new metastases. Such an 
approach could constrain cancerous cells within the primary tumor, which is typically 
treatable via surgery, radiation, and/or chemotherapy. To address the translatability of 
unnatural killer cells into future clinical trials, future work focused on the prevention 
of metastases in longer term animal models will be needed. I have initiated this work 
by developing a spontaneous metastasis model to assess the therapeutic efficacy of 
unnatural killer cells. My initial work in Chapter 7 demonstrated that unnatural killer 
cells kill circulating cancer cells in vivo. However, a spontaneous metastasis model is 
more physiologically relevant, due the fact the CTCs can disseminate from the 
primary tumor and form metastases spontaneously. The ultimate goal of this future 
work would be to reduce the formation of secondary tumors, and potentially exert a 
therapeutic effect on the primary tumor. 
 
Spontaneous Metastasis Model of Prostate Cancer 
 
I have developed a spontaneous metastasis model by injecting luciferase-
expressing metastatic DU145 prostate cancer cell orthotopically into mice. Utilizing 
bioluminescent imaging, luciferase-expressing DU145 cells can be detected in the 
primary tumor over time, and can also be used to determine the onset and location of 
anatomically distant metastases (Figure 9.1). The presence of CTCs can also be 
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detected with this model as blood can from mice via submandibular bleeds, or via 
cardiac puncture, for CTC isolation. I have demonstrated that CTCs can isolated from 
this model 6 weeks post-orthotopic injection (Figure 9.2). Additionally, I have shown 
that anatomically distant metastases do form within the lungs of this orthotopic mouse 
model over time, as shown by detection of metastases in lung via BLI (Figure 9.1) and 
also by the presence of white metastatic nodules on mouse lung (Figure 9.3). Taken 
together, a combination of CTCs detected in blood combined with the presence of 
metastases in anatomically distant organs suggest that metastases can form following 
the entry of CTCs within the circulation. 
Using this model, future work will focus on introducing unnatural killer cells 
upon first detection of CTCs in blood, before the formation of metastases, in order to 
prevent the formation of secondary tumors. I have shown that the enhanced apoptotic 
effect of cancer cells in the presence of unnatural killer cells also holds true for DU145 
metastatic prostate cancer cells. While DU145 cells remain viable after exposure to 
human blood under flow conditions, negligible viable cancer cells remain after 
treatment with unnatural killer cells in human blood under flow conditions (Figure 
9.4), which is consistent with the results from Chapter 7, where negligible COLO 205 
and PC-3 cancer cells remained after treatment in human blood under flow conditions. 
An appropriate therapeutic time point will be determined by detecting the 
presence of CTCs and metastases in the model over time. After orthotopic injection, 
mice will be sacrificed every week, ranging from a 1-12 week time period post-
orthotopic injection. At every week time point, each mouse will be assessed for (1) the 
presence of CTCs in blood, and (2) the presence of micrometastases in lymph nodes, 
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lungs, liver, bone and brain, using BLI imaging. After identifying the first week at 
which CTCs and micrometastases are detected in mice, the initial therapeutic 
treatments will begin 2 weeks before initial detection of CTCs. For example, if CTCs 
are first detected in mice 5 weeks post-orthotopic injection, then first therapeutic 
treatments of ES/TRAIL liposomes will begin 3 week post-orthotopic injection in new 
mice. ES/TRAIL liposomes will be injected daily over a 3-5 week time period, via tail 
vein and retro-orbital injections. To determine efficacy, the presence of CTCs, the 
number of metastases, the size of primary and secondary tumors, and overall survival 
of treated, orthotopically injected mice will be compared to untreated, orthotopically 
injected control mice. 
 
Combination Therapies 
 
Future work will utilize unnatural killer cells in combination with compounds 
that demonstrate minimal side effects in vivo, to expand this approach to cancers 
which show differential sensitivity to TRAIL. Results from Chapter 4 will also play a 
crucial role in this future work.  Due to the fact that fluid shear stress has been shown 
to enhance cancer cell apoptosis in the presence of TRAIL, it is possible that this 
phenomenon can also be applied to a variety of apoptosis-inducing ligands that can 
trigger cancer cell death. While TRAIL has been shown to be effect at inducing 
apoptosis in a variety of cancer cells, the use of other apoptosis-inducing ligands can 
expand our current approaches to therapeutically target even cancer cell types. One 
can envision using E-selectin functionalized liposomes with a variety to apoptosis-
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inducing ligands, to create various forms of unnatural killer cells within the 
circulation. I feel that the current approach, however, represents an important initial 
step in utilizing white blood cells within the bloodstream to eliminate CTCs in vivo. 
 
Unnatural Killer Cell-Mediated Therapies Targeting Primary Tumors 
 
 Due to the fact that surgical resection of primary tumors leads to immediate 
dissemination of CTCs in blood, which can lodge within anatomically distant organs 
and form micrometastases, it is important to also expand the unnatural killer cells 
approach to also target primary tumors. Given that subpopulations of leukocytes have 
the innate ability to infiltrate solid tumors, it is possible that unnatural killer cells can 
be utilized to infiltrate solid tumors, and deliver ligands such as TRAIL to induce 
cancer cell apoptosis. This would fill an immediate need, as currently drugs that are 
administered systemically will rarely reach the target tumor site, due to a lack of a 
functional vasculature. Unnatural killer cells present an entirely new approach to reach 
these sites, as leukocytes can use their innate ability to migrate along chemoattractant 
gradients to reach the primary tumor site.  
 
Shear Stress-Based Control of Leukocyte Infiltration to Primary Tumors 
 
While this innate ability of leukocytes suggests that unnatural killer cells can 
infiltrate the primary tumor, determining the number of leukocytes that invade the 
tumor, along with determining the number of unnatural killer cells needed to induce 
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reduction of primary tumors remains a challenge. Thus, a greater understand of 
leukocyte activation in the presence of shear forces will eventually be needed to 
harness the ability of unnatural killer cells to target primary tumors. Results from 
Chapter 2 and 3 have shown promise that this can potentially be accomplished. I have 
shown in these chapters that fluid shear forces can exert great control over how 
leukocytes activate under inflammatory conditions, which are also present in the case 
cancer. By further studying how these forces control leukocyte activation at the 
receptor level, we can potentially control the activation of leukocytes under the 
inflammatory conditions of cancer. One can envision altering the forces exerted on 
leukocytes in blood, in order to control the number of leukocytes that become 
activated and eventually disseminate to tumor sites. 
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FIGURE 9.1:  BIOLUMINESCENT IMAGING (BLI) OF A SPONTANEOUS 
METASTASIS MODEL OF PROSTATE CANCER. Luciferase-expressing 
DU145 metastatic prostate cancer cells were injected orthotopically into mice. The 
formation of primary and secondary tumors was detected over a time span of 12 
weeks. 
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FIGURE 9.2:  CIRCULATING TUMOR CELLS (CTC) ISOLATED FROM A 
SPONTANEOUS METASTASIS MOUSE MODEL OF PROSTATE CANCER. 
CTCs were isolated 6 weeks after orthotopic injection of DU145 prostate cancer cells 
into mice. Controls denote mice that were not injected orthotopically. Red cells denote 
luciferase-expressing DU145 cells. Blue denotes cell nuclei. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control Mouse DU145-Orthotopic 
 318 
FIGURE 9.3:  FORMATION OF METASTASES IN MOUSE LUNG IN A 
SPONTANEOUS METASTASIS MODEL OF PROSTATE CANCER. Mouse 
lungs were excised and assessed for the presence of metastases (indicated by white 
nodules) 9 weeks after orthotopic injection of DU145 prostate cancer cells. Control 
denotes mouse lungs from healthy mice. 
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FIGURE 9.4: UNNATURAL KILLER CELLS INDUCE DU145 CANCER 
CELL DEATH IN HUMAN BLOOD UNDER FLOW IN VITRO.  DU145 prostate 
cancer cells were labeled with a fluorescent viability dye and exposed to ES/TRAIL 
liposomes in human blood under flow conditions in a cone-and-plate viscometer for 3 
h. Viable cancer cells were gated and detected for fluorescence using flow cytometry. 
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APPENDIX I: THE ROLE OF CELL GLYCOCALYX IN VASCULAR 
TRANSPORT OF CIRCULATING TUMOR CELLS 
 
*This section is adapted from the following publication: M.J. Mitchell and M.R. King. 
American Journal of Physiology – Cell Physiology. 306(2): C89-C97, 2014. 
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I.1  INTRODUCTION 
 
Metastasis contributes to approximately 90% of cancer-related deaths [1,427], 
yet many aspects of metastasis remain poorly understood. Cancer cells originating 
from the primary tumor undergo a sequence of steps to metastasize via the 
bloodstream to anatomically distant organs, including detachment from the primary 
tumor, invasion into surrounding tissues, and intravasation into the vascular 
circulation as circulating tumor cells (CTCs) [51,223]. CTCs can then be transported 
through the vascular system to the postcapillary venules of distant tissues, undergo 
adhesive interactions with the microvessel wall, exit the bloodstream in a process 
known as extravasation, survive in distant tissues, and proliferate to form secondary 
tumors [365]. While primary tumors are generally treatable via radiation, 
chemotherapy, and/or surgical removal, the systemic nature of metastasis makes the 
disease difficult to treat [335]. A better understanding of the vascular transport of 
CTCs can reveal key checkpoints for the intervention and treatment of metastasis. 
Receptor-ligand interactions play a key role in both the adhesion and 
therapeutic treatment of CTCs in the bloodstream. To adhere to the microvasculature 
in distant tissues, sialylated carbohydrate ligands expressed on CTCs can bind to 
selectin receptors on the surface of inflamed endothelial cells [52,365]. This adhesion 
mechanism has been used in recent biomimetic approaches to target CTCs via 
immobilized E-selectin receptors under physiological flow conditions [84,85,335]. 
Such techniques can allow flowing cancer cells to interact with apoptosis-inducing 
ligands [84,85], which can bind with receptors on the cancer cell surface to trigger 
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programmed cell death. The ability of CTCs to undergo such receptor-ligand 
interactions can be dictated by a physical barrier on the surface of cells known as the 
glycocalyx. 
The glycocalyx is a sugar-rich coating that is found on the surface of both 
endothelial cells and tumor cells. The endothelial cell glycocalyx serves as a vascular 
permeability barrier, a mechanotransducer of hemodynamic shear forces to endothelial 
cells, and a regulator of adhesive interactions between circulating cells and the 
endothelium [428]. Tumor cells can overexpress certain building blocks of the 
glycocalyx, and which can facilitate tumor progression by enhancing angiogenesis, 
tumor growth, and invasion [429]. Given that the size of this layer can approach 0.5 
µm in thickness while receptors are mostly less than 100 nm in size, the glycocalyx 
can act to control receptor interactions with their respective ligands [428,430]. Thus, 
the thickness of the glycocalyx can affect CTC adhesion to the endothelium, along 
with therapeutic ligand delivery to the surface of CTCs. 
Herein, I discuss a range of potential effects on the vascular transport of CTCs 
due to the glycocalyx. First, the structure and composition of the glycocalyx, found on 
both endothelial cells and tumor cells, is reviewed. The factors that contribute to 
endothelial cell glycocalyx remodeling and disruption are then described, along with 
their subsequent effects on the adhesion of circulating cells. I conclude with novel 
therapeutic strategies for CTCs, the glycocalyx as a barrier for CTC drug delivery, and 
approaches to disrupt the glycocalyx for efficient therapeutic treatment of CTCs.  
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I.2  ENDOTHELIAL CELL GLYCOCALYX STRUCTURE 
 
The structure of the endothelial cell (EC) glycocalyx is discussed here briefly, 
as this has been discussed in detail by others [428,430-432]. The glycocalyx is a thin, 
gel-like layer of glycoproteins on the apical surface of vascular endothelial cells, with 
an estimated thickness ranging from 150-500 nm [428] (Figure I.1A). Glycocalyx 
measurements are based on in vivo experimental observations by Vink & Duling [433] 
using intravital microscopy, electron microscopy (EM) studies by van den Berg et al. 
[434], and others [435-437].  The glycocalyx on the surface of postcapillary venules 
has been measured using capillary tube hematocrit, or the instantaneous volume 
fraction of postcapillary venules filled with red blood cells [438-440]. Reductions in 
the perfused capillary volume are indicative of the glycocalyx extending from the EC 
surface [433,441]. EM images by Squire et al. [442] showed that the EC glycocalyx 
brush structure has a characteristic spacing of 20 nm in all directions (Figure 1A). 
Computational models [443,444] and experimental observations [445,446] have 
shown that such spacing can act as a “molecular sieve” for plasma proteins, and thus 
create differences in plasma protein concentration between tissue and the luminal 
surface of the endothelium.  
The glycocalyx on the EC surface primarily consists of glycosaminoglycans 
(GAGs), linear heteropolysaccharides that possess characteristic disaccharide unit 
repeats [447]. GAGs that comprise the EC glycocalyx include heparan sulfate, 
hyaluronan, and chondroitin sulfate [448]. Sulfated GAGs, specifically heparan sulfate 
and chondroitin sulfate, are linked to EC membrane-bound proteoglycans, which link 
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the glycocalyx to the actin cytoskeleton [442]. Proteoglycans are proteins that have 
specific sites to covalently link sulfated GAGs, and consist of transmembrane 
syndecans, membrane-bound glypicans, and matrix-localized perlecans [449]. 
Hyaluronan does not possess sulfated groups and is not covalently linked to 
proteoglycans; its interaction with the glycocalyx is mediated by cell surface receptors 
such as CD44, as well as by chondroitin sulfate chains [450]. Other important 
glycoproteins on the cell surface include adhesion receptors, such as integrins, 
immunoglobulins, and selectins [166]. Under normal physiological conditions, various 
bloodborne proteins will also incorporate into the EC glycocalyx [451]. 
 
I.3  TUMOR CELL GLYCOCALYX STRUCTURE 
 
The tumor cell glycocalyx, much like that of ECs, consists of a variety of 
proteoglycans and glycosaminoglycans, in addition to fibrous proteins, such as 
collagen, which comprise the surrounding extracellular matrix [452]. The synthesis of 
hyaluronan in tumor cells, however, is frequently impaired during malignant 
transformation and can result in the excess production of hyaluronan [453-456] 
(Figure I.1B). In nontransformed cells, hyaluronan incorporates into the surrounding 
cell matrix by forming aggregates with hyaluronan-binding molecules, and can 
regulate cell adhesion, motility, growth, and differentiation. Hyaluronan synthase 
genes (HAS1, HAS2, and HAS3) encode key enzymes in hyaluronan synthesis, which 
can regulate the ability to form hyaluronan matrices and determine hyaluronan 
molecular size [457]. In tumor cells, however, expression of HAS genes is often 
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increased, resulting in excess hyaluronan production. Experiments forcing expression 
of HAS2 and HAS3 resulted in a drastic increase of hyaluronan production and 
subsequent tumorigenicity of mesothelioma, melanoma, and fibrosarcoma [458-460]. 
Additionally, transfection of HAS1 into mouse mammary carcinoma mutants rescued 
hyaluronan matrix production and metastatic potential [461]. Expression of 
hyaluronan cell surface receptor CD44 has also been shown to be increased in tumor 
cells [462,463] (Figure 1B). CD44+ cancer cells from head and neck squamous cell 
carcinoma can possess properties of cancer stem cells, including cancer stem cell 
renewal and differentiation [464]. CD44 variant isoforms are highly expressed in 
carcinomas of epithelial origin, and relate to tumor progression and metastatic 
potential of some cancers [465-467]. In addition to these components, tumor cells 
have a variety of cell and matrix adhesion molecules embedded in the glycocalyx, 
including integrins and selectin ligands [12,48]. 
 To date, the circulating tumor cell (CTC) glycocalyx has not been well 
characterized. Paszek et al. recently developed scanning angle interference microscopy 
to measure variations in glycocalyx thicknesses of single epithelial cells on the 
nanometer scale [468]. This technique could be utilized to characterize the glycocalyx 
of CTCs. While typically associated with disease progression and poor prognosis, a 
significant number CTCs in blood are typically apoptotic [366,469]. This is in part due 
to anoikis, a form of programmed cell death that occurs due to the loss of cell-cell 
and/or cell-matrix adherence in CTCs [43]. This raises the intriguing possibility that 
viable CTCs that contribute to metastasis, which are typically characterized by the 
epithelial-mesenchymal transition (EMT) [470-472], can also retain their glycocalyx 
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and other matrix components. The glycocalyx coating could allow CTCs to evade 
anoikis or other forms of cell death due to harsh shear stress exposure in the 
circulation. In particular, clusters of CTCs known as circulating tumor microemboli 
(CTM) can retain their viability in part due to retention of glycocalyx, surrounding 
matrix components, and cell-cell adherence, in addition to processes such as EMT 
[471,473,474]. 
 
I.4  EC GLYCOCALYX EFFECTS ON CTC ADHESION 
 
It is believed that CTCs can leave the bloodstream during hematogenous 
metastasis in a manner similar to leukocyte extravasation during the inflammatory 
response. In this process, cells initially tether and roll on the activated endothelium, 
followed by firm adhesion and subsequent transmigration through the blood vessel 
wall into inflamed tissue [15,52]. The initial tethering and rolling of leukocytes to ECs 
is mediated by E-, L-, and P-selectins binding to ligands on both the microvilli of 
leukocytes or the surface of ECs [91,278,475,476], with firm adhesion mediated by 
ICAM-1 and β2 integrins on the EC and leukocyte surfaces, respectively [175,176]. E-
selectin on the EC surface has also been shown to facilitate cancer metastasis in vivo 
[183,184]. Additionally, E-selectin can induce the rolling and tethering of cancer cells 
originating from breast [54,180], colon [180,182], and prostate [53,179] under flow.  
The EC glycocalyx can control the spacing between E-selectin receptors on the 
EC surface and selectin ligands on CTCs, however its effects on CTC adhesion to the 
blood vessel wall has received less attention to date. Cell adhesion molecules on the 
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EC surface, such as ICAM-1 and selectins, can range in length from 20-40 nm 
[166,170]. However, the thickness of the glycocalyx can be several hundreds of 
nanometers, and thus affects receptor-mediated cell adhesion under physiological flow 
[428,477] (Figure I.2A). For example, Robert et al. utilized both computational and 
experimental models to measure the effect of the glycocalyx layer on the adhesion of 
functionalized microbeads to immobilized ICAM-1 under flow [478]. Using 
hyaluronan as a model glycocalyx, the frequency of adhesion to ICAM-1 under flow 
increased with decreasing concentrations of hyaluronan, along with an increase in the 
force between the bead and the substrate, and a decrease in the bead distance from the 
surface [478]. Multiple studies using leukocytes have shown that decreases in 
glycocalyx thickness directly correlate with increased cell adhesion [423,479,480]. 
Inflammation, exposure to extracellular proteases, and changes in 
hemodynamic shear stress can alter glycocalyx molecular composition and thickness 
(Figure I.2B), suggesting that such factors may promote or inhibit CTC-EC adhesion. 
 
Glycocalyx remodeling during inflammation 
 
The EC glycocalyx can be dramatically remodeled during inflammation, a 
process which is also critical to the progression of cancer metastasis [52,481].  In vivo, 
Henry and Duling found that exposure to proinflammatory cytokine tumor necrosis 
factor-α (TNF-α) can disrupt and increase the entry of macromolecules into the EC 
glycocalyx [482]. Mulivor and Lipowsky showed that superperfusion of the 
chemoattractant formyl-methionyl-leucyl-phenylalanine (fMLP) into rats induced 
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significant shedding of GAGs from the EC surface [483]. Treatment of postcapillary 
venules with either fMLP or heparinase increased exposure and availability of ICAM-
1 on the EC surface [484], as measured by the perfusion and adhesion of fluorescent 
microbeads coated with antibodies specific for ICAM-1. In an in vivo model of septic 
shock, administration of bacterial endotoxins induced a significant increase in 
circulating glycocalyx degradation products such as heparan sulfate [485]. Pro-
inflammatory low-density lipoproteins (LDL) have been shown to degrade the EC 
glycocalyx in postcapillary venules, as measured by increased capillary hematocrit 
[486]. There is also evidence that major cardiopulmonary bypass surgery can cause 
shedding of heparan sulfate and syndecan-1 from the EC glycocalyx of patients [487]. 
Given the increased thickness of the glycocalyx under normal physiological 
conditions, it is likely that inflammatory conditions promote CTC adhesion to the 
endothelium by both shedding and disruption of the EC glycocalyx, which increases 
the availability of EC cell adhesion molecules to CTCs. 
 
Matrix metalloproteinase (MMP) effects on glycocalyx shedding 
 
Extracellular proteases, such as matrix metalloproteinases (MMPs), can induce 
glycocalyx shedding and promote cell adhesion in the microvasculature (Figure I.2B). 
MMPs are a family of zinc-dependent enzymes that can regulate the turnover of the 
glycocalyx and other ECMs during processes including inflammation, wound healing, 
and tumor progression [52,488-490]. In vivo, arterial ECs show increased expression 
of MMPs in areas of atherosclerotic plaques and lesions [491,492]. MMPs have also 
 329 
been found by Gronski et al. and Endo et al. to directly cleave chondroitin sulfate and 
proteoglycan syndecan-1, respectively [493,494]. 
Endothelial cells have the ability to store, activate, and release MMPs into the 
surrounding glycocalyx. Utilizing matrix metalloproteinase (MMPs) inhibitors, 
Fitzgerald et al. found that multiple cell signaling pathways can converge and activate 
MMPs, after PMA treatment, to cleave syndecans from the cell surface [495]. 
Taraboletti et al. found that human umbilical vein endothelial cells shed microvesicles 
from the plasma membrane, which contain active and pro-enzyme forms of MMP-2 
and MMP-9 [496]. Yu et al. found evidence that both MMP-2 and MMP-9 can bind to 
heparan sulfate in the glycocalyx [497]. ECs were also found to utilize microvesicles 
to release tissue inhibitors of metalloproteinases (TIMPs), endogenous inhibitors 
which can regulate MMP activity [496]. Thus, shedding of the glycocalyx can in part 
be regulated by MMPs derived from the endothelium. Given that nearly all tumor cells 
overexpress MMPs [498], including MMP-2 and MMP-9 as mentioned previously, 
CTCs may also contribute to MMP-induced glycocalyx shedding. 
 
Glycocalyx response to fluid shear stress 
 
The EC glycocalyx is exposed to hemodynamic shear stresses ranging from 
4.0-30.0 dyn/cm2 and 0.5-4.0 dyn/cm2 in the arterial and venous circulation, 
respectively [46]. Shear rates can range from approximately 900 s-1 in arteries to 160 s-
1 in veins [159]. Exposure to such forces can affect the biosynthesis of EC glycocalyx 
components, activate EC-derived proteases, and disrupt glycocalyx structure and 
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molecular components [499]. In vivo studies by Mulivor and Lipowsky showed that 
induction of ischemia for 60 min led to an increase in glycocalyx thickness on the 
surface of the post-capillary venules [483], which then decreased upon reperfusion of 
the venules. Grimm et al. showed that exposure to low shear stress (1.0 dyn/cm2) 
inhibited GAG synthesis in cultured ECs, while Arisaka et al. showed that greater 
shear stresses (>15.0 dyn/cm2) stimulated the synthesis of GAGs in ECs [499]. Zeng 
et al. found that specific components of the EC glycocalyx, such as heparan sulfate, 
can cluster at endothelial cell junctions through the mobility of glypican-1 in lipid rafts 
[500]. Other components, such as chondroitin sulfate and syndecan, remained 
immobilized on the EC glycocalyx [500]. Koo et al. measured the components of the 
glycocalyx after human EC exposure to shear stress waveforms characteristic of 
atherosclerosis-resistant and atherosclerosis-susceptible regions of the arteries [501]. 
Glycocalyx components increased in expression and were distributed evenly on the 
EC surface after exposure to atherosclerosis-resistant waveforms, but was irregularly 
distributed and decreased in expression upon exposure to atherosclerosis-susceptible 
waveforms [501].   
In the tumor microenvironment, blood vessels are characterized as 
disorganized, tortuous, leaky, and dilated [502]. While normal vessels typically branch 
via bifurcations with even branch diameters, the tumor vasculature can exhibit 
trifurcations and uneven branch diameters [502], all of which can dramatically alter 
the local shear stress environment. Proliferating tumor cells can also exert solid 
stresses on the surrounding vasculature, causing blood and lymphatic vessels to 
collapse and inducing heterogeneous blood flows and subsequent shear stresses 
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[23,503]. Given that fluid shear stress can affect glycocalyx thickness and 
composition, it is likely that alterations are also seen in the cancer microenvironment. 
Such shear-induced effects on the EC glycocalyx have not been previously 
characterized, and could provide new insight into the vascular transport of CTCs. 
 
Glycocalyx effects on leukocyte adhesion 
 
 Like CTCs, leukocytes express selectin ligands that facilitate their adhesion to 
the endothelium. Given that selectins on the EC surface do not extend as far from the 
EC surface as the glycocalyx, it is likely that inflammatory conditions, MMP 
exposure, and fluid shear forces can remodel the glycocalyx to promote the adhesion 
of circulating cells. A theoretical model was developed by Zhao et al. to examine how 
fluid shear forces can amplify the penetration forces of leukocyte microvilli into the 
EC glycocalyx [422]. Leukocyte microvilli range from 0.3 to 0.7 µm in length, which 
can place leukocytes within a reactive distance of selectins of the EC surface [504]. 
The model predicts that physiological shear forces can amplify the gravitational 
contact forces of leukocytes by almost two orders of magnitude to 100 pN, which can 
allow leukocyte microvilli to penetrate the EC glycocalyx [422]. 
In vivo, TNF-α is found to disrupt the glycocalyx of postcapillary venules, 
decrease leukocyte rolling velocity, and increase the number of adherent leukocytes 
[482]. Treatment with the P-selectin antagonist fucoidan both reduced the number of 
adherent leukocytes and increased the average leukocyte rolling velocity, 
demonstrating that TNF-α-induced glycocalyx disruption enhances selectin-mediated 
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leukocyte adhesion [482]. Superperfusion of the rat mesentery with fMLP increased 
glycocalyx shedding in a process mediated by EC G-protein signaling [483], 
increasing exposure of EC adhesion receptors and subsequent leukocyte adhesion 
[484]. Treatment of mouse cremaster venules with the enzyme heparitinase degraded 
heparan sulfate from the EC glycocalyx, and increased the number of leukocytes 
adhered to the venules [505]. Doxycycline, a member of the tetracycline antibiotics, is 
a broad spectrum MMP inhibitor that was recently shown to both promote and inhibit 
leukocyte adhesion [506,507]. Superperfusion of rat mesentery with doxycycline alone 
increased baseline levels of leukocyte adhesion by reducing sheddase activity and 
subsequent cleavage of adhesion molecules [506]. However, treatment with fMLP 
followed by doxycycline significantly reduced leukocyte adhesion compared to 
treatment with fMLP alone, indicating the doxycycline treatment can also inhibit 
fMLP-induced glycocalyx shedding and reduce the availability of EC adhesion 
molecules [506]. 
Under normal physiological conditions, the thick EC glycocalyx can serve as a 
physical barrier that prevents the adhesion of immune cells and CTCs (Figure I.2A). 
This barrier can be compromised by a variety of factors, including pro-inflammatory 
molecules, MMPs, and fluid shear stress. Given that many CTCs present selectin 
ligands similar to leukocytes, it is expected that glycocalyx shedding and disruption 
may exert similar effects on the adhesion of CTCs (Figure I.2B). However, CTCs can 
differ greatly from leukocytes in terms of size, morphology, selectin ligand 
expression, deformability, and membrane composition [48,508-514]. Additionally, 
CTCs can possess glycocalyx components such as chondroitin sulfate GAGs, which 
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serve as major P-selectin ligands on metastatic breast cancer cells [515].Thus, the 
effects of glycocalyx thickness and composition on CTC adhesion and subsequent 
formation of distant metastases is not fully elucidated and deserves further study. 
 
I.5    GLYCOCALYX EFFECTS ON THERAPEUTIC TREATMENT OF CTCs 
 
CTC-targeted therapies 
 
Therapeutic treatment of CTCs in blood can potentially hinder the vascular 
transport of CTCs to anatomically distant organs, and prevent the onset of metastasis. 
Recently, novel approaches to both target and treat CTCs within the bloodstream have 
been developed [516]. E-selectin is currently being explored to target therapeutics to 
CTCs under blood flow conditions, due to the rapid, force-dependent binding kinetics 
between E-selectin and selectin ligands on CTCs [335] (Figure I.3). Our group 
recently developed an approach to deliver doxorubicin-containing E-selectin 
conjugated nanoparticles to flowing tumor cells [82,83]. Doxorubicin is an 
adriamyacin anthracycline antibiotic that is utilized as a chemotherapeutic agent, 
which can induce tumor cell death by DNA-intercalation, inhibition of topoisomerase-
II, and formation of free radicals [88,89,368]. Under physiological shear stresses, 
tumor cells rapidly bound to E-selectin conjugated nanoparticles, as confocal 
microscopy revealed fluorescent nanoparticles decorating the tumor cell surface [82]. 
Doxorubicin-loaded nanoparticles were subsequently internalized by tumor cells, and 
induced significant cell death. 
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The use of tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL) to induce apoptosis in circulating cancer cells has recently been investigated. 
TRAIL binds to trimeric death receptors DR4 and DR5 on the surface of a variety of 
tumor cells, and subsequently signals for apoptosis [84]. TRAIL is an ideal therapeutic 
for CTCs because it does not exert toxic effects on most normal cells, with the 
exception of hepatocytes [87,424]. Thus upon delivery to the bloodstream, TRAIL 
would likely have negligible effects on circulating cells such as erythrocytes and 
leukocytes. Utilizing immobilized E-selectin and TRAIL, Rana et al. created novel 
surfaces to both capture and deliver apoptotic signals to flowing cancer cells [84,85]. 
Cancer cells exhibited rolling adhesion on E-selectin, and subsequently interacted with 
immobilized TRAIL on the surface to induce apoptosis [84]. Combination therapy of 
aspirin pretreatment followed by perfusion over E-selectin/TRAIL surfaces sensitized 
tumor cells to TRAIL-induced apoptosis, significantly increasing the number of 
apoptotic tumor cells compared to cells exposed to E-selectin/TRAIL surfaces alone 
[85]. Mitchell et al. assessed the effects of physiological shear stress exposure on 
TRAIL-induced apoptosis of tumor cells. Fluid shear stress exposure of 2.0 dyn/cm2 
nearly doubled the amount of apoptotic cancer cells in the presence of TRAIL, 
compared to TRAIL-treated cells exposed to static conditions [86]. Interestingly, the 
response was found to be TRAIL-specific, as shear forces did not sensitize cancer 
cells to doxorubicin-induced apoptosis [86]. 
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Glycocalyx as a therapeutic barrier 
 
Increased expression of hyaluronan on the tumor cell glycocalyx can hinder the 
delivery of therapeutics. High expression levels of hyaluronan can create a hydrated 
connective tissue matrix, which can attach to the tumor cell surface via CD44 to form 
a protective coating around the cell [517]. This coating may limit therapeutic efficacy 
by providing a cover over drug binding sites on cancer cells (Figure I.4), along with 
attenuating the diffusion of drug molecules to the cell surface. Brekken et al. found 
that increased production of hyaluronan increased interstitial fluid pressure in solid 
tumors, which can limit the delivery of therapeutics via the circulation by collapsing 
nearby blood vessels [23,503] and eliminating pressure difference-driven transport of 
therapeutics toward the tumor interior [518]. To quantify glycocalyx effects on the 
diffusion of drugs to tumor cells, Eikenes et al. measured the diffusion of fluorescein 
isothiocyanate (FITC)-conjugated dextran macromolecules through the glycocalyx 
using fluorescence recovery after photobleaching (FRAP) based on two-photon 
scanning laser excitation [519]. The diffusion coefficient of 150-kDa FITC dextran 
molecules decreased in tumor spheroids, and even more so in human osteosarcoma 
xenografts, in part due to the presence of hyaluronan [519]. The delivery of drugs such 
as docetaxel and liposomal doxorubicin to PC-3 tumors was reduced, due to the 
accumulation of hyaluronan [520]. Pályi-Krekk et al. investigated the role of 
hyaluronan and CD44 in trastuzumab resistance [521,522]. Trastuzumab is a 
recombinant humanized anti-ErbB2 antibody used in the treatment of breast cancer, 
however the mechanisms of resistance are poorly understood [521]. CD44 was found 
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to be overexpressed in the trastuzumab-resistant cell line JIMT-1, and flow cytometry 
fluorescence resonance energy transfer (FRET) measurements showed that CD44 
interacts with ErbB2 [521]. In mouse JIMT-1 xenografts, CD44 enhanced trastuzumab 
internalization while hyaluronan blocked the availability of ErbB2 to bind to 
trastuzumab, implicating the CD44-hyaluronan complex in the attenuation of receptor-
mediated therapy of tumor cells [521]. 
 
Tumor cell glycocalyx-targeted treatments 
 
The use of glycocalyx-degrading enzymes, such as hyaluronidases, have been 
explored as agents to degrade the glycocalyx coating and subsequently increase 
therapeutic diffusion and uptake to tumor cells. Early work by Brekken et al. 
investigated the effects on hyaluronidase on interstitial fluid pressure in solid tumors 
[518]. Intratumoral injections of bovine testicular hyaluronidase reduced interstitial 
fluid pressure of solid tumors up to 40%, 60 min post-injection [518]. Hyaluronidase 
treatment increased the diffusion of FITC-conjugated dextran macromolecules in 
human osteosarcomas grown as tumor spheroids and in tumor tissue in vivo, as 
measured using FRAP [519]. In terms of therapeutic delivery, hyaluronidase-treated 
orthotopic tumors increased the uptake and distribution of liposomal doxorubicin 
[523]. Thompson et al. utilized recombinant human hyaluronan-degrading enzyme 
rHuPH20 to deplete HA from the tumor cell surface, but found that its short serum 
half-life (< 3 min) made in vivo use impractical [520]. However, PEGlyation of 
rHuPH20 (PEGPH20) increased the serum half-life to over 10 h, depleted hyaluronan, 
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decreased interstitial fluid pressure by 84%, and decompressed tumor blood vessels 
[520]. PEGPH20 treatment increased the activity of both liposomal doxorubicin and 
docetaxel in PC-3 tumors. 
Given its physiological role and its presence throughout the human body, 
systemic administration of hyaluronidase could have unwanted side effects. Enzymatic 
degradation via hyaluronidase can induce inflammation and pain in joints, and its pH 
sensitivity and short half life in serum makes it difficult to efficiently administer [524]. 
To combat this, Yang et al. recently developed oligosaccharides of hyaluronan (oHA)-
lipid-paclitaxel nanoparticles to breach the glycocalyx barrier for therapeutic delivery 
[525]. oHA is broken down from hyaluronan by hyaluronidase, possesses binding sites 
for CD44, and can act as an antagonist of CD44 interactions [526,527]. Additionally, 
due to its small size, oHA nanoparticles are able to breach through the glycocalyx 
barrier to access CD44 receptors. Upon treatment with oHA, the glycocalyx of MDA-
MB-231 and BT-249 breast cancer cells was disrupted via oHA interactions with 
CD44, and subsequent detachment of hyaluronan from the cell surface [525]. 
Compared to treatment with lipid-paclitaxel nanoparticles alone, which induced 
apoptosis in approximately 30% of both breast cancer cell lines, the addition of oHA 
to nanoparticles extended apoptosis to over 90% of cells [525]. The efficacy of the 
approach was also confirmed in vivo using a mouse xenograft model [525]. 
Surprisingly, little is known about CTC glycocalyx thickness and composition, 
and subsequent glycocalyx-mediated CTC resistance to therapeutics. While CTCs in 
blood are frequently apoptotic [469], it is possible that those that metastasize to 
anatomically distant organs have distinct survival advantages through retention of 
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their glycocalyx. The glycocalyx can allow CTCs to evade anoikis, while also 
providing a barrier for therapeutics to bind to cell surface receptors [43]. In particular, 
CTC therapeutic strategies involving E-selectin targeting and TRAIL-induced 
apoptosis can be affected by the presence of a CTC glycocalyx layer by blocking 
interactions with E-selectin ligands and death receptors on CTCs. Glycocalyx-
degrading enzymes can thus increase the availability of CTC ligands for therapeutic 
purposes. In contrast, if CTCs that remain viable do not possess a glycocalyx layer, 
then targeting mechanisms utilizing E-selectin can provide an efficient method to 
localize therapeutic ligands to the CTC surface under physiological flow conditions. 
Future work should focus on direct glycocalyx measurements on CTCs, tumor cell-
specific glycocalyx-degrading enzymes to increase the availability of drug binding 
sites, and subsequent therapeutic treatment of CTCs.  
 
I.6  CONCLUSION 
 
The transport of CTCs via the bloodstream can be altered due to the presence 
of the glycocalyx expressed on ECs and CTCs. On surface of ECs, the glycocalyx can 
act a barrier to prevent interactions between adhesion receptors on ECs and ligands on 
the CTC surface. Inflammation, MMPs, and changes in fluid shear stress can act to 
disrupt, remodel, and induce shedding of the glycocalyx. These factors can increase 
the availability of adhesion receptors on the EC surface, which in turn may promote 
CTC adhesion to the endothelium. Similar adhesive interactions can be utilized to 
target therapeutics to CTCs, such as apoptosis-inducing ligands, to potentially reduce 
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the spread of metastasis. However, overexpression of hyaluronan leads to the 
formation of thicker glycocalyx coating around tumor cells, providing a “shield” 
against therapeutic ligand delivery to the cell surface. Recent advances that aim to 
disrupt glycocalyx adhesion to the tumor cell surface provide a means to more 
effectively deliver therapeutic agents to CTCs. A better understanding of the factors 
that disrupt the EC glycocalyx to promote tumor cell adhesion, along with strategies to 
breach CTC therapeutic barriers, will lead to greater control and potential intervention 
of CTC vascular transport. 
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FIGURE I.1: SCHEMATICS OF THE ENDOTHELIAL CELL AND TUMOR 
CELL GLYCOCALYX. Schematics of the endothelial cell (A) and tumor cell (B) 
glycocalyx (not drawn to scale). (A) Endothelial cell glycocalyx can extend 150-500 
nm from the endothelial cell surface, with a typical spacing of 20 nm between 
glycocalyx components (adapted from Weinbaum et al. [528]). (B) Tumor cell 
glycocalyx consists of similar components, but is characterized by greater hyaluronan 
content, which is tethered to the tumor cell membrane by CD44.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Endothelial Cell Surface 
Glycocalyx Brush Structure 
150-500 nm
 
20 nm 
Tumor Cell Surface 
v"
CD44 
Hyaluronan 
B 
Figure 1 
 341 
FIGURE I.2: GLYCOCALYX EFFECTS ON CIRCULATING TUMOR CELL 
(CTC) ADHESION IN THE MICROVASCULATURE. Glycocalyx effects on 
circulating tumor cell (CTC) adhesion in the microvasculature. (A) Under normal 
physiological conditions, the endothelial cell glycocalyx thickness is greater than the 
length of most adhesion receptors, and acts as a barrier to cell adhesion. (B) 
Alterations in shear stress, inflammatory conditions, and matrix metalloproteinase 
(MMP) exposure can cause shedding and/or remodeling of the glycocalyx, increasing 
the number of available receptors to bind to adhesion ligands on CTCs. 
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FIGURE I.3: E-SELECTIN MEDIATED DELIVERY OF THERAPEUTICS TO 
CIRCULATING TUMOR CELLS (CTCS) IN THE BLOODSTREAM. Under 
physiological flow conditions, E-selectin conjugated nanoparticles can rapidly bind to 
E-selectin ligands on the CTC surface. This adhesive interaction can be utilized to 
deliver a variety of therapeutic ligands or small molecules to CTCs, which can then 
induce CTC apoptosis. 
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FIGURE I.4: GLYCOCALYX AS A BARRIER TO THERAPEUTIC 
DELIVERY. Overexpression of glycocalyx components, such as hyaluronan, can 
create a molecular barrier to “shield” therapeutic-binding receptors from interaction 
with therapeutic ligands. 
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APPENDIX II: MILLISECOND PULSES OF FLUID SHEAR STRESS 
SUPPRESS CHEMOATTRACTANT-INDUCED NEUTROPHIL 
ACTIVATION 
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II.1 INTRODUCTION 
 
Fluid shear stress (FSS) is a ubiquitous component of the microenvironment 
for leukocytes, as they carry out the physiological processes of initial adhesion to the 
endothelium, the formation of pseudopods, and migration into tissues [176]. Our lab 
has recently shown that leukocytes exposed to low venular fluid shear stresses (0.1-4.0 
dyn/cm2) develop a resistance to chemoattractant-induced activation [91]. However, 
leukocytes can transiently encounter FSS values >1000 dyn/cm2 in the heart, near the 
walls of large blood vessels, and at vessel bifurcations. Herein, we evaluated the effect 
of millisecond FSS pulses on the neutrophil response to chemoattractants. 
 
II.2 MATERIALS AND METHODS 
 
Neutrophils isolated from peripheral human blood following informed consent 
were exposed to 1-10 millsecond FSS pulses via perfusion through microscale 
conduits using a high-pressure syringe pump, followed by exposure to the 
chemoattractant formyl-methionyl-leucyl-phenylalanine (fMLP, 10 nM) or tumor 
necrosis factor alpha (TNF-alpha, 20 nM). Expression and spatial distribution of L-
selectin, activated αMβ2 integrins, and formyl peptide receptors (FPR) were analyzed 
using flow cytometry and confocal microscopy. Neutrophil morphology and the 
appearance of pseudopods were imaged using brightfield and phase contrast 
microscopy, with images used to measure neutrophil shape factor using an edge 
detection function.   
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II.3 RESULTS AND DISCUSSION 
 
In the absence of fMLP stimulation (Figure II.1), neutrophils exhibited 
minimal activation when exposed to either static conditions or 5 millisecond FSS 
pulses (wall shear stress (WSS) = 5920 dynes/cm2, exposure time = 1.08 ms). 
Neutrophil samples exposed to static conditions followed by 10 nM fMLP stimulation 
resulted in a 36% loss of L-selectin and 34% αMβ2 integrin activation (Figure II.1). 
However, neutrophil exposure to 5 millisecond FSS pulses followed by stimulation 
with 10 nM fMLP reduced L-selectin loss to 16%, and αMβ2 integrin activation to 9% 
(Figure II.1). No significant difference in L-selectin shedding and αMβ2 integrin 
activation was found between sheared and nonsheared neutrophils, whereas a 
significant reduction in fMLP-induced L-selectin shedding and αMβ2 integrin 
activation was found in neutrophils exposed to FSS pulses (Figure II.2). Neutrophil 
resistance to fMLP-induced activation was FSS pulse-dependent, as 5 pulses of FSS 
were required to induce neutrophil resistance to activation (Figure II.3). 
To compare the effects of increasing shear stress exposure time versus 
increasing shear stress magnitude, the integral of shear stress magnitude over exposure 
time was kept constant, while either shear exposure time or shear stress magnitude 
was increased (Figure II.4). With a decrease in shear stress magnitude (5920 to 2960 
dyn/cm2) and increase in shear exposure time (1.08 to 2.16 ms), fMLP-induced 
neutrophil activation decreased, as indicated by decreased L-selectin shedding from 
22% to 12%, and decreased αMβ2 integrin activation from 23% to 11% (Figure II.4). 
Further decreases in shear stress magnitude and increases in shear stress exposure time 
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decreased fMLP-induced neutrophil activation (Figure II.5), demonstrating that 
increasing shear stress exposure time has a greater effect on neutrophil resistance to 
fMLP-induced activation than increasing shear stress magnitude. 
To assess the effect of fluid shear stress on non-G protein coupled receptors, 
neutrophils were exposed to millisecond shear stress pulses followed by incubation 
with 20 nM TNF-alpha, which binds to membrane bound receptors TNFR1 and 
TNFR2. Millisecond fluid shear stress pulses did not have a significant effect on TNF-
alpha induced neutrophil activation, as compared to static controls (Figure II.6). 
To determine the effect of millisecond fluid shear stress on fMLP-induced 
neutrophil morphological changes, neutrophils were fixed and imaged using 
brightfield microscopy. Based on contrast, neutrophils were thresholded (Figure II.7), 
and shape factor was calculated as detailed in Chapter 2. Preliminary results indicate 
that millisecond pulses of fluid shear suppress fMLP-induced morphological changes, 
as indicated by increased shape factor values for neutrophils pre-exposed to FSS 
followed by fMLP treatment (Figure II.8) compared to static samples exposed to 
fMLP. These results suggest that millisecond pulses of high FSS can decrease fMLP-
induced neutrophil morphological changes. 
 
II.4. CONCLUSION 
 
We have shown that brief exposure to millisecond pulses of FSS can induce a 
mechanosensitive response in human neutrophils. Exposure to high FSS pulses reduce 
neutrophil activation in the presence of bacterial peptides, and likely serve as a 
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physiological regulator of neutrophil activation and invasion into tissues. Insight into 
the molecular basis of the neutrophil response can reveal important drug targets for 
inflammation and hemostasis. 
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FIGURE II.1: REPRESENTATIVE FLOW CYTOMETRY PLOTS OF FMLP-
INDUCED NEUTROPHIL ACTIVATION AFTER EXPOSURE TO 
MILLISECOND FLUID SHEAR STRESS PULSES. Neutrophils exposed to static 
conditions or 5 submillisecond pulses of FSS (WSS= 5920 dyn/cm2, pulse time = 1.08 
ms) followed by 10 nM fMLP treatment. As indicators of activation, neutrophils were 
labeled for L-selectin expression and αMβ2 activation and analyzed using flow 
cytometry.  
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Introduction: Fluid shear stress (FSS) exposure is critical for 
physiological functions of leukocytes, including initial 
adhesion to the endothelium, the formation of pseudopods, and 
migration into tissues. Our lab has recently shown that 
leukocytes exposed to low venular fluid shear stresses (0.1-4.0 
dyn/cm2) develop a resistance to chemoattractant-induced 
activation (1). However, leukocytes can transiently encounter 
FSS values >1000 dyn/cm2 in the heart, near the walls of large 
blood vessels, and at vessel bifurcations. Herein, we evaluated 
the effect of submillisecond FSS pulses on the neutrophil 
response to chemoattractants. 
 
Materials and Methods: Human neutrophils isolated from 
peripheral blood were exposed to 1-10 submillsecond FSS 
pulses via perfusion through microchannels using a high-
pressure syringe pump, followed by exposure to the 
chemoattractant formyl-methionyl-leucyl-phenylalanine 
(fMLP). Expression and spatial distribution of L-selectin, 
activated αMβ2 integrins, and formyl peptide receptors (FPR) 
were analyzed using flow cytometry and confocal microscopy. 
Neutrophil morphology and the appearance of pseudopods 
were imaged using brightfield and phase contrast microscopy, 
with images used to measure neutrophil shape factor using an 
edge detection function.  Expression of phosphorylated 
proteins including p38 MAPK and c-Abl were determined 
using a Bio-Plex phosphorylated protein detection system. 
 
Results and Discussion: In the absence of fMLP stimulation 
(Fig. 1A), neutrophils exhibited minimal activation when 
exposed to either static conditions or 5 submillisecond FSS 
pulses (wall shear stress (WSS) = 6400 dynes/cm2,  exposure 
time = 0.89 ms). Neutrophil samples exposed to static 
conditions followed by 10 nM fMLP stimulation resulted in a 
36% loss of L-selectin and 34% αMβ2 integrin activation (Fig. 
1A). However, neutrophil exposure to 5 submillisecond FSS 
pulses followed by stimulation with 10 nM fMLP reduced L-
selectin loss to 16%, and αMβ2 integrin activation to 9% (Fig. 
1A). No significant difference in L-selectin shedding and αMβ2 
integrin activation was found between sheared and nonsheared 
neutrophils, whereas a significant reduction in fMLP-induced 
L-selectin shedding and αMβ2 integrin activation was found in 
neutrophils exposed to FSS pulses (Fig. 1B). Neutrophil 
resistance to fMLP-induced activation was FSS pulse-
dependent, as 5 pulses of FSS were required to induce 
neutrophil resistance to activation (Fig. 1C). 
 
Conclusions:  We have shown that brief exposure to 
submillisecond pulses of FSS can induce a mechanosensitive 
Figure 1: Submillisecond FSS pulses suppress 
fMLP-induced neutrophil activation. (A) 
Neutrophils exposed to static conditions or 5 
submillisecond pulses of FSS (WSS= 6400 
dyn/cm2, pulse time = 0.89 ms) followed by 10 
nM fMLP treatment. As indicators of 
activation, neutrophils were labeled for L-
selectin expression and αMβ2 activation and 
analyzed using flow cytometry. (B) Neutrophil 
L-selectin shedding and αMβ2 activation from n 
= 4 donors, when exposed to FSS and/or fMLP. 
(C) Neutrophil fMLP-induced L-selectin 
shedding and αMβ2 activation after exposure to 
1-10 submillisecond FSS pulses. 
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FIGURE II.2: MILLISECOND PULSES OF FLUID SHEAR STRESS 
SUPPRESS FMLP-INDUCED NEUTROPHIL ACTIVATION. Neutrophil L-
selectin shedding and αMβ2 activation from n = 4 donors, when exposed to FSS 
(WSS= 5920 dyn/cm2, pulse time = 1.08 ms) and/or 10 nM fMLP.  
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Introduction: Fluid shear stress (FSS) exposure is critical for 
physiological functions of leukocytes, including initial 
adhesion to the endothelium, the formation of pseudopods, and 
migration into tissues. Our lab has recently shown that 
leukocytes exposed to low venular fluid shear stresses (0.1-4.0 
dyn/cm2) develop a resistance to chemoattractant-induced 
activation (1). However, leukocytes can transiently encounter 
FSS values >1000 dyn/cm2 in the heart, near the walls of large 
blood vessels, and at vessel bifurcations. Herein, we evaluated 
the effect of submillisecond FSS pulses on the neutrophil 
response to chemoattractants. 
 
Materials and Methods: Human neutrophils isolated from 
peripheral blood were exposed to 1-10 submillsecond FSS 
pulses via perfusion through microchannels using a high-
pressure syringe pump, followed by exposure to the 
chemoattractant formyl-methionyl-leucyl-phenylalanine 
(fMLP). Expression and spatial distribution of L-selectin, 
activated αMβ2 integrins, and formyl peptide receptors (FPR) 
were analyzed using flow cytometry and confocal microscopy. 
Neutrophil morphology and the appearance of pseudopods 
were imaged using brightfield and phase contrast microscopy, 
with images used to measure neutrophil shape factor using an 
edge detection function.  Expression of phosphorylated 
proteins including p38 MAPK and c-Abl were determined 
using a Bio-Plex phosphorylated protein detection system. 
 
Results and Discussion: In the absence of fMLP stimulation 
(Fig. 1A), neutrophils exhibited minimal activation when 
exposed to either static conditions or 5 submillisecond FSS 
pulses (wall shear stress (WSS) = 6400 dynes/cm2,  exposure 
time = 0.89 ms). Neutrophil samples exposed to static 
conditions followed by 10 nM fMLP stimulation resulted in a 
36% loss of L-selectin and 34% αMβ2 integrin activation (Fig. 
1A). However, neutrophil exposure to 5 submillisecond FSS 
pulses followed by stimulation with 10 nM fMLP reduced L-
selectin loss to 16%, and αMβ2 integrin activation to 9% (Fig. 
1A). No significant difference in L-selectin shedding and αMβ2 
integrin activation was found between sheared and nonsheared 
neutrophils, whereas a significant reduction in fMLP-induced 
L-selectin shedding and αMβ2 integrin activation was found in 
neutrophils exposed to FSS pulses (Fig. 1B). Neutrophil 
resistance to fMLP-induced activation was FSS pulse-
dependent, as 5 pulses of FSS were required to induce 
neutrophil resistance to activation (Fig. 1C). 
 
Conclusions:  We have shown that brief exposure to 
submillisecond pulses of FSS can induce a mechanosensitive 
Figure 1: Submillisecond FSS pulses suppress 
fMLP-induced neutrophil activation. (A) 
Neutrophils exposed to static conditions or 5 
submillisecond pulses of FSS (WSS= 6400 
dyn/cm2, pulse time = 0.89 ms) followed by 10 
nM fMLP treatment. As indicators of 
activation, neutrophils were labeled for L-
selectin expression and αMβ2 activation and 
analyzed using flow cytometry. (B) Neutrophil 
L-selectin shedding and αMβ2 activation from n 
= 4 donors, when exposed to FSS and/or fMLP. 
(C) Neutrophil fMLP-induced L-selectin 
shedding and αMβ2 activation after exposure to 
1-10 submillisecond FSS pulses. 
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Introduction: Fluid shear stre s (FSS) exposure is critical for 
physiological functions of leukocytes, including initial 
adhesion to the endothelium, the formation of pseudopods, and 
migration into ti sues. Our lab has recently shown that 
leukocytes exposed to low venular fluid shear stresses (0.1-4.0 
dyn/cm2) develop a resistance to chemoa tractant-induced 
activation (1). However, leukocytes can transiently encounter 
FSS values >1000 dyn/cm2 in the heart, near the wa ls of large 
blood ve sels, and at ve sel bifurcations. Herein, we evaluated 
the e fect of submi lisecond FSS pulses on the neutrophil 
response to chemoa tractants. 
 
Materials and ethods: Human neutrophils isolated fro  
peripheral blood were exposed to 1-10 sub i lsecond FSS 
pulses via perfusion through microchannels using a high-
pre sure syringe pump, fo lowed by exposure to the 
chemoa tractant formyl-methionyl-leucyl-phenylalanine 
(fMLP). Expre sion and spatial distribution of L-selectin, 
activated αMβ2 integrins, and formyl peptide receptors (FPR) 
were analyzed using flow cytometry and confocal icroscopy. 
Neutrophil morphology and the appearance of pseudopods 
were imaged using brightfield and phase contrast icroscopy, 
with images used to measure neutrophil shape factor using an 
edge detection function.  Expre sion of phosphorylated 
proteins including p38 APK and c-Abl were deter ined 
using a Bio-Plex phosphorylated protein detection syste . 
 
Results and Discu sion: In the absence of f LP sti ulation 
(Fig. 1A), neutrophils exhibited minimal activation when 
exposed to either static conditions or 5 submi lisecond FSS 
pulses (wa l shear stre s ( SS) = 6400 dynes/c 2,  exposure 
time = 0.89 ms). Neutrophil samples exposed to static 
conditions fo lowed by 10 n  f LP stimulation resulted in a 
36% lo s of L-selectin and 34% αMβ2 integrin activation (Fig. 
1A). However, neutrophil exposure to 5 submi lisecond FSS 
pulses fo lowed by stimulation with 10 n  f LP reduced L-
selectin lo s to 16%, and αMβ2 integrin activation to 9  (Fig. 
1A). No significant di ference in L-selectin shedding and αMβ2 
integrin activation was found between sheared and nonsheared 
neutrophils, whereas a significant reduction in f LP-induced 
L-selectin shedding and αMβ2 integrin activation was found in 
neutrophils exposed to FSS pulses (Fig. 1B). Neutrophil 
resistance to fMLP-induced activation was FSS pulse-
dependent, as 5 pulses of FSS were required to induce 
neutrophil resistance to activation (Fig. 1C). 
 
Conclusions:  e have shown that brief exposure to 
submillisecond pulses of FSS can induce a mechanosensitive 
Figure 1: Sub i lisecond FSS pulses s ress 
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FIGURE II.3: SUPPRESSION OF FMLP-INDUCED NEUTROPHIL 
ACTIVATION IS FLUID SHEAR STRESS PULSE-DEPENDENT. Neutrophil 
fMLP-induced (10 nM fMLP) L-selectin shedding and αMβ2 activation after exposure 
to 1-10 millisecond FSS pulses (WSS= 5920 dyn/cm2, pulse time = 1.08 ms). 
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dependent, as 5 pulses of FSS were required to induce 
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FIGURE II.4: DEPENDENCE OF SHEAR STRESS MAGNITUDE AND 
SHEAR STRESS EXPOSURE TIME ON FMLP-INDUCED NEUTROPHIL 
ACTIVATION. Neutrophil fMLP-induced (10 nM fMLP) L-selectin shedding and 
αMβ2 activation after exposure to FSS pulses of decreasing shear stress magnitude and 
increasing shear exposure time. 
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dependent, as 5 pulses of FSS were required to induce 
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Figure 1: Submillisecond FSS pulses suppress 
fMLP-induced neutrophil activation. (A) 
Neutrophils exposed to static conditions or 5 
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dyn/cm2, pulse time = 0.89 ms) followed by 10 
nM fMLP treatment. As indicators of 
activation, neutrophils were labeled for L-
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analyzed using flow cytometry. (B) Neutrophil 
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Figure 1: Submillisecond FSS pulses suppress 
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Neutrophils exposed to static conditions or 5 
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36% loss of L-selectin and 34% αMβ2 integrin activation (Fig. 
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selectin loss to 16%, and αMβ2 integrin activation to 9% (Fig. 
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Figure 1: Submillisecond FSS pulses suppress 
fMLP-induced neutrophil activation. (A) 
Neutrophils exposed to static conditions or 5 
submillisecond pulses of FSS (WSS= 6400 
dyn/cm2, pulse time = 0.89 ms) followed by 10 
nM fMLP treatment. As indicators of 
activation, neutrophils were labeled for L-
selectin expression and αMβ2 activation and 
analyzed using flow cytometry. (B) Neutrophil 
L-selectin shedding and αMβ2 activation from n 
= 4 donors, when exposed to FSS and/or fMLP. 
(C) Neutrophil fMLP-induced L-selectin 
shedding and αMβ2 activation after exposure to 
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FIGURE II.5: SHEAR STRESS EXPOSURE TIME HAS A LARGER EFFECT 
ON NEUTROPHIL ACTIVATION SUPPRESSION THAN SHEAR STRESS 
MAGNITUDE. Neutrophil fMLP-induced L-selectin shedding and αMβ2 activation 
after exposure to FSS pulses of decreasing shear stress magnitude and increasing shear 
exposure time for n = 2 donors. 
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FIGURE II.6: EFFECT OF MILLISECOND FLUID SHEAR STRESS PULSE 
PRE-EXPOSURE ON TNF-ALPHA INDUCED NEUTROPHIL ACTIVATION. 
Neutrophils exposed to static conditions or 5 submillisecond pulses of FSS (WSS= 
6400 dyn/cm2, pulse time = 0.89 ms) followed by 20 nM TNF-alpha treatment (treated 
samples). As indicators of activation, neutrophils were labeled for L-selectin 
expression and αMβ2 activation and analyzed using flow cytometry. 
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FIGURE II.7: REPRESENTATIVE NEUTROPHIL THRESHOLDING FOR 
SHAPE FACTOR CALCULATIONS. Neutrophils exposed to untreated static 
conditions or 10 nM fMLP were imaged using brightfield microscopy. Neutrophils 
were thresholded based on contrast, and utilized for shape factor calculations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Shearing and Shape Factor 
 Shape factor – A measure of a cell’s circularity (i.e. 
deviation from a non-activated neutrophil shape). 
A shape factor of 1 denotes a perfectly circular 
cell. 
 
 
 
 
 
 
 
Cells were thresholded (blue) and measured using 
Metamorph 
fcirc =
4πA
P23. Shearing and Shape Factor 
 Shape factor – A measure of a cell’s circularity (i.e. 
deviation from a non-activated neutrophil shape). 
A shape factor of 1 denotes a perfectly circular 
cell. 
 
 
 
 
 
 
 
Cells were thresholded (blue) and measured using 
Metamorph 
fcirc =
4πA
P2
Untreated 
10 nM fMLP 
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FIGURE II.8: SHAPE FACTOR CALCULATIONS OF NEUTROPHILS 
AFTER MILLISECOND SHEAR STRESS PULSE EXPOSURE AND FMLP 
TREATMENT. Neutrophils exposed to static conditions or 5 submillisecond pulses 
of FSS (WSS= 6400 dyn/cm2, pulse time = 0.89 ms) followed by 10 nM fMLP 
treatment. Shape factors were calculated based on thresholded neutrophils. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Shearing and Shape Factor 
Results have been consistent with previous 
experiments and expectations 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sheared treated cells have a higher shape factor 
than their static counterparts  
 
Treatment Shape Factor 
Static, Untreated 0.895973 
Static, Treated 0.812171 
Sheared, Untreated 0.883005 
Sheared, Treated 0.860058 
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APPENDIX III: LAMIN A/C DEFICIENCY REDUCES TUMOR CELL 
RESISTANCE TO FLUID SHEAR STRESS 
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III.1 INTRODUCTION 
 
Metastasis is the cause approximately 90% cancer-related deaths [1,333]. 
Metastasis can involve the presence of circulating tumor cells (CTCs) in the 
bloodstream, which are believed to undergo an adhesion cascade similar to leukocytes. 
This process consists of a discrete sequence of steps involving tethering, rolling, and 
firm adhesion between CTCs and the inflamed endothelium [51,52]. Cancer cells from 
the primary tumor detach, invade the surrounding tissue, and intravasate into the 
bloodstream as CTCs [1,51,365,366]. Following intravasation, CTCs interact with the 
vasculature by selectin-mediated rolling and cell arrest, can extravasate into the tissue 
of anatomically distant organs and proliferate to form a secondary tumor [1,51,52]. 
Although only a small fraction of CTCs survive within the circulation [334,367], the 
development of metastases remains as the primary cause of cancer-related mortality. 
Fluid shear stress is one of the key factors can affect the viability of cancer cells in 
the bloodstream. Cancer cells are exposed to fluid shear stresses in the bloodstream 
ranging from 1.0-4.0 dyn/cm2 in the venous circulation and 4.0-30.0 dyn/cm2 in 
arterial circulation [46]. Such shear stresses can affect cancer cell viability and thus 
the chances of metastasis. For example, B16 melanoma cell exposure to fluid shear 
stress in a cone-and-plate viscometer at shear rates greater than 300 s-1 induced a 
significant loss of cell viability [47].  
Recently, a microfluidic protocol was developed to assess the cancer cell response 
to fluid shear stress [92]. In the protocol, dilute cancer cell suspensions were drawn up 
into a syringe, which is then loaded into an automatic syringe pump. Cancer cell 
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suspensions were exposed to brief, millisecond pulses of high fluid shear stress as they 
were expelled from the syringe pump, and subsequently analyzed for cell viability 
using bioluminescent imaging. The maximum fluid shear stress that cancer cells were 
briefly exposed to in this experiment reached 6400 dyn/cm2. CTCs are momentarily 
exposed to shear stresses as high as 3000 dyn/cm2 at vessel bifurcations, in the heart, 
and near the walls of large blood vessels [93,94]. Notably, it was found that malignant 
epithelial cells were more resistant to fluid shear stress than their non-malignant 
counterparts. However, the cellular structural components that contribute to this 
resistance remain poorly understood. Herein, were assessed the contribution of lamin 
A/C nuclear structural proteins to cancer cell resistance to fluid shear stress. 
 
III.2 MATERIALS AND METHODS 
 
Neutrophils isolated from peripheral human blood (following informed 
consent), metastatic breast cancer MDA-MB-231, and mammary breast MCF10A cell 
lines were labeled with a fluorescent BCECF viability dye and exposed to 1-10 
millsecond FSS pulses (WSS: 5920 dyn/cm2, Pulse time = 1.08 ms) via perfusion 
through microscale conduits using a high-pressure syringe pump (Figure III.1A). 
siRNA knockdown was utilized to create lamin A/C deficient MDA-MB-231 cancer 
cells from both heterogeneous and clonal populations for FSS pulse studies. To mimic 
physiological exposure to high FSS, cells were exposed to a pulse of high FSS once 
over a 90 s time period. Cells were placed into culture overnight for ~ 24 h, and the 
number of viable cells expressing BCECF was quantified via flow cytometry.  
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To characterize the mode of cell death, non-labeled cells were exposed to 10 
pulses of high fluid shear stress (WSS: 5920 dyn/cm2), placed back into culture for 90 
min, and assessed for apoptosis and necrosis using a dual-labeling annexin-
V/propidium iodide (PI) assay. Cell populations were gated based on viable cell 
controls. Lower left-hand quadrant (Annexin-V negative, PI negative) denotes viable 
cells. Upper left-hand quadrant (Annexin-V negative, PI positive) denotes necrotic 
cells. Lower right-hand quadrant (Annexin-V positive, PI negative) denotes early-
apoptotic cells. Upper right-hand quadrant (Annexin-V positive, PI positive) denotes 
late-apoptotic cells. 
 
III.3 RESULTS AND DISCUSSION 
 
 We initially compared the viability of primary leukocytes, malignant breast 
MDA-MB-231, and non-malignant MCF10A cell lines after exposure to pulses of 
high FSS (Figure III.1). Under static conditions, all cell types remained generally 
viable (Figure III.1B). However, malignant MDA-MB-231 cell viability was 
significantly higher than the viability of non-malignant MCF10A cells after exposure 
to pulses of high fluid shear stress (Figure III.1B). The response is fluid shear stress 
pulse-dependent, as MDA-MB-231 cells remained significantly more viable than 
MCF10A cells, which significantly decreased in viability with increased number of 
high FSS pulses (Figure III.1C). Leukocytes, which are typically exposed to high FSS 
in the circulation, remained generally viable throughout all experiments.  
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 To assess the mode of cell death, MDA-MB-231 and MCF10A cells were 
assessed for apoptosis and necrosis using an Annexin-V assay. After FSS exposure, an 
increase in both apoptosis and necrosis was observed in both MDA-MB-231 and 
MCF10A cells (Figure III.2), compared to static controls. A significant increase in 
both apoptosis and necrosis was observed for non-malignant MCF10A cells exposed 
to pulses of high FSS, compared to malignant MDA-MB-231 cells exposed to high 
FSS (Figure III.3). Taken together, these results suggest that while cancer cell viability 
is decreased upon high FSS exposure, malignant epithelial cells are relatively more 
resistant to high FSS than their non-malignant epithelial counterparts. 
 To assess the role of lamin A/C nuclear structural proteins on cancer cell 
resistance to FSS, lamin A/C deficient MDA-MB-231 cancer cell lines (both clonal 
and heterogeneous populations) were developed via siRNA knockdown. All cell lines, 
including scambled controls, remained generally viable under static conditions, 
compared to parental cell line samples (Figure III.4). Upon exposure to pulses of high 
FSS, a significant decrease in cell viability was observed in lamin A/C deficient 
MDA-MB-231 cancer cell lines, both from clonal and heterogeneous populations, 
compared to scrambled and parental controls exposed to pulses of high FSS. The 
response is FSS pulse-dependent, as the viability of lamin A/C deficient MDA-MB-
231 cancer cell lines from clonal and heterogeneous populations significantly 
decreased with increasing number of FSS pulses, compared to scrambled and parental 
controls (Figure III.5). 
 To assess the mode of cell death, lamin A/C deficient MDA-MB-231 cells 
were assessed for apoptosis and necrosis using an Annexin-V assay. FSS exposure 
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was found to induce both apoptosis and necrosis in lamin A/C deficient MDA-MB-
231 cancer cells (Figure III.6). Interestingly, exposure to pulses of high FSS only 
induced a significant increase in apoptosis in lamin A/C deficient MDA-MB-231 cells, 
compared to scrambled and parental cell controls (Figure III.7). After exposure to 
pulses of high FSS, no significant differences in cell necrosis were observed between 
lamin A/C deficient MDA-MB-231 cells and controls (Figure III.7). Taken together, 
these results suggest lamin A/C deficiency can reduce tumor cell resistance to FSS, 
through an increase in cell apoptosis. 
 
III.4 CONCLUSIONS 
 
 I have shown that high pulses of FSS can affect cancer cell viability, compared 
to normal blood cells that typically reside in the circulation. However, malignant 
epithelial cells were shown to be relatively resistant to pulses of high FSS compared to 
non-malignant epithelial cells. Cancer cell resistance to FSS is pulse-dependent, as 
cancer cell viability remained significantly higher than non-malignant epithelial cells 
with increased number of FSS pulses. Utilizing cancer cells deficient of the lamin A/C 
nuclear structural protein, it was shown that cancer cell viability significantly 
decreased upon exposure to FSS, due to an increase in cellular apoptosis. Thus, lamin 
A/C could play a key role in CTCs survival in the bloodstream, and subsequent 
formation of secondary tumors. 
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FIGURE III.1: TUMOR CELLS RESIST FLUID SHEAR STRESS-INDUCED 
CELL DEATH COMPARED TO NON-MALIGNANT EPITHELIAL CELLS. 
(A) Schematic of microscale conduit used to expose cells in suspension to millisecond 
pulses of high fluid shear stress. WSS: wall shear stress. L: length of microscale 
conduit. R: radius of microscale conduit. (B) Percentage of viable leukocytes, tumor 
cells (MDA-MB-231), and non-malignant epithelial cells (MCF10A) after exposure to 
static conditions (static) or 10 millisecond pulses of fluid shear stress (shear). All cell 
types were labeled with a cell viability dye (BCECF), exposed to fluid shear stress, 
and immediately placed back into culture for ~ 24 h. Viability determined via flow 
cytometry by number of cells expressing BCECF. WSS = 5920 dyn/cm2. (C) Dose 
response of cells to fluid shear stress. Cell types were exposed to 0-10 pulses of fluid 
shear stress. *P < 0.05. **P < 0.01. NS: not significant. Data are mean ± SEM of three 
independent measurements. 
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FIGURE III.1: TUMOR CELLS RESIST FLUID SHEAR STRESS-INDUCED 
CELL DEATH COMPARED TO NON-MALIGNANT EPITHELIAL CELLS. 
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FIGURE III.2: EXPOSURE TO FSS INDUCES BOTH APOPTOTIC AND 
NECROTIC CELL DEATH IN MDA-MB-231 AND MCF10A CELLS. Cells 
were exposed to 10 pulses of high fluid shear stress (WSS: 5920 dyn/cm2), placed 
back into culture for 90 min, and assessed for apoptosis and necrosis using an annexin-
V/propidium iodide (PI) assay. (A-D) Annexin-V/propidium iodide (PI) flow 
cytometry plots of MDA-MB-231 (A,C) and MCF10A (B,D) cells exposed to static 
conditions (A,B) and millisecond pulses of fluid shear stress (C,D). Lower left-hand 
quadrant (Annexin-V negative, PI negative) denotes viable cells. Upper left-hand 
quadrant (Annexin-V negative, PI positive) denotes necrotic cells. Lower right-hand 
quadrant (Annexin-V positive, PI negative) denotes early-apoptotic cells. Upper right-
hand quadrant (Annexin-V positive, PI positive) denotes late-apoptotic cells. 
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FIGURE III.2: EXPOSURE TO FSS INDUCES BOTH APOPTOTIC AND 
NECROTIC CELL DEATH IN MDA-MB-231 AND MCF10A CELLS. 
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FIGURE III.3: DECREASED APOPTOSIS AND NECROSIS IN MALIGNANT 
MDA-MB-231 CELLS COMPARED TO NON-MALIGNANT MCF10A CELLS. 
Cells were exposed to 10 pulses of high fluid shear stress (WSS: 5920 dyn/cm2), 
placed back into culture for 90 min, and assessed for apoptosis and necrosis using an 
annexin-V/propidium iodide (PI) assay. (A) Percentage of viable MDA-MB-231 and 
MCF10A cells after exposure to static conditions (static) or 10 pulses of high fluid 
shear stress (shear). (B) Percentage of apoptotic MDA-MB-231 and MCF10A cells 
after exposure to static conditions (static) or 10 pulses of high fluid shear stress 
(shear). (C) Percentage of necrotic MDA-MB-231 and MCF10A cells after exposure 
to static conditions (static) or 10 pulses of high fluid shear stress (shear). *P < 0.05. 
NS: not significant. Data are mean ± SEM of three independent measurements. 
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FIGURE III.3: DECREASED APOPTOSIS AND NECROSIS IN MALIGNANT 
MDA-MB-231 CELLS COMPARED TO NON-MALIGNANT MCF10A CELLS. 
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FIGURE III.4: LAMIN A/C DEFICIENCY REDUCES TUMOR CELL 
RESISTANCE TO FLUID SHEAR STRESS. Percentage of viable parental, clonal 
(scrambled and lamin A/C siRNA knockdown), and heterogeneous (scrambled and 
lamin A/C siRNA knockdown) populations of MDA-MB-231 cells after exposure to 
static conditions or 10 millisecond pulses of fluid shear stress. All cell types were 
labeled with a cell viability dye (BCECF), exposed to fluid shear stress, and 
immediately placed back into culture for ~ 24 h. Viability determined via flow 
cytometry by number of cells expressing BCECF. WSS = 5920 dyn/cm2. 
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FIGURE III.5: FLUID SHEAR STRESS-INDUCED CELL DEATH IN LAMIN 
A/C-DEFICIENT MDA-MB-231 TUMOR CELLS IS FLUID SHEAR STRESS 
DOSE-DEPENDENT. Cell types were fluorescently tagged with a viability dye 
(BCECF) and exposed to 0-10 millisecond pulses of fluid shear stress (WSS = 5920 
dyn/cm2). Cells were placed back into culture for ~24 h and assessed for viability 
using flow cytometry. (A) Dose response of parental and heterogenous (scrambled and 
lamin A/C siRNA knockdown) populations of MDA-MB-231 cells to fluid shear 
stress. (B) Dose response of parental and clonal (scrambled and lamin A/C siRNA 
knockdown) populations of MDA-MB-231 cells to fluid shear stress. *P < 0.05. **P < 
0.01. NS: not significant. Data are mean ± SEM of three independent measurements. 
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FIGURE III.5: FLUID SHEAR STRESS-INDUCED CELL DEATH IN LAMIN 
A/C-DEFICIENT MDA-MB-231 TUMOR CELLS IS FLUID SHEAR STRESS 
DOSE-DEPENDENT.
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FIGURE III.6: EXPOSURE TO FSS INDUCES BOTH APOPTOTIC AND 
NECROTIC CELL DEATH IN LAMIN A/C-DEFICIENT MDA-MB-231 
CELLS. Cells were exposed to 10 pulses of high fluid shear stress (WSS: 5920 
dyn/cm2), placed back into culture for 90 min, and assessed for apoptosis and necrosis 
using an annexin-V/propidium iodide (PI) assay. (A-D) Annexin-V/propidium iodide 
(PI) flow cytometry plots of scrambled (A,C) and lamin A/C-deficient (B,D) MDA-
MB-231 cells derived a clonal population, exposed to static conditions (A,B) and 
millisecond pulses of fluid shear stress (C,D). Lower left-hand quadrant (Annexin-V 
negative, PI negative) denotes viable cells. Upper left-hand quadrant (Annexin-V 
negative, PI positive) denotes necrotic cells. Lower right-hand quadrant (Annexin-V 
positive, PI negative) denotes early-apoptotic cells. Upper right-hand quadrant 
(Annexin-V positive, PI positive) denotes late-apoptotic cells. 
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FIGURE III.6: EXPOSURE TO FSS INDUCES BOTH APOPTOTIC AND 
NECROTIC CELL DEATH IN LAMIN A/C-DEFICIENT MDA-MB-231 
CELLS. 
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FIGURE III.7: INCREASED APOPTOSIS AND NECROSIS IN LAMIN A/C-
DEFICIENT MDA-MB-231 TUMOR CELLS. Cells were exposed to 10 pulses of 
high fluid shear stress (WSS: 5920 dyn/cm2), placed back into culture for 90 min, and 
assessed for apoptosis and necrosis using an annexin-V/propidium iodide (PI) assay. 
(A,B) Percentage of viable MDA-MB-231 cells after exposure to static conditions (A) 
or 10 pulses of high fluid shear stress (B). (C,D) Percentage of apoptotic MDA-MB-
231 cells after exposure to static conditions (C) or 10 pulses of high fluid shear stress 
(D). (E,F) Percentage of necrotic MDA-MB-231 cells after exposure to static 
conditions (E) or 10 pulses of high fluid shear stress (F). Prtl: parental MDA-MB-231 
cell population. Scr: scrambled MDA-MB-231 cell population. *P < 0.05. NS: not 
significant. Data are mean ± SEM of three independent measurements. 
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FIGURE III.7: INCREASED APOPTOSIS AND NECROSIS IN LAMIN A/C-
DEFICIENT MDA-MB-231 TUMOR CELLS.
A B
C D
E F
50
40
30
20
10
0
%
 N
ec
ro
tic
 M
D
A
-M
B
-2
31
 (S
ta
tic
)
Scr  Lamin
A/C KD
 Lamin
A/C KD
ScrPrtl
NS
NS NS
50
40
30
20
10
0
%
 N
ec
ro
tic
 M
D
A
-M
B
-2
31
 (S
he
ar
)
Scr  Lamin
A/C KD
 Lamin
A/C KD
ScrPrtl
NS
NS NS
Hetero Pop Clonal Pop
Scr  Lamin
A/C KD
 Lamin
A/C KD
Scr
%
 V
ia
bl
e 
M
D
A
-M
B
-2
31
 (S
ta
tic
) 100
80
60
40
20
0
Prtl
NSNS
NS
50
40
30
20
10
0
%
 A
po
pt
ot
ic
 M
D
A
-M
B
-2
31
 (S
ta
tic
)
Scr  Lamin
A/C KD
 Lamin
A/C KD
ScrPrtl
NS
NS NS
50
40
30
20
10
0
%
 A
po
pt
ot
ic
 M
D
A
-M
B
-2
31
 (S
he
ar
)
Scr  Lamin
A/C KD
 Lamin
A/C KD
ScrPrtl
NS
*
*
%
 V
ia
bl
e 
M
D
A
-M
B
-2
31
 (S
he
ar
)
Scr  Lamin
A/C KD
 Lamin
A/C KD
Scr
100
80
60
40
20
0
Prtl
NS
*
*
 376 
REFERENCES 
 
[1] C.L. Chaffer, R.A. Weinberg, A Perspective on Cancer Cell Metastasis, 
Science. 331 (2011) 1559–1564. 
[2] A.F. Chambers, A.C. Groom, I.C. MacDonald, Dissemination and growth of 
cancer cells in metastatic sites, Nat Rev Cancer. (2002). 
[3] P.S. Steeg, Tumor metastasis: mechanistic insights and clinical challenges, 
Nature Medicine. 12 (2006) 895–904. doi:10.1038/nm1469. 
[4] C.C. DuFort, M.J. Paszek, V.M. Weaver, Balancing forces: architectural 
control of mechanotransduction, Nat Rev Mol Cell Biol. 12 (2011) 308–319. 
doi:10.1038/nrm3112. 
[5] D.T. Butcher, T. Alliston, V.M. Weaver, A tense situation: forcing tumour 
progression, Nat Rev Cancer. 9 (2009) 108–122. doi:10.1038/nrc2544. 
[6] D. Wirtz, K. Konstantopoulos, P.C. Searson, The physics of cancer: the role 
of physical interactions and mechanical forces in metastasis, Nat Rev 
Cancer. 11 (2011) 512–522. doi:10.1038/nrc3080. 
[7] Y. Tseng, J.S.H. Lee, T.P. Kole, I. Jiang, D. Wirtz, Micro-organization and 
visco-elasticity of the interphase nucleus revealed by particle nanotracking, 
Journal of Cell Science. 117 (2004) 2159–2167. doi:10.1242/jcs.01073. 
[8] A.D. Hughes, M.R. King, Nanobiotechnology for the capture and 
manipulation of circulating tumor cells, WIREs Nanomed Nanobiotechnol. 
4 (2011) 291–309. doi:10.1002/wnan.168. 
[9] F. Moazzam, F. DeLano, B. Zweifach, G. Schmid-Schonbein, The leukocyte 
 377 
response to fluid stress, Proc Natl Acad Sci USA. 94 (1997) 5338–5343. 
[10] M. Civelek, K. Ainslie, J.S. Garanich, J.M. Tarbell, Smooth muscle cells 
contract in response to fluid flow via a Ca2+-independent signaling 
mechanism, J. Appl. Physiol. 93 (2002) 1907–1917. 
[11] Y.-S.J. Li, J.H. Haga, S. Chien, Molecular basis of the effects of shear stress 
on vascular endothelial cells, J Biomech. 38 (2005) 1949–1971. 
doi:10.1016/j.jbiomech.2004.09.030. 
[12] M.A. Swartz, A.W. Lund, Lymphatic and interstitial flow in the tumour 
microenvironment: linking mechanobiology with immunity, Nat Rev 
Cancer. 12 (2012) 210–219. doi:10.1038/nrc3186. 
[13] F. Michor, J. Liphardt, M. Ferrari, J. Widom, What does physics have to do 
with cancer? Nat Rev Cancer. 11 (2011) 657–670. doi:doi:10.1038/nrc3092. 
[14] A.C. Shieh, M.A. Swartz, Regulation of tumor invasion by interstitial fluid 
flow, Phys Biol. 8 (2011) 015012. doi:10.1088/1478-3975/8/1/015012. 
[15] L.S.L. Cheung, P.S. Raman, E.M. Balzer, D. Wirtz, K. Konstantopoulos, 
Biophysics of selectin-ligand interactions in inflammation and cancer, Phys 
Biol. 8 (2011) 015013. doi:10.1088/1478-3975/8/1/015013. 
[16] G.W. Schmid-Schonbein, Microlymphatics and lymph flow, Physiol. Rev. 
(1990). 
[17] M.A. Swartz, M.E. Fleury, Interstitial flow and its effects in soft tissues, 
Annu Rev Biomed Eng. 9 (2007) 229–256. 
doi:10.1146/annurev.bioeng.9.060906.151850. 
[18] H. Dafni, T. Israely, Z.M. Bhujwalla, L.E. Benjamin, M. Neeman, 
 378 
Overexpression of Vascular Endothelial Growth Factor 165 Drives 
Peritumor Interstitial Convection and Induces Lymphatic Drain, Cancer 
Research. 62 (2002) 6731–6739. 
[19] S.R. Chary, R.K. Jain, Direct measurement of interstitial convection and 
diffusion of albumin in normal and neoplastic tissues by fluorescence 
photobleaching, Proc Natl Acad Sci USA. 86 (1989) 5385–5389. 
[20] J.A. Pedersen, F. Boschetti, M.A. Swartz, Effects of extracellular fiber 
architecture on cell membrane shear stress in a 3D fibrous matrix, J 
Biomech. 40 (2007) 1484–1492. doi:10.1016/j.jbiomech.2006.06.023. 
[21] J.M. Tarbell, Z.D. Shi, Effect of the glycocalyx layer on transmission of 
interstitial flow shear stress to embedded cells, Biomech Model 
Mechanobiol. (2012). doi:10.1007/s10237-012-0385-8. 
[22] M.I. Harrell, B.M. Iritani, A. Ruddell, Tumor-Induced Sentinel Lymph Node 
Lymphangiogenesis and Increased Lymph Flow Precede Melanoma 
Metastasis, The American Journal of Pathology. 170 (2007) 774–786. 
doi:10.2353/ajpath.2007.060761. 
[23] Y. Boucher, R.K. Jain, Microvascular pressure is the principal driving force 
for interstitial hypertension in solid tumors: implications for vascular 
collapse, Cancer Research. 52 (1992) 5110–5114. 
[24] Y. Boucher, M. Leunig, R.K. Jain, Tumor Angiogenesis and Interstitial 
Hypertension, Cancer Research. (1996). 
[25] Y. Boucher, L.T. Baxter, R.K. Jain, Interstitial pressure gradients in tissue-
isolated and subcutaneous tumors: implications for therapy, Cancer 
 379 
Research. 50 (1990) 4478–4484. 
[26] P.A. Netti, L.T. Baxter, Y. Boucher, R. Skalak, R.K. Jain, Time-dependent 
behavior of interstitial fluid pressure in solid tumors: implications for drug 
delivery, Cancer Research. 55 (1995) 5451–5458. 
[27] S.J. Lunt, A. Fyles, R.P. Hill, M. Milosevic, Interstitial fluid pressure in 
tumors: therapeutic barrier and biomarker of angiogenesis, Future Oncol. 4 
(2008) 793–802. doi:10.2217/14796694.4.6.793. 
[28] D.O. Miteva, J.M. Rutkowski, J.B. Dixon, W. Kilarski, J.D. Shields, M.A. 
Swartz, Transmural flow modulates cell and fluid transport functions of 
lymphatic endothelium, Circ. Res. 106 (2010) 920–931. 
doi:10.1161/CIRCRESAHA.109.207274. 
[29] J.D. Shields, M.S. Emmett, D.B.A. Dunn, K.D. Joory, L.M. Sage, H. Rigby, 
et al., Chemokine-mediated migration of melanoma cells towards 
lymphatics – a mechanism contributing to metastasis, Oncogene. 26 (2006) 
2997–3005. doi:10.1038/sj.onc.1210114. 
[30] L.A. Johnson, S. Clasper, A.P. Holt, P.F. Lalor, D. Baban, D.G. Jackson, An 
inflammation-induced mechanism for leukocyte transmigration across 
lymphatic vessel endothelium, The Journal of Experimental Medicine. 203 
(2006) 2763–2777. doi:10.1084/jem.20051759. 
[31] C.P. Ng, M.A. Swartz, Mechanisms of interstitial flow-induced remodeling 
of fibroblast-collagen cultures, Ann Biomed Eng. 34 (2006) 446–454. 
doi:10.1007/s10439-005-9067-3. 
[32] C.P. Ng, B. Hinz, M.A. Swartz, Interstitial fluid flow induces myofibroblast 
 380 
differentiation and collagen alignment in vitro, Journal of Cell Science. 118 
(2005) 4731–4739. doi:10.1242/jcs.02605. 
[33] P.-J. Wipff, D.B. Rifkin, J.-J. Meister, B. Hinz, Myofibroblast contraction 
activates latent TGF-beta1 from the extracellular matrix, The Journal of Cell 
Biology. 179 (2007) 1311–1323. doi:10.1083/jcb.200704042. 
[34] J. Ahamed, N. Burg, K. Yoshinaga, C.A. Janczak, D.B. Rifkin, B.S. Coller, 
In vitro and in vivo evidence for shear-induced activation of latent 
transforming growth factor-β1, Blood. 112 (2008) 3650–3660. 
doi:10.1182/blood-2008-04-151753. 
[35] O. De Wever, W. Westbroek, A. Verloes, N. Bloemen, M. Bracke, C. 
Gespach, et al., Critical role of N-cadherin in myofibroblast invasion and 
migration in vitro stimulated by colon-cancer-cell-derived TGF-β or 
wounding, Journal of Cell Science. 117 (2004) 4691–4703. 
[36] O. De Wever, Tenascin-C and SF/HGF produced by myofibroblasts in vitro 
provide convergent proinvasive signals to human colon cancer cells through 
RhoA and Rac, The FASEB Journal. (2004). doi:10.1096/fj.03-1110fje. 
[37] A. Orimo, R.A. Weinberg, Stromal Fibroblasts in Cancer: A Novel Tumor-
Promoting Cell Type, Cell Cycle. 5 (2006) 1597–1601. 
doi:10.4161/cc.5.15.3112. 
[38] B. Hinz, G. Gabbiani, C. Chaponnier, The NH2-terminal peptide of alpha-
smooth muscle actin inhibits force generation by the myofibroblast in vitro 
and in vivo, The Journal of Cell Biology. 157 (2002) 657–663. 
doi:10.1083/jcb.200201049. 
 381 
[39] A.C. Shieh, H.A. Rozansky, B. Hinz, M.A. Swartz, Tumor cell invasion is 
promoted by interstitial flow-induced matrix priming by stromal fibroblasts, 
Cancer Research. 71 (2011) 790–800. doi:10.1158/0008-5472.CAN-10-
1513. 
[40] M. Bockhorn, R.K. Jain, L.L. Munn, Active versus passive mechanisms in 
metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet 
Oncol. 8 (2007) 444–448. doi:10.1016/S1470-2045(07)70140-7. 
[41] S. Khuon, L. Liang, R.W. Dettman, P. Sporn, Myosin light chain kinase 
mediates transcellular intravasation of breast cancer cells through the 
underlying endothelial cells: a three-dimensional FRET study, Journal of 
Cell Science. 123 (2010) 431–440. 
[42] S. Maheswaran, D.A. Haber, Circulating tumor cells: a window into cancer 
biology and metastasis, Current Opinion in Genetics & Development. 20 
(2010) 96–99. doi:10.1016/j.gde.2009.12.002. 
[43] M. Yu, S. Stott, M. Toner, S. Maheswaran, D.A. Haber, Circulating tumor 
cells: approaches to isolation and characterization, The Journal of Cell 
Biology. 192 (2011) 373–382. 
[44] L.J. Gay, B. Felding-Habermann, Contribution of platelets to tumour 
metastasis, Nat Rev Cancer. 11 (2011) 123–134. 
[45] O. McCarty, S. Mousa, P. Bray, K. Konstantopoulos, Immobilized platelets 
support human colon carcinoma cell tethering, rolling, and firm adhesion 
under dynamic flow conditions, Blood. 96 (2000) 1789–1797. 
[46] V.T. Turitto, Blood viscosity, mass transport, and thrombogenesis, Prog 
 382 
Hemost Thromb. 6 (1982) 139–177. 
[47] D.E. Brooks, The biorheology of tumor cells, Biorheology. 21 (1984) 85–
91. 
[48] S. Gout, P. Tremblay, J. Huot, Selectins and selectin ligands in extravasation 
of cancer cells and organ selectivity of metastasis, Clinical & Experimental 
Metastasis. 25 (2008) 335–344. 
[49] S. Köhler, S. Ullrich, U. Richter, U. Schumacher, E-/P-selectins and colon 
carcinoma metastasis: first in vivo evidence for their crucial role in a 
clinically relevant model of spontaneous metastasis formation in the lung, 
British Journal of Cancer. 102 (2010) 602–609. doi:10.1038/sj.bjc.6605492. 
[50] H. Läubli, L. Borsig, Selectins promote tumor metastasis, Seminars in 
Cancer Biology. 20 (2010) 169–177. 
[51] A.F. Chambers, I.C. MacDonald, E.E. Schmidt, S. Koop, V.L. Morris, R. 
Khokha, et al., Steps in tumor metastasis: new concepts from intravital 
microscopy, Cancer and Metastasis Reviews. 14 (1995) 279–301. 
[52] L.M. Coussens, Z. Werb, Inflammation and cancer, Nature. 420 (2002) 860–
867. doi:10.1038/nature01322. 
[53] S.R. Barthel, G.K. Wiese, J. Cho, M.J. Opperman, D.L. Hays, J. Siddiqui, et 
al., Alpha 1,3 fucosyltransferases are master regulators of prostate cancer 
cell trafficking, Proc Natl Acad Sci USA. 106 (2009) 19491–19496. 
[54] R. Giavazzi, M. Foppolo, R. Dossi, A. Remuzzi, Rolling and adhesion of 
human tumor cells on vascular endothelium under physiological flow 
conditions, Journal of Clinical Investigation. 92 (1993) 3038–3044. 
 383 
[55] M. Fischer, U.K. Franzeck, I. Herrig, U. Costanzo, S. Wen, M. Schiesser, et 
al., Flow velocity of single lymphatic capillaries in human skin, American 
Journal of Physiology - Cell Physiology. 270 (1996) H358–H363. 
[56] V.A. Resto, M.M. Burdick, N.M. Dagia, L-selectin-mediated Lymphocyte-
Cancer Cell Interactions under Low Fluid Shear Conditions, Journal of 
Biological cHemistry. 283 (2008) 15816–15824. 
[57] H.C. Brinkman, A calculation of the viscous force exerted by a flowing fluid 
on a dense swarm of particles, Appl. Sci. Res. 1 (1949) 27–34. 
doi:10.1007/BF02120313. 
[58] El Rasheid Zakaria, J. Lofthouse, M.F. Flessner, In vivo hydraulic 
conductivity of muscle: effects of hydrostatic pressure, Am J Physiol Heart 
Circ Physiol. 273 (1997) H2774–H2782. 
[59] J.L. Bert, R.K. Reed, Flow conductivity of rat dermis is determined by 
hydration, Biorheology. 32 (1995) 17–27. 
[60] J.R. Levick, Flow through interstitium and other fibrous matrices, Q J Exp 
Physiol. 72 (1987) 409–437. 
[61] S. McGuire, D. Zaharoff, F. Yuan, Nonlinear dependence of hydraulic 
conductivity on tissue deformation during intratumoral infusion, Ann 
Biomed Eng. 34 (2006) 1173–1181. doi:10.1007/s10439-006-9136-2. 
[62] P.A. Netti, D.A. Berk, M.A. Swartz, A.J. Grodzinsky, R.K. Jain, Role of 
extracellular matrix assembly in interstitial transport in solid tumors, Cancer 
Research. 60 (2000) 2497–2503. 
[63] C.P. Ng, M.A. Swartz, Fibroblast alignment under interstitial fluid flow 
 384 
using a novel 3-D tissue culture model, American Journal of Physiology - 
Cell Physiology. 284 (2003) H1771–7. doi:10.1152/ajpheart.01008.2002. 
[64] S.L. Diamond, Engineering design of optimal strategies for blood clot 
dissolution, Annu Rev Biomed Eng. 1 (1999) 427–462. 
doi:10.1146/annurev.bioeng.1.1.427. 
[65] M.K. Kwan, W.M. Lai, V.C. Mow, Fundamentals of fluid transport through 
cartilage in compression, Ann Biomed Eng. 12 (1984) 537–558. 
[66] A.J. Grodzinsky, M.E. Levenston, M. Jin, E.H. Frank, Cartilage tissue 
remodeling in response to mechanical forces, Annu Rev Biomed Eng. 2 
(2000) 691–713. doi:10.1146/annurev.bioeng.2.1.691. 
[67] C. Hellmich, F.-J. Ulm, Drained and Undrained Poroelastic Properties of 
Healthy and Pathological Bone: A Poro-Micromechanical Investigation, 
Transp Porous Med. 58 (2005) 243–268. doi:10.1007/s11242-004-6298-y. 
[68] D.M. Wang, J.M. Tarbell, Modeling interstitial flow in an artery wall allows 
estimation of wall shear stress on smooth muscle cells, J Biomech Eng. 117 
(1995) 358–363. 
[69] M.A. Swartz, A. Kaipainen, P.A. Netti, C. Brekken, Y. Boucher, A.J. 
Grodzinsky, et al., Mechanics of interstitial-lymphatic fluid transport: 
theoretical foundation and experimental validation, J Biomech. 32 (1999) 
1297–1307. 
[70] D.A. Hammer, D.A. Lauffenburger, A dynamical model for receptor-
mediated cell adhesion to surfaces, Biophysical Journal. 52 (1987) 475–487. 
doi:10.1016/S0006-3495(87)83236-8. 
 385 
[71] D.A. Hammer, S.M. Apte, Simulation of cell rolling and adhesion on 
surfaces in shear flow: general results and analysis of selectin-mediated 
neutrophil adhesion, Biophysical Journal. (1992). 
[72] G.I. Bell, M. Dembo, P. Bongrand, Cell adhesion. Competition between 
nonspecific repulsion and specific bonding, Biophysical Journal. 45 (1984) 
1051–1064. doi:10.1016/S0006-3495(84)84252-6. 
[73] G.I. Bell, Models for the specific adhesion of cells to cells, Science. (1978). 
[74] M.R. King, R. Sumagin, C.E. Green, S.I. Simon, Rolling dynamics of a 
neutrophil with redistributed L-selectin, Math Biosci. 194 (2005) 71–79. 
doi:10.1016/j.mbs.2004.12.008. 
[75] K.C. Chang, D.F. Tees, D.A. Hammer, The state diagram for cell adhesion 
under flow: leukocyte rolling and firm adhesion, Proc Natl Acad Sci USA. 
97 (2000) 11262–11267. doi:10.1073/pnas.200240897. 
[76] K.E. Caputo, D.A. Hammer, Effect of microvillus deformability on 
leukocyte adhesion explored using adhesive dynamics simulations, 
Biophysical Journal. 89 (2005) 187–200. doi:10.1529/biophysj.104.054171. 
[77] M.R. King, D.A. Hammer, Multiparticle adhesive dynamics: Hydrodynamic 
recruitment of rolling leukocytes, Proc Natl Acad Sci USA. 98 (2001) 
14919–14924. doi:10.1073/pnas.261272498. 
[78] M.R. King, D.A. Hammer, Multiparticle Adhesive Dynamics. Interactions 
between Stably Rolling Cells, Biophysical Journal. 81 (2001) 799–813. 
doi:10.1016/S0006-3495(01)75742-6. 
[79] M.J. Smith, E.L. Berg, M.B. Lawrence, A direct comparison of selectin-
 386 
mediated transient, adhesive events using high temporal resolution, 
Biophysical Journal. 77 (1999) 3371–3383. doi:10.1016/S0006-
3495(99)77169-9. 
[80] V.S. Shirure, N.M. Reynolds, M.M. Burdick, Mac-2 Binding Protein Is a 
Novel E-Selectin Ligand Expressed by Breast Cancer Cells, PLoS ONE. 7 
(2012) e44529. doi:10.1371/journal.pone.0044529. 
[81] S.N. Thomas, F. Zhu, R.L. Schnaar, C.S. Alves, K. Konstantopoulos, 
Carcinoembryonic Antigen and CD44 Variant Isoforms Cooperate to 
Mediate Colon Carcinoma Cell Adhesion to E- and L-selectin in Shear 
Flow, J Biol Chem. 283 (2008) 15647–15655. 
[82] M.J. Mitchell, C.S. Chen, V. Ponmudi, A.D. Hughes, M.R. King, E-selectin 
liposomal and nanotube-targeted delivery of doxorubicin to circulating 
tumor cells, Journal of Controlled Release. 160 (2012) 609–617. 
doi:10.1016/j.jconrel.2012.02.018. 
[83] M.J. Mitchell, C.A. Castellanos, M.R. King, Nanostructured Surfaces to 
Target and Kill Circulating Tumor Cells While Repelling Leukocytes, 
Journal of Nanomaterials. 2012 (2012) 1–10. 
[84] K. Rana, J.L. Liesveld, M.R. King, Delivery of apoptotic signal to rolling 
cancer cells: A novel biomimetic technique using immobilized TRAIL and 
E-selectin, Biotechnol. Bioeng. 102 (2009) 1692–1702. 
doi:10.1002/bit.22204. 
[85] K. Rana, C.A. Reinhart-King, M.R. King, Inducing Apoptosis in Rolling 
Cancer Cells: A Combined Therapy with Aspirin and Immobilized TRAIL 
 387 
and E-Selectin, Molecular Pharmaceutics. 9 (2012) 2219–2227. 
doi:10.1021/mp300073j. 
[86] M.J. Mitchell, M.R. King, Fluid shear stress sensitizes cancer cells to 
receptor-mediated apoptosis via trimeric death receptors, New Journal of 
Physics. 15 (2013) 015008. doi:10.1088/1367-2630/15/1/015008. 
[87] A. Ashkenazi, Targeting death and decoy receptors of the tumour-necrosis 
factor superfamily, Nat Rev Cancer. 2 (2002) 420–430. doi:10.1038/nrc821. 
[88] R.C. Young, R.F. Ozols, C.E. Myers, The Anthracycline Antineoplastic 
Drugs, New England Journal of Medicine. 305 (1981) 139–153. 
[89] N. Osheroff, A.H. Corbett, M.J. Robinson, Mechanism of action of 
topoisomerase II-targeted antineoplastic drugs, Advances in Pharmacology. 
29 (1994) 105–126. 
[90] A. Makino, E. Prossnitz, M. Bunemann, J. Wang, W. Yao, G. Schmid-
Schonbein, G protein-coupled receptors serve as mechanosensors for fluid 
shear stress in neutrophils, American Journal of Physiology - Cell 
Physiology. 290 (2006) C1633–C1639. 
[91] M.J. Mitchell, M.R. King, Shear-Induced Resistance to Neutrophil 
Activation via the Formyl Peptide Receptor, Biophysical Journal. 102 
(2012) 1804–1814. doi:10.1016/j.bpj.2012.03.053. 
[92] J.M. Barnes, J.T. Nauseef, M.D. Henry, Resistance to Fluid Shear Stress Is a 
Conserved Biophysical Property of Malignant Cells, PLoS ONE. 7 (2012) 
e50973. doi:10.1371/journal.pone.0050973.t002. 
[93] A.M. Malek, S.L. Alper, S. Izumo, Hemodynamic Shear Stress and Its Role 
 388 
in Atherosclerosis, Jama. 282 (1999) 2035–2042. 
doi:10.1001/jama.282.21.2035. 
[94] J. Strony, A. Beaudoin, D. Brands, B. Adelman, Analysis of shear stress and 
hemodynamic factors in a model of coronary artery stenosis and thrombosis, 
Am J Physiol Heart Circ Physiol. 265 (1993) H1787–1796. 
[95] M. Terasaki, K. Miyake, P.L. McNeil, Large plasma membrane disruptions 
are rapidly resealed by Ca2+-dependent vesicle-vesicle fusion events, The 
Journal of Cell Biology. 139 (1997) 63–74. 
[96] J.D. Shields, M.E. Fleury, C. Yong, A.A. Tomei, G.J. Randolph, M.A. 
Swartz, Autologous chemotaxis as a mechanism of tumor cell homing to 
lymphatics via interstitial flow and autocrine CCR7 signaling, Cancer Cell. 
11 (2007) 526–538. doi:10.1016/j.ccr.2007.04.020. 
[97] H. Qazi, Z.D. Shi, J.M. Tarbell, Fluid Shear Stress Regulates the Invasive 
Potential of Glioma Cells via Modulation of Migratory Activity and Matrix 
Metalloproteinase Expression, PLoS ONE. 6 (2011) e20348. 
[98] Z.D. Shi, J.M. Tarbell, Fluid flow mechanotransduction in vascular smooth 
muscle cells and fibroblasts, Ann Biomed Eng. 39 (2011) 1608–1619. 
doi:10.1007/s10439-011-0309-2. 
[99] J.S. Garanich, R.A. Mathura, Z.D. Shi, J.M. Tarbell, Effects of fluid shear 
stress on adventitial fibroblast migration: implications for flow-mediated 
mechanisms of arterialization and intimal hyperplasia, American Journal of 
Physiology - Cell Physiology. 292 (2007) H3128–35. 
doi:10.1152/ajpheart.00578.2006. 
 389 
[100] H. Yokota, M.B. Goldring, H.B. Sun, CITED2-mediated regulation of 
MMP-1 and MMP-13 in human chondrocytes under flow shear, J. Biol. 
Chem. 278 (2003) 47275–47280. doi:10.1074/jbc.M304652200. 
[101] V.J. Fincham, The catalytic activity of Src is dispensable for translocation to 
focal adhesions but controls the turnover of these structures during cell 
motility, The EMBO Journal. 17 (1998) 81–92. doi:10.1093/emboj/17.1.81. 
[102] D.J. Sieg, D. Ilić, K.C. Jones, C.H. Damsky, T. Hunter, D.D. Schlaepfer, 
Pyk2 and Src-family protein-tyrosine kinases compensate for the loss of 
FAK in fibronectin-stimulated signaling events but Pyk2 does not fully 
function to enhance FAK- cell migration, The EMBO Journal. 17 (1998) 
5933–5947. doi:10.1093/emboj/17.20.5933. 
[103] W.J. Polacheck, J.L. Charest, R.D. Kamm, Interstitial flow influences 
direction of tumor cell migration through competing mechanisms, Proc Natl 
Acad Sci USA. (2011). 
[104] C.-H. Heldin, K. Rubin, K. Pietras, A. Ostman, High interstitial fluid 
pressure - an obstacle in cancer therapy, Nat Rev Cancer. 4 (2004) 806–813. 
doi:10.1038/nrc1456. 
[105] S. Li, M. Kim, Y.L. Hu, S. Jalali, D.D. Schlaepfer, T. Hunter, et al., Fluid 
shear stress activation of focal adhesion kinase. Linking to mitogen-
activated protein kinases, J. Biol. Chem. 272 (1997) 30455–30462. 
[106] S. Jalali, Y.S. Li, M. Sotoudeh, S. Yuan, S. Li, S. Chien, et al., Shear stress 
activates p60src-Ras-MAPK signaling pathways in vascular endothelial 
cells, Arteriosclerosis, Thrombosis, and Vascular Biology. 18 (1998) 227–
 390 
234. 
[107] Y. Yao, A. Rabodzey, C.F. Dewey, Glycocalyx modulates the motility and 
proliferative response of vascular endothelium to fluid shear stress, 
American Journal of Physiology - Cell Physiology. 293 (2007) H1023–30. 
doi:10.1152/ajpheart.00162.2007. 
[108] Z.D. Shi, H. Wang, J.M. Tarbell, Heparan sulfate proteoglycans mediate 
interstitial flow mechanotransduction regulating MMP-13 expression and 
cell motility via FAK-ERK in 3D collagen, PLoS ONE. 6 (2011) e15956. 
doi:10.1371/journal.pone.0015956. 
[109] H. Krähling, S. Mally, J.A. Eble, J. Noël, A. Schwab, C. Stock, The 
glycocalyx maintains a cell surface pH nanoenvironment crucial for 
integrin-mediated migration of human melanoma cells, Pflugers Arch. 458 
(2009) 1069–1083. doi:10.1007/s00424-009-0694-7. 
[110] T.W. Secomb, R. Hsu, A.R. Pries, Effect of the endothelial surface layer on 
transmission of fluid shear stress to endothelial cells, Biorheology. 38 
(2001) 143–150. 
[111] E.F. Krasik, K.L. Yee, D.A. Hammer, Adhesive dynamics simulation of 
neutrophil arrest with deterministic activation, Biophysical Journal. 91 
(2006) 1145–1155. doi:10.1529/biophysj.105.070706. 
[112] E.F. Krasik, K.E. Caputo, D.A. Hammer, Adhesive Dynamics Simulation of 
Neutrophil Arrest with Stochastic Activation, Biophysical Journal. 95 
(2008) 1716–1728. doi:10.1529/biophysj.107.119677. 
[113] K.E. Caputo, D.A. Hammer, Adhesive Dynamics Simulation of G-Protein-
 391 
Mediated Chemokine-Activated Neutrophil Adhesion, Biophysical Journal. 
96 (2009) 2989–3004. doi:10.1016/j.bpj.2008.12.3930. 
[114] M.T. Beste, D. Lee, M.R. King, G.A. Koretzky, D.A. Hammer, An 
integrated stochastic model of “inside-out” integrin activation and selective 
T-lymphocyte recruitment, Langmuir. 28 (2012) 2225–2237. 
doi:10.1021/la203803e. 
[115] M.J. Paszek, D. Boettiger, V.M. Weaver, D.A. Hammer, Integrin clustering 
is driven by mechanical resistance from the glycocalyx and the substrate, 
PLoS Comp Biol. 5 (2009) e1000604. doi:10.1371/journal.pcbi.1000604. 
[116] R.O. Hynes, Integrins: Bidirectional, Allosteric Signaling Machines, Cell. 
(2002). 
[117] C.K. Miranti, J.S. Brugge, Sensing the environment: a historical perspective 
on integrin signal transduction, Nat. Cell Biol. 4 (2002) E83–90. 
doi:10.1038/ncb0402-e83. 
[118] A.L. Berrier, K.M. Yamada, Cell–matrix adhesion, J. Cell. Physiol. 213 
(2007) 565–573. 
[119] M. Ostoja-Starzewski, P.Y. Sheng, K. Alzebdeh, Spring network models in 
elasticity and fracture of composites and polycrystals, Computational 
Materials Science. 7 (1996) 82–93. 
[120] C. Cluzel, F. Saltel, J. Lussi, F. Paulhe, B.A. Imhof, B. Wehrle-Haller, The 
mechanisms and dynamics of αvβ3 integrin clustering in living cells, The 
Journal of Cell Biology. (2005). 
[121] A. Schroeder, D.A. Heller, M.M. Winslow, J.E. Dahlman, G.W. Pratt, R. 
 392 
Langer, et al., Treating metastatic cancer with nanotechnology, Nat Rev 
Cancer. 12 (2011) 39–50. doi:10.1038/nrc3180. 
[122] T. Safra, F. Muggia, S. Jeffers, D.D. Tsao-Wei, S. Groshen, O. Lyass, et al., 
Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in 
patients reaching or exceeding cumulative doses of 500 mg/m2, Annals of 
Oncology. 11 (2000) 1029–1033. 
[123] G. Christofori, New signals from the invasive front, Nature. 441 (2006) 
444–450. doi:10.1038/nature04872. 
[124] J.M. Brown, The Hypoxic Cell, Cancer Research. 59 (1999) 5863–5870. 
[125] I. Mellman, G. Coukos, G. Dranoff, Cancer immunotherapy comes of age, 
Nature. 480 (2011) 480–489. 
[126] A.Z. Wang, R. Langer, O.C. Farokhzad, Nanoparticle Delivery of Cancer 
Drugs, Annu. Rev. Med. 63 (2012) 185–198. 
[127] D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, R. Langer, 
Nanocarriers as an emerging platform for cancer therapy, Nature 
Nanotechnology. 2 (2007) 751–760. doi:10.1038/nnano.2007.387. 
[128] S.H. Kim, J.H. Jeong, K.W. Chun, T.G. Park, Target-specific cellular uptake 
of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-
folate conjugate, Langmuir. 21 (2005) 8852–8857. doi:10.1021/la0502084. 
[129] O.C. Farokhzad, S. Jon, A. Khademhosseini, T.-N.T. Tran, D.A. Lavan, R. 
Langer, Nanoparticle-aptamer bioconjugates: a new approach for targeting 
prostate cancer cells, Cancer Research. 64 (2004) 7668–7672. 
doi:10.1158/0008-5472.CAN-04-2550. 
 393 
[130] L. Zhang, F.X. Gu, J.M. Chan, A.Z. Wang, Nanoparticles in Medicine: 
Therapeutic Applications and Developments, Clinical Pharmacology & 
Therapeutics. 83 (2008) 761–769. 
[131] F. Alexis, E. Pridgen, L.K. Molnar, O.C. Farokhzad, Factors affecting the 
clearance and biodistribution of polymeric nanoparticles, Molecular 
Pharmaceutics. 5 (2008) 505–515. doi:10.1021/mp800051m. 
[132] F. Gu, L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, et 
al., Precise engineering of targeted nanoparticles by using self-assembled 
biointegrated block copolymers, Proc Natl Acad Sci USA. 105 (2008) 2586–
2591. doi:10.1073/pnas.0711714105. 
[133] L. Brannon-Peppas, J.O. Blanchette, Nanoparticle and targeted systems for 
cancer therapy, Advanced Drug Delivery Reviews. 64 (2012) 206–212. 
doi:10.1016/j.addr.2012.09.033. 
[134] I. Bala, S. Hariharan, M.N.V.R. Kumar, PLGA nanoparticles in drug 
delivery: the state of the art, Crit Rev Ther Drug Carrier Syst. 21 (2004) 
387–422. 
[135] P. Calvo, C. Remuñan-López, J.L. Vila-Jato, M.J. Alonso, Chitosan and 
chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as 
novel carriers for proteins and vaccines, Pharm. Res. 14 (1997) 1431–1436. 
[136] J.S. Hrkach, M.T. Peracchia, A. Bomb, N. Lotan, R. Langer, 
Nanotechnology for biomaterials engineering: structural characterization of 
amphiphilic polymeric nanoparticles by 1H NMR spectroscopy, 
Biomaterials. 18 (1997) 27–30. doi:10.1016/S0142-9612(96)00077-4. 
 394 
[137] A.D. Bangham, Liposomes: the Babraham connection, Chemistry and 
Physics of Lipids. 64 (1993) 275–285. doi:10.1016/0009-3084(93)90071-A. 
[138] V.P. Torchilin, Recent advances with liposomes as pharmaceutical carriers, 
Nat Rev Drug Discov. 4 (2005) 145–160. doi:10.1038/nrd1632. 
[139] Y. Barenholz, Doxil® — The first FDA-approved nano-drug: Lessons 
learned, Journal of Controlled Release. 160 (2012) 117–134. 
[140] R.C.F. Leonard, S. Williams, A. Tulpule, A.M. Levine, S. Oliveros, 
Improving the therapeutic index of anthracycline chemotherapy: Focus on 
liposomal doxorubicin (Myocet™), The Breast. 18 (2009) 218–224. 
doi:10.1016/j.breast.2009.05.004. 
[141] S. Lal, S.E. Clare, N.J. Halas, Nanoshell-enabled photothermal cancer 
therapy: impending clinical impact, Acc. Chem. Res. 41 (2008) 1842–1851. 
doi:10.1021/ar800150g. 
[142] M.-R. Choi, K.J. Stanton-Maxey, J.K. Stanley, C.S. Levin, R. Bardhan, D. 
Akin, et al., A Cellular Trojan Horse for Delivery of Therapeutic 
Nanoparticles into Tumors, Nano Lett. 7 (2007) 3759–3765. 
doi:10.1021/nl072209h. 
[143] J.-H. Park, G. von Maltzahn, M.J. Xu, V. Fogal, V.R. Kotamraju, E. 
Ruoslahti, et al., Cooperative nanomaterial system to sensitize, target, and 
treat tumors, Proc Natl Acad Sci USA. 107 (2010) 981–986. 
doi:10.1073/pnas.0909565107. 
[144] C. Minelli, S.B. Lowe, M.M. Stevens, Engineering nanocomposite materials 
for cancer therapy, Small. 6 (2010) 2336–2357. 
 395 
doi:10.1002/smll.201000523. 
[145] S.K. Libutti, G.F. Paciotti, A.A. Byrnes, H.R. Alexander, W.E. Gannon, M. 
Walker, et al., Phase I and pharmacokinetic studies of CYT-6091, a novel 
PEGylated colloidal gold-rhTNF nanomedicine, Clin. Cancer Res. 16 (2010) 
6139–6149. doi:10.1158/1078-0432.CCR-10-0978. 
[146] N. Lewinski, V. Colvin, R. Drezek, Cytotoxicity of Nanoparticles, Small. 4 
(2008) 26–49. 
[147] W. Yang, P. Thordarson, J.J. Gooding, S.P. Ringer, F. Braet, Carbon 
nanotubes for biological and biomedical applications, Nanotechnology. 18 
(2007) 412001. doi:10.1088/0957-4484/18/41/412001. 
[148] P. Chakravarty, R. Marches, N.S. Zimmerman, A.D.-E. Swafford, P. Bajaj, 
I.H. Musselman, et al., Thermal ablation of tumor cells with antibody-
functionalized single-walled carbon nanotubes, Proc Natl Acad Sci USA. 
105 (2008) 8697–8702. doi:10.1073/pnas.0803557105. 
[149] K. Welsher, Z. Liu, D. Daranciang, H. Dai, Selective probing and imaging 
of cells with single walled carbon nanotubes as near-infrared fluorescent 
molecules, Nano Lett. 8 (2008) 586–590. doi:10.1021/nl072949q. 
[150] Z. Liu, K. Chen, C. Davis, S. Sherlock, Q. Cao, X. Chen, et al., Drug 
Delivery with Carbon Nanotubes for In vivo Cancer Treatment, Cancer 
Research. 68 (2008) 6652–6660. 
[151] H. Dumortier, S. Lacotte, G. Pastorin, R. Marega, W. Wu, D. Bonifazi, et 
al., Functionalized carbon nanotubes are non-cytotoxic and preserve the 
functionality of primary immune cells, Nano Lett. 6 (2006) 1522–1528. 
 396 
doi:10.1021/nl061160x. 
[152] D. Cui, F. Tian, C.S. Ozkan, M. Wang, H. Gao, Effect of single wall carbon 
nanotubes on human HEK293 cells, Toxicol. Lett. 155 (2005) 73–85. 
doi:10.1016/j.toxlet.2004.08.015. 
[153] C.-W. Lam, J.T. James, R. McCluskey, R.L. Hunter, Pulmonary toxicity of 
single-wall carbon nanotubes in mice 7 and 90 days after intratracheal 
instillation, Toxicol. Sci. 77 (2004) 126–134. doi:10.1093/toxsci/kfg243. 
[154] J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, S.L. 
Topalian, et al., A randomized trial of bevacizumab, an anti-vascular 
endothelial growth factor antibody, for metastatic renal cancer, N. Engl. J. 
Med. 349 (2003) 427–434. doi:10.1056/NEJMoa021491. 
[155] S.X. Yang, Bevacizumab and breast cancer: current therapeutic progress and 
future perspectives, Expert Rev Anticancer Ther. 9 (2009) 1715–1725. 
doi:10.1586/era.09.153. 
[156] H. de Lavallade, J.F. Apperley, J.S. Khorashad, D. Milojkovic, A.G. Reid, 
M. Bua, et al., Imatinib for Newly Diagnosed Patients With Chronic 
Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-
Treat Analysis, Journal of Clinical Oncology. 26 (2008) 3358–3363. 
doi:10.1200/JCO.2007.15.8154. 
[157] Y.-J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. 
Sawaki, et al., Trastuzumab in combination with chemotherapy versus 
chemotherapy alone for treatment of HER2-positive advanced gastric or 
gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, 
 397 
randomised controlled trial, The Lancet. 376 (2010) 687–697. 
doi:10.1016/S0140-6736(10)61121-X. 
[158] J. Baselga, E.A. Perez, T. Pienkowski, R. Bell, Adjuvant Trastuzumab: A 
Milestone in the Treatment of HER-2-Positive Early Breast Cancer, The 
Oncologist. 11 (2006) 4–12. 
[159] M.J. Mitchell, M.R. King, Computational and experimental models of 
cancer cell response to fluid shear stress, Frontiers in Oncology. 3 (2013) 1–
11. doi:10.3389/fonc.2013.00044/abstract. 
[160] G.W. Schmid-Schönbein, S. Usami, R. Skalak, S. Chien, The interaction of 
leukocytes and erythrocytes in capillary and postcapillary vessels, 
Microvasc. Res. 19 (1980) 45–70. doi:10.1016/0026-2862(80)90083-7. 
[161] K. Ley, Molecular mechanisms of leukocyte recruitment in the 
inflammatory process, Cardiovascular Research. 32 (1996) 733–742. 
[162] H.L. Goldsmith, S. Spain, Margination of leukocytes in blood flow through 
small tubes, Microvasc. Res. 27 (1984) 204–222. 
[163] J.C. Firrell, H.H. Lipowsky, Leukocyte margination and deformation in 
mesenteric venules of rat, Am J Physiol Heart Circ Physiol. 256 (1989) 
H1667–74. 
[164] U. Nobis, A.R. Pries, G.R. Cokelet, P. Gaehtgens, Radial distribution of 
white cells during blood flow in small tubes, Microvasc. Res. 29 (1985) 
295–304. 
[165] E.C. Butcher, Leukocyte-endothelial cell recognition: Three (or more) steps 
to specificity and diversity, Cell. 67 (1991) 1033–1036. doi:10.1016/0092-
 398 
8674(91)90279-8. 
[166] T.A. Springer, Adhesion receptors of the immune system, Nature. 346 
(1990) 425–434. 
[167] P. Sundd, M. Pospieszalska, L. Cheung, K. Konstatopoulos, K. Ley, 
Biomechanics of leukocyte rolling, Biorheology. 48 (2011) 1–35. 
[168] P. Sundd, M.K. Pospieszalska, K. Ley, Neutrophil rolling at high shear: 
flattening, catch bond behavior, tethers and slings, Mol. Immunol. 55 (2013) 
59–69. doi:10.1016/j.molimm.2012.10.025. 
[169] E. Finger, K. Puri, R. Alón, M. Lawrence, U. von Andrian, T. Springer, 
Adhesion through L-selectin requires a threshold hydrodynamic shear, 
Nature. 379 (1996) 266–268. 
[170] T.M. Cao, M.J. Mitchell, J. Liesveld, M.R. King, Stem Cell Enrichment 
with Selectin Receptors: Mimicking the pH Environment of Trauma, 
Sensors. 13 (2013) 12516–12526. 
[171] G.S. Kansas, Selectins and their ligands: current concepts and controversies, 
Blood. 88 (1996) 3259–3287. 
[172] M.J. Mitchell, K.S. Lin, M.R. King, Fluid Shear Stress Increases Neutrophil 
Activation via Platelet-Activating Factor, Biophysical Journal. 106 (2014) 
2243–2253. doi:10.1016/j.bpj.2014.04.001. 
[173] Z.M. Ding, J.E. Babensee, S.I. Simon, H. Lu, J.L. Perrard, D.C. Bullard, et 
al., Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and 
migration, J. Immunol. 163 (1999) 5029–5038. 
[174] M.S. Diamond, ICAM-1 (CD54): a counter-receptor for Mac-1 
 399 
(CD11b/CD18), The Journal of Cell Biology. 111 (1990) 3129–3139. 
doi:10.1083/jcb.111.6.3129. 
[175] B. Hughes, J. Hollers, E. Crockett-Torabi, C.W. Smith, Recruitment of 
CD11b/CD18 to the neutrophil surface and adherence-dependent cell 
locomotion, Journal of Clinical Investigation. 90 (1992) 1687–1696. 
[176] T.A. Springer, Traffic signals for lymphocyte recirculation and leukocyte 
emigration: The multistep paradigm, Cell. 76 (1994) 301–314. 
doi:10.1016/0092-8674(94)90337-9. 
[177] T.M. van Ginhoven, J.W. van den Berg, W.A. Dik, J.N.M. Ijzermans, 
R.W.F. de Bruin, Preoperative dietary restriction reduces hepatic tumor load 
by reduced E-selectin-mediated adhesion in mice, J Surg Oncol. 102 (2010) 
348–353. doi:10.1002/jso.21649. 
[178] B. McDonald, J. Spicer, B. Giannais, L. Fallavollita, P. Brodt, L. Ferri, 
Systemic inflammation increases cancer cell adhesion to hepatic sinusoids 
by neutrophil mediated mechanisms, International Journal of Cancer. 125 
(2009) 1298–1305. 
[179] C.J. Dimitroff, M. Lechpammer, D. Long-Woodward, J. Kutok, Rolling of 
Human Bone-Metastatic Prostate Tumor Cells on Human Bone Marrow 
Endothelium under Shear Flow Is Mediated by E-Selectin, Cancer Research. 
64 (2004) 5261–5269. doi:10.1158/0008-5472.CAN-04-0691. 
[180] A. Tözeren, H.K. Kleinman, D.S. Grant, D. Morales, A. Mercurio, S. Byers, 
E-selectin-mediated dynamic interactions of breast-and colon-cancer cells 
with endothelial-cell monolayers, Int. J. Cancer. 60 (1995) 426–431. 
 400 
[181] J.H. Myung, K.A. Gajjar, R.M. Pearson, C.A. Launiere, D.T. Eddington, S. 
Hong, Direct measurements on CD24-mediated rolling of human breast 
cancer MCF-7 cells on E-selectin, Analytical Chemistry. 83 (2011) 1078–
1083. doi:10.1021/ac102901e. 
[182] M.M. Burdick, J.T. Chu, S. Godar, R. Sackstein, HCELL Is the Major E- 
and L-selectin Ligand Expressed on LS174T Colon Carcinoma Cells, 
Journal of Biological cHemistry. 281 (2006) 13899–13905. 
doi:10.1074/jbc.M513617200. 
[183] P. Brodt, L. Fallavollita, R.S. Bresalier, S. Meterissian, C.R. Norton, B.A. 
Wolitzky, Liver endothelial E-selectin mediates carcinoma cell adhesion and 
promotes liver metastasis, Int. J. Cancer. 71 (1997) 612–619. 
[184] L. Biancone, M. Araki, K. Araki, P. Vassalli, I. Stamenkovic, Redirection of 
tumor metastasis by expression of E-selectin in vivo, The Journal of 
Experimental Medicine. 183 (1996) 581–587. 
[185] J.J. Rahn, J.W. Chow, G.J. Horne, B.K. Mah, J.T. Emerman, P. Hoffman, et 
al., MUC1 mediates transendothelial migration in vitro by ligating 
endothelial cell ICAM-1, Clinical & Experimental Metastasis. 22 (2005) 
475–483. doi:10.1007/s10585-005-3098-x. 
[186] D. Raman, T. Sobolik-Delmaire, A. Richmond, Chemokines in health and 
disease, Exp. Cell Res. 317 (2011) 575–589. 
[187] F.R. Balkwill, The chemokine system and cancer, J. Pathol. 226 (2011) 
148–157. doi:10.1002/path.3029. 
[188] T. Kishimoto, M. Jutila, E. Butcher, Identification of a human peripheral 
 401 
lymph node homing receptor: a rapidly down-regulated adhesion molecule, 
Proc Natl Acad Sci USA. 87 (1990) 2244–2248. 
[189] T. Kishimoto, M. Jutila, E. Berg, E. Butcher, Neutrophil Mac-1 and MEL-
14 adhesion proteins inversely regulated by chemotactic factors, Science. 
245 (1989) 1238–1241. doi:10.1126/science.2551036. 
[190] A.J. Ridley, M.A. Schwartz, K. Burridge, R. Firtel, M.H. Ginsberg, G. 
Borisy, et al., Cell Migration: Integrating Signals from Front to Back, 
Science. 302 (2003) 1704–1709. 
[191] R.P. McEver, K.L. Moore, R.D. Cummings, Leukocyte trafficking mediated 
by selectin-carbohydrate interactions, J. Biol. Chem. 270 (1995) 11025–
11028. 
[192] D. Vestweber, J.E. Blanks, Mechanisms That Regulate the Function of the 
Selectins and Their Ligands, Physiol. Rev. 79 (1999) 181–213. 
[193] P. Friedl, S. Alexander, Cancer Invasion and the Microenvironment: 
Plasticity and Reciprocity, Cell. 147 (2011) 992–1009. 
doi:10.1016/j.cell.2011.11.016. 
[194] S. Bajpai, M.J. Mitchell, M.R. King, C.A. Reinhart-King, A microfluidic 
device to select for cells based on chemotactic phenotype, Technology. 02 
(2014) 101–105. doi:10.1142/S2339547814200015. 
[195] G. Lazennec, A. Richmond, Chemokines and chemokine receptors: new 
insights into cancer-related inflammation, Trends in Molecular Medicine. 16 
(2010) 133–144. 
[196] V.S. Salsman, K.K.H. Chow, D.R. Shaffer, H. Kadikoy, X.-N. Li, C. 
 402 
Gerken, et al., Crosstalk between medulloblastoma cells and endothelium 
triggers a strong chemotactic signal recruiting T lymphocytes to the tumor 
microenvironment, PLoS ONE. 6 (2011) e20267. 
doi:10.1371/journal.pone.0020267. 
[197] N. Martinet, G. Beck, V. Bernard, F. Plenat, P. Vaillant, F. Schooneman, et 
al., Mechanism for the recruitment of macrophages to cancer site. In vivo 
concentration gradient of monocyte chemotactic activity, Cancer. 70 (1992) 
854–860. 
[198] A. Mantovani, Cancer: Inflaming metastasis, Nature. 457 (2009) 36–37. 
doi:10.1038/457036b. 
[199] A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related 
inflammation, Nature. 454 (2008) 436–444. 
[200] A.J. Swiston, J.B. Gilbert, D.J. Irvine, R.E. Cohen, M.F. Rubner, Freely 
suspended cellular “backpacks” lead to cell aggregate self-assembly, 
Biomacromolecules. 11 (2010) 1826–1832. doi:10.1021/bm100305h. 
[201] A.J. Swiston, C. Cheng, S.H. Um, D.J. Irvine, R.E. Cohen, M.F. Rubner, 
Surface Functionalization of Living Cells with Multilayer Patches, Nano 
Lett. 8 (2008) 4446–4453. doi:10.1021/nl802404h. 
[202] F.C. Vasconcellos, A.J. Swiston, M.M. Beppu, R.E. Cohen, M.F. Rubner, 
Bioactive Polyelectrolyte Multilayers: Hyaluronic Acid Mediated B 
Lymphocyte Adhesion, Biomacromolecules. 11 (2010) 2407–2414. 
doi:10.1021/bm100570r. 
[203] N. Doshi, A.J. Swiston, J.B. Gilbert, M.L. Alcaraz, R.E. Cohen, M.F. 
 403 
Rubner, et al., Cell-based drug delivery devices using phagocytosis-resistant 
backpacks, Advanced Materials. 23 (2011) H105–9. 
doi:10.1002/adma.201004074. 
[204] H.C. Loughrey, L.S. Choi, P.R. Cullis, M.B. Bally, Optimized procedures 
for the coupling of proteins to liposomes, Journal of Immunological 
Methods. 132 (1990) 25–35. doi:10.1016/0022-1759(90)90394-B. 
[205] L. Nobs, F. Buchegger, R. Gurny, E. Allémann, Current methods for 
attaching targeting ligands to liposomes and nanoparticles, J Pharm Sci. 93 
(2004) 1980–1992. doi:10.1002/jps.20098. 
[206] N. Donoghue, P.T. Yam, X.M. Jiang, P.J. Hogg, Presence of closely spaced 
protein thiols on the surface of mammalian cells, Protein Sci. 9 (2000) 
2436–2445. doi:10.1110/ps.9.12.2436. 
[207] D.A. Lawrence, R. Song, P. Weber, Surface thiols of human lymphocytes 
and their changes after in vitro and in vivo activation, Journal of Leukocyte 
Biology. 60 (1996) 611–618. 
[208] M.T. Stephan, J.J. Moon, S.H. Um, A. Bershteyn, D.J. Irvine, Therapeutic 
cell engineering with surface-conjugated synthetic nanoparticles, Nature 
Medicine. 16 (2010) 1035–1041. doi:10.1038/nm.2198. 
[209] M.J. Mitchell, E. Wayne, K. Rana, C.B. Schaffer, M.R. King, TRAIL-coated 
leukocytes that kill cancer cells in the circulation, Proc Natl Acad Sci USA. 
111 (2014) 930–935. doi:10.1073/pnas.1316312111. 
[210] J.A. Badwey, M.L. Karnovsky, Active oxygen species and the functions of 
phagocytic leukocytes, Annu. Rev. Biochem. 49 (1980) 695–726. 
 404 
doi:10.1146/annurev.bi.49.070180.003403. 
[211] D.C. Dale, L. Boxer, W.C. Liles, The phagocytes: neutrophils and 
monocytes, Blood. 112 (2008) 935–945. doi:10.1182/blood-2007-12-
077917. 
[212] J. Choi, H.Y. Kim, E.J. Ju, J. Jung, J. Park, H.K. Chung, et al., Use of 
macrophages to deliver therapeutic and imaging contrast agents to tumors, 
Biomaterials. 33 (2012) 4195–4203. 
[213] M.-R. Choi, R. Bardhan, K.J. Stanton-Maxey, S. Badve, H. Nakshatri, K.M. 
Stantz, et al., Delivery of nanoparticles to brain metastases of breast cancer 
using a cellular Trojan horse, Cancer Nano. 3 (2012) 47–54. 
doi:10.1007/s12645-012-0029-9. 
[214] A.M. Brynskikh, Y. Zhao, R.L. Mosley, S. Li, M.D. Boska, N.L. Klyachko, 
et al., Macrophage delivery of therapeutic nanozymes in a murine model of 
Parkinson’s disease, Nanomedicine (Lond). 5 (2010) 379–396. 
doi:10.2217/nnm.10.7. 
[215] E.V. Batrakova, S. Li, A.D. Reynolds, R.L. Mosley, T.K. Bronich, A.V. 
Kabanov, et al., A Macrophage−Nanozyme Delivery System for Parkinson's 
Disease, Bioconjug. Chem. 18 (2007) 1498–1506. doi:10.1021/bc700184b. 
[216] L.R. Hirsch, R.J. Stafford, J.A. Bankson, S.R. Sershen, B. Rivera, R.E. 
Price, et al., Nanoshell-mediated near-infrared thermal therapy of tumors 
under magnetic resonance guidance, Proc Natl Acad Sci USA. 100 (2003) 
13549–13554. doi:10.1073/pnas.2232479100. 
[217] C.L. Graff, G.M. Pollack, Drug Transport at the Blood-Brain Barrier and the 
 405 
Choroid Plexus, Curr Drug Metab. 5 (2004) 95–108. 
doi:10.2174/1389200043489126. 
[218] W.M. Pardridge, The blood-brain barrier: Bottleneck in brain drug 
development, Neurotherapeutics. 2 (2005) 3–14. doi:10.1602/neurorx.2.1.3. 
[219] G. Schackert, R.D. Simmons, T.M. Buzbee, D.A. Hume, I.J. Fidler, 
Macrophage Infiltration Into Experimental Brain Metastases: Occurrence 
Through an Intact Blood-Brain Barrier, Journal of the National Cancer 
Institute. 80 (1988) 1027–1034. 
[220] Robert A Morantz, Gary W Wood, Marsha Foster, Martina Clark, Katherine 
Gollahon, Macrophages in experimental and human brain tumors, Journal of 
Neurosurgery. 50 (1979) 305–311. 
[221] B.R. Smith, E. Ghosn, H. Rallapalli, J.A. Prescher, T. Larson, L.A. 
Herzenberg, et al., Selective uptake of single-walled carbon nanotubes by 
circulating monocytes for enhanced tumour delivery, Nature 
Nanotechnology. 9 (2014) 481–487. 
[222] M.T. Stephan, S.B. Stephan, P. Bak, J. Chen, D.J. Irvine, Synapse-directed 
delivery of immunomodulators using T-cell-conjugated nanoparticles, 
Biomaterials. 33 (2012) 5776–5787. 
doi:10.1016/j.biomaterials.2012.04.029. 
[223] S.Y. Wong, R.O. Hynes, Lymphatic or Hematogenous Dissemination: How 
Does a Metastatic Tumor Cell Decide? Cell Cycle. 5 (2006) 812–817. 
doi:10.4161/cc.5.8.2646. 
[224] H. Wikman, R. Vessella, K. Pantel, Cancer micrometastasis and tumour 
 406 
dormancy, Apmis. 116 (2008) 754–770. doi:10.1111/j.1600-
0463.2008.01033.x. 
[225] L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, et al., NK 
Cells and Cancer, The Journal of Immunology. 178 (2007) 4011–4016. 
doi:10.4049/jimmunol.178.7.4011. 
[226] B. Nieswandt, M. Hafner, B. Echtenacher, D.N. Männel, Lysis of Tumor 
Cells by Natural Killer Cells in Mice Is Impeded by Platelets, Cancer 
Research. 59 (1999) 1295–1300. 
[227] M. Bajénoff, B. Breart, A.Y.C. Huang, H. Qi, J. Cazareth, V.M. Braud, et 
al., Natural killer cell behavior in lymph nodes revealed by static and real-
time imaging, Journal of Experimental Medicine. 203 (2006) 619–631. 
doi:10.1084/jem.20051474. 
[228] G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, R.D. Schreiber, Cancer 
immunoediting: from immunosurveillance to tumor escape, Nat. Immunol. 3 
(2002) 991–998. 
[229] A.D. Hartkopf, M. Banys, N. Krawczyk, A. Staebler, S. Becker, J. Hoffman, 
et al., Bone marrow versus sentinel lymph node involvement in breast 
cancer: a comparison of early hematogenous and early lymphatic tumor 
spread, Breast Cancer Res Treat. 131 (2012) 501–508. 
[230] B. Gerber, A. Krause, H. Müller, D. Richter, T. Reimer, J. Makovitzky, et 
al., Simultaneous Immunohistochemical Detection of Tumor Cells in Lymph 
Nodes and Bone Marrow Aspirates in Breast Cancer and Its Correlation 
With Other Prognostic Factors, Journal of Clinical Oncology. 19 (2001) 
 407 
960–971. 
[231] B. Kubuschok, B. Passlick, J.R. Izbicki, O. Thetter, K. Pantel, Disseminated 
Tumor Cells in Lymph Nodes as a Determinant for Survival in Surgically 
Resected Non–Small-Cell Lung Cancer, Journal of Clinical Oncology. 17 
(1999) 19–24. 
[232] A. Ashkenazi, P. Holland, S.G. Eckhardt, Ligand-Based Targeting of 
Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis 
Ligand 2/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand 
(rhApo2L/TRAIL), Journal of Clinical Oncology. 26 (2008) 3621–3630. 
doi:10.1200/JCO.2007.15.7198. 
[233] H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, et 
al., Tumoricidal activity of tumor necrosis factor−related 
apoptosis−inducing ligand in vivo, Nature Medicine. 5 (1999) 157–163. 
doi:10.1038/5517. 
[234] S. Lopez-Verges, J.M. Milush, S. Pandey, V.A. York, J. Arakawa-Hoyt, H. 
Pircher, et al., CD57 defines a functionally distinct population of mature NK 
cells in the human CD56dimCD16+ NK-cell subset, Blood. 116 (2010) 
3865–3874. doi:10.1182/blood-2010-04-282301. 
[235] Q. Wing-Han Yuen, Y.P. Zheng, Y.P. Huang, J.F. He, M. Ying, In-vitro 
Strain and Modulus Measurements in Porcine Cervical Lymph Nodes, The 
Open Biomedical Engineering Journal. 5 (2011) 39–46. 
[236] X.D. Zhang, T. Nguyen, W.D. Thomas, J.E. Sanders, P. Hersey, 
Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary 
 408 
between different cell types, FEBS Lett. 482 (2000) 193–199. 
doi:10.1016/S0014-5793(00)02042-1. 
[237] M.J. Mitchell, M.R. King, Theme: Physical Biology in Cancer. 3. The role 
of cell glycocalyx in vascular transport of circulating tumor cells, AJP: Cell 
Physiology. 306 (2014) C89–C97. doi:10.1152/ajpcell.00285.2013. 
[238] W.J. Allard, J. Matera, M.C. Miller, M. Repollet, M.C. Connelly, C. Rao, et 
al., Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas 
but not in Healthy Subjects or Patients With Nonmalignant Diseases, 
Clinical Cancer Research. 10 (2004) 6897–6904. 
[239] L. Yan, Q. Cai, Y. Xu, The Ubiquitin-CXCR4 Axis Plays an Important Role 
in Acute Lung Infection-Enhanced Lung Tumor Metastasis, Clin. Cancer 
Res. 19 (2013) 4706–4716. doi:10.1158/1078-0432.CCR-13-0011. 
[240] P. Tucci, M. Agostini, F. Grespi, E.K. Markert, A. Terrinoni, K.H. Vousden, 
et al., Loss of p63 and its microRNA-205 target results in enhanced cell 
migration and metastasis in prostate cancer, Proc Natl Acad Sci USA. 109 
(2012) 15312–15317. doi:10.1073/pnas.1110977109. 
[241] C.-Y. Chang, S.-C. Lin, W.-H. Su, C.-M. Ho, Y.-S. Jou, Somatic LMCD1 
mutations promoted cell migration and tumor metastasis in hepatocellular 
carcinoma, Oncogene. 31 (2012) 2640–2652. doi:10.1038/onc.2011.440. 
[242] S. Kim, H. Takahashi, W.-W. Lin, P. Descargues, S. Grivennikov, Y. Kim, 
et al., Carcinoma-produced factors activate myeloid cells through TLR2 to 
stimulate metastasis, Nature. 457 (2009) 102–106. doi:10.1038/nature07623. 
[243] I.J. Fidler, Biological Behavior of Malignant Melanoma Cells Correlated to 
 409 
Their Survival in Vivo, Cancer Research. 35 (1975) 218–224. 
[244] I.J. Fidler, Inhibition of Pulmonary Metastasis by Intravenous Injection of 
Specifically Activated Macrophages, Cancer Research. 34 (1974) 1074–
1078. 
[245] I.J. Fidler, G.L. Nicolson, Organ Selectivity for Implantation Survival and 
Growth of B16 Melanoma Variant Tumor Lines, Journal of the National 
Cancer Institute. 57 (1976) 1199–1202. 
[246] M.J. Mitchell, M.R. King, Unnatural killer cells to preventbloodborne 
metastasis: inspiration frombiology and engineering, Expert Rev Anticancer 
Ther. 14 (2014) 641–644. doi:10.1586/14737140.2014.916619. 
[247] V. Subbiah, R.E. Brown, J. Buryanek, J. Trent, A. Ashkenazi, R. Herbst, et 
al., Targeting the apoptotic pathway in chondrosarcoma using recombinant 
human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor 
(DR4/DR5) agonist, Molecular Cancer Therapeutics. 11 (2012) 2541–2546. 
doi:10.1158/1535-7163.MCT-12-0358. 
[248] R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. O'Dwyer, M.S. 
Gordon, et al., Phase I Dose-Escalation Study of Recombinant Human 
Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With 
Advanced Cancer, Journal of Clinical Oncology. 17 (2010) 2839–2846. 
[249] S.K. Bhatia, M.R. King, D.A. Hammer, The state diagram for cell adhesion 
mediated by two receptors, Biophysical Journal. 84 (2003) 2671–2690. 
doi:10.1016/S0006-3495(03)75073-5. 
[250] S. Chandrasekaran, M.J. McGuire, M.R. King, Sweeping lymph node 
 410 
micrometastases off their feet: an engineered model to evaluate natural killer 
cell mediated therapeutic intervention of circulating tumor cells that 
disseminate to the lymph nodes, Lab Chip. 14 (2014) 118–127. 
doi:10.1039/C3LC50584G. 
[251] R.P. McEver, Selectins: lectins that initiate cell adhesion under flow, 
Current Opinion in Cell Biology. 14 (2002) 581–586. doi:10.1016/S0955-
0674(02)00367-8. 
[252] U. von Andrian, J. Chambers, E. Berg, S. Michie, D. Brown, D. Karolak, et 
al., L-selectin mediates neutrophil rolling in inflamed venules through sialyl 
LewisX-dependent and -independent recognition pathways, Blood. 82 
(1993) 182–191. 
[253] T.F. Tedder, D.A. Steeber, P. Pizcueta, L-selectin-deficient mice have 
impaired leukocyte recruitment into inflammatory sites, The Journal of 
Experimental Medicine. 181 (1995) 2259–2264. 
[254] D.A. Steeber, N.E. Green, S. Sato, T.F. Tedder, Humoral Immune Response 
in L-Selectin-Deficient Mice, The Journal of Immunology. 157 (1996) 
4899–4907. 
[255] A. Palecanda, B. Walcheck, D.K. Bishop, M.A. Jutila, Rapid activation-
independent shedding of leukocyte L-selectin induced by cross-linking of 
the surface antigen, Eur. J. Immunol. 22 (1992) 1279–1286. 
[256] G.S. Elemer, T.S. Edgington, Monoclonal Antibody to an Activation 
Neoepitope of Alpha-M Beta-2 Inhibits Multiple Alpha-M Beta-2 
Functions, J. Immunol. 152 (1994) 5836–5844. 
 411 
[257] M. Diamond, J. Garcia-Aguilar, The I domain is a major recognition site on 
the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion 
ligands, The Journal of Cell Biology. (1993). 
[258] H. Fan, Ectodomain shedding of TGF-alpha and other transmembrane 
proteins is induced by receptor tyrosine kinase activation and MAP kinase 
signaling cascades, The EMBO Journal. 18 (1999) 6962–6972. 
doi:10.1093/emboj/18.24.6962. 
[259] M. Jutila, L. Rott, E. Berg, E. Butcher, Function and regulation of the 
neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1, 
The Journal of Immunology. 143 (1989) 3318–3324. 
[260] K. Wenzel-Seifert, High Constitutive Activity of the Human Formyl Peptide 
Receptor, J Biol Chem. 273 (1998) 24181–24189. 
doi:10.1074/jbc.273.37.24181. 
[261] K. Wenzel-Seifert, J. Arthur, H. Liu, Quantitative Analysis of Formyl 
Peptide Receptor Coupling to Giα1, Giα2, and Giα3, J. Biol. Chem. 274 
(1999) 33259–33266. 
[262] A. Makino, M. Glogauer, G.M. Bokoch, S. Chien, G.W. Schmid-Schönbein, 
Control of neutrophil pseudopods by fluid shear: role of Rho family 
GTPases, American Journal of Physiology - Cell Physiology. 288 (2005) 
C863–71. doi:10.1152/ajpcell.00358.2004. 
[263] T. Dewitz, T. Hung, R. Martin, L. McIntire, Mechanical trauma in 
leukocytes, The Journal of Laboratory and Clinical Medicine. 90 (1977) 
728–736. 
 412 
[264] S. Fukuda, G. Schmid-Schonbein, Centrifugation attenuates the fluid shear 
response of circulating leukocytes, Journal of Leukocyte Biology. 72 (2002) 
133–139. 
[265] S. Fukuda, H. Mitsuoka, Leukocyte fluid shear response in the presence of 
glucocorticoid, Journal of Leukocyte Biology. 75 (2004) 664–670. 
[266] M. Coughlin, G. Schmid-Schonbein, Pseudopod Projection and Cell 
Spreading of Passive Leukocytes in Response to Fluid Shear Stress, 
Biophysical Journal. 87 (2004) 2035–2042. 
[267] S. Fukuda, T. Yasu, D. Predescu, G. Schmid-Schonbein, Mechanisms for 
Regulation of Fluid Shear Stress Response in Circulating Leukocytes, Circ. 
Res. 86 (2000) e13–e18. 
[268] J. Middleton, S. Neil, J. Wintle, I. Clark-Lewis, H. Moore, C. Lam, et al., 
Transcytosis and Surface Presentation of IL-8 by Venular Endothelial Cells, 
Cell. 91 (1997) 385–395. 
[269] A. Rot, Neutrophil attractant/activation protein-1 (interleukin-8) inducesin 
vitro neutrophil migration by haptotactic mechanism, Eur. J. Immunol. 23 
(1993) 303–306. doi:10.1002/eji.1830230150. 
[270] Y. Tanaka, D. Adams, S. Shaw, Proteoglycans on endothelial cells present 
adhesion-inducing cytokines to leukocytes, Immunology Today. 14 (1993) 
111–115. 
[271] D. Hall, I. Beresford, C. Browning, H. Giles, Signalling by CXC-chemokine 
receptors 1 and 2 expressed in CHO cells: a comparison of calcium 
mobilization, inhibition of adenylyl cyclase and stimulation of GTPgS 
 413 
binding induced by IL-8 and GROa, British Journal of Pharmacology. 126 
(1999) 810–818. 
[272] M. Burger, J. Burger, R. Hoch, Z. Oades, H. Takamori, I. Schraufstatter, 
Point Mutation Causing Constitutive Signaling of CXCR2 Leads to 
Transforming Activity Similar to Kaposi’s Sarcoma Herpesvirus-G Protein-
Coupled Receptor, The Journal of Immunology. 163 (1999) 2017–2022. 
[273] G. Chen, J. Way, S. Armour, C. Watson, K. Queen, C. Jayawickreme, et al., 
Use of Constitutive G Protein-Coupled Receptor Activity for Drug 
Discovery, Molecular Pharmacology. 57 (2000) 125–134. 
[274] M.B. Kim, I.H. Sarelius, Distributions of Wall Shear Stress in Venular 
Convergences of Mouse Cremaster Muscle, Microcirculation. 10 (2003) 
167–178. doi:10.1038/sj.mn.7800182. 
[275] D. Zhelev, A. Alteraifi, Controlled Pseudopod Extension of Human 
Neutrophils Stimulated with Different Chemoattractants, Biophysical 
Journal. 87 (2004) 688–695. 
[276] A. Makino, H. Shin, Y. Komai, S. Fukuda, M. Coughlin, M. Sugihara-Seki, 
et al., Mechanotransduction in leukocyte activation: A review, Biorheology. 
44 (2007) 221–249. 
[277] S. Fukuda, G.W. Schmid-Schönbein, Regulation of CD18 expression on 
neutrophils in response to fluid shear stress, Proc Natl Acad Sci USA. 100 
(2003) 13152–13157. 
[278] D. Lee, J.B. Schultz, P.A. Knauf, M.R. King, Mechanical Shedding of L-
selectin from the Neutrophil Surface during Rolling on Sialyl Lewis x under 
 414 
Flow, J. Biol. Chem. 282 (2007) 4812–4820. doi:10.1074/jbc.M609994200. 
[279] S.S. Su, G.W. Schmid-Schönbein, Internalization of Formyl Peptide 
Receptor in Leukocytes Subject to Fluid Stresses, Cel. Mol. Bioeng. 3 
(2010) 20–29. doi:10.1007/s12195-010-0111-5. 
[280] G.W. Schmid-Schonbein, Y.Y. Shih, S. Chien, Morphometry of human 
leukocytes, Blood. 56 (1980) 866–875. 
[281] J. Pillay, I. den Braber, N. Vrisekoop, L.M. Kwast, R.J. de Boer, J.A.M. 
Borghans, et al., In vivo labeling with 2H2O reveals a human neutrophil 
lifespan of 5.4 days, Blood. 116 (2010) 625–627. doi:10.1182/blood-2010-
01-259028. 
[282] A.Y. Chen, F.A. DeLano, S.R. Valdez, J.N. Ha, H.Y. Shin, G.W. Schmid-
Schonbein, Receptor cleavage reduces the fluid shear response in 
neutrophils of the spontaneously hypertensive rat, AJP: Cell Physiology. 
299 (2010) C1441–C1449. doi:10.1152/ajpcell.00157.2010. 
[283] H. Ali, R. Richardson, B. Haribabu, R. Snyderman, Chemoattractant 
Receptor Cross-desensitization, Journal of Biological cHemistry. 274 (1999) 
6027–6030. 
[284] R. Lefkowitz, G Protein-coupled Receptors III: New Roles for Receptor 
Kinases and β-Arrestins in Receptor Signaling and Desensitization, Journal 
of Biological cHemistry. 273 (1998) 18677–18680. 
[285] J. Didsbury, R. Uhring, E. Tomhave, C. Gerard, N. Gerard, R. Snyderman, 
Receptor class desensitization of leukocyte chemoattractant receptors, in: 
Proc Natl Acad Sci USA, 1991: pp. 11564–11568. 
 415 
[286] R. Richardson, H. Ali, E. Tomhave, B. Haribabu, R. Snyderman, Cross-
desensitization of Chemoattractant Receptors Occurs at Multiple Levels, 
Journal of Biological cHemistry. 270 (1995) 27829–27833. 
doi:10.1074/jbc.270.46.27829. 
[287] R. Richardson, B. Haribabu, R. Snyderman, Cross-desensitization Among 
Receptors for Platelet Activating Factor and Peptide Chemoattractants: 
Evidence for Independent Regulatory Pathways, Journal of Biological 
cHemistry. 271 (1996) 28717–28724. doi:10.1074/jbc.271.45.28717. 
[288] E.A. Sprague, B.L. Steinbach, R.M. Nerem, C.J. Schwartz, Influence of a 
laminar steady-state fluid-imposed wall shear stress on the binding, 
internalization, and degradation of low-density lipoproteins by cultured 
arterial endothelium, Circulation. 76 (1987) 648–656. 
[289] S. Funamoto, R. Meili, S. Lee, L. Parry, R. Firtel, Spatial and Temporal 
Regulation of 3-Phosphoinositides by PI 3-Kinase and PTEN Mediates 
Chemotaxis, Cell. 109 (2002) 611–623. 
[290] B. Heit, L. Liu, P. Colarusso, K. Puri, P. Kubes, PI3K accelerates, but is not 
required for, neutrophil chemotaxis to fMLP, Journal of Cell Science. 121 
(2008) 205–214. 
[291] S. Merlot, R. Firtel, Leading the way: directional sensing through 
phosphatidylinositol 3-kinase and other signaling pathways, Journal of Cell 
Science. 116 (2003) 3471–3476. 
[292] A. Sasaki, C. Chun, K. Takeda, R. Firtel, Localized Ras signaling at the 
leading edge regulates PI3K, cell polarity, and directional cell movement, 
 416 
The Journal of Cell Biology. 167 (2004) 505–518. 
[293] L.A. Sklar, D.A. Finney, Z.G. Oades, A.J. Jesaitis, R.G. Painter, C.G. 
Cochrane, The dynamics of ligand-receptor interactions. Real-time analyses 
of association, dissociation, and internalization of an N-formyl peptide and 
its receptors on the human neutrophil, J Biol Chem. 259 (1984) 5661–5669. 
[294] C. Koo, R.J. Lefkowitz, R. Snyderman, The oligopeptide chemotactic factor 
receptor on human polymorphonuclear leukocyte membranes exists in two 
affinity states, Biochem. Biophys. Res. Commun. 106 (1982) 442–449. 
[295] S.H. Zigmond, S.J. Sullivan, D.A. Lauffenburger, Kinetic Analysis of 
Chemotactic Peptide Receptor Modulation, The Journal of Cell Biology. 92 
(1982) 34–43. 
[296] M.P. Bevilacqua, R.M. Nelson, G. Mannori, O. Cecconi, Endothelial-
Leukocyte Adhesion Molecules in Human Disease, Annu. Rev. Med. 45 
(1994) 361–378. doi:10.1146/annurev.med.45.1.361. 
[297] S. Schmidt, M. Moser, M. Sperandio, The molecular basis of leukocyte 
recruitment and its deficiencies, Mol. Immunol. 55 (2013) 49–58. 
doi:10.1016/j.molimm.2012.11.006. 
[298] C.J. Ball, A.J. Reiffel, S. Chintalapani, M. Kim, J.A. Spector, M.R. King, 
Hydrogen Sulfide Reduces Neutrophil Recruitment in Hind-Limb Ischemia-
Reperfusion Injury in an L-Selectin and ADAM-17–Dependent Manner, 
Plastic and Reconstructive Surgery. 131 (2013) 487–497. 
doi:10.1097/PRS.0b013e31827c6e9c. 
[299] S.I. Simon, C.E. Green, Molecular mechanics and dynamics of leukocyte 
 417 
recruitment during inflammation, Annu Rev Biomed Eng. 7 (2005) 151–
185. doi:10.1146/annurev.bioeng.7.060804.100423. 
[300] W. Deng, S. Srinivasan, X. Zheng, J.A. Putkey, R. Li, Interaction of 
Calmodulin with l-Selectin at the Membrane Interface: Implication on the 
Regulation of L-Selectin Shedding, Journal of Molecular Biology. 411 
(2011) 220–233. doi:10.1016/j.jmb.2011.05.041. 
[301] G.A. Zimmerman, T.M. McIntyre, M. Mehra, S.M. Prescott, Endothelial 
cell-associated platelet-activating factor: a novel mechanism for signaling 
intercellular adhesion, The Journal of Cell Biology. 110 (1990) 529–540. 
[302] S.M. Prescott, G.A. Zimmerman, D.M. Stafforini, T.M. McIntyre, Platelet-
activating factor and related lipid mediators, Annu. Rev. Biochem. 69 
(2000) 419–445. 
[303] P. Anton, J. O'Connell, D. O'Connell, L. Whitaker, G.C. O'Sullivan, J.K. 
Collins, et al., Mucosal subepithelial binding sites for the bacterial 
chemotactic peptide, formyl-methionyl-leucyl-phenylalanine (FMLP), Gut. 
42 (1998) 374–379. 
[304] W.A. Marasco, S.H. Phan, H. Krutzsch, H.J. Showell, D.E. Feltner, R. 
Nairn, et al., Purification and identification of formyl-methionyl-leucyl-
phenylalanine as the major peptide neutrophil chemotactic factor produced 
by Escherichia coli, J. Biol. Chem. 259 (1984) 5430–5439. 
[305] F. Mariano, B. Bussolati, M. Migliori, S. Russo, G. Triolo, G. Camussi, 
Platelet-activating factor synthesis by neutrophils, monocytes, and 
endothelial cells is modulated by nitric oxide production, Shock. 19 (2003) 
 418 
339–344. 
[306] S.M. Prescott, G.A. Zimmerman, T.M. McIntyre, Platelet-activating factor, J 
Biol Chem. 265 (1990) 17381–17384. 
[307] E.J. Carolan, T.B. Casale, Degree of platelet activating factor-induced 
neutrophil migration is dependent upon the molecular species, J. Immunol. 
145 (1990) 2561–2565. 
[308] W. Zhou, M.A. Javors, M.S. Olson, Impaired surface expression of PAF 
receptors on human neutrophils is dependent upon cell activation, Archives 
of Biochemistry and Biophysics. 308 (1994) 439–445. 
[309] G.A. Zimmerman, T.M. McIntyre, S.M. Prescott, Adhesion and signaling in 
vascular cell-cell interactions, Journal of Clinical Investigation. 98 (1996) 
1699–1702. doi:10.1172/JCI118967. 
[310] J.A. Nick, N.J. Avdi, S.K. Young, C. Knall, P. Gerwins, G.L. Johnson, et 
al., Common and Distinct Intracellular Signaling Pathways in Human 
Neutrophils Utilized by Platelet Activating Factor and FMLP, Journal of 
Clinical Investigation. 99 (1997) 1–12. 
[311] C. Berends, B. Dijkhuizen, J.G. de Monchy, A.E. Dubois, J. Gerritsen, H.F. 
Kauffman, Inhibition of PAF-induced expression of CD11b and shedding of 
L-selectin on human neutrophils and eosinophils by the type IV selective 
PDE inhibitor, rolipram, Eur. Respir. J. 10 (1997) 1000–1007. 
[312] S.S. Segal, Regulation of Blood Flow in the Microcirculation, 
Microcirculation. 12 (2005) 33–45. doi:10.1080/10739680590895028. 
[313] J.E. Smolen, T.K. Petersen, C. Koch, S.J. O'Keefe, W.A. Hanlon, S. Seo, et 
 419 
al., L-selectin signaling of neutrophil adhesion and degranulation involves 
p38 mitogen-activated protein kinase, J. Biol. Chem. 275 (2000) 15876–
15884. doi:10.1074/jbc.M906232199. 
[314] A.-P.J. Huovila, A.J. Turner, M. Pelto-Huikko, I. Kärkkäinen, R.M. Ortiz, 
Shedding light on ADAM metalloproteinases, Trends Biochem. Sci. 30 
(2005) 413–422. doi:10.1016/j.tibs.2005.05.006. 
[315] P. Marschel, G.W. Schmid-Schönbein, Control of Fluid Shear Response in 
Circulating Leukocytes by Integrins, Ann Biomed Eng. 30 (n.d.) 333–343. 
doi:10.1114/1.1475342. 
[316] J. Pugin, How tissue injury alarms the immune system and causes a systemic 
inflammatory response syndrome, Annals of Intensive Care. 2 (2012) 27. 
doi:10.1186/2110-5820-2-27. 
[317] M.J. Eppihimer, H.H. Lipowsky, Effects of leukocyte-capillary plugging on 
the resistance to flow in the microvasculature of cremaster muscle for 
normal and activated leukocytes, Microvasc. Res. 51 (1996) 187–201. 
doi:10.1006/mvre.1996.0020. 
[318] G.S. Worthen, B. Schwab, E.L. Elson, G.P. Downey, Mechanics of 
stimulated neutrophils: cell stiffening induces retention in capillaries, 
Science. 245 (1989) 183–186. 
[319] H. Zhang, C. Sun, M. Glogauer, G.M. Bokoch, Human Neutrophils 
Coordinate Chemotaxis by Differential Activation of Rac1 and Rac2, The 
Journal of Immunology. 183 (2009) 2718–2728. 
doi:10.4049/jimmunol.0900849. 
 420 
[320] G.A. Zimmerman, T.M. McIntyre, S.M. Prescott, D.M. Stafforini, The 
platelet-activating factor signaling system and its regulators in syndromes of 
inflammation and thrombosis, Crit Care Med. 30 (2002) S294–S301. 
[321] J. Herter, A. Zarbock, Integrin Regulation during Leukocyte Recruitment, 
The Journal of Immunology. 190 (2013) 4451–4457. 
doi:10.4049/jimmunol.1203179. 
[322] J. Merlijn van den Berg, F.P.J. Mul, E. Schippers, J.J. Weening, D. Roos, 
T.W. Kuijpers, B1 integrin activation on human neutrophils promotes B2 
integrin-mediated adhesion to fibronectin, Eur. J. Immunol. 31 (2013) 276–
284. 
[323] J.F. DiPersio, P. Billing, R. Williams, J. Gasson, Human Granulocyte-
Macrophage Colony-Stimulating Factor and Other Cytokines Prime Human 
Neutrophils for Enhanced Arachidonic Acid Release and Leukotriene B4 
Synthesis, The Journal of Immunology. 140 (2001) 4315–4322. 
[324] S.D. Shukla, Platelet-activating receptor and signal transduction 
mechanisms, The FASEB Journal. 6 (1992) 2296–2301. 
[325] W. Chao, M.S. Olson, Platelet-activating factor: receptors and signal 
transduction, Biochem. J. 292 (1993) 617–629. 
[326] J.L. Parent, C. Le Gouill, A.J. de Brum-Fernandes, M. Rola-Plezscyznski, J. 
Stankova, Mutations of Two Adjacent Amino Acids Generate Inactive and 
Constitutively Active Forms of the Human Platelet-activating Factor 
Receptor, Journal of Biological cHemistry. 271 (1996) 7949–7955. 
doi:10.1074/jbc.271.14.7949. 
 421 
[327] N. Ohshima, S. Ishii, T. Izumi, T. Shimizu, Receptor-dependent metabolism 
of platelet-activating factor in murine macrophages, J. Biol. Chem. 277 
(2002) 9722–9727. doi:10.1074/jbc.M112406200. 
[328] D.J. Dupré, Z. Chen, C. Le Gouill, C. Thériault, J.-L. Parent, M. Rola-
Pleszczynski, et al., Trafficking, ubiquitination, and down-regulation of the 
human platelet-activating factor receptor, J. Biol. Chem. 278 (2003) 48228–
48235. doi:10.1074/jbc.M304082200. 
[329] D.J. Killock, A. Ivetić, The cytoplasmic domains of TNFα-converting 
enzyme (TACE/ADAM17) and L-selectin are regulated differently by p38 
MAPK and PKC to promote ectodomain shedding, Biochem. J. 428 (2010) 
293–304. doi:10.1074/jbc.275.19.14608. 
[330] T.A. Imaizumi, D.M. Stafforini, Y. Yamada, T.M. McIntyre, S.M. Prescott, 
G.A. Zimmerman, Platelet-activating factor: a mediator for clinicians, 
Journal of Internal Medicine. 238 (1995) 5–20. 
[331] P. Vadas, M. Gold, B. Perelman, G.M. Liss, G. Lack, T. Blyth, et al., 
Platelet-Activating Factor, PAF Acetylhydrolase, and Severe Anaphylaxis, 
New England Journal of Medicine. 358 (2007) 28–35. 
[332] D.E. Lorant, K.D. Patel, T.M. McIntyre, R.P. McEver, S.M. Prescott, G.A. 
Zimmerman, Coexpression of GMP-140 and PAF by Endothelium 
Stimulated by Histamine or Thrombin: A Juxtacrine System for Adhesion 
and Activation of Neutrophils, The Journal of Cell Biology. 115 (1991) 
223–234. 
[333] P. Mehlen, A. Puisieux, Metastasis: a question of life or death, Nat Rev 
 422 
Cancer. 6 (2006) 449–458. doi:10.1038/nrc1886. 
[334] I.C. MacDonald, A.C. Groom, A.F. Chambers, Cancer spread and 
micrometastasis development: Quantitative approaches for in vivo models, 
Bioessays. 24 (2002) 885–893. doi:10.1002/bies.10156. 
[335] J. Li, M.R. King, Adhesion receptors as therapeutic targets for circulating 
tumor cells, Frontiers in Oncology. 2 (2012) 1–9. 
doi:10.3389/fonc.2012.00079/abstract. 
[336] A.D. Hughes, J. Mattison, L.T. Western, J.D. Powderly, B.T. Greene, M.R. 
King, Microtube Device for Selectin-Mediated Capture of Viable 
Circulating Tumor Cells from Blood, Clinical Chemistry. 58 (2012) 846–
853. doi:10.1373/clinchem.2011.176669. 
[337] B.T. Greene, A.D. Hughes, M.R. King, Circulating Tumor Cells: The 
Substrate of Personalized Medicine? Frontiers in Oncology. 2 (2012) 1–6. 
doi:10.3389/fonc.2012.00069. 
[338] R.M. Pitti, S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore, A. 
Ashkenazi, Induction of Apoptosis by Apo-2 Ligand, a New Member of the 
Tumor Necrosis Factor Cytokine Family, Journal of Biological cHemistry. 
271 (1996) 12687–12690. 
[339] M. Plasilova, J. Zivny, J. Jelinek, R. Neuwirtova, J. Cermak, E. Necas, et al., 
TRAIL (Apo2L) suppresses growth of primary human leukemia and 
myelodysplasia progenitors, Leukemia. 16 (2002) 67–73. 
[340] M.J. Smyth, Y. Hayakawa, K. Takeda, H. Yagita, New aspects of natural 
killer cell surveillance and therapy of cancer, Nat Rev Cancer. 2 (2002) 
 423 
850–861. 
[341] E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J.J. Peschon, M.J. Smyth, 
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related 
Apoptosis-Inducing Ligand-Deficient Mice, The Journal of Immunology. 
168 (2002) 1356–1361. 
[342] K. Takeda, Y. Hayakawa, M.J. Smyth, N. Kayagaki, N. Yamaguchi, S. 
Kakuta, et al., Involvement of tumor necrosis factor-related apoptosis-
inducing ligand in surveillance of tumor metastasis by liver natural killer 
cells, Nature Medicine. 7 (2001) 94–100. 
[343] M.J. Smyth, E. Cretney, K. Takeda, R.H. Wiltrout, L.M. Sedger, N. 
Kayagaki, et al., Tumor Necrosis Factor–Related Apoptosis-Inducing 
Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell 
Protection from Tumor Metastasis, The Journal of Experimental Medicine. 
193 (2001) 661–670. 
[344] I.J. Fidler, S. Yano, R.D. Zhang, T. Fujimaki, C.D. Bucana, The seed and 
soil hypothesis: vascularisation and brain metastases, Lancet Oncol. 3 
(2002) 53–57. 
[345] M.M. Burdick, J.M. McCaffery, Y.S. Kim, B.S. Bochner, K. 
Konstantopoulos, Colon carcinoma cell glycolipids, integrins, and other 
glycoproteins mediate adhesion to HUVECs under flow, American Journal 
of Physiology - Cell Physiology. 284 (2003) C977–87. 
doi:10.1152/ajpcell.00423.2002. 
[346] J.P. Herbeuval, C. Lambert, O. Sabido, M. Cottier, P. Fournel, M. Dy, et al., 
 424 
Macrophages From Cancer Patients: Analysis of TRAIL, TRAIL Receptors, 
and Colon Tumor Cell Apoptosis, Journal of the National Cancer Institute. 
95 (2003) 611–621. 
[347] N.A. Thornberry, Y.L. Lazebnik, Caspases: Enemies Within, Science. 281 
(1998) 1312–1316. doi:10.1126/science.281.5381.1312. 
[348] K.M. Kim, J.J. Song, J.Y. An, Y.T. Kwon, Y.J. Lee, Pretreatment of 
Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-
inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene 
Expression, Journal of Biological cHemistry. 280 (2005) 41047–41056. 
doi:10.1074/jbc.M503713200. 
[349] S. Fulda, K.M. Debatin, 5-Aza-2′-deoxycytidine and IFN-γ cooperate to 
sensitize for TRAIL-induced apoptosis by upregulating caspase-8, 
Oncogene. 25 (2006) 5125–5133. doi:10.1038/sj.onc.1209518. 
[350] S. Fulda, W. Wick, M. Weller, K.M. Debatin, Smac agonists sensitize for 
Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression 
of malignant glioma in vivo, Nature Medicine. 8 (2002) 808–815. 
[351] T.J. Kemp, J.S. Kim, S.A. Crist, T.S. Griffith, Induction of necrotic tumor 
cell death by TRAIL/Apo-2L, Apoptosis. 8 (2003) 587–599. 
doi:10.1023/A:1026286108366. 
[352] N. Holler, R. Zaru, O. Micheau, M. Thome, A. Attinger, S. Valitutti, et al., 
Fas triggers an alternative, caspase-8-independent cell death pathway using 
the kinase RIP as effector molecule, Nat. Immunol. 1 (2000) 489–495. 
doi:10.1038/82732. 
 425 
[353] O. Meurette, A. Rebillard, L. Huc, G. Le Moigne, D. Merino, O. Micheau, et 
al., TRAIL induces receptor-interacting protein 1-dependent and caspase-
dependent necrosis-like cell death under acidic extracellular conditions, 
Cancer Research. 67 (2007) 218–226. doi:10.1158/0008-5472.CAN-06-
1610. 
[354] O. Meurette, L. Huc, A. Rebillard, G. Le Moigne, D. Lagadic-Gossmann, 
M.-T. Dimanche-Boitrel, TRAIL (TNF-related apoptosis-inducing ligand) 
induces necrosis-like cell death in tumor cells at acidic extracellular pH, 
Ann. N. Y. Acad. Sci. 1056 (2005) 379–387. doi:10.1196/annals.1352.018. 
[355] J.M. Rutkowski, M.A. Swartz, A driving force for change: interstitial flow 
as a morphoregulator, Trends Cell Biol. 17 (2007) 44–50. 
doi:10.1016/j.tcb.2006.11.007. 
[356] A. Arlt, J. Vorndamm, M. Breitenbroich, U.R. Fölsch, H. Kalthoff, W.E. 
Schmidt, et al., Inhibition of NF-κB sensitizes human pancreatic carcinoma 
cells to apoptosis induced by etoposide (VP16) or doxorubicin, Oncogene. 
20 (2001) 859–868. doi:10.1038/sj.onc.1204168. 
[357] S. Li, Y. Zhou, R. Wang, H. Zhang, Y. Dong, C. Ip, Selenium sensitizes 
MCF-7 breast cancer cells to doxorubicin-induced apoptosis through 
modulation of phospho-Akt and its downstream substrates, Molecular 
Cancer Therapeutics. 6 (2007) 1031–1038. doi:10.1158/1535-7163.MCT-
06-0643. 
[358] H.K. Koblish, S. Zhao, C.F. Franks, R.R. Donatelli, R.M. Tominovich, L.V. 
LaFrance, et al., Benzodiazepinedione inhibitors of the Hdm2:p53 complex 
 426 
suppress human tumor cell proliferation in vitro and sensitize tumors to 
doxorubicin in vivo, Molecular Cancer Therapeutics. 5 (2006) 160–169. 
doi:10.1158/1535-7163.MCT-05-0199. 
[359] A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, 
et al., Safety and antitumor activity of recombinant soluble Apo2 ligand, J. 
Clin. Invest. 104 (1999) 155–162. doi:10.1172/JCI6926. 
[360] S.A. Quast, A. Berger, N. Buttstädt, K. Friebel, R. Schönherr, J. Eberle, 
General Sensitization of Melanoma Cells for TRAIL-Induced Apoptosis by 
the Potassium Channel Inhibitor TRAM-34 Depends on Release of SMAC, 
PLoS ONE. 7 (2012) e39290. doi:10.1371/journal.pone.0039290. 
[361] E. Norberg, S. Orrenius, B. Zhivotovsky, Mitochondrial regulation of cell 
death: processing of apoptosis-inducing factor (AIF), Biochem. Biophys. 
Res. Commun. 396 (2010) 95–100. doi:10.1016/j.bbrc.2010.02.163. 
[362] V. Stagni, M. Mingardi, S. Santini, D. Giaccari, D. Barilà, ATM kinase 
activity modulates cFLIP protein levels: potential interplay between DNA 
damage signalling and TRAIL-induced apoptosis, Carcinogenesis. 31 (2010) 
1956–1963. doi:10.1093/carcin/bgq193. 
[363] S.V. Garimella, A. Rocca, S. Lipkowitz, WEE1 Inhibition Sensitizes Basal 
Breast Cancer Cells to TRAIL-Induced Apoptosis, Molecular Cancer 
Research. 10 (2012) 75–85. 
[364] A. Suliman, A. Lam, R. Datta, R.K. Srivastava, Intracellular mechanisms of 
TRAIL: apoptosis through mitochondrial-dependent and -independent 
pathways, Oncogene. 20 (2001) 2122–2133. 
 427 
[365] I. Fidler, The pathogenesis of cancer metastasis: the “seed and soil” 
hypothesis revisited, Nat Rev Cancer. 3 (2003) 1–6. 
[366] P. Paterlini-Brechot, N.L. Benali, Circulating tumor cells (CTC) detection: 
clinical impact and future directions, Cancer Letters. 253 (2007) 180–204. 
doi:10.1016/j.canlet.2006.12.014. 
[367] A. Chambers, G. Naumov, S. Vantyghem, Tuck, AB, Molecular biology of 
breast metastasis: Clinical implications of experimental studies on metastatic 
inefficiency, Breast Cancer Research. 2 (2000) 400–407. 
[368] J. Bouma, J.H. Beijnen, A. Bult, W.J.M. Underberg, Anthracycline 
antitumour agents, Pharmaceutisch Weekblad Scientific Edition. 8 (1986) 
109–133. doi:10.1007/BF02086146. 
[369] L. Reddy, Drug delivery to tumours: recent strategies, Journal of Pharmacy 
and Pharmacology. 57 (2005) 1231–1242. 
[370] A. Fritze, F. Hens, R. Kimpfler, R. Schubert, R. Peschka-Suss, Remote 
loading of doxorubicin into liposomes driven by a transmembrane phosphate 
gradient, Biochimica Et Biophysica Acta. 1758 (2006) 1633–1640. 
doi:10.1016/j.bbamem.2006.05.028. 
[371] M. Saad, O.B. Garbuzenko, E. Ber, P. Chandna, J.J. Khandare, V.P. 
Pozharov, et al., Receptor targeted polymers, dendrimers, liposomes: Which 
nanocarrier is the most efficient for tumor-specific treatment and imaging? 
Journal of Controlled Release. 130 (2008) 107–114. 
doi:10.1016/j.jconrel.2008.05.024. 
[372] E. Herman, A. Rahman, V. Ferrans, J. Vick, P. Schein, Prevention of 
 428 
Chronic Doxorubicin Cardiotoxicity in Beagles by Liposomal 
Encapsulation, Cancer Research. 43 (1983) 5427–5432. 
[373] R. Krishna, N. McIntosh, K. Riggs, Doxorubicin Encapsulated in Sterically 
Stabilized Liposomes Exhibits Renal and Biliary Clearance Properties That 
Are Independent of Valspodar (PSC 833) under Conditions That 
Significantly Inhibit Nonencapsulated Drug Excretion, Clinical Cancer 
Research. 5 (1999) 2939–2947. 
[374] A.A. Gabizon, Pegylated Liposomal Doxorubicin: Metamorphosis of an Old 
Drug into a New Form of Chemotherapy, Cancer Investigation. 19 (2001) 
424–436. 
[375] W. Saltzman, Drug delivery: engineering principles for drug therapy, New 
York: Oxford University Press, 2001. 
[376] A. Soundararajan, A. Bao, W. Phillips, R. Perez III, B. Goins, 
[186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, 
imaging and biodistribution in a head and neck squamous cell carcinoma 
xenograft model, Nuclear Medicine and Biology. 36 (2009) 515–524. 
[377] D.D. Lasic, Doxorubicin in sterically stabilized liposomes, Nature. 380 
(1996) 561–562. doi:10.1038/380561a0. 
[378] M. Silvander, Steric stabilization of liposomes - a review, Progress in 
Colloid Polymer Science. 120 (2002) 35–40. 
[379] A. Gabzion, H. Shmeeda, Y. Barenholz, Pharmacokinetics of Pegylated 
Liposomal Doxorubicin: Review of Animal and Human Studies, Clinical 
Pharmacokinetics. 42 (2003) 419–436. 
 429 
[380] C. Carrion, M. De Madariaga, J. Domingo, In vitro cytotoxic study of 
immunoliposomal doxorubicin targeted to human CD34+ leukemic cells, 
Life Sciences. 75 (2004) 313–328. 
[381] H.D. Han, A. Lee, T. Hwang, C.K. Song, H. Seong, J. Hyun, et al., 
Enhanced circulation time and antitumor activity of doxorubicin by 
comblike polymer-incorporated liposomes, Journal of Controlled Release. 
120 (2007) 161–168. doi:10.1016/j.jconrel.2007.03.020. 
[382] B. Ceh, M. Winterhalter, P. Frederik, J. Vallner, D. Lasic, Stealth® 
liposomes: from theory to product, Advanced Drug Delivery Reviews. 24 
(1997) 165–177. 
[383] J. Kitayama, N. Tsuno, E. Sunami, T. Osada, T. Muto, H. Nagawa, E-
selectin can mediate the arrest type of adhesion of colon cancer cells under 
physiological shear flow, European Journal of Cancer. 36 (2000) 121–127. 
[384] T. Krause, G.A. Turner, Are selectins involved in metastasis? Clinical & 
Experimental Metastasis. 17 (1999) 183–192. 
doi:10.1023/A:1006626500852. 
[385] A.D. Hughes, M.R. King, Use of Naturally Occurring Halloysite Nanotubes 
for Enhanced Capture of Flowing Cells, Langmuir. 26 (2010) 12155–12164. 
doi:10.1021/la101179y. 
[386] S. Amselem, R. Cohen, S. Druckmann, A. Gabizon, D. Goren, R.M. Abra, 
et al., Preparation and Characterization of Liposomal Doxorubicin for 
Human Use, Journal of Liposome Research. 2 (1992) 93–123. 
[387] G. Haran, R. Cohen, L. Bar, Y. Barenholz, Transmembrane ammonium 
 430 
sulfate gradients in liposomes produce efficient and stable entrapment of 
amphipathic weak bases, Biochimica Et Biophysica Acta. 1151 (1993) 201–
215. 
[388] Z. Huang, M. King, An immobilized nanoparticle-based platform for 
efficient gene knockdown of targeted cells in the circulation, Gene Therapy. 
16 (2009) 1271–1282. 
[389] J. Wojciechowski, S. Narasipura, N. Charles, D. Mickelsen, K. Rana, M. 
Blair, et al., Capture and enrichment of CD34-positive haematopoietic stem 
and progenitor cells from blood circulation using P-selectin in an 
implantable device, British Journal of Hematology. 140 (2008) 673–681. 
[390] C. Ball, M. King, Role of c-Abl in L-selectin shedding from the neutrophil 
surface, Blood Cells, Molecules, and Diseases. 46 (2011) 246–251. 
[391] X. Yin, K. Rana, V. Ponmudi, M. King, Knockdown of fucosyltransferase 
III disrupts the adhesion of circulating cancer cells to E-selectin without 
affecting hematopoietic cell adhesion, Carbohydrate Research. 345 (2010) 
2334–2342. 
[392] F. Orr, H. Wang, R. Lafrenie, S. Scherbarth, D. Nance, Interactions between 
cancer cells and the endothelium in metastasis, J. Pathol. 190 (2000) 310–
329. 
[393] Y. Kim, L. Borsig, H. Han, N. Varki, A. Varki, Distinct Selectin Ligands on 
Colon Carcinoma Mucins Can Mediate Pathological Interactions among 
Platelets, Leukocytes, and Endothelium, The American Journal of 
Pathology. 155 (1999) 461. 
 431 
[394] B. Ceh, D. Lasic, A rigorous theory of remote loading of drugs into 
liposomes, Langmuir. 11 (1995) 3356–3368. 
[395] C. Chemin, J. Péan, C. Bourgaux, G. Pabst, P. Wuthrich, P. Couvreur, et al., 
Supramolecular organization of S12363-liposomes prepared with two 
different remote loading processes, Biochimica Et Biophysica Acta. 1788 
(2009) 926–935. 
[396] E. Forssen, M. Willis, Ligand-targeted liposomes, Advanced Drug Delivery 
Reviews. 29 (1998) 249–271. 
[397] R. Nallamothu, G. Wood, C. Pattillo, R. Scott, M. Kiani, B. Moore, et al., A 
tumor vasculature targeted liposome delivery system for combretastatin A4: 
design, characterization, and in vitro evaluation, AAPS PharmSciTech. 7 
(2006) E1–E10. 
[398] R. Kannagi, M. Izawa, T. Koike, K. Miyazaki, N. Kimura, Carbohydrate-
mediated cell adhesion in cancer metastasis and angiogenesis, Cancer 
Science. 95 (2004) 377–384. 
[399] J. Magnani, The discovery, biology, and drug development of sialyl Lea and 
sialyl Lex, Archives of Biochemistry and Biophysics. 426 (2004) 122–131. 
[400] J. Ogawa, H. Inoue, S. Koide, Expression of α-1,3-Fucosyltransferase Type 
IV and VII Genes Is Related to Poor Prognosis in Lung Cancer, Cancer 
Research. 56 (1996) 325–329. 
[401] W. Tsuruta, H. Tsurushima, T. Yamamoto, K. Suzuki, N. Yamazaki, A. 
Matsumura, Application of liposomes incorporating doxorubicin with sialyl 
Lewis X to prevent stenosis after rat carotid artery injury, Biomaterials. 30 
 432 
(2009) 118–125. 
[402] A.N. Lukyanov, T.A. Elbayoumi, A.R. Chakilam, V.P. Torchilin, Tumor-
targeted liposomes: doxorubicin-loaded long-circulating liposomes modified 
with anti-cancer antibody, Journal of Controlled Release. 100 (2004) 135–
144. doi:10.1016/j.jconrel.2004.08.007. 
[403] C.G. Begley, A.F. Lopez, N.A. Nicola, D.J. Warren, M.A. Vadas, C.J. 
Sanderson, et al., Purified colony-stimulating factors enhance the survival of 
human neutrophils and eosinophils in vitro: a rapid and sensitive microassay 
for colony-stimulating factors, Blood. 68 (1986) 162–166. 
[404] S. Riethdorf, H. Wikman, K. Pantel, Review: Biological relevance of 
disseminated tumor cells in cancer patients, International Journal of Cancer. 
123 (2008) 1991–2006. doi:10.1002/ijc.23825. 
[405] P. Gassmann, M.L. Kang, S.T. Mees, J. Haier, In vivo tumor cell adhesion 
in the pulmonary microvasculature is exclusively mediated by tumor cell--
endothelial cell interaction, BMC Cancer. 10 (2010) 177. doi:10.1186/1471-
2407-10-177. 
[406] Y.S. Chang, E. di Tomaso, D.M. McDonald, R. Jones, R.K. Jain, L.L. 
Munn, Mosaic blood vessels in tumors: frequency of cancer cells in contact 
with flowing blood, Proc Natl Acad Sci USA. 97 (2000) 14608–14613. 
doi:10.1073/pnas.97.26.14608. 
[407] T.P. Butler, P.M. Gullino, Quantitation of cell shedding into efferent blood 
of mammary adenocarcinoma, Cancer Research. 35 (1975) 512–516. 
[408] C. Huang, J.T. Mason, Geometric packing constraints in egg 
 433 
phosphatidylcholine vesicles, Proc. Natl. Acad. Sci. U.S.a. 75 (1978) 308–
310. 
[409] T.A. Doherty, N. Khorram, J.E. Chang, H.-K. Kim, P. Rosenthal, M. Croft, 
et al., STAT6 regulates natural helper cell proliferation during lung 
inflammation initiated by Alternaria, Am. J. Physiol. Lung Cell Mol. 
Physiol. 303 (2012) L577–88. doi:10.1152/ajplung.00174.2012. 
[410] P. Malý, A. Thall, B. Petryniak, C.E. Rogers, P.L. Smith, R.M. Marks, et al., 
The alpha(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking 
through an essential role in L-, E-, and P-selectin ligand biosynthesis, Cell. 
86 (1996) 643–653. 
[411] E.M. Janssen, N.M. Droin, E.E. Lemmens, M.J. Pinkoski, S.J. Bensinger, 
B.D. Ehst, et al., CD4+ T-cell help controls CD8+ T-cell memory via 
TRAIL-mediated activation-induced cell death, Nature. 434 (2005) 88–93. 
doi:10.1038/nature03337. 
[412] H.L. Goldsmith, The microrheology of red blood cell suspensions, J. Gen. 
Physiol. 52 (1968) 5–28. 
[413] H.L. Goldsmith, D.N. Bell, S. Braovac, A. Steinberg, F. McIntosh, Physical 
and chemical effects of red cells in the shear-induced aggregation of human 
platelets, Biophysical Journal. 69 (1995) 1584–1595. doi:10.1016/S0006-
3495(95)80031-7. 
[414] N. Kato, Y. Yuzawa, T. Kosugi, A. Hobo, W. Sato, Y. Miwa, et al., The E-
Selectin Ligand Basigin/CD147 Is Responsible for Neutrophil Recruitment 
in Renal Ischemia/Reperfusion, Journal of the American Society of 
 434 
Nephrology. 20 (2009) 1565–1576. doi:10.1681/ASN.2008090957. 
[415] I.J. Fidler, G.L. Nicolson, Fate of Recirculating B16 Melanoma Metastatic 
Variant Cells in Parabiotic Syngeneic Recipients: Brief Communication, 
Journal of the National Cancer Institute. 58 (1977) 1867–1872. 
[416] H. Xiang, C.B. Nguyen, S.K. Kelley, N. Dybdal, E. Escandon, Tissue 
distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis 
factor-related apoptosis-inducing ligand in human colon carcinoma 
COLO205 tumor-bearing nude mice, Drug Metabolism and Disposition. 32 
(2004) 1230–1238. doi:10.1124/dmd.104.000323. 
[417] K. Takeda, E. Cretney, Y. Hayakawa, T. Ota, H. Akiba, K. Ogasawara, et 
al., TRAIL identifies immature natural killer cells in newborn mice and 
adult mouse liver, Blood. 105 (2005) 2082–2089. doi:10.1182/blood-2004-
08-3262. 
[418] I. Waldhauer, A. Steinle, NK cells and cancer immunosurveillance, 
Oncogene. 27 (2008) 5932–5943. doi:10.1038/onc.2008.267. 
[419] M.Y. Kim, T. Oskarsson, S. Acharyya, D.X. Nguyen, X.H.F. Zhang, L. 
Norton, et al., Tumor self-seeding by circulating cancer cells, Cell. 139 
(2009) 1315–1326. doi:10.1016/j.cell.2009.11.025. 
[420] M. Bernal, A. Concha, P. Sáenz-López, A.I. Rodriguez, T. Cabrera, F. 
Garrido, et al., Leukocyte infiltrate in gastrointestinal adenocarcinomas is 
strongly associated with tumor microsatellite instability but not with tumor 
immunogenicity, Cancer Immunol Immunother. 60 (2011) 869–882. 
[421] H. Shankaran, S. Neelamegham, Hydrodynamic forces applied on 
 435 
intercellular bonds, soluble molecules, and cell-surface receptors, 
Biophysical Journal. 86 (2004) 576–588. doi:10.1016/S0006-
3495(04)74136-3. 
[422] Y. Zhao, S. Chien, S. Weinbaum, Dynamic contact forces on leukocyte 
microvilli and their penetration of the endothelial glycocalyx, Biophysical 
Journal. 80 (2001) 1124–1140. doi:10.1016/S0006-3495(01)76090-0. 
[423] S. Sabri, M. Soler, C. Foa, A. Pierres, A. Benoliel, P. Bongrand, Glycocalyx 
modulation is a physiological means of regulating cell adhesion, Journal of 
Cell Science. 113 (2000) 1589–1600. 
[424] M. Jo, T.H. Kim, D.W. Seol, J.E. Esplen, K. Dorko, T.R. Billiar, et al., 
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-
related apoptosis-inducing ligand, Nature Medicine. 6 (2000) 564–567. 
doi:10.1038/75045. 
[425] T.M. Cao, T. Takatani, M.R. King, Effect of extracellular pH on selectin 
adhesion: theory and experiment, Biophysical Journal. 104 (2013) 292–299. 
doi:10.1016/j.bpj.2012.12.005. 
[426] D. Deeb, H. Jiang, X. Gao, M.S. Hafner, H. Wong, G. Divine, et al., 
Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related 
apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB 
through suppression of IkappaBalpha phosphorylation, Molecular Cancer 
Therapeutics. 3 (2004) 803–812. 
[427] B. Weigelt, J.L. Peterse, L.J. van't Veer, Breast cancer metastasis: markers 
and models, Nat Rev Cancer. 5 (2005) 591–602. doi:10.1038/nrc1670. 
 436 
[428] S. Weinbaum, J.M. Tarbell, E.R. Damiano, The structure and function of the 
endothelial glycocalyx layer, Annu Rev Biomed Eng. 9 (2007) 121–167. 
doi:10.1146/annurev.bioeng.9.060906.151959. 
[429] B.P. Toole, T.N. Wight, M.I. Tammi, Hyaluronan-cell interactions in cancer 
and vascular disease, J. Biol. Chem. 277 (2002) 4593–4596. 
doi:10.1074/jbc.R100039200. 
[430] H.H. Lipowsky, The endothelial glycocalyx as a barrier to leukocyte 
adhesion and its mediation by extracellular proteases, Ann Biomed Eng. 40 
(2012) 840–848. doi:10.1007/s10439-011-0427-x. 
[431] A.R. Pries, T.W. Secomb, P. Gaehtgens, The endothelial surface layer, 
Pflugers Arch. 440 (2000) 653–666. doi:10.1007/s004240000307. 
[432] S. Reitsma, D.W. Slaaf, H. Vink, M.A.M.J. Zandvoort, M.G.A. oude 
Egbrink, The endothelial glycocalyx: composition, functions, and 
visualization, Pflugers Arch. 454 (2007) 345–359. doi:10.1007/s00424-007-
0212-8. 
[433] H. Vink, B.R. Duling, Identification of distinct luminal domains for 
macromolecules, erythrocytes, and leukocytes within mammalian 
capillaries, Circ. Res. 79 (1996) 581–589. 
[434] B.M. van den Berg, H. Vink, J.A.E. Spaan, The endothelial glycocalyx 
protects against myocardial edema, Circ. Res. 92 (2003) 592–594. 
doi:10.1161/01.RES.0000065917.53950.75. 
[435] J. Rostgaard, K. Qvortrup, Electron Microscopic Demonstrations of 
Filamentous Molecular Sieve Plugs in Capillary Fenestrae, Microvasc. Res. 
 437 
53 (1997) 1–13. 
[436] E.R. Damiano, D.S. Long, F.H. El-Khatib, On the motion of a sphere in a 
Stokes flow parallel to a Brinkman half-space, Journal of Fluid Mechanics. 
500 (2004) 75–101. 
[437] E.R. Damiano, D.S. Long, M.L. Smith, Estimation of viscosity profiles 
using velocimetry data from parallel flows of linearly viscous fluids: 
application to microvascular haemodynamics, Journal of Fluid Mechanics. 
512 (2004) 1–19. 
[438] M.W. Keller, D.N. Damon, B.R. Duling, Determination of capillary tube 
hematocrit during arteriolar microperfusion, Am. J. Physiol. 266 (1994) 
H2229–38. 
[439] B. Klitzman, B.R. Duling, Microvascular hematocrit and red cell flow in 
resting and contracting striated muscle, Am J Physiol Heart Circ Physiol. 
237 (1979) H481–90. 
[440] I.H. Sarelius, B.R. Duling, Direct measurement of microvessel hematocrit, 
red cell flux, velocity, and transit time, Am J Physiol Heart Circ Physiol. 
243 (1982) H1018–26. 
[441] C. Desjardins, B.R. Duling, Heparinase treatment suggests a role for the 
endothelial cell glycocalyx in regulation of capillary hematocrit, Am. J. 
Physiol. 258 (1990) H647–54. 
[442] J.M. Squire, M. Chew, G. Nneji, C. Neal, J. Barry, C. Michel, Quasi-
periodic substructure in the microvessel endothelial glycocalyx: a possible 
explanation for molecular filtering? J. Struct. Biol. 136 (2001) 239–255. 
 438 
doi:10.1006/jsbi.2002.4441. 
[443] C.C. Michel, Starling: the formulation of his hypothesis of microvascular 
fluid exchange and its significance after 100 years, Exp. Physiol. 82 (1997) 
1–30. 
[444] X. Hu, S. Weinbaum, A New View of Starling's Hypothesis at the 
Microstructural Level, Microvasc. Res. 58 (1999) 281–304. 
[445] Z. Pang, J.M. Tarbell, In vitro Study of Starling's Hypothesis in a Cultured 
Monolayer of Bovine Aortic Endothelial Cells, J Vasc Res. 40 (2003) 351–
358. doi:10.1159/000072699. 
[446] R.H. Adamson, J.F. Lenz, X. Zhang, G.N. Adamson, S. Weinbaum, F.E. 
Curry, Oncotic pressures opposing filtration across non-fenestrated rat 
microvessels, The Journal of Physiology. 557 (2004) 889–907. 
doi:10.1113/jphysiol.2003.058255. 
[447] R.L. Jackson, S.J. Busch, A.D. Cardin, Glycosaminoglycans: molecular 
properties, protein interactions, and role in physiological processes, Physiol. 
Rev. 71 (1991) 481–539. 
[448] A. Oohira, T.N. Wight, P. Bornstein, Sulfated proteoglycans synthesized by 
vascular endothelial cells in culture, J. Biol. Chem. 258 (1983) 2014–2021. 
[449] R.D. Rosenberg, N.W. Shworak, J. Liu, J.J. Schwartz, L. Zhang, Heparan 
sulfate proteoglycans of the cardiovascular system. Specific structures 
emerge but how is synthesis regulated? Journal of Clinical Investigation. 99 
(1997) 2062–2070. doi:10.1172/JCI119377. 
[450] C.B. Henry, B.R. Duling, Permeation of the luminal capillary glycocalyx is 
 439 
determined by hyaluronan, Am J Physiol Heart Circ Physiol. 277 (1999) 
H508–14. 
[451] V.H. Huxley, F.E. Curry, Differential actions of albumin and plasma on 
capillary solute permeability, Am. J. Physiol. 260 (1991) H1645–54. 
[452] R.K. Sironen, M. Tammi, R. Tammi, P.K. Auvinen, M. Anttila, V.-M. 
Kosma, Hyaluronan in human malignancies, Exp. Cell Res. 317 (2011) 383–
391. doi:10.1016/j.yexcr.2010.11.017. 
[453] N. Itano, K. Kimata, Altered hyaluronan biosynthesis in cancer progression, 
Seminars in Cancer Biology. 18 (2008) 268–274. 
doi:10.1016/j.semcancer.2008.03.006. 
[454] D. Hamerman, G.J. Todaro, H. Green, The production of hyaluronate by 
spontaneously established cell lines and viral transformed lines of 
fibroblastic origin, Biochimica Et Biophysica Acta (BBA) - Mucoproteins 
and Mucopolysaccharides. 101 (1965) 343–351. doi:10.1016/0926-
6534(65)90013-8. 
[455] J.J. Hopwood, A. Dorfman, Glycosaminoglycan synthesis by cultured 
human skin fibroblasts after transformation with simian virus 40, Journal of 
Biological cHemistry. 252 (1977) 4777–4785. 
[456] J.G. Leonard, A.H. Hale, D.E. Roll, H.E. Conrad, M.J. Weber, Turnover of 
Cellular Carbohydrates in Normal and Rous Sarcoma Virus-transformed 
Cells, Cancer Research. 38 (1978) 185–188. 
[457] N. Itano, T. Sawai, M. Yoshida, P. Lenas, Y. Yamada, M. Imagawa, et al., 
Three isoforms of mammalian hyaluronan synthases have distinct enzymatic 
 440 
properties, J. Biol. Chem. 274 (1999) 25085–25092. 
[458] N. Liu, F. Gao, Z. Han, X. Xu, C.B. Underhill, L. Zhang, Hyaluronan 
Synthase 3 Overexpression Promotes the Growth of TSU Prostate Cancer 
Cells, Cancer Research. 61 (2001) 5207–5214. 
[459] Y. Li, P. Heldin, Hyaluronan production increases the malignant properties 
of mesothelioma cells, British Journal of Cancer. 85 (2001) 600–607. 
doi:10.1054/bjoc.2001.1922. 
[460] R. Kosaki, K. Watanabe, Y. Yamaguchi, Overproduction of Hyaluronan by 
Expression of the Hyaluronan Synthase Has2 Enhances Anchorage-
independent Growth and Tumorigenicity, Cancer Research. 59 (1999) 1141–
1145. 
[461] N. Itano, T. Sawai, O. Miyaishi, K. Kimata, Relationship between 
hyaluronan production and metastatic potential of mouse mammary 
carcinoma cells, Cancer Research. 59 (1999) 2499–2504. 
[462] P. Klingbeil, R. Natrajan, G. Everitt, R. Vatcheva, C. Marchio, J. Palacios, 
et al., CD44 is overexpressed in basal-like breast cancers but is not a driver 
of 11p13 amplification, Breast Cancer Res Treat. 120 (2010) 95–109. 
[463] M. Götte, G.W. Yip, Heparanase, hyaluronan, and CD44 in cancers: a breast 
carcinoma perspective, Cancer Research. 66 (2006) 10233–10237. 
doi:10.1158/0008-5472.CAN-06-1464. 
[464] M.E. Prince, R. Sivanandan, A. Kaczorowski, G.T. Wolf, M.J. Kaplan, P. 
Dalerba, et al., Identification of a subpopulation of cells with cancer stem 
cell properties in head and neck squamous cell carcinoma, Proc. Natl. Acad. 
 441 
Sci. U.S.a. 104 (2007) 973–978. doi:10.1073/pnas.0610117104. 
[465] O. Nagano, S. Okazaki, H. Saya, Redox regulation in stem-like cancer cells 
by CD44 variant isoforms, Oncogene. (2013). doi:10.1038/onc.2012.638. 
[466] S. Seiter, R. Arch, S. Reber, D. Komitowski, M. Hofmann, H. Ponta, et al., 
Prevention of tumor metastasis formation by anti-variant CD44, The Journal 
of Experimental Medicine. 177 (1993) 443–455. 
[467] U. Günthert, M. Hofmann, W. Rudy, S. Reber, M. Zöller, I. Haussmann, et 
al., A new variant of glycoprotein CD44 confers metastatic potential to rat 
carcinoma cells, Cell. 65 (1991) 13–24. 
[468] M.J. Paszek, C.C. DuFort, M.G. Rubashkin, M.W. Davidson, K.S. Thorn, 
J.T. Liphardt, et al., Scanning angle interference microscopy reveals cell 
dynamics at the nanoscale, Nat Meth. 9 (2012) 825–827. 
doi:10.1038/nmeth.2077. 
[469] G. Méhes, A. Witt, E. Kubista, P.F. Ambros, Circulating breast cancer cells 
are frequently apoptotic, The American Journal of Pathology. 159 (2001) 
17–20. doi:10.1016/S0002-9440(10)61667-7. 
[470] M. Yu, A. Bardia, B.S. Wittner, S.L. Stott, M.E. Smas, D.T. Ting, et al., 
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and 
Mesenchymal Composition, Science. 339 (2013) 580–584. 
doi:10.1126/science.1228522. 
[471] R. Kalluri, R. Weinberg, The basics of epithelial-mesenchymal transition, 
The Journal of Clinical Investigation. 119 (2009) 1420. 
doi:10.1172/JCI39104. 
 442 
[472] J.P. Thiery, Epithelial–mesenchymal transitions in tumour progression, Nat 
Rev Cancer. 2 (2002) 442–454. doi:10.1038/nrc822. 
[473] D.G. Duda, A.M.M.J. Duyverman, M. Kohno, M. Snuderl, E.J.A. Steller, D. 
Fukumura, et al., Malignant cells facilitate lung metastasis by bringing their 
own soil, Proc. Natl. Acad. Sci. U.S.a. 107 (2010) 21677–21682. 
[474] J.-M. Hou, M.G. Krebs, L. Lancashire, R. Sloane, A. Backen, R.K. Swain, 
et al., Clinical significance and molecular characteristics of circulating 
tumor cells and circulating tumor microemboli in patients with small-cell 
lung cancer, Journal of Clinical Oncology. 30 (2012) 525–532. 
doi:10.1200/JCO.2010.33.3716. 
[475] M.B. Lawrence, T.A. Springer, Leukocytes roll on a selectin at physiologic 
flow rates: distinction from and prerequisite for adhesion through integrins, 
Cell. 65 (1991) 859–873. 
[476] M.B. Lawrence, T.A. Springer, Neutrophils roll on E-selectin, The Journal 
of Immunology. 151 (1993) 6339–6346. 
[477] J. Vitte, A.M. Benoliel, A. Pierres, P. Bongrand, Regulation of cell 
adhesion, Clinical Hemorheology and Microcirculation. 33 (2005) 167–188. 
[478] P. Robert, A. Nicolas, S. Aranda-Espinoza, P. Bongrand, L. Limozin, 
Minimal encounter time and separation determine ligand-receptor binding in 
cell adhesion, Biophysical Journal. 100 (2011) 2642–2651. 
doi:10.1016/j.bpj.2011.04.011. 
[479] M. Soler, S. Desplat-Jego, B. Vacher, L. Ponsonnet, M. Fraterno, P. 
Bongrand, et al., Adhesion-related glycocalyx study: quantitative approach 
 443 
with imaging-spectrum in the energy filtering transmission electron 
microscope (EFTEM), FEBS Lett. 429 (1998) 89–94. 
[480] M. Soler, C. Merant, C. Servant, M. Fraterno, C. Allasia, J.C. Lissitzky, et 
al., Leukosialin (CD43) behavior during adhesion of human monocytic 
THP-1 cells to red blood cells, Journal of Leukocyte Biology. 61 (1997) 
609–618. 
[481] S.I. Grivennikov, F.R. Greten, M. Karin, Immunity, Inflammation, and 
Cancer, Cell. 140 (2010) 883–899. doi:10.1016/j.cell.2010.01.025. 
[482] C.B.S. Henry, B.R. Duling, TNF-α increases entry of macromolecules into 
luminal endothelial cell glycocalyx, American Journal of Physiology - Cell 
Physiology. 279 (2000) H2815–H2823. 
[483] A.W. Mulivor, H.H. Lipowsky, Inflammation- and ischemia-induced 
shedding of venular glycocalyx, American Journal of Physiology - Cell 
Physiology. 286 (2004) H1672–80. doi:10.1152/ajpheart.00832.2003. 
[484] A.W. Mulivor, H.H. Lipowsky, Role of glycocalyx in leukocyte-endothelial 
cell adhesion, American Journal of Physiology - Cell Physiology. 283 
(2002) H1282–91. doi:10.1152/ajpheart.00117.2002. 
[485] K.F. Hofmann-Kiefer, G.I. Kemming, D. Chappell, M. Flondor, H. Kisch-
Wedel, A. Hauser, et al., Serum heparan sulfate levels are elevated in 
endotoxemia, European Journal of Medical Research. 14 (2009) 526–531. 
doi:10.1186/2047-783X-14-12-526. 
[486] A.A. Constantinescu, H. Vink, J.A.E. Spaan, Elevated capillary tube 
hematocrit reflects degradation of endothelial cell glycocalyx by oxidized 
 444 
LDL, American Journal of Physiology - Cell Physiology. 280 (2001) 
H1051–H1057. 
[487] M. Rehm, D. Bruegger, F. Christ, P. Conzen, M. Thiel, M. Jacob, et al., 
Shedding of the endothelial glycocalyx in patients undergoing major 
vascular surgery with global and regional ischemia, Circulation. 116 (2007) 
1896–1906. doi:10.1161/CIRCULATIONAHA.106.684852. 
[488] N. Mitsiades, W. Yu, V. Poulaki, M. Tsokos, I. Stamenkovic, Matrix 
Metalloproteinase-7-mediated Cleavage of Fas Ligand Protects Tumor Cells 
from Chemotherapeutic Drug Cytotoxicity, Cancer Research. 61 (2001) 
577–581. 
[489] M. Madlener, W.C. Parks, S. Werner, Matrix metalloproteinases (MMPs) 
and their physiological inhibitors (TIMPs) are differentially expressed 
during excisional skin wound repair, Exp. Cell Res. 242 (1998) 201–210. 
doi:10.1006/excr.1998.4049. 
[490] P. Martin, Wound Healing--Aiming for Perfect Skin Regeneration, Science. 
276 (1997) 75–81. 
[491] Z.S. Galis, G.K. Sukhova, M.W. Lark, P. Libby, Increased expression of 
matrix metalloproteinases and matrix degrading activity in vulnerable 
regions of human atherosclerotic plaques, Journal of Clinical Investigation. 
94 (1994) 2493–2503. 
[492] Z. Li, L. Li, R. Zielke, L. Cheng, R. Xiao, M.T. Crow, et al., Increased 
expression of 72-kd type IV collagenase (MMP-2) in human aortic 
atherosclerotic lesions, The American Journal of Pathology. 148 (1996) 121. 
 445 
[493] T.J. Gronski, R.L. Martin, D.K. Kobayashi, B.C. Walsh, M.C. Holman, M. 
Huber, et al., Hydrolysis of a broad spectrum of extracellular matrix proteins 
by human macrophage elastase, J. Biol. Chem. 272 (1997) 12189–12194. 
[494] K. Endo, T. Takino, H. Miyamori, H. Kinsen, T. Yoshizaki, M. Furukawa, 
et al., Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 
stimulates cell migration, J. Biol. Chem. 278 (2003) 40764–40770. 
doi:10.1074/jbc.M306736200. 
[495] M.L. Fitzgerald, Z. Wang, P.W. Park, G. Murphy, M. Bernfield, Shedding 
of syndecan-1 and -4 ectodomains is regulated by multiple signaling 
pathways and mediated by a TIMP-3-sensitive metalloproteinase, The 
Journal of Cell Biology. 148 (2000) 811–824. 
[496] G. Taraboletti, S. D'Ascenzo, P. Borsotti, R. Giavazzi, A. Pavan, V. Dolo, 
Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-
MMP as membrane vesicle-associated components by endothelial cells, The 
American Journal of Pathology. 160 (2002) 673–680. doi:10.1016/S0002-
9440(10)64887-0. 
[497] W.H. Yu, J.F. Woessner, Heparan sulfate proteoglycans as extracellular 
docking molecules for matrilysin (matrix metalloproteinase 7), J. Biol. 
Chem. 275 (2000) 4183–4191. 
[498] L.M. Coussens, B. Fingleton, L.M. Matrisian, Matrix metalloproteinase 
inhibitors and cancer: trials and tribulations, Science. 295 (2002) 2387–
2392. doi:10.1126/science.1067100. 
[499] T. Arisaka, M. Mitsumata, M. Kawasumi, T. Tohjima, S. Hirose, Y. 
 446 
Yoshida, Effects of shear stress on glycosaminoglycan synthesis in vascular 
endothelial cells, Ann. N. Y. Acad. Sci. 748 (1995) 543–554. 
[500] Y. Zeng, M. Waters, A. Andrews, P. Honarmandi, E. Ebong, V. Rizzo, et 
al., Fluid Shear Stress induces the Clustering of Heparan Sulfate via 
Mobility of Glypican-1 in Lipid Rafts, AJP: Heart and Circulatory 
Physiology. (2013). doi:10.1152/ajpheart.00764.2012. 
[501] A. Koo, C.F. Dewey, G. Garcia-Cardena, Hemodynamic shear stress 
characteristic of atherosclerosis-resistant regions promotes glycocalyx 
formation in cultured endothelial cells, AJP: Cell Physiology. 304 (2013) 
C137–C146. doi:10.1152/ajpcell.00187.2012. 
[502] R.K. Jain, Determinants of tumor blood flow: a review, Cancer Research. 48 
(1988) 2641–2658. 
[503] D. Fukumura, R.K. Jain, Tumor microenvironment abnormalities: causes, 
consequences, and strategies to normalize, J. Cell. Biochem. 101 (2007) 
937–949. doi:10.1002/jcb.21187. 
[504] R.E. Bruehl, T.A. Springer, D.F. Bainton, Quantitation of L-selectin 
distribution on human leukocyte microvilli by immunogold labeling and 
electron microscopy, J. Histochem. Cytochem. 44 (1996) 835–844. 
[505] A.A. Constantinescu, H. Vink, J. Spaan, Endothelial Cell Glycocalyx 
Modulates Immobilization of Leukocytes at the Endothelial Surface, 
Arteriosclerosis, Thrombosis, and Vascular Biology. 23 (2003) 1541–1547. 
doi:10.1161/01.ATV.0000085630.24353.3D. 
[506] H.H. Lipowsky, R. Sah, A. Lescanic, Relative roles of doxycycline and 
 447 
cation chelation in endothelial glycan shedding and adhesion of leukocytes, 
AJP: Heart and Circulatory Physiology. 300 (2011) H415–H422. 
doi:10.1152/ajpheart.00923.2010. 
[507] H.H. Lipowsky, A. Lescanic, The effect of doxycycline on shedding of the 
glycocalyx due to reactive oxygen species, Microvasc. Res. (2013). 
doi:10.1016/j.mvr.2013.07.004. 
[508] C.A. Reis, H. Osorio, L. Silva, C. Gomes, L. David, Alterations in 
glycosylation as biomarkers for cancer detection, Journal of Clinical 
Pathology. 63 (2010) 322–329. doi:10.1136/jcp.2009.071035. 
[509] J. Guck, S. Schinkinger, B. Lincoln, F. Wottawah, S. Ebert, M. Romeyke, et 
al., Optical deformability as an inherent cell marker for testing malignant 
transformation and metastatic competence, Biophysical Journal. 88 (2005) 
3689–3698. doi:10.1529/biophysj.104.045476. 
[510] J.S. Kuo, Y. Zhao, P.G. Schiro, L. Ng, D.S.W. Lim, J.P. Shelby, et al., 
Deformability considerations in filtration of biological cells, Lab Chip. 10 
(2010) 837–842. doi:10.1039/b922301k. 
[511] S.J. Tan, L. Yobas, G.Y.H. Lee, C.N. Ong, C.T. Lim, Microdevice for the 
isolation and enumeration of cancer cells from blood, Biomed Microdevices. 
11 (2009) 883–892. doi:10.1007/s10544-009-9305-9. 
[512] S. Zheng, H. Lin, J.-Q. Liu, M. Balic, R. Datar, R.J. Cote, et al., Membrane 
microfilter device for selective capture, electrolysis and genomic analysis of 
human circulating tumor cells, Journal of Chromatography A. 1162 (2007) 
154–161. doi:10.1016/j.chroma.2007.05.064. 
 448 
[513] G. Vona, A. Sabile, M. Louha, V. Sitruk, S. Romana, K. Schütze, et al., 
Isolation by size of epithelial tumor cells : a new method for the 
immunomorphological and molecular characterization of circulating tumor 
cells, The American Journal of Pathology. 156 (2000) 57–63. 
doi:10.1016/S0002-9440(10)64706-2. 
[514] S. Matsumoto, Y. Imaeda, S. Umemoto, K. Kobayashi, H. Suzuki, T. 
Okamoto, Cimetidine increases survival of colorectal cancer patients with 
high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on 
tumour cells, British Journal of Cancer. 86 (2002) 161–167. 
doi:10.1038/sj.bjc.6600048. 
[515] B. Monzavi-Karbassi, J.S. Stanley, L. Hennings, F. Jousheghany, C. Artaud, 
S. Shaaf, et al., Chondroitin sulfate glycosaminoglycans as major P-selectin 
ligands on metastatic breast cancer cell lines, Int. J. Cancer. 120 (2007) 
1179–1191. doi:10.1002/ijc.22424. 
[516] M.R. King, Rolling in the deep: therapeutic targeting of circulating tumor 
cells, Frontiers in Oncology. 2 (2012). doi:10.3389/fonc.2012.00184. 
[517] K. Rilla, R. Tiihonen, A. Kultti, M. Tammi, R. Tammi, Pericellular 
hyaluronan coat visualized in live cells with a fluorescent probe is 
scaffolded by plasma membrane protrusions, J. Histochem. Cytochem. 56 
(2008) 901–910. doi:10.1369/jhc.2008.951665. 
[518] C. Brekken, C. de Lange Davies, Hyaluronidase reduces the interstitial fluid 
pressure in solid tumours in a non-linear concentration-dependent manner, 
Cancer Letters. 131 (1998) 65–70. 
 449 
[519] L. Eikenes, I. Tufto, E.A. Schnell, A. Bjorkoy, C. de L. Davies, Effect of 
Collagenase and Hyaluronidase on Free and Anomalous Diffusion in 
Multicellular Spheroids and Xenografts, Anticancer Research. 30 (2010) 
359–368. 
[520] C.B. Thompson, H.M. Shepard, P.M. O'Connor, S. Kadhim, P. Jiang, R.J. 
Osgood, et al., Enzymatic depletion of tumor hyaluronan induces antitumor 
responses in preclinical animal models, Molecular Cancer Therapeutics. 9 
(2010) 3052–3064. doi:10.1158/1535-7163.MCT-10-0470. 
[521] Z. Pályi-Krekk, M. Barok, J. Isola, M. Tammi, J. Szöllosi, P. Nagy, 
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab 
internalisation in trastuzumab resistant breast cancer, Eur. J. Cancer. 43 
(2007) 2423–2433. doi:10.1016/j.ejca.2007.08.018. 
[522] Z. Pályi-Krekk, M. Barok, T. Kovács, H. Saya, O. Nagano, J. Szöllosi, et al., 
EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, 
internalization and motogenic effect of CD44, Cancer Letters. 263 (2008) 
231–242. doi:10.1016/j.canlet.2008.01.014. 
[523] A. Erikson, I. Tufto, A.B. Bjønnum, Ø.S. Bruland, C. de L. Davies, The 
impact of enzymatic degradation on the uptake of differently sized 
therapeutic molecules, Anticancer Research. 28 (2008) 3557–3566. 
[524] C.J. Whatcott, H. Han, R.G. Posner, G. Hostetter, D.D. Von Hoff, Targeting 
the Tumor Microenvironment in Cancer: Why Hyaluronidase Deserves a 
Second Look, Cancer Discovery. 1 (2011) 291–296. 
[525] C. Yang, Y. Liu, Y. He, Y. Du, W. Wang, X. Shi, et al., The use of HA 
 450 
oligosaccharide-loaded nanoparticles to breach the endogenous hyaluronan 
glycocalyx for breast cancer therapy, Biomaterials. 34 (2013) 6829–6838. 
doi:10.1016/j.biomaterials.2013.05.036. 
[526] B.P. Toole, M.G. Slomiany, Hyaluronan: a constitutive regulator of 
chemoresistance and malignancy in cancer cells, Seminars in Cancer 
Biology. 18 (2008) 244–250. doi:10.1016/j.semcancer.2008.03.009. 
[527] C. Yang, M. Cao, H. Liu, Y. He, J. Xu, Y. Du, et al., The high and low 
molecular weight forms of hyaluronan have distinct effects on CD44 
clustering, Journal of Biological cHemistry. 287 (2012) 43094–43107. 
doi:10.1074/jbc.M112.349209. 
[528] S. Weinbaum, X. Zhang, Y. Han, H. Vink, S.C. Cowin, 
Mechanotransduction and flow across the endothelial glycocalyx, Proc. Natl. 
Acad. Sci. U.S.a. 100 (2003) 7988–7995. doi:10.1073/pnas.1332808100. 
 
